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PREFACE

The material in chapters I-IX is intended to be an introduction to the experiments of the author and the reader
who is familiar with the glucocorticoid effects treated in
these chapters may elect to omit them.

However, each of

these chapters is intended to be a complete summary of an
aspect of glucocorticoid action related to the experimental
problem.

Since most of these aspects of glucocorticoid ac-

tion are still under investigation, no final evaluation can
be made.

Rather, these chapters may suggest interrelations

between glucocorticoids, growth hormone and insulin, one of
which has been chosen for experimental study.
It may be helpful to the reader to put these chapters
into context.

Chapter I explores the relationship between

hereditary diabetes and cortisol metabolism.

Having found

support for such a relationship, Chapter II examines the
relationship of other hormones to the diabetogenic effect
of cortisol.

Chapter I I I describes those insulin inhibitors
iv

p
which have been reported but not yet characterized.

These

chapters clarify the concept of insulin inhibition.
Chapter IV discusses the relationship between glucocorticoids and mineralcorticoids with respect to the use
of the latter in maintenance therapy in the study of glucocorticoid effects in adrenalectomized rats.

Chapter V

relates current concepts of the action of glucocorticoids
in_ glycolytic inhibition.

Chapter VI describes the role

of growth hormone and glucocorticoids in lipolysis and
shows that lipolysis is not necessary for the anti-insulin
effect of cortisol.

In Chapter VII the mechanism of the

glucocorticoid effect is discussed in light of known control mechanisms.
Chapter VIII describes lipoprotein structure relative to the problem of the lipoprotein insulin inhibitor.
The transport function of the lipoprotein is emphasized.
Chapter IX compares the effect of glucocorticoids and
other steroids on serum lipoproteins. 'Similarities between the effects of glucocorticoids and estrogens are
noted, especially with respect to their interaction with
growth hormone.
Lipoprotein lipase is discussed because it also affects serum lipids.

In addition, the effects of steroid

hormones on its activity are reviewed.

v

The mechanism

•
which decreases the activity of this enzyme in diabetes·
is discussed in conjunction with the mechanism of action of
insulin.

Finally, an analysis of the efficacy of steroids

in the treatment of mammary cancer leads to the concept that
glycolytic inhibition is an important factor in the effects
of glucocorticoid analogs.

vi
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GLUCOCORTICOIDS AND GLYCOLYTIC INHIBITION OF LIPOPROTEINS
(Abstract) by Theodore S. Musiala, Loyola University of
Chicago.
The effect of the synthetic glucocorticoid 6a-fluoro11s, 17a, 21-trihydroxy-l, 4-pregnadiene-3, 20-dione (f1uprednisolone, m p 206-208°C) on the production of physiologic
inhibition of glucose oxidation in male alloxan-diabetic
adrenalectomized Sprague-Dawley rats was studied.

Flupred-

nisolone was chosen for study to minimize mineralcorticoid
effects on glucose oxidation.

Electrolyte balance was main-

tained in the adrenalectomized rats by the oral administration of sodium chloride and the sodium salt of. 8-glycyrrhetinic acid.

The rats were maintained on a diet containing

approximately 55% casein, 21% fructose, 4.4% succinate, 5%
safflower oil, plus vitamins, minerals and fiber.
Only those anti-insulin factors transported by a-lipoproteins at least 6 hours after final injection of 10 mg/kg
of steroid were evaluated.

In order to define the relative

specificity of the effect, the fluprednisolone metabolite 6afluoro-11S,17~,208,21-tetrahydroxy-l,4-pregnadiene-3-one

(mp

188-192°C) was synthetized and administered to control donor
rats.

Anesthetized steroid-treated donor rats were exsan-

guinated via the abdominal aorta and the 8-lipoprotein fraction was isolated by dextran sulfate and transferred to
vii

isotonic tris(hydroxymethyl)aminomethane-HCl buffer, pH 7.40
at 37°c, through use of a gel exclusion column containing diethylaminoethyl anion exchange groups.

In alternate experi-

ments one week apart, each recipient rat received intraperitoneally the S-lipoprotein fraction from f luprednisolonetreated donors and weight-matched 6a-fluoro-11S,17a,20S,21tetrahydroxy-l,4-pregnadiene-3-one treated donors.

The re-

cipient rats anesthetized with 2,2-dichloro-1,1-difluoroe.thyl methyl ether also received a priming dose of glucose-

6~14c followed by a continuous infusion of excess insulin
and labeled glucose so that glucose transport was not ratelimi ting for glucose oxidation.

The specific activity of

expired carbon dioxide was measured at 45-minute intervals
during a 225-minute period by liquid scintillation spectrometry.
The rate of glucose oxidation was apparently less following the administration of S-lipoproteins from f luprednisolonetreated rats than following the administration of S-lipoproteins from rats treated with 6a-fluoro-11S,17a,20S,21-tetrahydroxy-l,4-pregnadiene-3-one.

Provided that the latter

steroid treatment did not enhance glucose oxidation, the
apparent effect is indicative of high specificity for C-21
steroids.

It is possible that structurally related compounds

with hyperglycemic effects act by binding to the same growth
hormone-dependent receptor protein hypothesized to bind glucocorticoids and mediate their anti-insulin effects.
viii
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CHAPTER I

.

INTRODUCTION TO DIABETES MELLITUS

~tiology

of Beta Cell Exhaustion

The academic problem presented by diabetes mellitus is
not the relative insulin deficiency but how it develops.
The two most important expressions of this disease from this
standpoint are "juvenile" diabetes and "maturity-onset" or
adult diabetes.

These two types of diabetes differ primarily

in their rates of development.

That juvenile diabetes is an

accelerated form of adult diabetes is not unreasonable in
view of the rapid rate of fetal growth.
What is the genetic basis of inherited insulin antagonism?
for it?

In particular, what single gene might be responsible
What is the relationship of known diabetogenic fac-

tors to the genetic factor?

The purpose of this dissertation

is to explore the role of cortisol in insulin resistance and
the possibility that a genetic defect in cortisol metabolism
may lead to the overproduction of a circulating insulin
antagonist.
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Knowledge of the genetic defect in diabetes mellitus
will not only aid in understanding the progression of the
disease, but also will aid in its more accurate detection
·in the population before it is expressed clinically.
The Relationship to Obesity, Cancer, and Vascular Disease
Yalow and Berson (118) found that the response of insulin to glucose was delayed in obesity.

This delay is

apparently related to the high fasting insulin levels which
are also found in obese subjects.

The continuous output of

insulin in the fasting state prevents the maximal storage
of insulin granules in the B cells and abolishes the initial
burst of insulin release in response to glucose.
Arendt and Pattee (19) performed combined insulin-glucose tolerance tests on obese subjects.

They administered

0.1 unit of insulin per kilogram of body weight intravenously followed in 30 minutes by 0.8 grams of glucose per
kilogram of body weight orally.

In 32 obese subjects the

response to this procedure was a fall in blood glucose to
50 percent of its fasting level at 90 minutes and then a
maximum rise to 164 percent of fasting levels at 120 minutes.
Glucose remained high at 180 minutes.

In contrast, the

normal response consisted of an initial fall in blood glucose to 38 percent of the fasting level followed by a maximum rise to 114 percent of the fasting level at 90 minutes.
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rurthermore, the blood glucose level in control subjects fell
J:)elow the fasting level before 180 minutes had elapsed. · The
obese group was clearly resistant

to the administered insulin.

In addition, their insulin response· to glucose was clearly
subnormal.
That this subnormal response is not due to lower serum
insulin levels is illustrated in the work of Karam· et' al
(562).

These workers measured blood insulin levels at 30, 60,

90, and 120 minutes after oral and intravenous glucose administration.

They found that obese diabetic patients had

higher insulin levels at each interval compared to normal
subjects.

In addition, basal insulin levels were 30-146

microunits per ml in the obese group compared to 30-84 microunits per ml in the control group.
the decreased glucose tolerance in

These results show that
ob~sity

decreased level of insulin in the blood.

is not due to a
It is clear evidence

for increased insulin antagonism in obesity.

More than 51

percent of male diabetics and 59 percent of female diabetics
are 20 percent heavier than ideal weight.

In many cases a

remission of diabetes follows weight loss.
Another interesting finding in this interrelationship
has been reported by Yalow et ·al (1181).

They found that

prolonged fasting Aecreases the glucose tolerance of normal
subjects but that it did not affect the glucose tolerance of

•
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obese or diabetic obese subjects.

These results indicate that

obesity impairs the response to insulin by the same mechanism
operative during fasting.
The Heredity and Detection of the Diabetic Genotype
Although the inheritance of abnormal

~lucose

tolerance

does not follow a simple recessive or dominant pattern, if
diabetes melli tus is due to .. a single gene, its inheritance
must follow one of these patterns.

As noted earlier, insulin

resistance will not produce abnormal glucose tolerance unless
insulin output is deficient.

Therefore, in the general pop-

ulation, the inheritance of the diabetic phenotype may be
multi-factorial, including genes for insulin production and
insulin destruction as well as for insulin resistance.

Be-

cause of these modifying genes, the incidence of diabetes
among the children of O, 1, and 2 diabetic parents is 0.2,
1.6, and 12-14 percent respectively.
In more homogeneous populations containing more uniform
modifying genes diabetes is inherited in dominant fashion.
Pavel and Pierptea (817) studied a homogeneous population of
14,000 diabetics

~n

Bucharest over a 26-year period.

They

observed a 27.7 percent incidence of diabetic descendants
in 385 families in which both parents were diabetic.

When

this figure was corrected for the increasing life span of
the descendants, the corrected incidence was 31.7 percent.
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This percentage is less than the 50 percent incidence of
heterozygotes expected for dominant inheritance.

However,

the difference could be due to an increased mortality among
diabetic compared to non-diabetic fetuses.

Vallance-Owen

(1086) also found that the synalbumiri insulin antagonist
was inherited as an autosomal dominant but that overt diabetes developed in only 16 out of 58 individuals with inherited insulin antagonism.

This percentage (27.7 percent)

is similar to that noted above.
Glucocorticoid-Glucose and Fucose Tolerance Tests
The detection of the diabetic genotype is much more
difficult than the detection of the diabetic phenotype.

Al-

though elevated fasting glucose is often indicative of diabetes mellitus, the results of the standard glucose tolerance
test are less definitive.

Fajans et al (303) have shown that

standard glucose tolerance is randomly distributed in the population.

Therefore, only a probability factor can be assigned

from the results of this test.
In contrast to the random distribution of standard glucose tolerance, the cortisone-glucose tolerance test of Fajans
and Conn (300) is somewhat more definitive in that 30 percent
of the positive responders to this test later suffer marked
deterioration in standard glucose tolerance due to the presence of the diabetic genotype.

Since diabetes mellitus is
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responsible for only one out of three positive cortisone-glucose tolerance tests, other factors besides the gene may
impair glucose tolerance following cortisone.

Three factors

which may influence the cortisone-glucose tolerance test
are:

1) the rate of cortisone metabolism; 2) hepatic glucose

output in response to cortisone, and 3) peripheral glucose
utilization in response to cortisone.

Apparently, the gene

for diabetes mellitus influences only the last factor.
Fajans and Conn (301) reported the details of the cortisone-glucose tolerance test.

In the test approximately 8.0

mg/kg of cortisone acetate is administered to the subject
8.5 hours and 2.0 hours before the administration of 1.75 gm
of glucose per kg of ideal weight.

The long treatment period

is noteworthy in reference to the mechanism of cortisone in
this effect.

When glucose is measured by the Somogyi-Nelson

method, the 2-hour value should be less than 1.40 gm/l compared to 1.20 gm/l in the standard glucose tolerance test.
Fajans and Conn pointed out the utility of the cortisoneglucose tolerance test in deciding borderline results from
the standard glucose tolerance test.

They found that 90

percent of "probable" positive responders to the latter test
to be positive responders to the cortisone-glucose tolerance
test.

They also observed that 28 percent of the relatives

Of diabetics gave positive cortisone-glucose tolerance tests,
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but that only 4 percent of non-diabetics did so.

This latter

percentage is that expected from random error alone.
Prior to the cortisone-glucose tolerance test Thorn et al
(1064) found that when a daily dose of 50 mg of prednisolone
is withdrawn from normal and diabetic subjects, the latter
continue to excrete glucose after 3 days while the non-diabetic subjects do not.

This result suggests that glucocor-

ticoid effects are prolonged in diabetics.
Duncan (259) has described an intravenous cortisone. glucose tolerance test in which 200 mgs of cortisone is administered 2 hours before glucose.

He described the merits

of plotting the glucose tolerance curve on semi-log paper.
When the logarithm of the increase in blood glucose above
the fasting level is plotted versus time,. a straight line
is obtained.

A glucose disappearance rate can be calcu-

lated from the slope of this line.

Approximately 83 percent

· of patients with mild diabetes but no non-diabetics have
s~bnormal

glucose disappearance rates.

These results suggest

that the severity of diabetes may be measured by the halflife of blood glucose.

Thus, one may refer to 30-minute

diabetics, 60-minute diabetics, etc.

Furthermore, .since

half-lives are inversely proportional to glucose disappearance rates, relatively few equally spaced half-lives encompass a wide .variation in the severity of diabetes.

These
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reports also indicate that glucocorticoids are involved in
the mechanism of genetic diabetes.

Berger et al (68) con-

cluded that the mechanism of the cortisone-glucose tolerance
test involved peripheral insulin antagonism.

The fact that

juvenile diabetes is often evident at birth may be an indication of the effect of insulin inhibitor

on

concentr~tion

the rate of S cell exhaustion.
The standard glucose tolerance test has two deficiencies:
elevations in glucose stimulate insulin release and, secondly,
most of the glucose is converted to glycogen so that the
rate of glucose disappearance is not equal to the rate of
glycolysis.
Pituitary basophilism results in an overproduction of
ACTH in Cushing's Syndrome.

Conn (103) has observed that

· . 70 percent of these patients exhibit an insulin-resistant
diabetes mellitus.

Pfeiffer (831) found that both Cushing's

Syndrome and acromegaly were preceded by long periods of ·impaired glucose tolerance associated with elevations in plasma
insulin and an inverted circadian rhythm of ACTH secretion.
On the other hand, insulin resistance due to insulin antibodies is not associated with the excretion of cortisol
metabolites.

The insulin requirement is not proportional

to cortisol production even though cortisol output may be
4-23 fold elevated when the diabetes is uncontrolled.

Rose

9
(g03) has also demonstrated increased adrenocortical activity

in alloxan-diabetic rats.

The treatment of insulin resist-

ance with excess insulin may actually increase the resistance.
Somogyi (1003) noted that insulin hypoglycemia increases glucagon and glucocorticoid secretions which have hyperglycemic
and anti-insulin effects.
What is needed is an extracellular indicator of the
int~acellular

concentration of glucose-6-phosphate.

This

·hexose phosphate is the precursor of several other hexoses
~hich

are incorporated into serum glycoproteins.

convenient of

glycoprot~in

6-deoxy-L-galactose.

The most

hexoses to measure is fucose,

The level of free serum fucose is

negligible and it can be quantitated specifically in the
presence of other reducing sugars by means of the Dische
methylpentose reaction using cysteine and sulfuric acid.
This colorimetric reaction at 400 nm is no more difficult
than glucose measurement by ferricyanide reduction.
Fucose is incorporated into glycoproteins by a multistep reaction sequence consisting of the conversion of
_9lucose-6-phosphate to fructose-6-phosphate, then to
mannose-1-phosphate, then to guanosine

diphosphate~D-mannose.

This .nucleotide sugar is converted to guanosine diphosphateL-fucose and subsequently attached to the completed protein
chains of serum glycoproteins.

Shaw et al (975) performed
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the standard oral glucose tolerance test on a group of patients

and classified all those whose one and two hour glucose concentrations were above 1.60 gm/l and 1.20 gm/1 respectively
as frank or overt diabetics.

The cortisone-glucose toler-

ance tests was performed on the remaining patients and all
positive responders were classified as subclinical or genetic
diabetics.

The remainder served as normal controls.

When

serum fucose levels during the standard glucose tolerance test
were evaluated, the overt diabetics had two-hour fucose levels
in excess of 0.75 gm/l, the subclinical diabetics had fucose
levels in excess of 0.50 gm/l, and the controls all had
fucose levels lower than 0.30 gm/1.

Little overlap was ob-

served between these groups, indicating that glycolytic inhibition is a good indication of

gen~tic

diabetes.

Navarete and Torres (776) reported the superiority of
the synthetic glucocorticoid dexamethasone (9a-fluoro-11B,
16a, 17a, 21-tetrahydroxy-l, 4-pregnadiene-3, 20-dione) in
glucocorticoid-glucose tolerance tests. They found 80 percent positive responses in prediabetics compared to 30 percent positive responses in the cortisone-glucose tolerance
test.

This is an important finding because it suggests

that differences in the rates of the metabolism of synthetic
and endogenous glucocorticoids may exist.

In particular, a

more rapid metabolism of cortisone in certain individuals
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may prevent the expression of the diabetic gene.

Lundback

(G83) has also noted that individual variations in the response to cortisone or prednisolone were partly responsible
for the false negative responses in the cortisone-glucose
tolerance test.
These results suggest that the measurement of serum
glycoprotein fucose during the dexamethasone-glucose tolerance test may provide almost complete detection of subclinical diabetes and, as such, may be of great utility in
genetic studies of diabetes, including genetic counselling.
More

importantly~

these reports indicate glucocorti-

coids are involved in the expression of genetic diabetes.
Berger et al (68) concluded that the mechanism of the cortisone-glucose tolerance test involved peripheral insulin
antagonism.

Furthermore, if juvenile diabetes is simply

a double dose of insulin antagonism, the fact that juvenile
diabetes is of ten evident at birth may be an indication of
the effect of insulin-inhibitor concentration on the rate
of 8 cell exhaustion.

These same considerations also sug-

gest that fetal glucocorticoid metabolism may be an important factor in the development of juvenile diabetes.

The

extent to which juvenile diabetes may be influenced by
maternal glucocorticoid metabolism remains to ·be determined.
Insulin resistance in tissues other than adipose tissue
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may lead to obesity as long as the islet cells can respond
with increased insulin output because andipose tissue is
especially sensitive to insulin.

Both the. B lipoprotein

insulin inhibitor and the synalbumin insulin antagonist are
more active on muscle than on adipose tissue.

In

c~ntrast,

Antoniades (16) has demonstrated that bound insulin is more
active on adipose tissue than on muscle.

However, all of

the insulin effects reported here have been demonstrated
with unbound insulin in vitro.

Therefore, the activity of

bound insulin in the presence of excess of unbound insulin
appears to be insignificant.

Furthermore, an effect of

glucocorticoids or other hormones on bound insulin has not
been demonstrated.
Does diabetes mellitus like sickle cell anemia have
.,

survival value under certain conditions?

When Eskimos

subsist on a diet of lipid and protein with minimal carbohydrate,· their incidence of overt diabetes is low.

How-

ever, when they switch to a standard American diet, their
incidence of diabetes is increased.

Apparently, insulin

resistance is relatively unimportant when dietary carbohydrate is low.

As noted previously, an insulin antag-

onist which is active on muscle but not on adipose tissue
t

·f

promotes fat synthesis as long as islet cell insulin reserve can meet the demand.

Accordingly, the gene for
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with gonadal dysgenesis.

Although a small amount of cortisol

is found in normal urine, patients with gonadal dysgenesis
up to 5 percent of administered cortisol unchanged.
Forbes and Engel (323) have also noted a high incidence of
gonadal dysgenesis in diabetics and their close relatives.
Interestingly, Dilman et al (233) also attributed an observed lower incidence of endometrial carcinoma in diabetic
women to hypothalamopituitary hypoactivity.

This negative

correlation between diabetes mellitus and malignancy has
also been observed by others.

Hudan (487) observed that

the occurence of malignant tumors in diabetic males was
87 percent of that in the total population; the corres. ponding figure for diabetic females was 37 percent.

Al-

though diabetes is equally prevalent among men and women,
the ratio of male to female diabetic deaths observed by
Malins et al (702), 0.60 in recent years, indicates that
diabetes mellitus more adversely affects women despite
the protection which it affords against cancer.
Although the above studies have ruled out a causative
role of ring A reduced metabolites in diabetes mellitus,
this does not imply that such steroids are devoid of antiglycolytic effects.
5~-pregnane-3,

The anesthetic activity of 21-hydroxy-

20-dione 21 succinate (Viadril) has been

noted previously.

Furthermore, Dundee (261) has recently

15

-compared 3a-hydroxy-Sa-pregnane-ll, 20-dione and 3a, 21-dihydroxy-Sa-pregnane-ll, 20-dione 20 acetate (CT 1341) with
other intravenous anesthetics.

Compounds of this type seem

to produce anesthesia by reducing the rate of glycolysis in
brain (398-399).

The overall impression of these studies

.is that glucocorticoids may have an especially effective
anti-glycolytic effect in brain and in malignant tissues
with high glycolytic rates.
Some preliminary experiments were conducted with the
aim of studying cortisol metabolism in diabetes.

Basically,

one may expect to find higher levels of cortisol in the
plasma of diabetics •. However, since the level of cortisol
may fluctuate, meaningful results can only be obtained if
the rate of metabolism of labeled cortisol is corrected
for the rate of cortisol production.

If there is deficient

SB reduction of cortisol in diabetes, this will be reflected
.; ·

in an increased ratio of Sa to SB reduced urinary cortisol
metabolites.
The determination of cortisol metabolites in urine by
published procedures is lengthy because of the long period
of glucuronidase treatment which is necessary to hydrolyze
glucuronide conjugates.

Furthermore, the large number of

closely related metabolites present often necessitates

~~'.

l
..

.
.

.

multiple successive chromatographic steps in which the
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separated metabolites must be located by non-destructive
techniques.

The problem of detecting ring A reduced cor-

tisol metabolites during column chromatography can be
solved by chromatographing ultraviolet-absorbing aromatic
steroid esters.

The choice of the particular ester for

this use is based on several considerations.

First, the

esterifying reagent should form distinct steroid derivatives.

Practically, this requirement translates into a

reagent that will esterify only unhindered primary and
secondary hydroxyl groups.
~ormed

Secondly, the derivative

should be more soluble in carbon disulfide than

their parent compounds to facilitate infra-red analysis
'•'.t:

in solution.

Thirdly, the esterifying reagent should be

capable of being conveniently labeled with an isotope
that can be distinguished from both carbon-14 and tritium.
In addition, a procedure using such a reagent should be
designed to minimize the number of metabolites which must
be separated and quantitated without reducing the metabolic information present in the metabolites.

Although

these studies are primarily concerned with 11-oxygenated
steroid metabolites, the procedure described below is
applicable to 11-deoxy steroids as well.
Generally, the first step in urinary steroid analysis
begins with the collection of a 24-hour specimen.

Secondly,

17

an aliquot of pooled urine from non-diabetics who have previously received an identical dose of glucocorticoid labeled
with an indicator is added to both non-diabetic and diabetic
urines.

For example, if the metabolism of carbon-14 labeled

cortisol is being studied in diabetics then pooled urine
from diabetics given a comparable dose of tritiated cortisol
will be added to each carbon-14 containing urine.

If iden-

tical aliquots of indicator metabolites are added to the
24-hour specimens from control non-diabetics and diabetics
such an addition then permits recovery corrections to be
..

applied to each steroid metabolite measured.

This proce-

dure has the advantage that each indicator conjugate is
similar to the conjugate which is to be measured so that
it is a true indication of procedural losses.
The next step is to separate the urinary steroids
and their conjugates from the bulk of the urine.

This has

been achieved by the absorption of both the free and conjugated steroids on diethylaminoethyl Sephadex anion exchange dextran gels.

The absorbed steroids are washed

with buffer to remove residual urine and then eluted from
the gel with an aqueous base.

Methanolic ammonia has been

used, but other volatile organic amines such as triethylamine might also be used to elute the conjugated and nonconjugated steroids.

i::

L

The eluate from such a separation is
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evaporated to dryness under reduced pressure and the residue
is dissolved in water.

A solution of sodium borohydride is

. then added which reduces steroid ketones over a period of
several hours.

Although many different ketone groups may

react with this reagent, its primary function is to reduce
.the c-20 ketone to the corresponding C-20 hydroxyl group
60

that glucocorticoid metabolites with the dihydroxyace-

tone side chain will be measured along with their corres_ponding metabolites with glycerol side chains after the
latter are converted to 17-ketosteroids by sodium metaperiodate treatment.

Metaperiodate oxidation of vicinal

glycols provides an alternate method for liberating steroids
from their glucuronide conjugates.

Essentially, the proce-

dure oxidizes the glycerol side chain to a 17-ketosteroid
and other glucuronides to formate esters which are readily
hydrolyzed by weak bases.

As in the enzymatic glucuroni-

dase hydrolysis procedure, the metaperiodate procedure
. may give low yields when applied directly to diabetic urines
,.~;:

containing high levels of glucose.

However, this is not a

problem if the conjugates are first isolated by column absorption as they are here.

The chemical equations illus-

trating these reactions are shown in the Figure I.
Following oxidation and destruction of excess periodate
the mixture is treated with sodium bicarbonate to saponify
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FIGURE I
PERIODATE OXIDATION OF STEROID GLUCURONIDES

'98URE %
PERIODATE OXIDATIO• CW STEROID 8LUCURONIDES
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anY formate esters produced.

Treatment with sodium boro-

hydride is then repeated to convert alkehyde groups arising
from corticosterone and deoxycorticosterone to primary
hydroxyl groups.

Although newly formed 17-ketosteroids may

also be reduced, such hydroxyl groups are later re-oxidized
along with llB-hydroxyl groups by chromium trioxide in pyridine.

During these reactions all 17a-hydroxy steroids

which differ only in their side chains are converted to the
same compound.

This conversion affords a real advantage

in the diagnosis of virilizing adrenal hyperplasia in, which
both 5$-pregnane-3a,17a-208-triol, characteristic of C-21
hydroxylase deficiency (salt-losing type) and 3a,17a-dihy: _
droxy-58-pregnane-20-one, characteristic of 118-hydroxylase
deficiency (hypertensive type) are converted to 58-androstane-3a,178-diol.

This latter steroid is also formed in

a negative metapyrone [2-methyl-l,2-bis(3-pyridyl)-l-propenone] test thereby indicating normal feedback control of
adrenocorticotrophin production by the pituitary.
Following acidification and concentration under reduced
pressure, the sulfate conjugates are solvolyzed by the procedure of Burstein and Lieberman (139).

In this procedure,

the sulfate conjugates are protonated by p-toluenesulfonic acid and transferred to the tetrahydrofuran phase.
The low dielectric constant of this solvent discourages

·..

~.

..

.

·~

..
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the ionization of the conjugate and promotes the following
reaction:
H
\

I

I
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OH
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The fact that oxygen from water is not incorporated into the
steroid product supports the above mechanism.
Following solvolysis, sodium hydroxide is added and the
non-phenolic steroids are salted out in the tetrahydrofuran
phase.
gen.

This phase is then evaporated to dryness under nitroThe steroid mixture is then dissolved in pyridine and

esterified with o-chlorobenzoyl chloride.

The temperature

·and reaction time are controlled so that llS-hydroxy and
17S-hydroxy groups present in the metabolites are not esterified.

They will therefore be available for subsequent

oxidation with chromium trioxide in pyridine.

The conver-

sion of llS-hydroxyl and 178-hydroxyl groups to their corresponding ketones reduces the total·number of individual
steroids in the complex mixture of urinary steroids, thus
simplifying the subsequent chromatographic separation.
Ketone groups in these positions also produce more definitive steroid spectra in the fingerprint region and aid
"

~

I
!~

~

~
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in the separation of steroids from other steroids which
cannot be converted to 11- and/or 17-ketosteroids, i.e.
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ll-deoxy and 17a-alkyl steroids.
Ellingboe et al (281) have described the use of Sephadex
LH-20 in the separation of steroid ketones.

Their work indi-

cates the feasibility of partition chromatography using ultraviolet-transparent solvent systems such as dichloromethane-cyclooctane combined with ultraviolet detection and
collection of steroid o-chlorobenzoates directly in liquid
scintillation counting vials.

Each fraction can then be

heated to remove the dichloromethane which would otherwise
quench the liquid scintillation process.

Following this

· step a concentrated toluene solution of scintillation f luor
could be added to the higher boiling cyclooctane solution
of the steroid ester.
Although many gas-liquid chromatography procedures
have been developed for steroids, these are not as useful
as liquid partition chromatography when the recovery of
the separated steroids is required.

The principles in-

volved in these liquid partition procedures have been
described by Bush (144) and by Cartensen (161) and useful
chromatographic separations have been reported by Katzenellenbogan et al (569) and by Wilson et al (1158).

The

following compounds derived from the metabolites of
labeled corticosteone and cortisol are listed below in
order of their elution from a straight-phase column:
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Major Derived Steroid Esters

-3

18)-lactol-513-androstane-1713,18-.
a, lla-dihydroxy-18-oxo(ll
µ

carbolectone 3-o-chlorobenzoate
5 6-pregnane-3a,2013-diol di-o-chlorobenzoate
21-nor-513-pregnane-3a,20-diol di-o-chlorobenzoate
3a-hydroxy-5a-androstane-ll,17-dione o-chlorobenzoate
Ja-hydroxy-513-androstene-11,17-dione o-chlorobenzoate
3a-hydroxy-5a-androstane-17-one o-chlorobenzoate
Ja-hydroxy-513-androstane-17-one o-chlorobenzoate
In the method described so far for the separation of corticosterone and cortisol metabolites the detection and collection of steroid peaks is less of a problem than their
identification and quantification.

The exact identity of

the eluted steroids must be made by comparison with authentic compounds on the basis of chromatographic behavior and
infrared spectra.

Quantification is also dependent on

identification since the number of o-chlorobenzoate groups
,...

per steroid molecule varies.

Furthermore, synthesis must

also be used to confirm the identity of the metabolites
of synthetic glucocorticoids.

The synthetic glucocorti-

coids most difficult to prepare are those reduced in ring
A of the steroid nucleus.

These derivatives, however,

may be prepared using serum enzymes.
~:·
~~.
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Rongone et ·a1 (809)

have shown that ring A reduction of steroids takes place

24
the presence of serum, isocitrate, and NADPH.
Although the actual chromatographic separation of steroid
o-chlorobenzoate esters has not been achieved, Ellingboe ·et al

2

~ 91)

have studied the factors which influence the separation

of ketonic from non-ketonic C-19 steroids during molecular
sieve chromatography.

They found that ketonic steroids were

eluted more rapidly due to the interaction of polar solvent
molecules with the ketone which increases the solvated molecular weight and excludes it from gel pores.

Although

they used chloroform in their studies, a similar effect may
be expected with dichloromethane which is more polar than
chloroform.

Cyclooctane may be used as the second component

of the solvent system to adjust the partition coefficients
of steroids between the polar Sephadex LH-20 stationary
phase and the non-polar mobile phase in the straight phase
separation.
Many procedures employing double isotope dilution for
the analysis of urinary steroids have been devised.

In

these procedures accuracy is achieved through the use of
indicator isotopic steroids which permit correction for
incomplete recovery of steroid metabolites.

Sensitivity,

on the other hand, is achieved by stoichiometrically forming
a steroid derivative with a reagent of accurately known
specific activity.

However, procedures using only carbon-14
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and tritium isotopes cannot be used to measure the excretion

of carbon-14 or tritium-labeled steroids.

Either recovery

or mass measurement must be sacrificed.
. esters are used to estimate
.
when 36 Cl-o-chloro b enzoate
mass, tritiated steroids can be used to estimate recovery
.of carbon-14 labeled steroids and vice-versa, i.e. a triple

isotope dilution procedure can be employed.

Chlorine-36 can

be readily distinguished from both tritium and carbon-14 by
liquid scintillation spectrometry.

The energies of the 8

emissions are 0.710, 0.018 and 0.156 Mev. respectively.
In addition, a simple route exists for the preparation of
chlorine-36-labeled o-chlorobenzoic acid via the diazonium
salt of anthranilic acid.

The labeled acid can be con-

verted to its acid chloride in refluxing thionyl chloride.
Alternately, the tritiated or carbon-14-labeled acid chloride may be formed more directly from labeled o-nitrotoluene
in a vapor phase reaction with thionyl chloride at 200-220°C
as described by Meyer (738).

~

The use of the o-chlorobenzoy1- 36 c1 group to estimate
steroid mass is limited in sensitivity by the maximum possible specific activity of chlorine-36, which, on the basis

Of its half-life of 3 x 10 5 years, is 0.3 percent of the
maximum specific activity of the u- 14 C-labeled acyl group
and to only 0.0006 percent of the maximum specific activity
~

t

l~.·.·
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of the same o-chlorobenzoyl or acetyl group containing three
tritium atoms.

However, even the tritiated o-chlorobenzoyl

group has only 7.5 percent of the maximum specific activity
of a sulfur-35-containing acyl group such as the o-methyl35
sulfonylbenzoyl- S group which contains only one sulfur-35
atom.
A three-step synthesis of o-methylsulfonylbenzoic acid
from acetophenone and chlorosulfonic acid has been described
by Weston and Suter (1135} and it appears to be well-suited

for the preparation of the labeled compound.

Although the

sulfone is resistant to base and to chromium trioxide oxidation, it appears that o-methylsulfonylbenzoyl chloride
may spontaneously cyclize in pyridine to 3(2)-thianapthenone-1, 1-dioxide and therefore may not be useful as an esterifying reagent.

An alternate sulfur-containing aromatic

acid chloride is 4-chlorothiophene-3-carboxylic acid chloride.

Whether this latter reagent is best prepared from

fumaric or maleic acid is an interesting chemical question.
A suggested synthesis from the less stable maleic acid is
shown below.
It is not possible to distinguish the B emissions of
carbon-14 (0.156 Mev.} from those of sulfur-32 (0.167 Mev.}
efficiently.

However, these isotopes may be distinguished

by the 10.4 percent decay in sulfur-32 activity which occurs
~··
~.

·.
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FIGURE II
SUGGESTED SYNTHESIS OF 4-CHLOROTHIOPHENE3-CARBOXYLIC ACID CHLORIDE
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when measurements of the total activity of both isotopes are
made at exactly two-week intervals.

This delay in the analy-

tical procedure is relatively unimportant for the types of
clinical determinations for which the triple isotope dilution procedure would be used.

Furthermore, the delay is not

necessary for the measurement of unlabeled steroid metabolites using 35 s-4-chlorothiophene-3-carboxylic acid chloride
and tritiated indicator steroids since radioactive tritium
and sulfur can be readily distinguished.

Thus, sulfur-

labeled esters could be used routinely in both double and
triple isotope dilution procedures.
Brooks et·al (121) have investigated the absorption
chromatography of steroid benzoates on alumina.

They

formed the benzoyl derivatives by treatment of the alcohols with the acid· chloride in pyridine for 18 hours at
room temperature.

Under these conditions 17S hydroxyl

groups as well as the less hindered C-20 and C-3 hydroxyl
groups were esterified.

Esterification of the 17S hydroxyl

group has also been observed with pentafluorobenzoyl chloride after 48 hours under similar conditions.

Brooks et ·a1 ·

achieved separation of the benzoates by eluting them from
the alumina with increasing proportions of benzene in petroleum ether.

They observed that the separation of C-5

epimers of steroid benzoates was better in every case than
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that obtained with the acetate esters.
In particular, the benzoyl esters appear to magnify the
stereochemical difference between epimeric C-20 hydroxyl
groups.

Those differences are relatively

steroid alcohols and acetate esters.

s~all

in the

This effect of the

c-20 benzoyl group occurs despite the free rotation about
the bonds involved.

Therefore, there is reason to expect

that separations will.be further improved by chromatographing
ortho substituted benzoyl esters.

In addition, the electron

withdrawing chlorine substituent, increases the selectivity
of the acid chloride for unhindered hydroxyl groups such
as those in the C-3;. C-17, and C-21 positions.
The separation of steroid derivatives by partition
chromatography depends on their physiochemical differences
relative to their similarities.

Steroids epimeric at C-5

differ primarily in conformation and therefore may show
their greatest differences in partition coefficient in
rigid allicyclic solvents which interact simultaneously
with portions of the A and B rings of these steroids.
Examples of ultraviolet-transparent solvents that have been
used for this purpose are cyclopentane, cyclohexane, and
methylcyclohexane.

Commercial decalin is a mixture of cis

and trans isomers which may have opposing interactions with
steroid solutes.

Although cis decalin may be useful, it
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must be separated from trans decalin which forms a hydroperoxide that may adversely affect steroid solutes and the
liquid scintillation process.
Hayes et al (438) have reported the pulse heights of
several aromatic and allicyclic solvents relative to toluene.

They found that methylcyclohexane and dioxane pro-

duced 25 and 20 percent of the toluene pulse height respec· - tively.

However, their most significant finding was that

dicylohexyl had 48 percent of the toluene pulse height.
Although contamination of the dicyclohexyl (m.p. 2.5-3.0,
b.p. 236.5-237.5) with phenylcyclohexane (m.p. 7.0-8.0,
b.p. 235-236) formed during the catalytic hydrogena.tion
of biphenyl could explain the results, the high pulse
height obtained may be due to the greater rigidity of
dicyclohexyl compared to methylcyclohexane.
The counting efficiencies of aromatic and non-aromatic liquid scintillation solvents increases as their viscosity increases.
n-hexane.

Cyclohexane is 3 times as viscous as

Cyclooctane and decalin are 7 and 8 times as

viscous as n-hexane respectively.

The aromatic ether

phenetole is over twice as viscous as toluene.
~'

A compari-

son of aromatic alcohols reveals that phenethyl alcohol
is 50 percent more viscous than benzyl alcohol which, in

i,,_

turn, is over 16 times more viscous than n-hexane.

"l~
.•.·. .
-~
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Thus,
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viscosity may explain why 2-phenoxyethanol is 86 percent as
efficient as toluene as a scintillation solvent while benzyl
alcohol is only 60 percent as efficient as toluene.
Non-bonded interactions contribute to the rigidity and
viscosity of cyclooctane.

Brown and Borkowski (123) found

that l-chloro-1-methyl-cyclooctane had a solvolysis rate
in 80 percent ethanol at 25°C. that was greater than any
other ring containing up to 15 methylene units.

A cyclo-

pentane analog, the next most active compound, was less
than half as reactive.
More polar solvents of this type such as L-3,3-difluoro-p-menthane and 1,1-difluorocyclooctane may be prepared
by the reaction of L-menthone and cyclooctanone with sulfur
tetrafluoride (434) or carbonyl fluoride (308).

Cyclooctan-

one may be prepared from cyclooctene by hydroboration followed by chromic acid oxidation (126).
Efforts designed to optimize the steroid partition
chromatographic process by the use of selective solvent
systems and stationary phases are justified (144, 161, 365).
Many chromatographic procedures used in clinical determinations require many steps to separate steroid derivatives
from labeled urinary impurities.

No systematic study of

the liquid partition chromatography of steroids has been
made in spite of the availability of automated equipment
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adaptable to such a study.

The criterion of adequate separa-

tion in the above processes is the presence of a constant
isotope ratio across each elution peak.
steroid partition chromatography may also provide a
model in which to study the thermodynamic interactions of
solvents and solutes, especially departures from non-ideal
behavior.

Those solvents, especially cyclic hydrocarbons,

which can interact with steroid solutes in only a limited
number of conformations, appear to afford a better chance
of separation, but the theoretical and experimental basis
of such an assumption has not been determined (144, 365).
However, the partition chromatographic process described
above may be optimized with the aid of infrared analytical
techniques.

For example, solutions of the Sa and 58 epimers

of steroid benzoates dissolved in cyclooctane solutions
'

containing various mole fractions of dichloromethane may

r-.

be added to a given amount of the stationary phase support,
Sephadex LH-20.

After an equilibration period, the sta-

tionary phase can be separated by centrifugation and the
composition change in the mobile phase determined by infrared spectrometry.

Such a procedure could permit a deter-

mination of the optimal mole fraction of dichloromethane
required for the separation.

Furthermore, there appears

'to be no theoretical reason which would rule out the
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· separation of a large number of compounds in a single chrostep, provided that derivatives and solvent
systems are chosen so that all the compounds to be separated
·have significantly different partition coefficients.

CHAPTER II
DIABETOGENIC FACTORS

Human Placental Lactogen
Normal pregnancy is accompanied by a two-fold increase
in fasting insulin levels and a lower fasting blood glucose.

Insulin response to intravenous glucose may be three

times that postpartum (1206).

Kalkhoff et al (283) also

found decreased glucose tolerance during pregnancy, especially in diabetic women.

Although the absolute values of

plasma non-esterified fatty acids were significantly
higher throughout the glucose tolerance test in diabetic
subjects, the percent decrease from initial fasting levels
was the same pre- and post-partum in normal and diabetic
women despite more marked deterioration of glucose tolerance in the latter groups.

Subclinical diabetes may be

detected by the standard glucose tolerance test during
pregnancy.

The detection of latent diabetes is especially

important because the fetus may develop hyperplastic islets as well as other abnormalities if the diabetes of
34
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the mother is not properly managed.

Conn and Fajans have

estimated that the mother of a twelve-pound baby will develop
overt diabetes in the next 25 years of her life.
Fitzgerald et al (320) noted that the incidence of diabetes increases with parity.

Compared to nulliparous

women, the incidence of diabetes in women with three child-

ren is twice as great, and in women with six children, six
times as great.
Human placental lactogen and estriol appear to be responsible for the diabetogenic effect of pregnancy.

Josim-

ovich (550) attributed this effect of human piacental lactogen to a potentiation of the effect of growth hormone.
Samaan et al (929) also came to this conclusion.
exact nature of this potentiation is obscure.

The

One interpre-

tation is that the placental hormone can occupy some of the
non-specific binding sites which are normally available to
growth hormone, thereby rendering the secreted grow_th hormone more effective at specific sites.
Beck and Daughday (59) estimated that 290 mg per day
of the placental hormone was produced near term.

They also

noted that the hormone impaired glucose tolerance even
though it increased insulin response to glucose.
Growth Hormone
The overall effect of growth hormone is to stimulate
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the formation of lean body mass at the expense of adipose
tissue.

Growth hormone promotes the secretion of insulin

and glucagon, both of which promote the transfer of carbo'.

hydrate from the liver to the extrahepatic tissues.

For

example, the decreased levels of free fatty acids (FFA)
following hypophysectomy have been implicated in the failure
of the heart to accumulate glycogen as it normally does in
fasting.
Young (1192) first indicated that the diabetogenic
principle of the pituitary might be identical with growth
hormone.

Although growth hormone is not diabetogenic in

normal rats, it is diabetogenic in animals with less pancreatic reserve.

Dohan and Lukens (247) observed that in-

sulin resistance was associated with diabetogenic doses of
growth hormone but not with the permanent diabetes that
followed the cessation of hormone administration.

Similarly,

Coggeshall and Root (185) noted that the diabetes occurring
in 17 percent of patients with acromegaly was not marked
by insulin resistance.

However, they reported that 36 per-

cent of all patients, more females than males, had some
degree of glucosuria and that diabetes generally became
overt 9.2 years after the diagnosis.

Froesch

~t

al (342)

have also been able to obtain hyperglycemia without anabolic
effects with bovine growth hormone in hypopituitary dwarfs.
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It appears that the anti-insulin effect of growth hormone in
man is independent of the anabolic effect so that separate
regions of the protein may be responsible for each function.
Reid (872) demonstrated that the diabetogenic activity of
bovine growth hormone paralleled its growth activity during
a series of structural modifications when the assays where
conducted in rats.

These results suggest that the anti-

insulin effect of human growth hormone is in an invariant
sequence in the hormone while the anabolic effect is in
a more variable sequence.
De Bodo and Sinkoff (218) also found that growth hormone increased gluconeogenesis and insulin release from
the pancreas.

When an increased dose of 3.0 mg/kg/day of

growth hormone is administered to normal dogs, they become
diabetic in 5-7 days.

De Bodo and Altzuler (221) observed

that growth hormone was also diabetogenic in hypophysectomized dogs maintained with deoxycorticosterone.

Low

doses of growth hormone alleviated the insulin hypersensitivity of these animals.

Glucocorticoids also partially

reduced this hypersensitivity.

The combination of

gluco~

corticoids and growth hormone abolished the hypersensitivity.

These workers also observed that the adrenalec-

tomized dog was not as sensitive to insulin as the hypophysectomized dog, but that both glucocorticoids and

l
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growth hormone were necessary to restore normal insulin
sensitivity.
Luft et al (679) confirmed the ketogenic effect of
growth hormone in hypophysectomized diabetic patients.

And

both Hunter and Greenwood (498) as well as Roth et al (912)
reported that hypoglycemia is a potent stimulus to the production of somatotrophic releasing factor.and growth hormone secretion.

Patients with pituitary stalk section fail

to respond to hypoglycemia with increased growth hormone
secretion.

The production of the releasing factor is in-

versely related to the level of blood glucose.

Also, the

inhibitory effect of glucose on the production of somatotrophic releasing factor can be blocked by 2-deoxyglucose,
as can glucose-stimulated insulin release from the pancreas.
Alloxan-Diabetes
Alloxan (pyrimidinetetrone) produces experimental diabetes by destroying the insulin-secreting cells of the pancreas.

This effect was discovered by Dunn et al (263) and

several reviews of the use of this drug have appeared (31,
679).

Repeated doses of 100 mg/kg are also capable of

destroying human islet tissue as demonstrated by Cann· ·et al
(192) in their description of the treatment of islet tumors.
Blood glucose undergoes a triphasic change after alloxan
is administered (479).

L

First, there is a hyperglycemia
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due to glycogenolysis in the liver.

Secondly, a hypoglycemic

phase occurs which is not due to the liberation of insulin
from the pancrease.

While uncertain, the cause of this hypo-

. glycemia may be due to a block in gluconeogenesis in the
liver.

It is this hypoglycemic phase which damages the B

cells.

Thirdly, permanent hyperglycemia ensues due to the

destruction of the

insulin~producing

B cells.

The effects of alloxan in hypophysectomized and adrenalectomized animals has been studied by Kirshbaum et al
(593).

They stressed the necessity of feeding these animals

after the administration of alloxan to avoid deaths from hypoglycemia and of allowing at least 48 hours for the diabetic state to fully develop.
Interactio·n of Growth Hormone and Cortisol
Moody et al (756) showed that insulin increased the
formation of glycogen in the absence of glucose, indicating
that some of the glycogen was derived from glycolytic intermediates.

Bornstein and Trewhella (95) noted that al-

loxan-diabetic rats had low levels of muscle glycogen
which could be restored to normal by hypophysectomy or
adrenalectomy.

Thus, adrenal hormones increase glycogen

formation in the non-diabetic animal but decrease it in
the diabetic animal.

Furthermore, they observed that in-

sulin in vitro could not reverse the 50 percent drop in
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glycogen levels in the muscles of diabetic rats, but that
adrenalectomy could.

On the other hand, Park and Daughaday

(808) observed that the glycogen content of the hypophysectomized rat was unaffected by either growth hormone or adrenal cortical extract.

However, hypophysectomized and adren-

alectomized rats had higher glycogen levels that normal.
These results suggest that growth hormone is necessary
for the glucocorticoid effect on glycogen synthesis.
Russell (919) reported that pituitary extracts alone_
were sufficient to maintain muscle glycogen in fasting
hypophysectomized animals but that adrenal cortical hormones were also required to maintain muscle glycogen in
fed animals.

These results may indicate that growth hor-

mone increased basal glucose transport in the fasted animals
but that growth hormone and glucocorticoids are both required to reduce glycolysis, increase glucose-6-phosphate
concentration, arid thereby increase glycogen formation.
Long and Lukens (672) reported similar findings in
hypophysectomized-adrenalectomized-alloxan-diabetic cats.
They demonstrated that the beneficial effects of hypophysectomy on survival were partly due to the loss of
ACTH.

The removal of the source of adrenal epinephrine

by adrenodemedullation did not protect the animals from
ketosis.

.
"

l

Although hypophysectomy and adrenalectomy did
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immediately improve carbohydrate oxidation, the animals
who survived longest had the best glucose tolerance.

Des-

pite the absence of growth hormone, ACTH and glucocorticoids,
the doubly-operated animals eventually utilized all their
depot fat so that inanition rather than acidosis was the
ultimate cause of death.

These experiments emphasize the

lipogenic effect of insulin.
Villee and Hastings (1103) also found that hypophysectomized rats had higher rates of glycogenesis compared to
adrenalectomized rats.

Growth hormone treatment, however,

decreased glycogenolysis more than glycogenesis.
Luft (679) investigated the effect of growth hormone
on the levels of pyruvate, lactate, and citrate during the
intravenous glucose tolerance test in diabetes.

He found

that growth hormone elevated all three metabolites when it
accentuated the diabetic-type glucose tolerance curve.
Although growth hormone had no effect on fasting blood
glucose, it did raise the concentration of free fatty acids
and fasting insulin 3-fold.

However, the drop in free fatty

acids in response to glucose was not affected by growth hormone.

These results suggest that the anti-insulin effect of

growth hormone is not mediated by free fatty acids.
Renold et al (877) have shown that hormones affect the
metabolism of glucose by the liver.

L

Liver slices from

r

i; .
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hypophysectomized rats have a rate of glucose uptake which
is 80 percent of normal.

On the other hand, liver slices

from alloxan-diabetic rats assimillated glucose at 50 percent of the normal rate.

Hypophysectomy of the alloxan-dia-

betic rats restored their hepatic glucose uptake to the
level of that obtained with livers from hypophysectomized
animals.

From these experiments it can be concluded that

insulin increases and pituitary factors decrease glucose
.uptake by the liver.

Krahl (614) demonstrated that insulin

'in vitro could overcome the pituitary inhibition of hepatic
glucose uptake.

When 0.1 unit of insulin per milliter was

added, the maximal rates of glucose uptake by liver slices
from normal and hypophysectomized animals were the same ..
Hypophysectomy increases hepatic glucose uptake in spite
of the fact that it also increases glucose-6-phosphase
activity.

Furthermore, Steiner and Williams (1028) found

that the levels of glucose-6-phosphate in the livers of
alloxan-diabetic rats was one-third normal.
merit further investigation.

These reports

However, these hepatic ef-

fects are in agreement with the extrahepatic results of
Russell (916) who found that the rate of glucose utilization in the hypophysectomized-eviscerated rat was 2 to 3fold greater than that in eviscerated controls.
In addition to the effects of the adrenal and pituitary
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hormones studied separately, many investigations have been
carried out in which the combined effects of both types of
hormones have been determined under identical conditions.
Russell (915) found that anterior pituitary extract in-.
creased the amount of muscle glycogen in adrenalectomized
rats without influencing the amount of liver glycogen.
Also, the extract did not depress glucose oxidation in the
adrenalectomized rat although it did cause this effect in
intact rats.

In contrast, adrenal extract did not increase

muscle glycogen but it did slightly decrease glucose oxidation in adrenalectomized rats.

These results show that

the adrenal gland is necessary for the anti-insulin effect
of growth hormone.

The increased production of lactate

and pyruvate following the administration of pituitary
extracts to adrenalectomized rats is not sufficient to
influence their glucose oxidation.

In an attempt to assess

the role of the liver in these effects, Russell (917) determined the effects of the extracts in hypophysectomizedeviscerated rats.

She eviscerated fed rats which had been

hypophysectomized for two weeks or adrenalectomized for 4-14
days prior to the experiment.

When administered, anterior

pituitary extract was given 24 hours before evisceration
and cortical extract 1/2 hour before this procedure.
found that anterior pituitary extract alone as well as

.

.!-''.

,L.

.

She
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adrenal extract alone were capable of reducing the amount of
glucose which had to be infused to maintain the blood glucose
of the hypophysectomized-eviscerated rat.

No synergism was

noted when both extracts were administered.

The anterior

pituitary extract, however, was more potent than the adrenal
extract in maintaining muscle glycogen.

The fact that the

anterior pituitary extract did not exert its effect until
one hour after its administration does not allow one to
rule out the possibility that the effect was mediated by
the adrenals and was due to ACTH in the crude pituitary
extract.

The absence of synergism may mean that the liver

is required for the synergistic effect of pituitary and
adrenal hormones (growth hormone and cortisol).
Deoxycorticosterone did not affect the glucose requirement of the hypophysectomized-eviscerated rat but
I

it did reduce the glucose requ,irement of the adrenalectomized-eviscerated rat.

It appears from these studies

that deoxycorticosterone exerts an inhibitory influence
on glucose utilization only when pituitary factors are
present.

Ventura and Selye (1092) also found that grow~h

hormone was required for the inhibitory effect of deoxycorticosterone on the anti-inflammatory action of glucocorticoids.

These results suggest that growth hormone

may affect the metabolism of these steroids.

L

In Russell's

45
e~periments

this effect could have required the presence of

the liver since both hormones were administered prior to
evisceration.

However, she attributed the lower glucose

requirement of the deoxycorticosterone-treated animals to
. their "better condition."

McGarack et al (689) also found

that the abnormal glucose tolerance curve seen in Addison's
disease could be restored to normal by deoxycorticosterone
acetate.
Russell (915, 919) further demonstrated that glucocorticoids were necessary for the glycogenic effect of
growth hormone.

She postulated that glucocorticoids in-

hibited the conversion of carbohydrate to fat thereby
making it more available for glycogenesis.

Heart muscle

was found to be especially sensitive to the glycostatic
effects of growth

hormone~

Heart glycogen is elevated

in diabetes while the glycogen content of other tissues
remains essentially normal.

This elevation in cardiac

glycogen is probably caused by the stress-induced increase
in glucocorticoid levels.

Furthermore, the well-known

preference of the heart for the respiration of fatty
acids, which is probably related to its rapid rate of
acylcoenzyme A formation, may also be the basis for its
increased glucocorticoid sensitivity.
Park (810) investigated the influence of the pituitary

,L
. "·
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on glucose metabolism in the isolated rat diaphragm from alioxan-diabetic rats.

This muscle is thin enough so that

diffusion is not rate-limiting for glucose metabolism.

Park

studied the effects of crude pituitary extracts and purified
growth hormone in vivo and in vitro.

The administration of

2 µg of crystalline growth hormone to alloxan-diabetichypophysectomized rats caused an initial drop in their blood
glucose which was followed by a prolonged period of hyperglycemia.

In vitro, purified growth hormone caused an increase

in the glucose uptake of the isolated rat diaphragm muscle.
The secondary in vivo elevation of blood glucose was also
produced by injections of crude pituitary extracts.

In

fact, the crude extracts had a more rapid and direct effect
compared to purified growth hormone.
•·

In addition, adrenal

cortical extract was found to potentiate the effect of the
pituitary hormone.

Since these in vitro experiments were

carried out in protein-free media, the results cannot be
attributed to changes in insulin binding by serum proteins.
Spiro (1012) found that growth hormone is necessary
for normal glucose transport in the liver.

Hypophysectomy

of alloxan-diabetic rats did not effect the rate of hepatic
glucose phose phosphorylation but it did restore to normal
the reduced rate of hepatic glucose uptake in the alloxan-

.,
l
..

'

diabetic rat.

Goodman (303) reported that the intravenous
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administration of growth hormone 30-45 minutes before sacrifice stimulated the uptake of xylose and a-aminoisobutyrate,
a non-utilizable amino acid, by the diaphragm.
[,
fi

He showed

that this effect could be produced in vitro and that it was

t

~"
F

not secondary to lipolysis.

r:

hours before sacrifice, the uptake of the sugar and the

[

amino acid was not increased.

~~':
~·

was then refractory to the addition of growth hormone in

~-

vitro.

If the hormone was injected 3

In addition, the diaphragm

The development of this refractory response was

blocked in vitro by 10 µg/ml of actinomycin D.

This indi-

cates that DNA synthesis was required in order to block
the stimulatory effect of growth hormone and raised the
possibility that some of the effects of actinomycin D
'·

in vivo may be due to blockade of this growth hormone effeet.

It is important to note that these findings do not

explain the secondary hyperglycemia obtained when hypophysectomized animals are treated with growth hormone.
Ottaway (802) showed that the stimulatory effect of
growth hormone in vitro is inversely related to the fasting
blood glucose of the hypophysectomized-diabetic rats from
which the diaphragms are obtained.

This is expected if

the effect of growth hormone is primarily on glucose transport.

Glucose transport becomes increasingly rate-limiting

for glucose uptake as the blood glucose concentration is
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iowered.
Milman and Russell (749) reported that alloxan-diabetic
rats were rendered hyperglycemic by the administration of
JO mg/kg of purified growth hormone while normal rats were
not.

However, they were if the treatment had been repeated

2 to 4 hours previously.

They also exhibited decreased

glucose tolerance, depressed respiratory quotients and glycogenesis.

These results suggest that alloxan-diabetic rats

are more sensitive to the effects of growth hormone.
Effects of Steroids and Related Compounds on the Pancreas
Lewis and co-workers (659) investigated the influence
of 178-hydroxy-4-androsten-3-one 17-proprionate and 178hydroxy-17a-methyl-4-androsten-3-one on the incidence of
diabetes in rats after subtotal pancreatectomy and also
found that the androgens increased the incidence of diabetes.

Hast (424) has recently reviewed these effects.

While testosterone caused atrophy, estrogens generally
exerted a protective or trophic effect.
terone and progesterone had no effect.

DeoxycorticosThe estrogen ef-

fect could also be produced with 3,4-bis(p-hydroxyphenyl)trans-3-hexene, a synthetic estrogen.

This effect may ac-

count for the lower incidence of diabetes in pre-menopausal
women and the more serious nature of the disease when it
occurs in post menopausal women.

Nonetheless, large .doses
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of estrogens are diabetogenic in spite of their beneficial
effect on the pancreas.
James et al (523) found that 17B-hydroxy-17a-methyl-l,
4-androstadiene-3-one lowered fasting glucose and impaired
glucose tolerance by inhibiting ACTH secretion.
Arginine, leucine, and tris (hydroxymethyl)-aminomethane stimulate insulin release, but arginine also stim. ulates growth hormone release.

This action of arginine can

be used to test the pituitary reserve of growth hormone.
The mechanism of action of the two amino acids on insulin
release is different.

The effect of leucine is counter-

acted by glucocorticoids, but that of arginine is not.
Also, since leucine is a ketogenic amino acid, gluconeogenesis is not involved.
Houssay (481) compared the incidence of diabetes in
95 percent depancreatized male and female rats.

He found

that the incidence was three times greater in male rats.
The administration of androgens to female rats also increased their incidence of diabetes.

On the other hand,

the administration of 50 µg/day of estradiol or 21-hydroxy4-pregnane-3, ll, 20-trione in combination with 150 µg/day
cortisone initially increased the incidence of diabetes,
but this initial response was followed by hypertrophy of
the pancreas with amelioration of the diabetes.

L

Furthermore,
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the glucocorticoids alone at 50 µg/day exerted just a pro.· tective effect.

Therefore, physiological levels of gluco-

corticoids are not diabetogenic but elevated levels are
diabetogenic •.
Renold et al (879) demonstrated that the anti-insulin
action of growth hormone and cortisol is not due to their
effect on insulin release.

Growth hormone and cortisol

treatment corrected the weak and slow response of the B
cells to glucose which is seen in the hypophyse·ctomized
dog.

However, cortisol, as previously noted, also reduced

the tendency of the insulin response to be prolonged when
growth hormone alone was administered.

Thus, cortisol

actually prevents B cell exhaustion due to growth hormone.
However, the ability of cortisol to oppose the stimulatory
effect of growth hormone on insulin secretion is noteworthy because serotonin is believed to mediate the effect
of growth hormone (986, 987).
Beck (58), Vermeulen et al (1098) and Starup et al
(1022) have further indicated that

6~chloro-17a-hydroxyl-4,

6-pregnadiene-3,20-dione acetate (chlormadinone acetate)
closely resembles glucocorticoids in its effects.

This

compound increased the insulin response to glucose while
it decreased the glucose response to insulin.

It should

therefore serve as a model compound for future studies of
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the anti-insulin effects of steroids.

The stimulation of

insulin release by progestins may explain the report of
Gershberg et al (361) that carbohydrate tolerance was improved in women who had impaired glucose tolerance before
treatment.

It appears that the stimulation of insulin

response by the pr6gestin in these cases overrides the
increase in insulin resistance also produced.

However,

the medication is still diabetogenic because it decreases
glucose response to insulin and leads to pancreatic
exhaustion.
Houssay (480) studied the effect of thyroid hormone
on alloxan diabetes in the rat.

He found that pretreat-

ment with thyroid hormone, like estrogen treatment, hypert~ophied

alloxan.
~

>

the pancreas and made the

r~t

more resistant to

On the other hand, thyroidectomy proved bene-

· ficial in alloxan-diabetic rats and thyroxine intensified
their diabetes.

This latter effect may be related to in-

hibition of lipoprotein lipase and glutamic dehydrogenase
and stimulation of adipose tissue lipase produced by the
hormone.

These effects will be discussed in later chapters.

An endocrine question closely related to the action of
estrogens concerns the physiological function of fetal
estriol in pregnancy.

On one hand, it is widely held that

the formation of 36-hydroxy-5-androsten-17-one by the fetal

L
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adrenal and its subsequent 16a-hydroxylation by the fetal
liver are good indications of fetal viability.

On the other

hand, the exact role of fetal estriol in the fetal or maternal economy has not been determined.

Lemon (651) has

postulated that high estriol levels during pregnancy may
serve to protect maternal tissues from the tumorigenic potential of estradiol which is also elevated.

However,

other workers (716) have demonstrated increased estriol
excretion in breast tumor patients thereby casting doubt
on this hypothesis.

The function of fetal estriol may

be to decrease fetal insulin response to glucose.

Diabe-

tic women excrete a lower proportion of total urinary estrogens as estriol during pregnancy; they also tend to
deliver larger infants.

The unopposed action of insulin

appears to be responsible for this effect.

Furthermore,

the inf ants of diabetic women tend to have hyperplastic ·
islets.

The decreased formation of estriol by the fetus

may represent one of the early manifestations ·of the diabetic gene.
Lewis and co-workers (659) investigated the influence

..
~

of 17S-hydroxy-4-androsten-3-one 17-propionate and 17Shydroxy-17a-methyl-4-androsten-3-one on the incidence of
diabetes in rats after subtotal pancreatectomy and also
found that the androgens increased the incidence of

t .
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diabetes.

Hast (213) has recently reviewed these effects.

While testosterone caused atrophy, estrogens generally exerted a protective or trophic effect.
and progesterone had no effect.

Deoxycorticosterone

The estrogen effect could

also be produced with 3,4-bis(p-hydroxyphenyl)-trans-3-

.
hexene, non-steroidal estrogen.

This effect may account

for the lower incidence of diabetes in pre-menopausal women
and the more serious nature of the disease when it occurs
in post-menopausal women.

Notwithstanding, pharmacological

doses of estrogens are diabetogenic so that this effect. is
not on the pancreas.
Lewis and McCullough (322) found that 17B-hydroxy-17amethyl-4-androsten-3~one

caused hepatic changes which de-

creased glucose tolerance in the rabbit by blocking glycogen formation.

Also, the conjugation of bilirubin was

inhibited producing reversible symptoms of hemolytic
jaundice reversible when the steroid was withdrawn.

These

effects were not obtained in thyroidectomized animals suggesting that these steroids may affect tpe metabolism of
thyroxine.

James et al (251) found that 17B-hydroxy-17a-

methyl-1,4-androstadien-3-one lowered fasting glucose and
impaired glucose tolerance while inhibiting ACTH secretion.
Many efforts have been made to define the effects of
estrogens on glucose metabolism.

McKeins and Bell (691)
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· found that estrogen treatment stimulated glucose uptake by
the isolated rat diaphragm.

Ecktern and Villes (265) found

that castration lowered the activities of glucose-6-phosphate dehydrogenase, aconitase and isocitrate dehydrogenase
in rat uterus.

The ablation had no effect on the tricar-

boxylic acid cycle, however.
McKeins and Bell (691) also found that the administration of 25 µg/day of 3,4-bis(p-hydroxyphenyl)-trans-3-hexene
increased the activity of the pentose shunt in diaphragm
muscle, adipose tissue and liver.

At 100 µg/day no effect

on insulin response was observed, but glucose metabolism
via the pentose shunt was inhibited.

The synthetic estro-

gen had no effect on the glucose metabolism of diaphragm
in vitro at a concentration of 5 µg/ml.
Villee et al (1104) studied the effects of estradiol17S on the transhydrogenation of pyridine nucleotides in
estrogen dependent tissues.

They concluded that estradiol

may increase the rate of transhydrogenation and thereby
provide NADP+ necessary for the utilization of glucose-6phosphate via the pentose shunt and for the oxidation of
isocitrate by mitochondrial threo-Ds-Isocitrate:
oxidoreductase (decarboxylating)
,,

transhydrogenase, NADPH:

(EC 1.1.1.42).

NADP
The

NAD oxidoreductase (EC 1. 6. 1. 1)

is distinct from 17S-hydroxysteroid dehydrogenase,
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l?S-hydroxysteroid:

NAD 178-oxidoreductase (EC 1.1.1.63) and

from 178-hydroxysteroid:

NADP 178-oxidoreductase (EC 1.1.1.64).

It is possible that estradiol may catalyze transhydrogenation
·by acting as a coenzyme between these two enzymes.

In con-

trast, Warren and Christ (1166) have demonstrated that a
true estradiol-responsive transhydrogenase is present in
human placenta.

This enzyme combines with estradiol or es-

trone before pyridine nucleotides are bound.

Also, the en-

zyme has one binding site which is specific for NAD+ and
another site which can be occupied by either NADH or NADPH.
Estradiol does not leave its binding site when it exerts
its stimulatory effect on transhydrogenation.

Apparently,

the hormone functions more efficiently in this fashion
rather than as a coenzyme.

However, it is not clear

whether estradiol undergoes oxidoreduction when it is
bound to the enzyme and the effects of 17a-alkylated estrogens on the activity of this enzyme have not been
reported.
The adverse effect of estrogens on glucose tolerance
has rather broad structural specificity.

Estradiol-176-

.monobenzoate, bis-3,4-(p-hydroxyphenyl)-trans-3-hexene
and 17a-ethinyl-17S-hydroxy-5(10)-estren-3-one also produced the effect.
Gershberg et al (361) reported that 46 percent of
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their patients treated with norethynodrel and mestranol had
elevated two-hour glucose levels during the standard glucose
tolerance test.
i853) who

~ound

Similar results were found by Puchulu

~t

al

that the incidence of abnormal glucose tol-

erance curves was increased from 11.1 percent to 66.7 percent if the phenolic C-3 hydroxyl group was methylated.
Also, the incidence of abnormal tolerance was greater in
patients who had a family history of diabetes.

However,

Gershberg et al (362) subsequently reported that the administration of 0.75 mg/day of mestanol improved the glucose tolerance of diabetic women.

Triglyceride levels in-

creased during mestranol treatment in both normal and diabetic women.

These results suggest that the C-3 phenolic

hydroxyl group of estrogens is not required for anti-insulin activity.
Spellacy and Carlson (1007, 1008) found both elevated
·glucose tolerance curves and elevated plasma insulin levels
during the glucose tolerance test performed on patients
receiving 9.85 mg 17a-ethinyl-17B-hydroxy-5(10)estren-3-one
and 0.15 mg 17a-ethinyl-3-methoxy-l,3,5(10)-estrien-17B-ol
daily.

In contrast, when intravenous glucose tolerance

tests were performed under similar conditions, Spellacy et

· !.!.

found normal glucose tolerance but two-fold increases

in plasma insulin levels.
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In similar experiments Yen and Vela (1187) reported no
changes in either oral or intravenous glucose tolerance but
noted 3-fold increases in serum growth hormone levels.

In-

creased insulin resistance associated with estrogen-stimulated growth hormone release may be the mechanism behind
this effect.

Growth hormone secretion normally occurs in

response to hypoglycemia and presumably leads to increased
lipolysis of depot lipid.

Apparently, insulin released in

response to growth hormone does not exacerbate the hypoglycemia under these circumstances.

This may be due to

the simultaneous action of glucocorticoids.

The failure

of diabetic women to respond to estrogens with decreased
glucose tolerance could mean that the anti-insulin effects
of growth hormone are already manifest in these women.
Estrogens increase the hepatic synthesis of both
thyroid binding globulin and corticosteroid-binding globulin.

Indeed, Metcalf and Beaven (736) and Marks et al

(715) observed 3-fold increases in transcortin during mestranol treatment.

Furthermore, Goldman and Ovadia (384)

confirmed that estrogens increase ACTH secretion in both
rats and man.

However, when estrogens increase ACTH se-

cretion, they also increase trancortin synthesis so that
most of the increased glucocorticoid output is bound in
inactive form.

Thus, estrogens permit ACTH levels to
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remain elevated and to exert its effects on adenyl cyclase
in target tissues.

Cross-conjugated steroids such as 17S-

hydroxy-l 7a-methyl-l,4-androstadien-3-one also have this
effect (1160).
Plager and Matsui (837) investigated the effects of
bound and unbound cortisol on the metabolism of glucose
in slices of mouse ear in vitro.

They found that 0.06 µg/
14

ml of cortisol decreased the evolution of
cose-1-

14

C more than from glucose-6-

14

co 2 from glu-

C or fructose-U-

14

c.

These results suggest that cortisol decreases glucose oxidation via the pentose shunt.

Matsui and Plager also found

that high doses of estrogens in vivo also depressed the
oxidation of glucose by mouse ear strips.
confirms the findings of Ingle

This result

(515) who demonstrated

that the administration of 0.5 mg of estradiol per day
to partially depancreatized rats produced glucosuria
amounting to 4.0 grams per day.

The mechanism of this ef-

feet may be similar to that which decreases glucose tolerance in women during estrogen therapy.

Overell et al

(804) were also able to obtain significant inhibitory
effects on.glucose uptake by mouse skin
. 0.01 µg/ml of cortisol or prednisolone.

~n

vitro using

The absence of

the tricarboxylic acid cycle in mouse skin indicates
that it is not involved in the steroid effect.

~···

[.
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Slaunwhite and Sanberg (992) described transcortin, the
glucocorticoid-binding protein of serum, and methods for its
isolation.

They showed that the level of transcortin was

elevated during pregnancy •. This elevation had two significant effects.
of cortisol.

First, it decreased the rate of metabolism
Secondly, it removed non-specifically-bound

cortisol from albumin binding sites enabling the albumin
to bind more testosterone.

Warren and Salhanick (1115)

also described some of the properties of transcortin.
They found that the strength of cortisol binding decreased
with increasing temperature and advocated the comparison
of diluted pathologic serum with control serum at 37°C to
speed the attainment of equilibrium using equilibrium dialysis techniques.
Wira

~t

al (1171) have pointed out that the criteria

that must be met by a hormone receptor include hormone
specificity, tissue specificity, high affinity and saturation.

High-affinity steroid binding sites are generally

specific sites.

In the case of transcortin both the strength

of binding as well as the total number of binding sites decrease with increasing temperature.

However, even at con-

stant temperature the equilibrium binding may be affected
by cooperative ·interactions between binding protein subunits as protein concentration varies.

Regardless of the
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method chosen to separate free and bound steroids, the proportion graph of Balieu and Raynaud (52} in which the log
of the fraction of steroid bound is plotted versus the
total steroid concentration appears to be a simple and
sensitive indicator of the heterogeneity of binding sites.
Scholtz and Huther (947} have measured the levels of
cortisol and corticosterone in normal and diabetic women
during pregnancy, labor and delivery.

They found that

diabetic women had 42 percent higher levels of cortisol
and 63 percent higher levels of corticosterone during
delivery.

The higher levels observed suggest that decreased

glucocorticoid metabolism in diabetic women is especially
, evident in times of stress.

CHAPTER III
INSULIN INHIBITORS

!!.uman Insulin Antagonists
Insulin resistance in man is associated with abnormally high insulin requirements.

Baird and Bornstein (38)

noted that insulin-resistant diabetics were of two types.
One type had no biologically active insulin in their sera
and none could be isolated

aft~r

a lipid solvent extrac-

tion procedure which permitted 85 percent recovery of
added labeled insulin.

On the other hand, the second

type was characterized by serum insulin which, while not
active in native serum, could be separated from an inhibitory factor by solvent extraction of the inhibitor.
After separation, the insulin was active.

Since the in-

hibitory factor was present in only one type of insulintreated diabetic, it does not appear to be an insulin
antibody.

Rather, the insulin inhibitor in these patients

appears to be a lipid.

Furthermore, these observations do

not eliminate an intracellular site of action for the lipid
61
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inhibitor.

The factors which cause the rise and decline of

insulin resistance are important in the management of diabetes even though they are not well defined.
Plotz et al (841) noted that insulin-resistant diabetes occurred in 25 percent of all patients with Cushing's
syndrome.

Whether this is a direct glucocorticoid effect

or is produced by the effect of the pituitary. tumor on glu. cocorticoid metabolism is unclear.
_synalbumin In Vivo and In Vitro
Stadie et al (1015) studied the anti-insulin effect of
growth hormone on rat diaphragm.

They found that both pitu-

itary and adrenal factors were necessary for the refractory
response to insulin.

Vallance-Owen et al (1085) studied

the nature of an insulin.antagonist which they found associated with human plasma albumin.

They found that it was

not due to albumin per se since it could be absorbed on
a cellulose column leaving a non-inhibitory albumin fraction.

The factor absorbed to the column was not identified.

However, in assays of glucose uptake by rat diaphragm incubated in the

~resence

of diluted diabetic serum, the depen-

dency of the inhibitor on the pituitary was established.
Vallance-Owen studied the levels of the synalbumin
insulin antagonist in the serum of normal, obese and adult
diabetics.

He found that the levels of the antagonist

~'-

l
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were not different in the three cases when the whole serum
was tested by the rat diaphragm assay.

By itself this

finding casts doubt on the in vivo significance of the antagonist.

However, when the albumin fraction of the serum

was isolated and tested separately, the amount of inhibitor
bound to albumin was higher in obese and adult diabetics
than in control groups.

Of children who were synalbumin

positive, 65 percent had at least one synalbumin-positive
parent, suggesting the dominance of the trait.
The method used to assay the synalbumin insulin antagonist deserves comment.

If the albumin fractions from

normal and diabetic patients are prepared,. both of these
fractions inhibit the effects of 1 milliunit of insulin
on the rat diaphragm.

However, if the fractions are di-

luted 4-fold with buffer before the assay, the diabetic
albumin retains its inhibitor effect while the normal
albumin loses its inhibitory effect.

The final albumin

concentration in both cases is 1.25 percent.

These char-

acteristics appear to indicate that some reversibly bound
factor is becoming unbound and diluted when the albumin
is diluted.

The denaturation of the albumin by heat ren-

ders the antagonist dialyzable even though the dialyzable
fraction is partially inactivated by heat.

Also, the

active factor bound to albumin can be removed completely
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by extraction with boiling ethanol.
:"•

In contrast, chloroform

and a mixture of isooctane and acetic acid, known to be effective in the extraction of fatty acids from albumin, did
not remove the inhibitor from the albumin.

Vallance-Owen

also noted that the synalbumin inhibitor was inactive on
adipose tissue.

This finding led him to propose that dia-

betics become obese because they are diabetic.
Alp et al (9} purified the synalbumin antagonist 150fold and separated it from albumin.

As previously noted,

they varified that the antagonist could be dialyzed free
from 0.001

percen~

albumin solutions.
Vallance-Owen.

albumin but not from 0.2-3.0 percent
This finding supports the work of

However, Davidson and Goodner (215) were

unable to show any physiological effects of the synalbumin antagonist in vivo.

It did not affect

pl~sma

insulin,

nor blood glucose, nor the disposal of a glucose load.
It even had no effect in partially depancreatized

rats~

Therefore, the physiological significance of the antagonist remains to be determined.
Vargas et al (1089) reported that an inhibitor of
glucose uptake in muscle was present in the a
globulin fractions of normal human plasma.
activity was associated with the a 1
·

l

2

and

B

Insulin

globulin fraction.

·Taylor et al (1054) showed that growth hormone was required.
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for the production of this inhibitor which reduced glucose

f

r·
ii

t.,

uptake in the absence of insulin.

Growth hormone alone was

capable of producing the inhibitor in hypophysectomized rats.

1

!/.-:

It was not removed by passage through a cellulose column.
It was thought to be identical to the inhibitor of Baird
and Bornstein.
The possible role of an insulin inhibitor in the etiology of diabetes has attracted the attention of many investigators.

Park and Krahl (802) initiated studies of

the effects of hormones on the glucose utilization of the
isolated rat diaphragm.

Using crude pituitary extract,

they found that the injection of 3 mg/100 gm into intact
rats three hours before sacrifice led to a depression of
glucose uptake by the isolated diaphragm.

This effect

did not occur .in hypophysectomized rats unless adrenal
extract was also administered.

The adrenal extract alone

also intensified the anti-insulin effect in isolated diaphra-gms.

These experimental results were obtained three

hours post-injection.

Krahl and Cori (612) further in-

vestigated the effect of adrenalectomy on glucose uptake
of the diaphragm.

They found that this operation in-

creased the glucose uptake from 1.38 mg/gm/hr to 2.40 mg/
gm/hr.

In their work with alloxan-di.abetic rats, these

authors noted that the 6-hour fasting glucose levels of

L
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the diabetic rats dropped from 300-800 mg/100 ml before adrenalectomy to 200-400 mg/100 ml after adrenalectomy.

In

later work, Krahl (613) studied the effects of crystalline

l

growth hormone on this same system.

He observed the fol-

1\o

f·1..

lowing effects:

1) an increase in muscle glycogen, 2) an

"j;
increase in glucose uptake, 3) a decrease in glycogenolysis,
4) a decrease in respiratory quotient, 5) a secondary decrease in the response to insulin which followed the initial
stimulation.

In addition, he measured the concentration

of adenosine triphosphate in the diaphragms and found that
it was the same in ·normal and diabetic diaphragms.

Park

et al (411) confirmed.the biphasic nature of the growth
hormone response on diaphragm muscle.
'·.

The initial stimu-

lation of glucose uptake could be obtained by the addition
of growth hormone in vitro.

The secondary inhibitory ef-

feet could be produced by the injection of 2 µg of growth
hormone and the effect was potentiated by adrenal cortical
extract.
Inhibition b:z Beta -Lipoproteins
In 1953 Bornstein (98) reported that lipoproteins from

..

diabetic rat serum could inhibit the glucose uptake of normal rat diaphragm.

He isolated the lipoproteins both by

ultracentrifugal flotation and by
(188).
..

l

Meth~d

10 of Cohn et al

He dialyzed the isolated lipoproteins against
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Krebs-Henseleit bicarbonate buffer for 2-2.5 hours at 21°C
and then used the lipoprotein in the glucose uptake test.
He noted that dialysis was associated with instability of
the lipoprotein inhibitor, as was storage at 0°C.

The

fraction appeared to be most stable when stored undiluted
and undialyzed at 4-7°C.

These observations indicate

that some type of lipoprotein complex is involved.

When

he tested the lipoproteins thus obtained for their inhibitory effects on glucose uptake by rat diaphragm, he added
the lipoprotein either to 4 percent albumin in buffer or
to the lipoprotein-poor serum from which the lipoproteins
had been removed.

This latter serum had also been dialyzed.

Bornstein reported that initially inhibitory diabetic serum
became non-inhibitory after the removal of its lipoproteins.
Addition of lipoprotein·from normal diabetic serum to either
normal or lipoprotein-free diabetic serum caused inJ;iibition.
• The lipoproteins obtained from the serum of hypophysectomized-diabetic rats did not display inhibitory activity.
Bornstein noted that the

e1 -lipoprotein

fraction obtained

from normal human plasma was not inhibitory, while the
same fraction III obtained from a patient rendered hypoglycemic by insulin was inhibitory.

The stimulation of

growth hormone release in hypoglycemia may explain this
observation.

However, this does not mean that the

r
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lipoprotein bound factor was growth hormone.

Normal rat dia-

·phragms were used for these tests, and, as previously shown,
these are not sensitive to the direct effects of growth hormone.

In hypophysectomized-diabetic rats, Bornstein found

that glucocorticoids which are inactive alone enhance the
activity of growth hormone in producing the lipoprotein-bound
inhibitor.

The injection of growth hormone and cortisone in-

to diabetic-hypophysectomized serum donors restored the inhibitory capacity of the serum.

Injection of either hormone

alone was ineffective, the serum behaving as normal.

These

hormones, 0.2 mg of growth hormones, and 0.1 mg of cortisone were injected interperitoneally for 2 days prior to
drawing blood.

After the production of the inhibitor is

stimulated by the combined action of these two hormones,
it continues to be produced for at least one week.

The in

vitro addition of growth hormones and cortisone, 0.1 mg/ml
and 0.01 mg/ml, respectively, did not significantly affect

•

glucose uptake during a one-hour incubation.

The magni-

tudes of the in vivo treatments on glucose uptake are
large.

The rate of glucose uptake by diabetic diaphragms

was 50 percent of normal and ·38 percent of that found in
hypophysectomized diaphragm.

The anti-insulin effect of

the lipoprotein-bound inhibitor was not completely overcome by insulin in vitro.

Glucose uptake was only 88
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percent normal in the presence of 0.1 unit of insulin per
ml.

Therefore, although growth hormone and glucocorticoids

may affect glucose transport, they also decrease glucose
phosphorylation as well.
Krahl et al (615) carried out additional experiments
on the S-lipoprotein-bound inhibitor discovered by Bornstein.
They succeeded in isolating inhibitory lipoproteins from
normal rat serum.
.Pulously

Every part of their procedure was scru-

s~andardized.

The keys to the preparation of

inhibitory lipoproteins from normal rat serum were speed
and a reduction in the alcohol concentration used in
Method 6 (187) for the isolation of lipoprotein fractions.
The fractionation had to start within one hour after the
blood was drawn.

Inhibitory activity of fractions from

diabetic rat sera was not correlated with protein-bound
lipid or glucose levels of sera.

The fact that the elec-

trophoretic patterns of normal and inhibitory fractions
were identical rules out the presence of fatty acids as
the cause for the difference.

Fractions prepared from

fasting normal rats were just as inhibitory as fractions
from

diabeti~

rat sera.

Non-inhibitory fractions could

be obtained if the sera were kept at room temperature
·for 1 or more hours before fractionation, if the fraction was exposed to 15% ethanol solution for 30 minutes
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or more, or if individual sera with protein-bound-lipid
values above 1100 mg/100 ml were included in the serum pool.
The effect of the alcohol was probably on the lipoprotein
rather than on the inhibitor itself.

An alteration in the

structure of the lipoprotein could prevent the binding of
the inhibitor and its transport into rat diaphragm where
it exerts its effects.

The absence of the inhibitor from

lipoprotein fractions with high lipid contents may indicate that the binding site for the inhibitor was blocked
by the excess lipids.

In contrast to this instability in

solution, the inhibitory fractions could be stored as
precipitated protein cakes for 4 days without loss of activity.

The inhibitory activity of the lipoproteins could

be enhanced by the intraperitoneal injection of the serum
donors with 2 mg of g~owth hormone 24 hours prior to the
experiment.

That this effect is not secondary to lipolysis

produced by growth hormone is indicated by the lack of an
effect of ACTH and TSH hormones on the activity.

The inhib-

itory activity of lipoprotein fraction could be destroyed
by repeated freezing and thawing.

The inhibitory activity

'

of the amount of the inhibitor in l ml of fasted or diabetic rat serum could counteract 0.0003 units of insulin
per ml.

The significance of this finding can be judged

when one considers that the normal insulin concentration
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is approximately 0.0010 units/ml.

Thus, the effect could be

of physiological importance.
Whitney and Young (1141) confirmed the basic findings
of Bornstein and Krahl on the hormonal dependence of the
inhibitor.

They found that the inhibitor did not increase

in concentration in normal rats unless both growth hormone
and cortisol were administered.

The long term treatment

which they described in order to see the effect may have
':.,.

been necessitated by the presence of the pituitary and
adrenal in their animals.

Essentially, they obtained an

increase in the inhibition rather than an all or none
effect.

Their criterion was an inhibition of glucose µp-

take over a 90 minute incubation of the diaphragm at 37°C.
Kipnis and Stein (389) have reviewed insulin antagonism of all types and have put them into perspective,

•

clarifying disputed points by some of their own experimental work.

One of the first points they stressed was

that the defective phosphorylation observed in diabetes
did not imply a defect in the enzyme hexokinase.

This

will be discussed further in a later section of this
dissertation.

Secondly, glucose transport and utiliza-

tion are decreased in the intact diaphragm of hypophysectomized rats whereas they are increased in the cut diaphragm.

L
>

This statement does not explain the inhibition
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produced by growth hormone and cortisol.

However, Kipnis

reported that growth hormone and cortisol injections into
intact normal rats decreased the transport of glucose into rat diaphragm.

He confirmed that purified albumin has

a stimulatory effect on glucose uptake •. Also, he was unable to verify the presence of bound insulin in serum and
concluded that growth hormone did not release insulin
from the pancreas.

He observed that the sugar transport

system is rate limiting at all times in the normal rat,
even in the presence of insulin.

This is not the case in

the diabetic rat in which phosphorylation can be shown
to be limiting after insulin administration corrects the
defect in transport.

Summarizing his findings, the defects

in transport in alloxan-diabetic rats can be corrected
rapidly by the addition of insulin in vitro.

The defect

in phosphorylation cannot be so corrected and limits glucose uptake in the w:-esence of excess insulin.

The mech-

anism of this decreased phosphorylating activity is unknown.
In a discussion of Kipnis' results, Bornstein confirmed that
the lipoprotein inhibitor was not active on adipose tissue.
The experiments of Bornstein showed that the factor
bound to lipoproteins was neither cortisone nor growth hormone.

It was immediately active on the diaphragm and did

not require a latent period.

One might suppose that the

73
factor was cortisol rather than cortisone.

In general, i t

has been found that only 11-hydroxy glucocorticoids are effective in in vitro systems in which protein synthesis mediates the glucocorticoid effect.
cortisol in his experiments.

Bornstein did not try

However, Antoniades et al

(15, 17) have shown that glucocorticoids are the steroids
least strongly bound to the lipoprotein fraction of serum.
Randle et al (431) have shown that fatty acid oxida.tion leads to a decrease in glucose oxidation.

For ex-

ample, in the perfused rat heart, octanoate at 0.40 mg/ml
inhibits glucose uptake 41 percent while 0.70 mg/ml 8-hydroxybutyrate inhibits glucose uptake 50 percent.

These

changes are accompanied by an increase in the NADH/NAD+
ratio of mitochondria and an elevation in cytoplasmic
citrate.

These changes are somewhat similar to those

observed during ethanol perfusion.

The fact that oxygen

consumption is not affected indicates that the oxidation
of pyridine nucleotides is also unef fected by fatty acid
respiration.

In contrast, oxygen consumption is reduced

by steroids when they produce similar changes in citrate
and in the reduction potential of mitochondrial pyridine
nucleotides.
Mor~an

et al (758) reported that glucose phosphoryl-

ation is the rate limiting reaction in glucose uptake by

L
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the perfused rat heart at all glucose concentrations over
2.00 gm/l, even in the presence of 0.1 unit/ml of insulin.
since insulin secretion is stimulated when glucose phosphorylation is inhibited, these results indicate that glycolytic inhibitors can be affective insulin antagonists
under conditions similar to thbse encountered in diabetes
in vivo.
The Specificity of Glucocorticoid Effects
Huisman (494} had observed that adrenalectomy or hypophysectomy increased the glucose uptake of the isolated rat
diaphragm.

He found that 0.5-2.5 mg/ml cortisone acetate

in vitro decreased the glucose uptake of the isolated rat
diaphragm 30-40 percent.

Herman and Ramey (452} reported

that 0.04 mg/ml cortisol inhibited glucose uptake of the
diaphragm by 15 percent.

At about the same time, Grossman

and Ryder (205} reported that 0.3 mg/ml (8 x l0- 4M} cortisol decreased the glucose uptake of diaphragm by 32 percent.
The effect was specific since 2 x 10-

4

Molar cortisone was

active while twice this concentration of corticosterone
was inactive.

Thus, the 17a-hydroxy group is required

for this effect.

This latter concentration of cortisone

depressed glucose oxidation by 41 percent.

These authors

also reported that 1.63 µMolar deoxycorticosterone inhibited glycogen synthesis 31 percent and accelerated

.
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glycogenolysis while having no effect on either glucose uptake or oxidation.

These results with deoxycorticosterone

have been confirmed by Verzar (577) and will be discussed
in relation to glycogen metabolism.

Rosenkrantz (455), in

addition to confirming the observations of Grossman and
Ryder on deox::(corticosterone, also reported that _this
steroid inhibited yeast hexokinase 60 percent at a concentration of 1.0 mg/ml.

The interpretation of this finding

is difficult because yeast does not contain steroid hormanes or insulin.

l

CHAPTER IV
MINERALCORTICOIDS AND ELECTROLYTE BALANCE

Problems of Mineralcorticoid Therapy
At the present time it is not possible to define the
specificity of the glucocorticoid effect on insulin antagonism by S-lipoprotein.

However, some of the effects

of cortisol on carbohydrate metabolism are non-specific
in that they may also be produced by other steroids and
non-steroids (12, 747, 1099).
In order to study glucocorticoid effects it is necessary to control endogenous cortisol levels.

This is best

done by adrenalectomy which, in addition, increases the
sensitivity of the experimental animals to minute amounts
of adrenal hormones.

However, adrenalectomy also pro-

duces electrolyte imbalance which may indirectly affect
carbohydrate metabolism.

Therefore, since the amount of

exogenously administered mineralcorticoid required to maintain electrolyte balance is greater than the amount endo·

genously secreted, the problem of mineralcorticoid therapy
76
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is to obtain electrolyte balance without mineralcorticoid
effects on carbohydrate metabolism.
Not all mineralcorticoid effects on carbohydrate metabolism are mediated by changes in electrolyte levels.

Rather,

some of these effects may be due to the interaction of the
mineralcorticoids at glucocorticoid receptor sites.

There-

fore, the best mineralcorticoid for this application is
that which interacts least at glucocorticoid receptor sites.
Grollman (413, 414) found that most of the deaths from
adrenal insufficiency in rats occur about 18 days after
adrenalectomy.

Sabatini ·et ·a1 (922) have made a sub-micro-

scopic study of the effect of the pituitary on the adrenocortex of the rat.

They found that cortical atrophy fol-

lowing hypophysectomy is due to shrinkage of the zona
fasciculata and zona reticularis.

In contrast, the zona

glomerulosa remained normal two weeks after hypophysectomy.
ACTH
ACTH formed in the pituitary stimulates the production
of glucocorticoids in the adrenal and can produce all glucocorticoid effects when administered to animals with normal adrenal glands.

However, ACTH also has lipolytic ef-

fects which are not mediated by the adrenal glands.

In

Cushing' s Syndrome there is an overproduction o,f ACTH due
to hyperplasia of the basophil cells of the adenohypophysis.
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In Addison's disease there is also an overproduction of ACTH,
but this overproduction is secondary to the decreased cortisol production by the adrenal cortex causing decreased cortisol feedback of ACTH release.

Cox and Hodges (203) also found

that at least two weeks after adrenalectomy were required before the pituitary adapts itself to secrete and maintain an
enormously increased output of ACTH in response to the complete absence of glucocorticoids.
Although potassium enhances glucose uptake and inhibits
insulin release from the S cells of the pancreas, changes in
potassium and other electrolyte effects may be avoided in the
study of glucocorticoid effects by the use of synthetic glucocorticoids which have little or no effect on electrolytes (1195).
Perhaps the most potent

glucocort~coid

which still shows low or

neglible mineralcorticoid effects is 6a,9a-difluoro-11S,17a,21_.
trihydroxy-16a-methyl-l,4-prenadiene-3,20-dione (Flumethasone).
In this compound the 16a-methyl counteracts the salt retention
produced by the 9a-fluorine substitution.

A less potent .gluco-

corticoid but one which still possesses minimal mineralcorticoid effects is 6a-fluoro-ll13,17a,21-trihydrowy-l,4-pregnadiene-3,20-dione (Fluprednisolone).

In addition to the reduction

in mineralcorticoid activity produced by the introduction of the
double bond at C-1, the glucocorticoid potency is further enhanced by the Ga-fluorine substitution which electronically
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interferes with the reduction of the double bond at C-4 (887).
Interestingly, the higher potency of Ga-fluorinated derivatives compared to Ga-methylated derivatives indicates the
superiority of the electronic block compared to the steric
block with respect to the specific reductases involved.
Th~

use of specific glucocorticoids, defined by their

potency in glycogen deposition, along with specific mineralcorticoid therapy in control and experimental adrenalectomized rats simplifies the interpretation of the effects
observed.

But, these specific glucocorticoids may still

have non-glucocorticoid effects even though they are devoid
of mineralcorticoid effects.

It is hoped that these dis-

tinctions will become clearer to the reader as the dissertation progresses.
In addition to their effect on hepatic glycogen deposition, specific glucocorticoids promote the mobilization
of phospholipids from the liver while mineralcorticoids
do not (GS4, 797, 1197).

However, the latter steroids

.have a more potent hypercholesterolemic effect that is not
generally appreciated, probably because mineralcorticoids
are not normally in pathological excess (779).
Adrenal Insufficiency and Diabetes Mellitus
Adrenalectomized rats cannot be maintained for long
periods simply by increasing their dietery sodium and
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restricting their potassium.

The pioneering work in this

particular.area was performed by Grollman (204).

He demon-

strated that completely adrenalectomized rats could not
survive longer than approximately 18 days on sodium chloride
therapy alone, but could survive if they were also given
mineralcorticoids such as deoxycorticosterone.

However,

the failure to remove only 5 percent of the adrenal gland
leads to the survival of the animals without mineralcorticoids due to the hypertrophy of the remaining tissue.
Grollman also noted that young, untreated adrenalectomized
animals survived for much .shorter periods than adults, as
did animals exposed to stress before adrenalectomy.

Pro-

longed ether anesthesia during the adrenalectomy reduced
the survival period from 14 to 7 days.

Barbiturate anes-

thesia resulted in better survival rates than ether, but
high-protein diets and post-operative stress reduced survival rates.
Grollman found that body weight loss was the most responsive non-chemical indicator of adrenal insufficiency
in adrenalectomized rats.

Other indicators have compen-

satory mechanisms which only break down during adrenal
crisis.

Body weight, however, may not be a specific index

of adrenal insufficiency in alloxan-diabetic-adrenalectomized rats, because insulin deficiency itself causes weight
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1oss and protein depletion.

The most sensitive chemical in-

dicator of adrenal insufficiency is blood urea nitrogen (BUN).
This is especially true when it is measured daily in each
animal.

The blood urea nitrogen will rise in adrenalec-

tomized rats due to hemoconcentration at constant urea production and due to reduced urea clearance by the kidney as
glomerular filtration rate falls.

Diabetic-adrenalectomized

rats will have a higher rate of urea production due to increased protein catabolism, especially if they are maintained on a high-protein, low-carbohydrate diet.

However,

the day to day changes in blood urea will still be a valid
indicator of blood volume, the goal of mineralcorticoid
therapy, despite the osmotic diuresis caused by glucosuria.
Although insulin treatment is specifically indicated to
control the hemoconcentration produced by glucosuria, insulin treatment was not used in these studies for reasons
already discussed.

Therefore, daily glucose determinations

were not necessary.
The serum sodium levels in diabetic rats are somewhat
low.

Weisberg {1128) has shown that a reduction in serum

sodium is a necessary consequence of the increased amounts
of glucose and urea in blood.

A rise of 100 mg/l in serum

glucose will result in a sodium reduction of 0.28 meg/l

.
l

r,

'~..·
'

while the same rise in urea nitrogen will decrease the
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concentration of serum sodium by 1.8 meq/l.

The relative

amounts of glucose and urea which will displace 1 meq/l of
sodium are 350 mg/l and 50 mg/l respectively.

These results

indicate that serum sodium levels can be altered by both
urea and glucose.
The decreased ability of the adrenalectomized rat to
excrete potassium is alleviated by the glucosuria of diabetes.

The resulting high fluid intake effectively dilutes

the elevated levels of potassium in the adrenalectomized
rat.

The same holds true for the

found in adrenalectomized rats.

elevat~d

magnesium levels

Potassium and magnesium

levels in the non-diabetic-adrenalectornized rat are elevated approximately 42 percent and 23 percent respectively.
Adrenalectomized rats, however, share with diabetic rats
their tendency toward acidosis.

The acidosis of adrenal

insufficiency is due to the decreased reabsorption of sodium
ion and increased reabsorption of potassium and hydrogen ions.
Electrolyte Therapx
Grollman (414) has shown that adequate replacement therapy of adrenalectomized rats cannot consist of electrolytes
alone, although the reasons for this are obscure.

The oral

administration of 10 mg/kg daily deoxycorticosterone acetate admixed with the animal's food was found to result in
adequate replacement therapy.

l

The dose of mineralcorticoid
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could be reduced if additional sodium chloride was also administered.

McGarack et al (689) showed in humans that the

dose of mineralcorticoid was inversely related to the total
dietary sodium.

However, it should be noted that the cor-

rect therapy of Addison's disease requires the use of both
mineralcorticoids and glucocorticoids.
An example from McGarack et al (689) also illustrates
the effects which mineralcorticoids can have on carbohydrate metabolism.

They showed that normal glucose toler-

ance could be obtained in their Addisonian patients on a
normal diet if 15-20 mg of deoxycorticosterone acetate was
administered daily.

Althauser et al (12) have also shown

that electrolyte balance in the rat is required for normal
intestinal absorption of glucose.

In adrenalectomized rats

this function can be almost completely restored by the
administration of 1 percent sodium chloride as drinking
fluid.
In the treatment of alloxan-diabetic-adrenalectomized

..

rats with varying degrees of glucosuria it is advantageous
to administer the mineralcorticoid in the drinking fluid
rather than admixed with the solid food for two reasons.
First, since the bulk of dietary sodium is also in the
drinking flu.id, the dose of mineralcorticoid is in direct
proportion to the filtered sodium load in the glomerulus.
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secondly, the administration of the mineralcorticoid in the
drinking fluid distributes the total dose throughout the day
thereby making it more effective than the same total dose
consumed mainly with solid food according to the nocturnal
eating habits of the rat.

The total dose of hormone admin-

istered is thereby reduced as are the dangers of

hyperten~

sion, hypokalemia, paralysis, cardiac failure, and myocardial necrosis resulting from overdosage.
The administration of mineralcorticoids in drinking
fluid, while eliminating the chance of infection associated
with daily injections of the hormones, is not without problems.

According to Grollman (414} a 200-gram rat requires

approximately 2.0 milligrams of oral deoxycorticosterone
acetate daily.

While this requirement may be reduced if

the hormone is administered in conjunction with 1 percent
saline, the low solubility of deoxycorticosterone in this
medium--approximately 17.0 mg/1--could supply about only
one-third of the required dose.
This dilemma might be solved by the use of more potent
mineralcorticoids.

Bergstrom and Dodson (69} reported the

synthesis of 9a-fluoro-21-hydroxy-4-pregnane-3,20-dione
from corticosterone acetate.

They treated the latter

steroid with 70 percent hydrofluoric acid in anhydrous
pyridine.

Kagawa and Jacobs (553} bioassayed the main
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product and found it to be 12-14 times as

poten~

as deoxy-

corticosterone.
Aldosterone might also be used to maintain adrenalectomized rats in these studies.

Although it is 15 times as

potent as deoxycorticosterone, Desaulles (230) has estimated that it has 0.5 percent of the glucocorticoid potency
of cortisol.

The ratio of mineralcorticoid to glucocorti-

coid activity in aldosterone might be increased by the introduction of a 9a-fluorine atom.

Barton and Beaton (49)

have describe.a the conversion of corticosterone to aldosterone.

In this transformation llS-nitrites react photo-

chemically to yield C-18 or C-19 oximes which can be hydrolyzed to aldehydes.

This reaction applied to 9a-fluoro-

11B ,21-dihydroxy-4-pregnane-3, 20-dione would yield 9a-fluoro-11S,21-dihydroxy-3,20-dioxo-4-pregn-18al (11--18) lactol.
Although intravenous fluid therapy introduces an additional variable in the maintenance of alloxan-diabeticadrenalectomi zed rats, it often saves a rat who has not
adapted to this state by increasing his saline intake.
Slow infusion of the following solution often corrects
the hemoconcentrations and acidosis of these animals in
this crisis.
When rats are first rendered alloxan-diabetic, they
tend to undergo a period of ketosis until their excess
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TABLE I
INTRAVENOUS FLUID REPLACEMENT SOLUTION

,.

COMPONENT

MEQ/L

GM/L

Sodium chloride

103.0

6.020

Potassium chloride

4.0

0.298

Calcium phosphate, dibasic

4.0

0.306

30.0

2.521

~·

Sodium bicarbonate

~f:

f.

Glucose

1.000

Fructose

2.000
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lipid stores are depleted.
rats.

This is especially true of larger

The oral hypoglycemic agent 1-phenethylbiguanide

might be used to enable the animals to get through this period without resorting to the administration of insulin.
This particular compound does not act by increasing insulin
"':
r

output but by .another mechanism which has not been completely
elucidated.

Superficially, the effects of the compound re-

semble the effects of low concentrations of epinephrine on
glucose metabolism, but differences no doubt exist.

The

point made here is that the use of this compound may enable
the animals to get through a period of high mortality and
,..

"
'.

thereby improve overall experimental efficiency.
Large doses of glucocorticoids, 17 mg/kg for 10 days,
can produce glucosuria similar to that found in alloxan
qiabetes.

This phenomenon is known as steroid diabetes

(509, 510, 513, 517).

Ingle et al (511) compared steroid

diabetes with pancreatic diabetes in the rat and noted
that glucocorticoid diabetes was resistant to insulin
whereas pancreatic diabetes was not.
Diabetes Mellitus can also occur in patients with
Addison's disease.

This disease is characterized by

adrenal insufficiency and its associated disturbances in
mineral and carbohydrate metabolism.

Thorn et al (1062)

demonstrated impairment of the intestinal absorption of
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glucose and an elevated respiratory quotient that is diminished by cortisol treatment.

Althauser et al (12) have

shown that oral sodium chloride can partially restore the
defect in the intestinal absorption of glucose.
•

When dia-

I

betes complicates adrenal insufficiency, proper management
of the patient becomes more complex (1061).

If the severity

of the diabetes corresponds to the degree of glucocorticoid
deficiency, the patient can often be maintained by mineralcorticoids alone.

In fact, adrenalectomy was used as one

treatment for diabetes before insulin was discovered.

How-

ever, if insulin is needed to control glucosuria, then
glucocorticoids should be given as protection against hypoglycemia.

Other considerations of the adrenal in diabetes

have been reviewed (1063).
Excessive glucocorticoid treatment in Addison's
disease may precipitate clinical diabetes (57), generally
within 3 years.

Carbohydrate and mineral balance are best

maintained separately with cortisol and its 9a-fluoro
derivative.
Glycyrrhetic Acid
If mineralcorticoids produce some glucocorticoid effects in adrenalectomized rats, what other means are available to maintain electrolyte balance in these animals?
Louis and Cohn (678) isolated an electrolyte-active principle
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from licorice extracts and used this compound to maintain
adrenalectomized patients before deoxycorticosterone became readily available.

The compound, glycyrrhetic acid,

was isolated in the form of the ammonium salt of its 3-(2-0s-D-glucuronopyranosyl)-a-D-glucuronopyranoside known as
glycyrrhizin.

This glycoside is intensely sweet and has

been used as an artificial sweetener.

The mineralcorti-

coid properties of the licorice glucuronoside are those of
the parent compound glycyrrhetic acid, often termed gly_cyrrhetinic acid.
Glycyrrhetic acid is a molecule of great theoretical
interest because it possesses anti-inflammatory and min'

.

eralcorticoid effects, but not glucocorticoid effects
(318).

The relationship between anti-inflammatory and

. glucocorticoid potency has been reviewed by Glenn et al
(371).
'··

In general these two potencies parallel each other

so that the reported separation of these effects . in glycyrrhetic acid by Finney and Somers

(318) should be further

investigated.
In man the anti-inflammatory dose of licorice extract,
w~ich

constitutes 6-14 percent of the dried rhizone and

roots of the licorice plast, Glycyrrhizia glabra, is about
20-25 grams per day.

Although this dose is large compared

to anti-inflammatory steroids, treatment with licorice
\.

FIGURE III
STRUCTURE OF GLYCYRRHIZIC ACID
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extract and carbonoxalone, the hemi-succinate ester of glycyrrhetic acid, is preferred for the· treatment of peptic
ulcers which are adversely affected by anti-inflammatory
steroids.
Not all commercial samples of glycyrrhetinic acid have
anti-inflammatory activity because the active 188 form of
the molecule with a cisD-E ring juncture may be converted
to the more stable trans form during the acid hydrolysis
of the glucuronoside glycyrrhizin.

This transformation is

readily explained by the allylic nature of the 186 hydrogen due to the presence of the conjugated double bond at
c-12.

Presumably the trans E ring cannot fit the receptor

site for mineralcorticoid activity while the cis E ring
can.

The active S form of glycyrrhetinic acid crystal1

lized from alcohol has a melting point of 140°, [a]~ =+86°
(c=O.l in chloroform), while the properties of the inactive a form are 335° and +98° respectively.

The pure

compound has an extinction coefficient of 12,200 at 242 nm
in ethanol.

Additional aspects of the stereochemistry of

glycyrrhetinic acid have been reported by Beaton and Spring
(55) •
The role of the 11-ketone of glycyrrhetic acid in its
mineral corticoid and anti-inflammatory activity has not
been determined.

However, the related compound, S amyrin,

r--·.
~.
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which is identical except for the lack of the 11-ketone and
c-30 carboxyl groups, also has anti-inflammatory activity

equal to that of cortisol.

Gupta ·et al (418) also found

that a amyrin had only about one-half the anti-inf lammatory activity of the S isomer.
The role of the C-11 carbonyl group in the mineralcorticoid activity of glycyrrhetic acid is unknown but
could be determined by

compariso~

with its 11-deoxy analog.

Alternately, the mineralcorticoid activity of S amyrin and
its C-11 carbonyl derivative could be compared.

Such studies

may clarify the function of the llS-hydroxyl group in aldosterone despite its absence in the mineralcorticoid deoxycorticosterone.

In addition, it is not known whether the C-11

ketone in glycyrrhetic ac.id is reduced to an llS- hydroxyl
group in vivo.

However, it is known that the analogous

reaction with glucocorticoids takes place primarily in the
liver by the action of the enzyme llS-hydroxysteroid dehydrogenase.

This enzyme is inactive with SS pregnene deriv-

atives (486) but may or may not be blocked by the 4S-methyl
group of glycyrrhetic acid.
Although previous paragraphs have indicated that it is
feasible to maintain alloxan-diabetic-adrenalectomized rats
by the administration of a mineralcorticoid in their
.•

drinking fluid, there are other reasons for not using
'·
t;

i l. . ' ·
.

.
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mineralcorticoids for this purpose.

Verzar (1099) and Verzar

and Wenner (1100) have shown that deoxycorticosterone decreases muscle glycogen by increasing glycogenolysis.

Bart-

lett and Mac Kay (47) and Bartlett et al (48) have confirmed
these findings in rat diaphragm muscle.

Bacila and Baron

(34) noted that deoxycorticosterone was equal to cortisol
with respect to its inhibition of the anerobic glycolysis
of lymphocytes.

Interestingly, while cortisol appeared to

·inhibit only the hexokinase reaction as observed also by
Ilyin (506) and Ilyin and Titova (507), deoxycorticosterone
appeared to inhibit other glycolytic reactions as well.
Blecker (84) and Blecker and White (82, 83) have reviewed
.c

these effects.

~·

androsten-3-one was as potent as deoxycorticosterone while

' .

They found that 17S-hydroxy-17a-methyl-4-

17a-ethyl-17S-hydroxy-4-estren-3-one was three times more
inhibitory to the glycolysis of lymphoctes.
Roberts and Nezamis

(891) and Russell (917) also ob-

served that deoxycorticosterone could produce some glucocorticoid effects in adrenalectomized rats especially when
hepatic metabolism of the steroid is impaired.

Glenn (372)

similarly noted the local glucocorticoid effects of locally
administered deoxycorticosterone.

To the extent to which

mineral corticoids produce glucocorticoid effects, mineralcorticoid maintenance of adrenalectomized rats may reduce
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some glucocorticoid effeets.
Disputes concerning the efficacy of glycyrrhetic acid
in the maintenance of adrenalectomized subjects emphasize
that this molecule has no glucocorticoid activity and cannot fulfill glucocorticoid requirements.

Cristol et al

(297) reported that glycyrrhetic acid could maintain adrenalectomized rats and
tion.

reduc~

their urinary sodium excre-

In addition, a dose of 300 mg/kg/day caused hyper-

tension in rats similar to that caused by excess deoxycorticosterone.

Hudson et al (488) found that adrenalectom-

ized cancer patients could be maintained on a regular diet
and glycyrrhizin.

The dose required was 100 times the

subcutaneous maintenance dose of deoxycorticosterone.

On

the other hand, Elmadjian et al (282) reported that two
Addisonian-schizophrenic women could not be maintained by
the administration of 56 mg/kg/day of ammonium glycyrrhizate in the absence of glucocorticoids.

However, this

dose of the compound reduced their cortisol requirement
from 25 mg/day to 10 mg/day and maintained the patients
in excellent electrolyte balance.

These results indicate

that glycyrrhetic acid has no glucocorticoid activity in
the absence of glucocorticoids but that the compound may
reduce the rate of metabolism of active glucocorticoids
when they are also present.
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Glucocorticoids may exert specific electrolyte effects.
Mills and Thomas (747) found that cortisol and prednisolone,
but not deoxycorticosterone stimulated the uptake of inor-·
~·

ganic phosphate by muscle but. not liver.

These results sug-

'~.

t

gest that the glucocorticoids increased the pool of glycoly-

~·
g·

tic intermediate~ in m~scle without affecting the pool size

f

~;

of these intermediates in liver.

The difference in these

tissues may be related to the presence of glucose-6-phosphatase in liver.

A similar increase· in muscle phosphor-

ylated intermediates has been observed by others (759·, 760).
Block et al· (85) found that a sodium retaining factor
could be found in the fetal adrenal gland.

The intermedi-

ates 4-androstene-3,17-dione and.313-hydroxy-5-androsten-17,

one were also found.

The compound 1113-hydroxy-4-androstene-

3,17-dione, normally formed almost exclusively from cortisol
in the adult, was produced earlier in development than cortisoi.

Although the latter 17-ketosteroid has the highest

anabolic/androgenic ratio of any naturally occurring steroid (737), its effect on fetal carbohydrate metabolism has
not been studied.

The 1113-hydroxyl group reduces its andro-

genie activity to one-fifth that of androsterone.

Rosenberg

and Dorfman (906) also reported that the related steroid
9a-fluoro-1113-hydroxy-4-androstene-3,17-dione was also devoid of androgenic activity but that it did have

r
rt
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mineralcorticoid activity.

t>-,'

Effects of Steroids on Blood Pressure
At least part of the hypotensive effect of some steroids
may represent an action on glucose utilization in vascular
muscle.

Sturtervant (1037) showed that llS-hydroxy-4-andros-

tene-3,17-dione was the most potent naturally occurring
potensive steroid.

hy-

It was capable of reducing the blood

pressure of rats with metacortical hypertension 33-49 mm
.of mercury for 5.5 hours.

In comparison, testosterone and

1713-hydroxy-4-androstene-3,ll-dione reduced blood pressure
by 18-22 mm and 4-androstene-3,17-dione and 4-androstene-3,
11,17-trione reduced it by 9-18 mm.

Most surprising was

the finding that 116,178-dihydroxy-4-androstene-3-one was
inactive.

While these results indicate considerable steroid

specificity with respect to hypotensive action, additional
_studies (1038) with synthetic hypotensive steroids based
on 178-hydroxy-4-estrene-3-one did not confirm such specificity.

Sturtevant found that the parent compound as well

as its 5(10) unsaturated derivative were inactive.

Sub-

stitution in the 17a position with vinyl, allyl, or methyl
groups resulted in inactive compounds, but the 17a-ethyl
and 17a-propyl compounds were active.

The most potent deriv-

ative was 17S-hydroxy-17a-propyl-58-estren-3-one.

Apparently,

unsaturation at C-4 is not an absolute requirement for

l
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physiological activity.

Sturtevant did not test llS-hydroxy-

19-nor steroids but, judging from his earlier work, these
compounds should be even more active.

Such derivatives

might be prepared by microbiological hydroxylation of estrenes or from androstenes by the technique of Barton and
Beaton discussed in conjunction with the synthesis of mineralcorticoids.

The finding that a long 17a alkyl group

enhanced hypotensive activity indicates that the mechanism
involved may be similar to that which operates with some
progestational steroids.

In the rabbit, 17a-(l-butynyl)-

17S-hydroxy-4-estrene-3-one is 83 times as potent as 17aethinyl-17S-hydroxy-4-estrene-3-one by subcutaneous injection but only 63 percent as effective orally.
The influence of long 17a alkyl groups on hypotensive and progestational activity is reminiscent of
Selye's (965) finding of increased anesthetic potency in
a compound which he described as "21-ethylprogesterone"
·~·.

(21,25,26,27-tetranor-4-cholestone-3,20-dione) except
that the alkyl group is in the S rather than in the a po-

~

sition.

~

may have hypotensive effects but additional relations be-

These results suggest that some C-18 progestens

tween the two activities remain to be investigated.

How-

ever, the results indicate that hypotensive steroids are
able to interfere with the action of catecholamines on
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smooth muscle so that similar interference with the action of
catecholamines may be found in other tissues.
The approach to mineralcorticoid replacement therapy
taken in these experiments has been to administer an electrolyte-active compound in the drinking fluid of the experimental animals.
used.

Sodium glycyrrhetinate was the compound

Although this compound contains a C-11 ketone, it

possesses only mineralcorticoid and not glucocorticoid
activity.
The differences between mineralcorticoid and glucocorticoids are generally appreciated, but the effects which
these types of steroids may have in common are not.

It

seems that 11-deoxy steroids may meet the steric requirements of glucocorticoid sites but not vice versa.

Glycyr-

rhetic acid is unique in that it has an oxygen at C-11
but shows only mineralcorticoid activity.

It has been

shown that the presence of the llS-hydroxyl group alters
the surface activity of the glucocorticoids relative to
mineralcorticoids.
~'..

It may also be possible that the C-30

carboxyl group in glycyrrhetic acid counteracts the surface effect of the llS-hydroxyl group.

In this regard it

is noteworthy that surface activity was used in determining
the configuration of the C-30 carboxyl group (55).
The concern about the possible interaction of

r

f'
'

~

~·
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mineralcorticoids at glucocorticoid sites may seem inordinate
to the reader.

However, the basis of this concern is that

such mineralcorticoid effects present in all experimental
animals could mask similar effects produced by glucocorticoid derivatives.

Unfortunately, while measures were taken

to eliminate this problem, its actual magnitude was not
determined.

CHAPTER V
GLUCOCORTICOIDS AND HEXOKINASE

Glycolysis in Muscle Cells and Erythrocytes
The amelioration of diabetes by hypophysectomy seen in
the Houssay animal prompted further investigation into the
effects of pituitary and adrenal extracts on the first reaction of glucose metabolism.

Price et al (833) found that

.anterior pituitary extracts inhibited muscle hexokinase
in vitro and that insulin reversed the inhibition in all
cases.

Stadie et al (1016) also reported that exposure

of the rat diaphragm to pituitary extracts abolished its
subsequent response to excess insulin.

?

The factors in-

volved in these observations have not been studied further.
On the other hand, Price et al (852) found that crude adrenal cortical extract, but not crystalline cortisone, corticosterone or 21-hydroxy-4-pregnene-3,11,20-trione, in;;
.··

hibited muscle hexokinase.
..

were reported by Sharma

~t

Essentially similar findings
al (974).

These reports indi-

cate that the identity of the active adrenal factor is
100
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known.
Bornstein (100) reported that S lipoproteins from norrats were less inhibitory than S lipoproteins from diabetic rats towards muscle hexokinase.

Although up to 27

percent inhibition was observed, other non-glycolytic enzymes were also inhibited.

Insulin did not reverse the

inhibition of the enzyme which was attributed to the phosphatidyl choline in S lipoprotein.
Bacila and Baron (34) have studied the effect of glucocorticoids on the anaerobic glycolysis of appendix lymphatic cells.

Cortisol at a concentration of 50 µg/ml in-

hibited glycolysis 12 percent.

At 100 µg/ml

cortisol inhibited glycolysis 40 percent.

(2.8 x 10 -4 )

Mouse diaphragm

was inhibited 45 percent at a cortisol concentration of
50 µg/ml in a two-hour incubation in which the glucose
concentration was 180 mg/ml.

Cortisone acetate and de-

oxycorticosterone were as effective as cortisol in eliciting this effect.

In contrast, the anaerobic glycolysis

of acites tumor and lymphosarcoma were not affected at
these steroid concentrations.

These results may indicate

that these tumors have lost their sensitivity to cortisol.
Human and rabbit erythrocyts glycolysis as well as
yeast glycolysis were not affected by steroids under these
,,

conditions.

A possible explanation for the resistance of
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erythrocytes to t.hese steroid effects is suggested by the
work of Margraf et al (713).

These workers found that red

cells form glucocorticoid C-21 acetates and that 50 percent
of circulating glticocorticoids are present in this form.
The key role of red cell glycolysis in the generation of
its major product, 2,3-diphospho-glycerate, and the role
of the latter compound in hemoglobin function indicates
that glycolytic inhibitors could adversely affect oxygen
transport if their action in red cells was not prevented
·~

by acetylation.

These acetate esters are rapidly hydro-

lyzed in plasma by pseudocholinesterase.
Effects of Sulfhydr:z=l Compounds and Reagents
Besides alloxan, both dehydroascorbic acid (693) and
uric acid (412) deplete insulin storage granules in the B
cells.

These compounds appear to exert their degranula-

tion effect through reaction with glutathione.

Indeed,

alloxan has been used as an analytical reagent in the determination of glutathione. Degranulation is due to the
f

~'

f

reduction in glutathione levels.

Lazarow (644) reported

that glutathione increased the hyperglycemic response to
growth hormone and glucocorticoids.

However, he.also

noted that growth hormone and glucocorticoids suppressed
glutathione levels before these hormones produced glucosuria.

This observation is another indication that the

103
diabetogenic effects of these hormones are produced in the
presence of elevated concentrations of insulin.
Bacila and Baron also observed an insulin-like effect
of glutathione on the isolated rat diaphragm.

They demon-

strated that glutathione could prevent the inhibitory effect of cortisol on glucose metabolism and postulated that
glutathione reacted with cortisol to form an inactive derivative.

Although C-3 carbonyl group of dihydrosteroids

had previously been shown to form thiazolidine derivatives
,.

with cysteine, this reaction is much less facile with conjugated C-3 steroid ketones.
The possibility that sulfhydryl compounds may exert
an effect on the enzyme hexokinase has been investigated
by several groups.

Lazarus ·et al (645) studied the sulf-

hydryl groups of yeast hexokinase and found that the
enzyme contained 8 sulfhydryl groups.

Four of these re-

acted with methyl mercury iodide in the native enzyme

f

with no loss in activity.

t~·

hydryl groups were simultaneously exposed and their sub-

,.

sequent reaction with methyl mercury resulted in dissoci-

l"~

ation and inactivation of the enzyme.

fi.

sions were reached by Schulze and Colowick (955) in their

~i

experiments with methyl mercury nitrate in 5. 4 M guani-

~

dine hydrochloride and with mercaptoethanol.

However, four additional sulf-

i·

[

f:',

~r .

Similar conclu-

These
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findings indicate that simple mercaptide formation does not
iead to inhibition of yeast hexokinase activity.
Ilyin (506) and Ilyin and Titova (507) performed some
interesting experiments relative to the role of hexokinase
sulfhydryl groups in an effect of glucocorticoids.

When

cortisone acetate was added to rabbit serum B lipoproteins,
the lipoproteins inhibited yeart hexokinase.

This effect

could be reversed by 0.5 units of insulin in vitro.

The

reversal by insulin required the presence of free sulfhydryl groups, but inhibition by cortisol or cortisone
acetate could still be demonstrated after the enzyme had
reacted with N-ethylmaleimide or p-chloro-mercuribenzoate.
Insulin prevented or reversed the binding of the steroid
to the enzyme which remained active after treatment with
sulfhydryl reagents.

Titova (l067) reported that both

oxytocin and vasopresson, which have disulfides similar
to those in the A chain of insulin, could also reverse
steroid inhibition of the enzyme.

Insulin had no effect

on yeast hexokinase activity in the absence of glucocorticoids.

The effect appeared to be some what specific since

insulin did not affect the free sulfhydryl groups of hemoglobin or the enzyme aldolase.

Glucose-6-phosphate dehy-

drogenase, however, was also inhibited by the cortisone
acetate-a lipoprotein complex.
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The glucocorticoid effect on the enzyme hexokinase is
also specific.

The phosphorylation of glucose and mannose

was inhibited, but that of fructose and 2-deoxyglucose was

no t ·

Zinc and silver cations prevented the inhibition of

hexokinase by glucocorticoids as did N-ethylmaleimide.

On

the other hand, p-chloromercuribenzoate reversed glucocorticoid inhibition of the enzyme (506, 507, 1067).

Thus,

p-chloromercuribenzoate had the same effect as the hormone
insulin.

Although these results were obtained in a very

heterogeneous system, i.e. rabbit B-lipoproteins, bovine
insulin, and kinase from yeast which lacks both of the
latter as well as glucocorticoids, the data validly indicate some of the pitfalls in work with hormones in vitro.
Properties of Hexokinase Isoenzymes
Schimke and Grosslard (744) studied the distribution
of hexokinase isoenzymes in animal tissues.

They also

presented detailed kinetic and physiochemical data on
these enzymes.

Hexokinase isoenzymes are enumerated in

the order in which they migrate during electrophoresis.
This order is the same as the order in which the enzymes
are eluted from the ion-exchanger diethylaminoethylcellulose by potassium chloride gradients.

Type I hexokinase

is found in brain and is the isoenzyme most stable at 45°C
in the presence of glucose.
,•
•.t'

Both types I and II hexokinase
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are found in heart muscle and adipose tissue.
e.nzyme is least stable to heat.

The type II

Type III hexokinase, which

is found in liver, is most inhibited by high concentrations
of glucose and least inhibited by glucose-6-phosphate.
Kidney contains all three hexokinase isoenzymes.

These

three low km hexokinases have molecular weights of 96,000
and a similar pH optimum of 7.8-8.8.

Glucose, mannose and

glucosamine have the same km value but that of fructose is
1000 times greater.

However, these substrates and 2-deoxy-

glucose have the same Vmax·
is very heat labile.

Type IV glucokinase in liver

It is inactive with fructose and glu-

cosamine but phosphorylates mannose and 2-deoxyglucose in
addition to glucose.

It has a molecular weight of 50,000

and a more acidic pH optimum of 7.5-8.5.

Pilkis et al

(836) have found that insulin is necessary for the induction of both glucokinase and hexokinase II.

Hypophysec-

tomy decreases hexokinase II but has no effect on glucokinase and this could explain why hypophysectomized rats
lose muscle glycogen.
Hanson and Fromm (426) demonstrated that both types
I and II hexokinase were present in skeletal muscle.
Using D-fructose as substrate, these makers demonstrated
that the mechanisms of the type I enzyme was sequential.
In the sequential mechanism, the Michaelis constant of
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the variable substrate remains the same or decreases as the
concentration of the fixed substrate rises.

Their proof of

the sequential mechanism corrects their earlier claim that
this enzyme followed a ping-pong mechanism.

In this latter

mechanism one of the products is released from the enzyme
before the second substrate is bound.
On the other hand, type II hexokinase unlike type I
hexokinase was found to be inhibited by

mannose-6-phos~hate

and to possess kinetic properties similar to those of yeast
hexokinase.

Since adenosine-5'-triphosphate showed a mixed

type of inhibition with respect to both glucose and adenosine-5'-triphosphate, the authors concluded that the mechanism of the enzyme was random, i.e. that the binding of either
substrate influenced the km for the other substrate.
Glucose-6-phosphate appears to be a mixed inhibitor of
all rat hexokinase isoenzymes with respect to glucose.

The

decrease in the affinity of the enzymes for glucose produced by glucose-6-phosphate may decrease glucose transport
by elevating the intracellular concentration of glucose
which, in turn, decreases the rate of glucose'transport by
decreasing the concentration gradient for glucose.

Yorke

(1189) has observed in isolated rat diaphragm that dexamethasone simultaneously decreased the concentration of
sn-3-glycerolphosphate and glucose transport at low steroid
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concentrations that did not increase lipolysis.

These find-

ings could be explained by citrate inhibition of phosphofructokinase.
on Isoenzymes
-EffectItofhasInsulin
been observed that insulin increases

the propor-

tion of type II hexokinase in adipose tissue while total
hexokinase activity remains constant.

The mechanism leading

to this coordinate elevation in one isoenzyme and depression of another has not been studied.
Grossbard and Schimke (416) have examined the kinetics
'·

of rat hexokinase isoenzymes.

Al though the Michaelis con-

stant of type II hexokinase for glucose if five times greater
than that of the type I enzyme, the type II enzyme is about
three times less sensitive to inhibition by complex of magnesium and adenosine-5'-diphosphate.

MgATP inhibition of

the rat isoenzymes appears to be more important that that
produced by glucose-6-phosphate.
changes near pH 6.8.

It is sensitive to pH

Bohnensack and Hofmann (88) have

found that the Michaelis constant of the enzyme for glucose
increases with increasing pH.

Furthermore, the product in-

hibition of the enzyme seems to decrease with increasing pH.
Noat et al (787) have determined that the inhibitory effect
of uncomplexed ATP under certain conditions may ne due to
an interaction with a yeast hexokinase-glucose complex and
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that the inhibitor effect of excess magnesium under certain
conditions may be due to the formation of a Mg 2ATP_ complex
which decreases the concentration of the substrate MgATP.
such observations emphasize the importance of the proper
ratio of magnesium to adenine nucleotides in the control of
the activity of the enzyme.
Inhibition by Mg.ADP may be more important in the con·trol of the enzyme because it can be removed only by oxidative or substrate phosphorylation of the nucleotide.
since most of the studies with MgADP have not been carried
out with an equivalent amount of inorganic phosphate, the
full regulatory significance of MgADP inhibition of the
enzyme remains to be determined.

However, Blair (80} has

simulated the hexokinase reaction with the aid of a computer and he concluded that magnesium ion. may act as a
feedback signal to the enzyme from the adenine nucleotide pool.
The interactions of magnesium and nucleotides is perhaps best seen in the complex kinetics of mitochrondrial
nucleoside diphosphate kinase which has been studied by
Goffeau et al (378).

They also demonstrated that the true

substrates for this enzyme were magnesium-nucleotide
complexes:
MgATP + MgXDP

~-

~

l

.

.

= MgADP

+ MgXTP
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The complex MgADP was found to be fifty times more inhibitory
to the enzyme than excess MgATP.

From a study of the kinetic

behavior of the enzyme, Goffeau et ·a1 concluded that the mechEP
anism was of the order~ping-pong type, i.e. a phosphorylated
enzyme was an intermediate in the reaction.

Furthermore,

from differences in the pH dependencies of substrates and
inhibitors of the reaction these workers concluded that the
enzyme had an allosteric site for MgXDP in addition to the
substrate site and that the enzyme was a regulatory enzyme
in metabolism.

This conclusion was strengthened by the

studied of Thompson and Atkinson (1058) who found that the
activity of the enzyme was regulated by the energy charge
of the adenine nucleotide pool.

Klachko (395)

~as

also

postulated that the mechanism of action of insulin could
be explained by its activation of the enzyme.

Further

studies are necessary.
The interpretation of the inhibition patterns of two
substrate reactions is complex.

However, if a reaction

is ordered, a mixed or non-competitive inhibitor of the
first substrate will usually appear to be a competitive
inhibitor with respect to the second substrate.

Hanson

and Fromm (426) as well as Toews (1069) have studied the
kinetics of rat skeletal muscle hexokinases.
Toews demonstrated that at pH 8.0 MgADP was a
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non-competitive inhibitor of MgATP while glucose-6-phosphate
was a mixed inhibitor of glucose and a non-competitive inhibitor of MgATP.

Since a non-competitive inhibitor may be an

uncompetitive inhibitor, these results are compatible with
an ordered mechanism for rat skeletal muscle type II hexokinase in which MgATP adds first to the enzyme.

It should

be noted that the above results were observed at low MgADP
levels.

Kosow (609) noted that high levels of MgADP may

.produce mixed inhibition with respect to MgATP by blocking
the release of glucose-6-phosphate may produce mixed

in-

hibition with respect to MgATP by interacting at an allos:

.

teric site on the enzyme.

These latter effects are similar

to those which have been observed with nuc.leoside diphosphate kinase.
In contrast to the mechanism of rat type II hexokinase, Noat et al (785) in their study of yeast hexokinase
noted that the reaction is ordered at pH 8.5 and that glucose adds first to the enzyme.

Glucose-6-phosphate inhibi-

tion was found to be competitive with respect to glucose
at an ionic strength of 0.30 but non-competitive with respect to MgATP.

On the other hand, Fromm (343) has demon-

strated mixed inhibition by glucose-6-phosphate with respect to glucose at pH 7.7, 0.05 ionic strength.

Other

workers (88) have confirmed that the non-competitive
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component of this inhibition decreases with increasing pH.
These results indicate that apparent enzyme mechanisms may
change with pH.
The regulatory significance of the difference in mechanism between yeast and type II hexokinase is unclear.

How-

ever, while glucose-6-phosphate is generally a competitive
inhibitor of yeast hexokinase with respect to glucose, glucose-6-phosphate is a competitive inhibitor of the type II
enzyme with respect to MgATP only at low MgADP levels.

The

main effect of MgADP inhibitiqn in the muscle enzyme appears
to be to change glucose-6-phosphate inhibition with respect
to MgATP from a competitive to a mixed type.
Neat et al (786) obtained good agreement between calculated and experimentally produced curves of the progress of
the hexokinase reaction versus time.

They have used this

curve to substantiate their conclusions regarding the mechanism of yeast hexokinase.

A similar technique may be used for

general isoenzyme analysis.

It appears that if all isoenzymes

of a given enzyme have the same mechanism, but different kinetic constants including product inhibition constants, the kinetic constants of the isoenzyme mixture will be a linear combination of the kinetic constant of the purified isoenzymes.
Computer analysis of the reaction progress curve should then
permit calculation of the isoenzyme composition.

This approach
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may be most successful with the five lactic dehydrogenase
isoenzymes which are of no little clinical importance (956).
Type II hexokinase is very similar in structure to
the other mammalian hexokinase isoenzymes with respect to
molecular weight, number of subunits, pH optimum, and
other kinetic parameters.

It presumably contains both

type I and type III protein subunits since it migrates
between types I and III on electrophoresis.

On this ba-

sis one would expect type II hexokinase to respond similarly to type III hexokinase under a variety of experimental conditions.
Shanygina (973) found that glucocorticoid treatment
decreased heart hexokinase II 60 percent and liver hexokinase II by 73 percent.

Although some compensatory in-

crease in hexokinase I activity occurred in both tissues,
the total hexokinase activity was reduced.

Hexokinase II

is also the isoenzyme which responds to insulin treatment
which reverses the glucocorticoid effect.

The effect of

cortisol and its blockade by insulin are probably effects
on the transcription of DNA and different from the in
vitro effects of these hormones on yeast hexokinase as
described by Ilyin and Titova (507, 508, 1066, 1067).
Recently, effects of insulin on metabolism in the absence of glucose have been demonstrated (897).

This implies

114

that insulin has effects other than its effects on glucose
transport.

In a study of the transport of 2-deoxyglucose

in muscle, Kipnis and Cori (584) found that insulin in vitro
could further increase the accumulation of 2-deoxyglucose-6phosphate after initial accumulation in the absence of insulin had ceased.

,•
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CHAPTER VI

.

GLUCOCORTICOIDS AND CYCLIC ADENYLATE

.

~fects

on Triglyceride Synthesis and Lipolys·is

Glucocorticoids inhibit the formation of glyceride glycerol in the absence of epinephrine but enhance its formation in the presence of epinephrine.

These glucocorticoid

effects may be mediated via citrate inhibition of the phosphofructokinase and pyruvate dehydrogenase reactions in
the absence of cyclic adenylate.

The abolition of the in-

hibitory effect of citrate on phosphofructokinase by cyclic
adenylate, will also be considered.

In addition, the mech-

anism by which glucocorticoids may affect citrate levels
will be discussed.
tc

~·

r
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As in any study of hormonal effects, observations must
begin with those on intact animals.

Levin and Farber (653)

found that adrenalectomized rats could not mobilize fat

i!.'

t

to the liver during fasting because glucocorticoids are

i

required for the lipolytic effects of growth hormone in

1·
~

'

fasting.

Wilhelmi (1150) found that insulin was required
115
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for lipogenesis from acetate and carbohydrate.

However, cor-

tisone administration inhibited lipogenesis from these
sources. He noted that growth hormone treatment increased
fatty acid oxidation and reduced the respiratory quotients
in the animals and that this action of growth hormone required the administration of a small amount of cortisone
which was ineffective when administered alone.

At a con-

stant level of administered growth hormone, glucosuria also
remained constant throughout a 10-f old elevation of adrenocorticotrophin~

On the other hand, at a constant level of

administered adrenocorticotrophin, glucosuria was directly
proportional to the dose of growth hormone.

These results

indicate that the glucocorticoid requirement is saturated
by relatively small amounts of the hormone while the growth
hormone requirement is not.
Welt and Wilhelmi (1133) found that growth hormone and
adrenocorticotrophin decreased the incorporation of deuteriurn into the body fat of the rat while adrenalectomy had
the opposite effect.

The importance of such a decrease is

.indicated by the observation of Lukens (680) who pointed
out that the normal rat converted 3 percent of its daily
intake of carbohydrate to glycogen, 30 percent to fat, and
67 percent to carbon dioxide.

This action of growth hor-

mone and glucocorticoids may also be important in diabetes
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for, as noted by Chaikoff (166), lipogenesis from glucose
was much more depressed than glycogen formation in this
condition.

Lukens noted that, although glucocorticoids and

growth hormone depressed deuterium incorporation into fat,
normal rats incorporated almost three times as much acetate
as pyruvate into fatty acids as hypophysectomized rats indicating that inhibition of pyruvate dehydrogenase was a
major effect of growth hormone and glucocorticoids in nor· mal rats.

In addition, the fact that adrenalectomized

rats did not accumulate total body fat in spite of greater
fat synthesis, indicates that adrenalectomy also increased
fat oxidation.

The mechanism whereby the adrenal inhibits

fat oxidation is unknown but appears to be related to the
catabolic effects of glucocorticoids on peripheral tissues
leading to a sparing of body fat stores.
I

Effect of Growth Hormone on Fatty Acid Oxidation
Although glucorticoids may decrease fat oxidation in
~'

growth hormone treatment leads to increased fatty

acid oxidation.

Greenbaum (407) observed that total body

fat fell from 40 percent to 20 percent after growth hormone
administration.

Greenbaum and Mc Lean (408) also observed

increased hepatic fatty acid oxidation between 12 and 24
hours after growth hormone in rats, but noted that fatty
acid oxidation was inhibited 6 hours after administration
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of the hormone.
~--

These findings may indicate that growth hor-

mone does not directly increase fatty acid oxidation in the
liver, but, rather, that the increased hepatic oxidation is
secondary to increased lipolysis in the adipose tissue.
Swislocke and Szego (1043) also observed a reduction in
serum free fatty acids in dogs within 30-60 minutes of growth
hormone administration.

In contrast, the increase in serum

free fatty acids which was simultaneous with the increased
fatty acid oxidation noted above was not observed until 12

..

hours due to the requirement of DNA and protein synthesis for
the lipolytic response (407).

Presumably, the protein synthe-

sized under these conditions interacts with glucocorticoids
and activates adipose tissue lipase.

The early reduction of

serum free fatty acids is believed to be due to a stimulation of insulin secretion by growth hormone.
·Irifluence of Dietary Carbohydrate
Goodman (391) found that the effect of growth hormone
on glucose metabolism in adipose tissue depends on the carbohydrate and fat content of the diet.

On high-carbohydrate,

low-fat diets, the effects of growth hormone in hypophysectomized rats is similar to the effects of growth hormone in
normal rats.

Serotonin released by growth hormone may func-

tion as a glucocorticoid under these conditions.·

Goodman

(397) has also found that growth hormone inhibits glucose
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oxidation and lipogenesis in fed hypophysectomized rats at
;·

concentrations which are not lipolytic.

However, the fact

that the rats used in these experiments had not been hypophysectomized by the author far enough in advance of the experiments to permit cortical atrophy does not eliminate a necessity for glucocorticoids in the effects of growth hormone.
Growth hormone and glucocorticoids are ineffective in stimulating lipolysis when added in vitro to such a system unless
.the hypophysectomized rat has been treated with growth hormone for two days prior to the experiment.
'

Toxicity of Growth Hormone
The accelerating effect of growth hormone on fatty
acid oxidation may not persist during chronic growth hormone administration.

Winkler et al (1166) observed that

this effect of the hormone could not be observed following
7 days of continuous treatment.

De Bodo and Sinkoff (218)

also observed this effect and further noted that growth
hormone was toxic on prolonged administration.

·Glucocor-

ticoids eliminated the toxicity and counteracted growth
hormone-stimulated insulin release.
Hypophysectomy greatly reduces the lipolytic effect
of epinephrine, abolishing the response at low epinephrine
levels.

Part of the effect of hypophysectomy has been at-

tributed to the absence of ACTH-stimulated cortisol synthesis.
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cyclic adenylate produced in response to epinephrine activates
phosphofructokinase and enhances the formation of glyceride
glycerol.

In the presence of epinephrine, adipose tissue

from hypophysectomized rats esterifies 80 percent of the free
fatty acids hydrolyzed during lipolysis compared to 70 percent in the presence of all pituitary hormones.

Glucocorti-

coids alone enhance the effects of low epinephrine levels in
hypophysectomized rats.

However, the effects of high epi-

· nephrine levels are not enhanced.

Furthermore, the fact that

glucocorticoids exert no effects in hypophysectomized rats in
the absence of epinephrine indicates that the effect of glucocorticoids under these conditions is due to an inhibition
of the enzyme phosphodiesterase which has been described {969}.
Role of Phosphodiesterase and Theophylline
Changes in phosphodiesterase activity cannot explain
the effects of glucocorticoids in the presence of growth
hormone because these effects occur with no change in.the
~-

concentration of cyclic adenylate {395}.

~}1!

Fain {299} noted

fc.

that insulin, nicotinic acid, prostaglandin E

1

and 1-phen-

ethylbiquanide inhibited the basal lipolysis of isolated
fat cells as well as lipolysis caused by catecholamines,
ACTH, growth hormone and glucocorticoids.
Weiss et al (1129} were among the first investigators
,,,

to postulate .a role for cyclic adenylate in adipose tissue

l.,;: .
.....

------------------

---

----
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lipolysis.

They also noted that the 1,3-dimenthylated xan-

thine theophylline and adrenocorticotrophin had lipolytic
effects.

They reported that the maximal response to nore-

pinephrine was only one-third that of theophylline suggesting that theophylline had lipolytic effects which were not
mediated by cyclic adenylate.

Compared with

norepinep~rine

adrenocorticotrophin was 100 times as active on a molar
basis.

Epinephrine and adrenocorticotrophin activate

adenyl cyclase by different mechanisms

(146, 148).

f.

The single phosphodiesterase enzyme which controls the
degradation of cyclic adenylate is just as important as
that which controls the formation of this nucleotide.
Senft et al (968) noted that the activity of the enzyme was
decreased in liver and adipose tissue of alloxan-diabetic
rats thus explaining the increase in cyclic adenylate in
these organs.

Senft et al (969) observed that glucocorti-

coids also depressed the synthesis of phosphodiesterase

by a mechanism that involved DNA and protein biosynthesis.
Neither the action of insulin in increasing the synthesis
of the enzyme nor that of glucocorticoids in decreasing
enzyme synthesis can account for the lipolytic effects of
theophylline which do not involve an elevation in cyclic
adenylate.

Bernbaumer et al (137) noted that neither growth

hormone nor glucocorticoids alone directly affected enzyme

-.
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activity.
·~

Cyclic Adenylate
-N6-2 '-Dibutryl
Many investigators have used the N6-2'-dibutryl derivative of cyclic adenylate in their experiments because of
its more rapid penetration into cells.

They have assumed

that all of the effects of the derivative are due to its
conversion to cyclic adenylate.

However, Solomon et al

(1002) have shown that the dibutyrl derivative may have
opposite effects •. The dibutyrl derivative has an inhibitory effect on glucose utilization whereas the unsubstituted nucleotide stimulates glucose utilization.

The

reason for this difference is not immediately apparent
but the phenomenon should be kept in mind when interpreting
the actions of the cyclic adenylate derivative.
Glucocorticoids have two distinct effects on adipose
tissue both of which requires the action of growth hormone.

The glucocorticoid effect which occurs at lowest

concentration is only relatively specific in that it can
also be produced by deoxycorticosterone (293).

This ef-

feet is produced by the interaction of these steroids with
a growth hormone-dependent protein.

The steroid-protein

complex then increases cytoplasmic citrate levels.

Higher

concentrations of glucocorticoids specifically interact
·With another growth hormone-dependent protein to increase
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the activity of adipose tissue lipase.

At 0.01 µg/ml dex-

amethasone, 9a-fluoro-11S,17a,21-trihydroxy-16a-methyl-l,
4-pregnadiene-3,20-dione, has no significant effect on lipolysis but decreases palmitate-1-

14

c

incorporation into

triglycerides from 82 percent to 58 percent of the total
fatty acids released by lipolysis (370, 371).

Similar

results were reported by Jeanrenaud and Renold (526) and
are shown in Table II.

Glucocorticoids alohe in the ab-

sence of growth hormone also have effects on transcription
in adipose tissue.

For example, Senft et al (969) found

that glucocorticoids depressed the biosynthesis of the
enzyme phosphodiesterase in adipose tissue thereby enhancing the effects of theophylline, a phosphodiesterase
inhibitor, on adipose tissue.

Butcher et al (146) also

showed that nicotinic acid could inhibit the enzyme while
imidazole activated the enzyme, but the biological significance of these observations has not been determined.
Moskowitz and Fain (762) also showed that cycloheximide inhibits phosphodiesterase and increases cyclic
adenylate.

They found that growth hormone could also in-

crease cyclic adenylate but only after a one-hour lag
period in which DNA, RNA and protein synthesis was mandatory.

However, their most. surprising finding was that

1 mM theophylline stimulated lipolysis maximally so that

Jlll#JM2?4J>14111Z-144#$A.@4&41l£1&a;:;aJJP::•::M4Ai&l-••·""_,,..._ _."."444AAQ!,
EFFECT OF 9a-FLUORO-llS,17a,21-TRIHYDROXY-16a-METHYL-l,4-PREGNADIENE-3,20-DIONE
IN VITRO ON GLYCEROL-FFA BALANCE IN ADIPOSE TISSUE FROM FASTED RATS

µrroles/gm of wet tissue wt
Total Lip:'.)lysis
(Net Glycerol x 3)

Net FFA
Production

Controls

30.6

22.0

Glucocorticoid

33.5

30.5

-

FFA ReEsterif ied

Re-Esterification
Percent of
Total Lip:'.)lysis

8.6

28

3.0

9

0.1 µg/ml

From Jeanrenaud and Renold (526)

Incubations carried out for 4 hours in a Krebs-Ringer bicarl:x:mate buffer containing
5 rrM glurose.
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it was not increased by growth hormone and glucocorticoids.

Furthermore, this effect occurred with no elevation in cyclic adenylate.

These results indicate that growth hormone

and glucocorticoids do not increase lipolysis by increasing
cyclic adenylate.

Rather, these hormones produce an ef-

fect similar to that of theophylline which is also not active by virtue of its inhibition of phosphodiesterase.

'·

The mechanism whereby the combination of the growth hormone-dependent protein and glucocorticoid affects citrate
levels has not been determined.
Munk (769) found that deoxycorticosterone in vitro
could also reverse the effect of adrenalectomy but that
it was less effective than either corticosterone or cortisol.

Inhibitory effects of cortisol on the incorpora-

:{<

tion of acyl coenzyme A into triglycerides were observed
at concentrations of 10- 6 Molar during a 2.5 hour incuba-

'i'

tion.

Fain et al· (299) demonstrated that the lipolytic

effect of growth hormone appeared immediately if the glucocorticoid was added to adipose tissue which had previously
been incubated for 2.5 hours with growth hormone.

The

fact that deoxycorticosterone can block triglyceride synthesis at higher concentration suggests that other steroids
and non-steroids may also produce this effect by occupying
glucocorticoid sites.

Although glucocorticoids may have
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the highest affinity for this site, it is not as specific a
receptor site as that which leads to the stimulation of hepatic glycogenesis.
Hepatic Glucocorticoid Receptor Proteins

-

An example of a specific glucocorticoid effect is seen

in the work of Beato et al (54) who have isolated a glucocorticoid receptor protein from liver which they have implicated in the transport of the cytoplasmic hormone to
the nucleus where the glucocorticoid inducation of gluconeogenic enzymes occurs.

On the other hand, an example of

a non-specific glucocorticoid effect is seen in the study
of Dugle et al (510) on the diabetogenic action of steroids.
They found that those steroids with keto groups at C-11
were more diabetogenic than llS-hydroxy compounds.

The com-

pound·4-pregnene-3,ll,20-trione was more diabetogenic than
llS-hydroxy-4-pregnene-3,20-dione.

This observation is

somewhat similar to observations that have been made concerning the anti-tumor potencies of steroids (369).
Effect of Triiodothyronine in Hypoehysectomized Rats
In hypophysectomized rats, triiodothyronine has effects similar to growth hormone and glucocorticoids.

It

increases the sensitivity of adipose tissue to epinephrine
after a three-hour incubation and to theophylline after a
twelve-hour incubation (397).

These findings indicate
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that the hormone has at least two effects, one of which may
be related to phosphodiesterase activity.
Norepinephrine is probably responsible for most of
the glycerol release from adipose tissue.

However, when

the basal.state is altered by epinephrine from the adrenal
medulla, this catecholamine increases the synthesis of
cyclic adenylate.

''

.

Cyclic . adenylate activates a specific

lipase which non-stereo-specifically hydrolyzes one fatty
acid from triglyceride substrates.
The degree to which glycolysis is coupled to pyruvate oxidation is determined by the lactic dehydrogenase isoenzyme composition in the tissue.
ing occurs with LDH

1

Tight coupl-

in heart and the level of NADH is

more stritctly regulated than it is by LDH

5

in liver so

that elevated levels of pyruvate and NADH prevail during
gluconeogenesis.
Effects of Diabetes on Citrate and Pyruvate Levels
Dixit et al (238) have reported that a 2-3 fold elevation in muscle citrate is found in alloxan-diabetic rats.
More importantly, they found a decreased rate of citrate
oxidation by muscle but not by liver.

.
l
I:·
'

.

These results may

be due to the more rapid glucocorticoid metabolism of the
liver in comparison to peripheral tissues.

If true, the

rate of glucocorticoid metabolism could influence diabetes
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by this mechanism.

Henneman and Bunker (450) reported that human diabetics
had higher levels of serum pyruvate due to a reduced capacity to oxidize pyruvate.

This appears to be a direct con-

sequence of the unopposed action of glucocorticoids since
Haugaard and Haugaard (435) observed the same phenomena in
alloxan-diabetic rats.
The degree of inhibition of pyruvate utilization relative to glycolysis is indicated by the percentage of blood
glucose carbon which returns to the liver as glycerol or
lactate to be incorporated into hepatic glycogen.
process has been termed recycling.

Friedman et al

This
(3~7)

demonstrated that diabetic rats recycle 2.4 percent of
their glucose compared to.1.2 percent for normal rats •
.,
f'

This finding indicates that insulin decreases recycling.
However, these same workers found that glucocorticoids
did not affect recycling.

This could be interpreted to

mean that glucocorticoid-induced elevations in .. citrate
inhibited glycolysis and pyruvate utilization to approximately the same extent.
Elevations in muscle citrate in diabetes have been
demonstrated by Garland et al (358) and by Garland and
Randle (359).

Wieland and Wies (1147) hav:e shown that a

3-fold elevation in hepatic acetyl coenzyme A occurs in
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cortisol-treated diabetic rats compared to similar rats
treated only with insulin.

Cahill et al (i51) reported that

insulin decreased the conversion of glucose to glyceride
glycerol 5-fold.but that this conversion was increased by
epinephrine.

Epinephrine increases cyclic adenylate which

decreases the km of phosphofructokinase for fructose-6phosphate.
·

Apparently, this effect is sufficient to over-

come the inhibition of phosphofructokinase by MgATP.

In

addition, the depletion of ATP produced by the activation
of phosphofructokinase and hexokinase increases the conversion of triose phosphates to pyruvate.
Renold et ~l (878) and Phillips ~t ~l (833) reported
that lipogenesis from pyruvate was reduced 9-fold while
glucose utilization was reduced only 25 percent by cortisol in the presence of 10- 4 Molar epinephrine.

Deoxycor-

ticosterone in vitro is 50 percent as effective as cortisol
at a concentration of 30 µg/ml

(769).

Munk also found that

lipogenesis was depressed in fat pads from adrenalectomized
rats by the administration of 2.5 mg/kg cortisol before
sacrifice.
Fain et al (299) reported that 0.004 µg/ml dexamethasone reduced the glucose uptake of the fat pad from 3.19
to 1.24 µmoles per 100 mg of tissue while pretreatment of
the tissue with higher concentrations

(0.032 µg/ml)

for
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1.5 hours resulted in up to 75 percent inhibition of glucose
'

'

uptake.

Goodman and Knobil (389) also noted that glucocor-

ticoid treatment of hypophysectomized rats restored their
lipolytic response to epinephrine but not to

~rowth

hormone.

This finding is important because it indicates that glucocorticoids can enhance the effect of cyclic adenylate quite
independently of its action with the growth hormone-dependent protein which leads to_ an increase in citrate levels.
The effect of glucocorticoids on cyclic adenylate in the
absence of growth hormone appears to be due to the induction of a glucocorticoid-dependent protein which .inhibits
the enzyme phosphodiesterase (969).

This inducation does

not explain glucocorticoid effects in the absence of changes
·in the level of cyclic adenylate.
Yorke (1189) has found that glucose transport is inhibited by low glucocorticoid concentrations which are not
lipolytic.

Citrate inhibition of phosphofructokinase

raises glucose-6-phosphate which, in turn, may raise the
km of hexokinase for glucose, thereby reducing enzyme
activity and the glucose concentration gradient which
partly determines glucose transport.
Control of Lipogenesis
Adipose tissue can respond to both the specific and
non-specific effects of glucocorticoids.

In 1951 Brady
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al (112) observed that cortisone treatment depressed both

triglyceride and carbon dioxide formation from glucose.
Landau and Katz (628) estimated that from 11-23 percent of
glucose in adipose tissue was metabolized via the pentose
phosphate shunt.

However, Wies and Ball (1172) noted that

most of the NADPH necessary for fatty acid synthesis in
adipose tissue was formed in the tissue by the operation
of the malate cycle:
Pyruvate +

co 2

+ATP = Oxalacetate +ADP + Pi

Oxalacetate + H+ + NADH = Malate + NAD+
Malate + NADP
Sum:

+ = Pyruvate +

co 2

+ NADPH

NADH + NADP+ +ATP.= NAD+ + NADPH +ADP + P.

1

The operation of this cycle explains the observations of
Landau et al (629) that.the amount of NADH'generated during
fatty acid synthesis was excessive while the rate of operation of the pentose shunt

cou~d

NADPH required for synthesis.
xylase in this cycle explains

not account for all of the
The role of pyruvate carbo-

~ts

presence in adipose

tissue in the absence of gluconeogenesis.

Furthermore,

those factors which inhibit the pyruvate dehydrogenase
reaction may increase the malate cycle.
Ball (40) determined that epinephrine could activate
glycolysis in adipose tissue about 24 percent.

As men-

tioned earlier this effect is due to an action of cyclic
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adenylate on phosphofructokinase as well as to an elevation
of long-chain acyl coenzyme A.
The anti-insulin effects of growth hormone and glucocorticoids occur in isolated adipose tissue and do not require the presence of B lipoprotein.

However, the fact

that growth hormone and glucocorticoids increase B lipoprotein insulin inhibition in vivo but not in vitro simply
reflects the role of the liver in B lipoprotein synthesis.
Therefore, B lipoproteins may transport the factor which
mediates the citrate elevation caused by growth hormone
and glucocorticoids in isolated tissues.

Furthermore,

the B lipoprotein insulin antagonist may be identical
with the lysolecithin species described by Bolton et al
(89) which increases the inhibitory effect of ADP on
platelet metabolism.
Investigations of the hormonal dependence of the synalbumin insulin antagonist by Vallance-Owen et al (1084) indicate that this antagonist is also dependent on both
growth hormone and glucocorticoids.

Although the exact

nature of the synalbumin antagonist is unknown, its reported properties are not inconsistent with those of a
polar lipid.

Lysolecithin is found in association with

plasma albumin as is the synalbumin antagonist.
~

If the

synalbumin insulin antagonist is a lysolecithin dependent

133
on growth hormone and glucocorticoids, then another lysolecithin species bound to 8 lipoprotein may also be dependent on these two hormones.
Winternitz

~t

al (1170) showed that the effect of epi-

nephrine on glycogenolysis and glycolysis was enhanced in
adrenalectomized rats.

Epinephrine produced a 62 percent

fall in muscle glycogen in adrenalectomized rats compared
to a 34 percent fall in normal rats.

In addition, in the

normal rat the muscle glycogen which disappeared could be
accounted for as liver glycogen while that in the adrenalectomized rat could not.

Thus, it ·appears that glucocor-

ticoids also enhance the gluconeogenic process under these
conditions.

The extent of glycogenolysis in muscle com-

pared to liver depends on the catecholamine used to elicit
the effect.

Isopropyl noradrenaline preferentially in-

creases muscle glycogenolysis and has little or no effect
on liver glycogen.
creased glycolysis.

Glycogenolysis in muscle implies inThe normal response of adrenalec-

tomized rats to epinephrine could be restored by the administration of adrenal cortical extract 12 hours prior·
to the experiment or by the administration of cortisone
for 24 hours beforehand.

In diabetic rats, liver glyco-

gen as well as muscle glycogen falls after epinephrine,
suggesting that insulin is required for the formation of

L
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iiver glycogen from glucose synthesized in the liver.

The

enhanced effect of epinephrine was not seen in adrenalectomi zed-eviscerated rats and this may indicate that the
liver produces a factor under the influence of glucocorticoids which increases the effect of epinephrine.

This

factor may or may not be identical to the anti-insulin
factor discovered by Bornstein (98) which is transported
to peripheral tissues as a lipoprotein complex.

Winternitz

has pointed out that the necessity for the liver in the proauction of the epinephrine opposing factor may partially
explain Russell's (917) finding that there was no difference in the glucose tolerance of normal eviscerated and
adrenalectomized-eviscerated rats maintained on deoxycor·,

·

ticosterone.

It would also explain her finding that the

increased sensitivity of the adrenalectomized rat to insulin is abolished by evisceration.

If the primary ef-

feet of the hepatic factor is to decrease the levels of
cyclic adenylate (290), it may be the same as that of the
lysolecithin reported by Bolton et al to combine with

B

lipoprotein and increase platelet aggregation.
Friedman et al (337) have found that ·glucocorticoids

.
I
~·.

'·

are required for the effect of hepatic cyclic adenylate
on gluconeogenesis even though these steroids do not alter
the concentration of the nucleotide.

Bernbaumer et al
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(137) have also shown that growth hormone and glucocorticoids either alone or in combination do not activate adenyl
cyclase but they do enhance the action of cyclic adenylate
already formed.
Scrutton and Utter (960) noted that glucagon and therefore cyclic adenylate enhanced pyruvate carboxylase activity
in liver.

Furthermore, Friedman· ·et ·a1 (337) found that the

rate of gluconeogenesis from lactate was enhanced by glucagon in livers from intact rats but not in livers from ad~

renalectomized rats.

This response could be restored by

'

the addition of glucocorticoids to the perfused liver.
Meismann and Segal (730) have noted ·similar behavior in
the effects of cyclic adenylate on the kinase which acti~·

vates hepatic glycogen synthetase.
Although the induction of gluconeogenic enzymes is
enhanced by glucocorticoids and opposed by growth hormone,·
not all of the effects of glucocorticoids on the liver can
be blocked by inhibitors of DNA and protein synthesis.
Long et al (676) found that doses of cortisol which have
no effect on gluconeogenesis from protein have a marked .
inhibitory effect on glucose utilization in adrenalectomized-diabetic rats.

These results suggest that the same

glucocorticoid-dependent factor formed in the liver inhibits glycolysis there and in peripheral ·tissues.
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One of the factors regulating gluconeogenesis is lipolys is.

Williamson et al (1156, 1157) have pointed out

that none of the steps in the conversion of fatty acids to
acetyl coenzyme A or to acyl carnitine are rate-limiting
for fatty acid oxidation.

The ratio of NADH to NAD+ is

increased by fatty acid oxidation and NADH is the main
source of reducing equivalents for gluconeogenesis.
Vohainy et al (1107) have similarly commented on the
failure of added carnitine to enhance palmitate oxidation
in the perfused rat heart in vitro.

On the other hand,·

carnitine reduced the rate of palmitate oxidation and increased the labeling of the phospholipid fraction.

The

reported enhancement of fatty acid oxidation by carnitine
in isolated mitochondria may be related to the loss of
endogenous carnitine during the preparation of the mitochondria.
Effect of Ethanol on Gluconeogenesis
Although gluconeogenesis is increased by an increase
in the reduction potential of the pyridine nucleotides,
excessive reduction potentials may actually inhibit gluconeogenesis as well as peripheral glucose utilization. ·In
a study of ethanol-induced hypoglycemia Lochner et al (671)
found that the cause was an inhibition of gluconeogenesis
in spite of the fact that ethanol inhibited peripheral
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glucose utilization 25 percent.

Both the inhibition of glu-

cose utilization as well as the decrease in gluconeogenesis
may be attributed to an excessive reduction of pyridine nucleotides.

Krebs (618) has shown that NADH depletes hepat-

ic pyruvate by converting it to lactate thereby reducing
the rate of the pyruvate carboxylase reaction.
The increase in the reduction potential of the pyridine nucleotides by ethanol depends on the preferential
utilization of ethanol over other respiratory substrates.
The conversion of ethanol to acetate does not require the
utilization of adenosine-5'-triphosphate.

On the contrary,

NADH is generated in the alcohol dehydrogenase and aldehyde dehydrogenase steps.

Thus, ethanol is oxidized in

preference to other respiratory substrates because its
oxidation is associated with a greater free energy decrease
than the oxidation of other substrates.
Effects of Clavine Alkaloids
The fact that theophylline can produce all of the effects of growth hormone and glucocorticoids indicates the
possibility that a similar. endogenous compound may be involved in the effects of these hormones.

Brek et al (116)

reported that serotonin was lipolytic in vitro.
~

Hotta et

(477) further demonstrated that dihydroergotamine en-

hanced lipolysis in isolated rat adipose tissue cells.
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This effect is opposite to that expected from an adrenergic
blocking agent.

In related experiments Harvey et al (432)

showed that the non-peptide ergot alkaloid ergonovine could
block the hyperglycemic effect of epinephrine, although the
dose required was about 40 times higher than that required
for the same effect with the a-adrenergic blocking agent
ergotamine.

These results suggest that only non-peptide

ergot alkaloids can block the effects of cyclic adenylate.
Fain (298) has also shown that the lipolytic effect of dihydroergotamine was potentiated by theophylline suggesting
that the two drugs share a common receptor site.
Hotta et al (477) reported the lipolytic effects of dihydroergotamine on adipose tissue cells.

They noted that

the effect ·in· Vitro was similar to that observed in vivo and
also noted that insulin could counteract the effect.

Prior

treatment with theophylline and/or growth hormone enhanced
the effect which was similar to that of glucocorticoids in
that dihydroergotamine had no effect on lipolysis produced
by adrenocorticotrophin, thyroid-stimulating hormone, or
glucagon.

These effects were confirmed by Nakano ·et al

(775) and Fain (208).

These results are unrelated to the

blockade of adrenocorticorophin release by ergotamine observed by Levy and Raney (657) in adrenalectomized rats.
Northrop and Parks (789) also reported lipolytic effects
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obtained with growth hormone and glucocorticoids.
In contrast, Efendo and Ostman (271) found that theophylline did not increase the lipolytic effect of dexamethasone.

They observed that theophylline blocked the

conversion of glucose to glyceride glycerol without affecting the levels of cyclic adenylate.

Butcher and

Sutherland (145) have reported some properties of phosphodiesterase including its requirement for magnesium, stimulation by imidazole, and preferential inhibition by 10M theophylline.

2

The finding that theophylline blocks the

conversion of glucose to glyeride glycerol could mean that
theophylline has the same site of action as glucocorticoids, i.e. inhibition of triglyceride synthesis.

This

interpretation is born out by the finding that theophylline did not increase the lipolytic effect of glucocorticoids (397).
Bray and Goodman (115) also found that epinephrine
increased glycolysis in adipose tissue independently of
its lipolytic effect indicating that phosphofructokinase
~-

is affected by lower concentrations of cyclic adenylate
than the levels required to activate adipose tissue lipase.
On the other.hand, Karl et al (564) found that when the
synalbumin insulin antagonist acted on rat diaphragm, the
concentration of sn-3-glycerophosphate was increased even
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though glucose uptake was decreased.

This indicates that

the synalbumin antagonist inhibits the glycolysis of D-glyceraldehyde-3-phosphate.
Flatt (323) has emphasized that insulin-stimulated
fatty acid synthesis is an energy-yielding process for
adipose tissue cells.

It is therefore limited by the ca-

pacity of the cell to utilize the energy which is produced.
Because lipolysis in effect functions as an adenosine
triphosphatase in the metabolism of the cell, the rates of
fatty acid synthesis in the presence of epinephrine and insulin are greater than the rates in the absence of epinephrine.

Furthermore, Flatt has shown that fatty acid syn-

thesis is limited by the rate of triglyceride formation.
Rodbell (897) showed that insulin increased free
fatty acid uptake by adipose tissue cells in the absence
of glucose.

Larner, however, detected no change in eye-

lie adenylate after insulin.

These results suggest that

insulin decreases lipolysis by a mechanism independent of
cyclic adenylate.

This effect of insulin may explain why

adipose tissue is more sensitive to insulin than muscle
(151).

Anti-Lipolytic Effects of Oral Hypoglycemic Agents
Brown and Stone (129) observed that tolbutamide (1butyl-3-(p-tolylsulfonyl)urea] inhibits the lipolytic

141
effect of dexamethasone and growth hormone immediately and

~oes not require a lag period.

Likewise, Stone and Brown

(1034) determined that phenformin (1-phenethylbiquanide)
had an anti-lipolytic effect in the absence of glucose.
The lipolytic effects of DL-arterenol, ACTH, glucagon, and
theophylline were opposed by phenformin.

These results

suggest that tolbutamide directly opposes the anti-insulin
effect of glucocorticoids but that phenformin blocks the
action of cyclic adenylate as one of its principle effects.
Phenformin may also lead to inhibition of pyruvic dehydrogenase.

Moorhouse et al (757) observed that the drug de-

creased pyruvate tolerance more in diabetics than in control subjects.

These results suggest that phenformin may

also enhance citrate inhibition of pyruvate dehydrogenase
(721) in addition to its effects on cyclic adenylate.

CHAPTER VII
METABOLIC EFFECTS OF GLUCOCORTICOIDS

The non-lipolytic effects of glucocorticoids and
growth hormone. on glucose metabolism are most important
in the production of insulin resistance.
;·.,

~,.

Unfortunately,

most previous investigators of the anti-insulin action

~\

;,

~

of the hormones have studied them at lipolytic concentra-

f

tions.

A second complication of published investigations

is that they have been done on adipose tissue in which
{_'

the proportion of glucose metabolized via the EmbdenMeyerhof path varies with hormone concentration.
Effects of Hormones on Glycolysis in Rat Diaphragm
The effects of insulin and of other hormones on glucose metabolism have been extensively studied with the
isolated rat diaphragm preparation.

This technique was

introduced by Gemmill who found that insulin increased
both glucose uptake and glycogen synthesis.
hormone~

Adrenal

have also been studied with this preparation.

Epinephrine, the first known adrenal hormone, was

'
l

.
.
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investigated by Cori et al (200).

They found that epineph-

rine decreased glucose utilization.
firmed by Walaas and Walaas

This effect was con-

(1111) who found that 12 µg/ml

epinephrine significantly decreased glucose uptake but significantly increased lactate output by the rat diaphragm
preparation.

Glycogenolysis also increased so that muscle

glycogen was depleted within one hour.

These results sug-

gest that glucose-6-phosphate formed from glycogen glucose
can inhibit glucose uptake by causing end-product inhibition of muscle hexokinase isoenzymes.
On the other hand, Ingle and Nezamis
the infusion of glucose and

epi~ephrine

rats had no effect on glucose tolerance.

(518) found that

into eviscerated
Furthermore,

Bray and Goodman (115) found that epinephrine increases
glucose uptake

in

adipose tissue and Williamson (1154)

found the same effect in rat heart.

These latter findings

suggest that only high concentrations of epinephrine inhibit glucose uptake.
Ingle and Nezamis (514) also examined the effects of
adrenalectomy on the glucose tolerance of the eviscerated
rat.

They found that adrenalectomy increased the uptake

of glucose at low levels of glucose and insulin.

On the

other hand, at high levels of glucose and insulin, the
adrenalectomized rats had higher blood glucose levels at

..
IL:._
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the end of the infusion.

These results suggest that adrenal

hormones enhance glycogen formation in extrahepatic tissues
in the presence of insulin.

One possible explanation of

this effect is that adrenal hormones inhibit glycolysis
and thereby increase the intracellular concentration of
glucose-6-phosphate.

Another possible explanation is that

glucocorticoids increase glycogenesis by the kidney.

How-

ever, other studies have shown that the kidneys release
,;:

glucose into the blood only during hypoglycemia.

,

the first explanation is more probable.

Thus,

Additional sup-

port for it is provided by Bowman and Deimer (107) who
demonstrated that adrenalectomy increases the glycogenolytic effect of epinephrine.
Kipnis (585) confirmed these results with intact rat
diaphragm.

He noted that adrenalectomy did not affect

glucose transport, but that it did increase glucose phosphorylation in the presence of ,insulin.

Hypophysectomy,

while it decreased basal glucose transport in the absence
of insulin, also increased glucose phosphorylation in the
presence of insulin.

With the cut·diaphragm, in contrast,

hypophysectomy increased basal glucose transport but decreased glucose phosphorylation in response to insulin.
·Both adrenal and pituitary hormones decrease glucose phosphory],ation in the intact rat.

L
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Kipnis et al (586) also demonstrated intracellular free
glucose in muscle stimulated with epinephrine.

As discussed

previously, glucose-6-phosphate inhibits muscle hexokinases.
England and Randle (138) have shown that this mechanism may
account for over 90 percent of the inhibition of these enzymes under certain conditions.
less

im~ortant

phatase.

However, this mechanism is

in liver because it contains glucose-6-phos-

In addition, Ashmore et al (24) have reported

that the concentration of glucose-6-phosphate in diabetic
·liver is one-third normal.

These results suggest that the

effect of growth hormone and glucocorticoids on glycolysis
is more important in muscle and adipose tissue than in the
liver.

Ashmore et al (23) also noted that the rate of glu-

cose phosphorylation was markedly depressed in liver slices
from alloxan-diabetic rats.
Effect of Bicarbonate
Shaw and Stadie (977) first demonstrated the presence
.~,,,

~

of two identical Embden-Meyerhof pathways in normal rat

1".

~·

diaphragm.

f

and the other is intracellular.

ff

!:
"·t

One of these is located on the cell surface,
The fact that insulin

is effective in bicarbonate-phosphate buffer but· not in
phosphate buffer led to the discovery of these pathways.
Only intracellular glycogen formation and glycolysis were
increased by insulin.

On the other hand extracellular
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glycolysis was not responsive to insulin.

Apparently, in-

tracellular phosphofructokinase is inactive in the absence
of bicarbonate according to these workers.

Zahnd at al

(1195) also found that the effect of insulin on glucose
oxidation in adipose tissue was greater in the presence o.f
bicarbonate (Table III).

Most of these findings were con-

firmed by Landau and Sims (631, 985) using the intact rat
diaphragm.

They carried out all their experiments in bi-

carbonate buffer using either non-labeled or labeled glucose and glucose-6-phosphate.

They were, therefore, un-

able to confirm or deny the effect of bicarbonate on intracellular phosphofructokinase.

On the other hand, they

did show that insulin has no effect on the conversion of
added glucose-6-phosphate into glycogen or lactate.

They

also demonstrated that 11.6 percent of_ the total lactate
produced in the absence of insulin was produced by the
extracellular pathway.

This percentage was 11.1 percent

in the presence of insulin, but intracellular glycolysis
was increased only 5 percent under these conditions.

How-

ever, glycogen synthesis was increased 226 percent by 0.1
unit/ml insulin.
These results indicate that total glucose uptake is a
poor measure of glycolysis, especially in the presence of
insulin.

Lactate and carbon dioxide production are better
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TABLE III
EFFECT OF BICARBONATE AND PHOSPHATE ON THE RATIO OF
GLUCOSE CARBON 1 TO GLUCOSE CARBON 6 INCORPORATED
INTO co2, FATTY ACIDS AND GLYCEROL BY
ISOLATED EPIDIDYMAL ADIPOSE TISSUE

Percent of Control
Krebs-Henseleit
Bicarbonate
. OXidation to

Bicarbonate
Phosphate

co2

Horm:me

100.0

123.5

0.810

957.2

246.3

3.89

Epinephrine 18 µg/ml

72.3

57.8

1.25

G. H. (100 µg/ml)

65.7

60.2

1.09

100.0

111.3

0.90

59.7

56.5

1.06

125.8

80.7

1.56

75.8

137.1

.55

100.0

53.6

1.87

42.3

53.6

0.79

Epinephrine

140.2

110.3

1.27

G. H.

145.4

151.6

0.96

·No

Insulin (O.l U/ml)
-'~·

Kreb's Ringer
Phosphate

.

..,

Fatty Acids

...
No Honrone
.

Insulin
Epinephrine
G. H.
Gl::r:cerol

--i-

No Honrone
Insulin
~·

:

...

Zahnd et al (1195)
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indicators.

Also, the fact that the effect of insulin on

glycolysis is relatively small means that even a slight inhibition of its effect may be consequential.

The small in-

crease in glycolysis in response to insulin could be secondarY to insulin-stimulated glycogen formation.
zyme UTP:

As the en-

a-S-glucose-1-phosphate uridyltransferase [EC

2.7.7.9] utilizes UTP, it is regenerated from ATP by
nucleoside diphosphate kinase with depletion of the energy
charge (one-half the number of pyrophosphate bonds) of the
adenine nucleotide pool.

Glycolysis increases when this

occurs due to the action of control mechanisms which will
be discussed later.
in pco

2

Furthermore, physiological variations

may exert significant effects on glycolysis.

How-

ever, the effects of bicarbonate buffers on glycolytic enzymes have not been thoroughly studied.
clear.

One other point is

Since insulin in vitro can reverse the effect of the

insulin-inhibitor dependent on growth hormone and glucocorticoids, it must affect only the ·intracellular glycolytic pathway.
In their authoritative work on the influence of the
adrenal cortex on carbohydrate metabolism Long et al (673)
described several fundamental actions of glucocorticoids.
They found that in adrenalectomized animals "cortical extract produces a smaller proportion of glucose oxidation
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and a larger deposition of the absorbed glucose as liver

t

glycogen, while the muscle glycogen level is not increased."

l

In contrast to liver glycogen which can be increased in the
fasted rat by glucocorticoid administration, muscle glycogen cannot be increased by glucocorticoids unless the animals are fed

(676, 768).

Herring and Crans (453) noted that low doses of cortisol were much more effective in hypophysectomized rats
in maintaining muscle glycogen than in maintaining liver
glycogen.

Villee and Hastings (1103) confirmed these

findings using the isolated rat diaphragm and also demonstrated that part of the drop in muscle glycogen could be
attributed to increased glucose utilization following
adrenalectomy.

The greater effect on muscle glycogen com-

pared to liver glycogen indicates that gluconeogenesis is
not involved in this effect.
Long et al {674) further studied the effect of cortisol on the glucose tolerance of the eviscerated rat.

They

found that the infusion of 0.2 mg of cortisol per hour at
2, 3 or 5 hours before glucose administration or during
glucose administration did not decrease the glucose tolerance of the rat.

However, these tests were performed

without insulin so that glucose transport rather than glucose phosphorylation was limiting for glucose utilization.

l.
t·
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ce the fact that glucose phosphorylation is limiting
the conditions of the normal glucose tolerance test,
t

results are often cited as evidence for the lack of
feet of glucocorticoids on peripheral glucose utiliza-

t

E

c on Peripheral Glucose Utilization
~vidence

that glucocorticoids do depress the extra-

h:

LC utilization of glucose has been provided by Boutwell

a:

iiang (102).

t'

,irnover time of glucose was increased 50 percent while

tl

lte of glucose utilization was decreased to 65 percent

o::

> control value 4-6 hours after the administration of

l

c)f cortisone.

a

3e priming dose of 33 mg of cortisol to dogs prior to

t~

Jntinuous infusion of 1.3 mg of cortisol per minute.

T

~ound

o

t within 30 minutes with little change in blood glu-

e

Frawley (328) also showed that cortisol eliminated

In experiments with mice they noted that

Also, Lecoco 'et al (648) administered

that a 38 percent decrease in hepatic glucose

l

rmptoms of hypoglycemia before any changes in blood

g,

3e occurred.

C

~s

in Hepatic Glycolytic Intermediates

,ecoco et al (648) attributed the glycogen formation
F;
t

they observed to an increase in the hepatic concenan of glucose-6-phosphate, an activator of glycogen
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synthesis.

However, Hornbrook et al (476) observed a fall

in hepatic glucose-6-phosphate and uridine diphosphate glucose after cortisol administration.

Furthermore, the he-

patic concentrations of a number of other glycolytic intermediates did not change after cortisol.

Munk and Koritz

(768) observed that an elevation in blood glucose always
preceded the increase in liver glycogen by at least 30 minutes.

It appears that glucose-6-phosphatase is also acti-

vated under these conditions (22).
One reason for these discrepancies may be the diff iculty involved in measuring small significant changes in
blood glucose.

However, it appears that the activation of

glycogen synthetase cannot explain the increased glucose
output by the liver.

This can only pe explained by acti-

vation of glucose-6-phosphatase.

Furthermore, the explan-

ation that the initial increase in hepatic glycogen synthesis is not secondary to glucose-stimulated insulin release is supported by the fact that muscle glycogen rises
1 hour after both blood glucose and liver glycogen are
elevated.

If hepatic glycogen synthesis was caused by

insulin, it should have coincided with insulin-stimulated
muscle glycogen formation.
The Catabolic Effect of Cortisol
Long et al (676) also observed that glucose synthesis
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was not a consequence of protein catabolism.

Dur1ng the

first 4 hours following cortisol the total carbohydrate
content of the fasted rat increased 250 mg/kg with no increase in blood urea nitrogen.

The catabolic effect of glu-

cocorticoids appears to be due to an inhibition of amino
acid transport in peripheral tissues.

Tilton and Torralla

(1065) showed that the administration of cortisone acetate
to adrenalectomized-eviscerated rats accelerated the rate
of rise of plasma amino acids under all of the conditions
which they studied.

This finding has been confirmed in

eviscerated-adrenalectomized-alloxan-diabetic rats by Smith
and Long (997).
,...

Kostyo {610) showed that the effect of cor-

tisol, corticosterone, deoxycorticosterone, and 17a,21-dihydroxy-4-pregnene-3,20-dione occured after a three-hour
induction period at l0- 7M concentration.

.

Effects of Steroids on Glycogen
Shortly after the total synthesis of the adrenal steroids the effects of these hormones on glycogen formation
in rat diaphragm was determined.

Bartlett et al (48) used

labeled glucose to show that corticosterone was less potent
than deoxycorticosterone at 10 µg/ml in inhibiting glycogen
formation, thus confirming the earlier findings of Bartlett
and MacKay (41).

Verzar and Wenner (1099) further observed

that 5-10 mg/100 ml deoxycorticosterone increased.
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glycogenolysis while completely inhibiting glycogen synthesis caused by 10 milliunit/ml insulin.

In a subsequent

study Verzar and Wenner (1100) compared various hormones
in the inhibition of glycogen synthesis.

They found that

the order of potency was 3,4-bis(p-hydroxyphenyl)-trans-3hexene>progesterone>deoxycorticosterone>corticosterone.
This order of hormones is not correlated with hormone action
but is the order of decreasing polarity of the hormones, suggesting that they interact at a hydrophobic site.
Control of Gluconeogenesis and

Gly~ogenesis

Seubert et al (970) found that gluconeogenesis does
not require de novo enzyme biosynthesis.

However, the ac-

tion of pyruvate carbon dioxide ligase (ADP) (EC 6.4.1.1)
and GTP:

oxalacetate carboxy-lyase (transphosphorylating)

(EC 4.1.1.32) require the expenditure of four moles of high
energy phosphate in addition to those derived from glycolysis in order to reverse this process.
of pyruvate kinase, ATP:

Also, the activity

pyruvate phosphotransferase

(EC 2.7.1.40), is so much greater than that of the latter
enzyme that no reversal of glycolysis could occur unless
pyruvate kinase were inhibited •. Shrago et al (982) found
an elevation of phosphoenolpyruvate carboxykinase activity in alloxan-diabetes and following glucocorticoid
treatment.
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The low activity of fructose-1,6-diphosphate 1-phosphohydrolase (EC 3.1.3.11} in muscle prevents gluconeogenesis
in this tissue.

This enzyme is inhibited by high concen-

trations of its substrate and also by its product fructose6-phosphate (752).

This means that the enzyme cannot func-

tion unless phosphofructokinase is inhibited.

Inhibition

of phosphofructokinase is also important because hepatic
pyruvate kinase is also activated by fructose-1,6-diphos.Phate.

The required inhibition of this enzyme is produced

by elevated levels of ATP and citrate.

Martin and Silbert

(721} found that citrate also inhibits pyruvate dehydrogenase.

The effect was significant at 1 mM citrate and

maximal at 12 mM citrate.
Larner investigated the mechanism by which insulin
activates liver glycogen synthetase.

He found that the

activation of the enzyme by insulin is mediated by an
inhibition of the protein kinase which phosphorylates
[.

the I form of the enzyme to the D form (636}.

Insulin

decreases the affinity of Transferase I kinase for cyclic
adenylate which increases the affinity of the kinase for
ATP (637).

Since the activity of the D form of the en-

zyme is dependent on the concentration of glucose-6-phosphate while the activity of the I form is not, a decrease
in the phosphorylation of the I form increases the activity

155
of glycogen synthetase.

Glucose-6-phosphate increases the

affinity of glycogen synthetase D for its substrate uridine
diphosphate glucose.

However, the synthesis of uridine di-

phosphate glucose is not affected by this activation mechanism.

Epinephrine increases the concentration of cyclic

adenylate and thereby promotes the conversion of glycogen
synthetase to its active D form.

On the other hand, glu-

cocorticoids may increase glycogen synthesis by interfering with the action of this nucleotide (204).
Vardanis {1088) found that both glucose-6-phosphate
and inorganic phosphate activated mammalian liver glycogen synthetase by increasing the affinity of the enzyme
for glycogen 50 fold.

The concentration of inorganic

phosphate required for half-maximal activation was 7.75
x l0- 4M, well within the physiological range.

Steiner

et al (1027) also determined that the enzyme could be activated by fructose-6-phosphate.
Stetten et al (1029) reported that the rate of oxidation of glucose to carbon dioxide was one-third normal in
alloxan-diabetic rats.

In more severely diabetic depan-

creatized dogs Feller (310) found the rate of glucose
oxidation to be one-fifth normal.

However, Chernick and

Chaikoff (178) found that the oxida~ion of fructose and
acetate to carbon dioxide was not impaired in the absence
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of insulin, indicating that the block in glucose metabolism is at the phosphofructokinase reaction.

This block

is surmounted when fructose-1-phosphate is split to form
o-glyceraldehyde-3-phosphate.

In addition, Chaikoff (166)

reported that lipogenesis from glucose was reduced to 10

r

percent of normal in the diabetic animal.

These findings

were confirmed by Feller (310) as well as by Stetten·

·~

al (1029) who concluded that lipogenesis from glucose was
depressed more than glucose oxidation.

Diabetic liver

slices, for example, incorporate virtually no glucose into fatty acids compared to the 0.8 percent incorporated
by normal liver slices.
The influence of insulin on the formation of pyruvate
and glycogen in rat diaphragm has been studied by Villee
et al (1104).

They found that insulin increased the per-

centage of pyruvate formed from glucose more than it increased pyruvate oxidation.

Diaphragms from adrenalec-

tomized rats synthesized less glycogen than normal but
more of it from glucose.

The marked inhibitory effect of

the pituitary on glycogen synthesis is shown in Table II.
Adrenalectomy of diabetic rats restores glycolysis more
than glycogenesis.
Cori (199) compared the rates of glycogen formation
from glucose, fructose and galactose.

Although glucose
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was absorbed from the intestine twice as fast as fructose,
both hexoses formed liver glycogen equally well and more
rapidly than galactose.
~

Galactose is probably a poor gly-

cogen precursor because the conversion of uridine diphospha te galactose to uridine diphosphate glucose by UTPglucose-4-epimerase (EC 5.1.3.2) depends on the concentration of NAD +

Peak glycogen values are obtained four hours

after galactose administration.

Cori also noted that 39

percent of fructose administered to rats was converted to
liver glycogen compared to 17 percent in the case of glucose.

These results indicate that fructose rather than

glucose is more rapidly converted to liver glycogen.
Re·gulation· of Fructolysis
The metabolism of fructose illustrates several important aspects of glycolytic control mechanisms.

Fructose

can be phosphorylated by all of the low km hexokinases,
but its affinity for these enzymes is one-tenth of its
affinity for a specific ATP:
ferase (EC 2.7.1.3) in liver.

D-fructose 1-phosphotransThis latter enzyme is as

important as glucokinase in sucrose metabolism.

In addi-

tion, the incorporation of fructose into glycogen is onesixth normal in alloxan-diabetes (23).

Since gluconeo-

genesis is increased in this disorder, this finding suggests that glycerolkinase or triokinase may be depressed
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this condition.
Liver, muscle and adipose tissue contain fructokinase
isoenzymes.

Hers and Kusaka (454, 455) have described

.some of the differences between the hepatic and muscle enzymes.

The muscle isoenzyme has a low affinity for fruc-

tose compared to the hepatic isoenzyme Michaelis constant
4
of 5 x l0- Molar.

However, the hepatic isoenzyme is ex-

ceptionally sensitive to competitive inhibition by ADP.
This inhibition may involve the ribose moiety of the nucleotide.

Gromora (415) has shown that the fructokinase

present in adipose tissue decreases during fasting.

This

isoenzyme is probably different from the low km forms
found in intestinal mucosa and liver.
The

f~uctose-1-phosphate

has two fates.
by ATP:

formed by the above kinases

In muscle it is further phosphorylated

D-fructose-1-phosphate 6-phosphotransferase (EC

2.7.1) which has not been extensively studied since its
discovery by Slein et al (995).

In liver, fructose-1-

phosphate is split to form D-glyceraldehyde and dihydroxy~

acetone phosphate by aldolase B, an isoenzyme of ketose-1phosphate aldehyde lyase {EC 4.1.2.7).

When saturated,

this enzyme can split fructose-1-phosphate and fructose1,6-diphosphate at the same rate.

Liver aldolase B has

both a lower km and higher maximum velocity with fructose-
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!-phosphate compared to the muscle isoenzyme.
,

f

Aldolase A,

however, has a maximum velocity with fructose-1,6-diphos-

~~

f

phate which is over 12 times that of the hepatic enzyme.

~

Phosphoglucokinase may also be an important regula-

~:
~-

tory enzyme because its product a-D-glucose-1,6-diphosphate, in addition to its catalysis of glucose-6-phosphate
utilization via the phosphoglucoseisomerase reaction, is
equally potent as this glycolytic intermediate in causing
end-product inhibition of hexokinase isoenzymes (609).
Fructose metabolism in liver can proceed by a pathway which bypasses the reaction catalyzed by the regulatory enzyme ATP:

D-fructose-6-phosphate 1-phosphotrans-

ferase (EC 2.1.1.11) because liver contains glycerolkinase, ATP:

D-glycerol-phosphotransferase (EC 2.7.1.30),

and triokinase, ATP:
ferase (EC 2.7.1.28).

D-glyceraldehyde 3-phosphotransIn contrast, neither muscle nor

adipose tissue contain significant amounts of these enzymes.
D-glyceraldehyde arising from peripheral fructose
metabolism may be reduced to glycerol by alcohol dehydrogenase rather than being transported unchanged to the
liver.

Landau and Merlevede (626) found extensive label-

ing in positions 3 and 4 as well as in positions 1 and 6
of liver glycogen glucose following the administration
of D-glyceraldehyde-3- 14c.

However, their conclusion
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that this could have resulted from the intermediate formation of glycerol does not appear to be justified in view
of the asymmetric nature of glycerol phosphorylation.

Gly-

cerol formed in peripheral tissues may serve the function
of lactate in transferring reducing equivalents from the
pituitary to the liver.
~ff

ects on Sugar Tran·sport
Cori and Cori (200} compared the utilization of three

hexoses in eviscerated rats in the presence and absence of
insulin.

They found that fructose was utilized 5.3 times

as fast as glucose while mannose was utilized 4.3 times as
fast in the absence of insulin.

However, in the presence

of insulin fructose and mannose disappeared at the same
rate but only 38 percent as fast as glucose.

The more

rapid rates of fructose and mannose disappearance in the
absence of insulin cannot be explained by the km values
of hexokinase for these hexoses.

Since mannose and glu-

cose are transported by different.membrane carriers, insulin apparently decreases the k

m

of the carrier for glu-

cose more than the km of the carrier for mannose.
The use of fructose in the diet of the alloxan-diabetic rats has been reviewed by Sarett and Snipper (935}.
Since the liver converts fructose to glucose, they found
no decrease in glucosuria when fructose constituted 60
I! .

L
.
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percent of the diet.

Only 5 percent of the dietary fruc-

tose was excreted as fructose.

However, many of the rats

fed fructose recovered from their diabetic symptoms and
excreted less urine than the rats fed glucose.

These re-

sults suggest that a significant fraction of the ingested
fructose is metabolized directly by peripheral tissues in
the absence of insulin via the f ructokinase reaction which
bypasses the citrate-inhibited phosphofructokinase reaction.
In rat heart Battaglia and Randle (50) showed that
insulin stimulated the transport of glucose, mannose, D3-0-methylglucose, 2-deoxyglucose, D-xylose, D-arabinose,
D-lyxose and L-arabinose by one mechanism and the transport of fructose and galactose by another.

Mackler and

Guest (696) also showed that the increased utilization
of fructose by diaphragm in the presence of insulin could
be counteracted by glucose.

This implies that fructose

in the absence of glucose is phosphorylated mainly by
hexokinase and only by f ructokinase when hexokinase is
saturated.
It has been shown that fructose re-feeding restored
the glucose tolerance 6f the fasted rat more effectively
than isocaloric sucrose re-feeding, despite the fact that
the fructose re-fed rats had lower hepatic glucokinase
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activity.

".

This result indicates that the latter enzyme does

not influence glucose tolerance in the rat.
Burch

~t ~l

(132) found that fructose feeding increased

hepatic glucose and glucose-6-phosphate without increasing
hepatic glycogen synthesis.

They attributed the lack of

glycogen synthesis to a decrease in uridine diphosphate
glucose secondary to a decrease in ino!ganic phosphate due
to its incorporation into

fr~ctose-1-phosphate.

The activ-

ity of liver aldolase becomes rate-limiting for oxidative
phosphorylation under these conditions.

Therefore, fruc-

tose may be a tool for decreasing hepatic ATP.

The pos-

sibility that fructose-1-phosphate directly inhibited UTP:
a-D-glucose-1-phosphate uridyl

transfer~se

(EC 2.7.7.9)

was not investigated.
Fructose is converted to glucose by the intestinal
mucosa during its absorption.

This transformation is

catalyzed by ketose reductase and aldose reductase with
sorbitol as an intermediate.

This process results in the

transhydrogenation of NADH to NADPH which is required for
the synthesis of fatty acids from carbohydrate.

The ex-

tent to which this process contributes to carbohydrateinduced lipemia following sucrose ingestion has not been
determined.
~·

l
.

.

.

Although Wick et al (143) observed that fructose
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was but poorly utilized in eviscerated rabbits in the presence of glucose, Miller et al (744) found that intravenous
fructose disappeared faster than glucose in normal and diabetic subjects.

Furthermore, Pearson and Rimer (820) ob-

.served that a patient unable to utilize glycogen because
of phosphorylase deficiency (type V glycogen disease)
could perform on a treadmill when plasma fructose was maintained at 0.10 mg/l.

In contrast, a glucose level of 1.60

gm/l was required for this activity.

These findings in-

dicate that peripheral fructose utilization becomes more
~·

~'.
~.

l

significant when glucose utilization is blocked.

There-

fore, the metabolic significance of fructokinase in peri-

l•
~:·

~

pheral tissues under normal conditions remains obscure.

~,,,

Papper et al (806) studied the effect of cortisone
on the fructose and glucose tolerance of normal man.

An

oral dose of 200 mg of cortisone acetate decreased glu~

cose tolerance of normal men.

An oral dose of 200 mg

of cortisone acetate decreased glucose tolerance but
did not impair fructose tolerance.

This result suggests

that most of the fructose is metabolized by the liver
under the conditions of the test.

On the other hand,

Frawley et al (328) observed that glucocorticoids could
reduce the dis.appearance of fructose from the serum at
low glucose concentrations possibly because some fructose
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is phosphorylated by hexokinase urider these conditions.
Frawley also noted_that the cortisol effect could not be
produced by corticosterone administration, indicating ·the
necessity of the 17a.-hydroxyl group in the effect of cortisol.

Sprague et al (1013) al?o demonstrated that 11-

dehydrocorticosterone had little effect on carbohydrate
metabolism in Addison's disease.
The key role of triokinase and glycerolkinase in
fructose metabolism suggests that

f~uctose

metabolism

will be impaired when the activity of these kinases is
reduced.

For example, Glenn et al (370) reported that

cortisol decreased the oxidation of glycerol to carbon
dioxide.

The extent to which the inhibition of these en-

zymes is due to the direct interaction of the dihydroxyacetone side chain of the glucocorticoid with the enzymes
has not been determined.

Nor has the effect of growth

hormone in triokinase activity been reported.
Randle

~t

al (861, 863) have attributed the reduced

glycolysis of diabetic rat heart to the increased lipolysis which occurs in these tissues.

They have termed their

hypothesis the "glucose-fatty acid cycle."

According to

this hypothesis fatty acids are utilized in preference to
glucose when they are present as respiratory substrates.
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Lipolysis in muscle as well as in adipose tissue is increased by insulin deficiency.
be due

~·

an increase in cyclic adenylate formation which

is normally prevented by insulin.
'

Since the rate at which

fatty acids are oxidized is proportional to fatty acid concentration (341), lipolysis tends to increase the ratio of
NADH to NAD+ as well as the ratio of acyl coenzyme A to
coenzyme A.
The ratio of NADH to NAD+ in cytoplasm has been estimated from the ratio of lactate to pyruvate or from the
ratio of sn-3-glycerolphosphate to dihydroxyacetone phos-

-"

.,.

t

~o

This effect is believed to

phate.

Insulin deficiency reduces the lactate/pyruvate

ratio to 54 percent of its control value in heart and to
74 percent of its control value in diaphragm.

On the

other hand, the ratio of sn-3-glycerolphosphate to

dihy~

droxyacetone phosphate was reduced to 50 percent of its
control value in heart and to 57 percent of its control

~;

:;

value in diaphragm.

In contrast, this ratio was unchanged

in diabetic hepatic cytoplasm.

These.cytoplasmic ratio

changes are opposite to those expected in mitochondria
where fatty acid oxidation occurs.
Glycolysis is inhibited by citrate in extrahepatic
tis.sues in diabetes even though the ratio of NADH to NAD+
is decreased.

Garland and Randle (359) have found that
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that the citrate concentration was 53 µmoles/100 gm in diabetic rat heart compared to 22 µmoles/100 gm in normal rat
heart.

Garland et al (358) also determined that 1 mmolar

citrate reduced the rate of the phosphofructokinase reac'

tion by 23 percent in diabetic rat heart.

These results

were confirmed by Beatty and Peterson (56) who found that
the excretion of citrate was increased in alloxan-diabetic
and in depancreatized rats.

Given the inhibition of phos-

phofructokinase by citrate in diabetes, the reversal of
this inhibition by the reduction of citrate levels is a
key to the mechanism of acti9n of insulin.

Although in-

sulin may ipcrease isocitrate oxidation in mitochondria,
an action of insulin on isolated mitochondria has 'not
been conclusively demonstrated.

Also, since the NADH/

NAD+ ratio is one of the factors which controls mitochondriql isocitrate oxidation, insulin may act by changing
this ratio.
Garland and Randle (359) found that the ratio of
acetyl coenzyme A to coenzyme A was increased 3-fold in
diabetic rat heart.

In addition, the free fatty acid

concentration was increased 2.3-fold in diabetic heart
and 1.8-fold in diabetic diaphragm.

The output of gly-

cerol was increased 2.3-fold in heart, 1.6-fold in. diaphragm and 1.7-fold in adipose tissue.

In muscle the
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increase in the ratio of acetyl coenzyme A to coenzyme A
ieads to a 30 percent inhibition of pyruvate oxidation.
However, in liver it leads to increased formation of ketone
bodies.
Newsholme et al (781) also found that pyruvate perfusion inhibits glycolysis in muscle but not in liver.

In

muscle pyruvate inhibits the pyruvate kinase reaction.

How-

ever, in liver pyruvate may enter the citric acid cycle as
oxalacetate.

This reaction is catalyzed by pyruvate:

car-

bon-dioxide ligase (ADP) (EC 6.4.1.1) and is more endergonic
than the entry of pyruvate into the cycle vta the pyruvate
dehydrogenase reaction.
The fatty acids released during lipolysis are activated to acyl coenzyme A derivatives.

However, Garland

and Randle (359} observed that the concentration of acyl
coenzyme A in diabetic rat heart was only 66 percent of
normal.

This finding suggests that the incorporation of

acyl coenzyme A into triglycerides is increased.

Denton

and Randle (227) have shown that the incorporation of
sn-3-glycerolphosphate into glyceride glycerol increases
in diabetic rat heart and epididymal adipose tissue as
expected.

However, the mechanism of this effect is obscure

even though Denton and

Ran~le

indicated that it was depen-

dent on growth hormone and glucocorticoids.
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Lipogenesis and Ketosis
Denton and Halperin (228) studied the factors which con-

trol triglyceride formation and found that the rate did not
correlate with either the concentration of sn-3-glycerolphosphate nor with the concentration of acyl coenzyme A.
Therefore, the mechanism whereby triglyceride synthesis is
increased in diabetes has not been determined.
Jungas and Ball (551) have calculated that 40 percent
of the oxygen consumption of fat cells from fed rats is
related to the energy requirements of triglyceride synthesis.

Triglyceride synthesis is virtuall¥ absent in

3-day fasted rats; inhibition of triglyceride synthesis
thus is important to the conservation of glucose during
fasting.
Flatt (323) has shown that fatty acid synthesis is
increased in adipose tissue when triglyceride synthesis
is increased because acyl coenzyme A inhibits acetyl coenzyme A carboxylase.

Fatty acid synthesis in this tis-

r

sue is limited by the ability of the cell to utilize ap-

!'.

proximately 1. 8 moles of high energy phosphate per acetyl

~~

•~

r

~.
~

coenzyme A unit from glucose incorporated into fatty acids.
Therefore, at any level of tissue respiration, the total

""

~·~

ATP derived from fatty acid synthesis and fatty acid oxidation is constant.

Consequently, the control of the rate
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of fatty acid oxidation by control of the rate of actyl
· coenzyme A incorporation into triglycerides represents an
important control point for glucocorticoid action.
Scow et ·a1 (957) studied ketosis in pancreatectomized
rats.

They found that either hypophysectomy or adrenal-

ectomy abolished the ketosis.

They also found that the

administration of growth hormone alone to hypophysectomized-pancreatectomized rats had no effect on blood glucose or ketone bodies.

On the other hand, cortisone

alone at a dose of 2 mg/day killed 50 percent of the animals in 48 hours.

Deoxycorticosterone had no effect

under these conditions.

The glucocorticoid also increased

glycerides in the liver under these conditions.
]'.

These re-

sults demonstrate that glucocorticoids alone accelerate
ketosis and that growth hormone enhances this action.
Scow and Chernik (958) also showed that dexamethasone was very ketogenic in hypophysectomized-depancreatized rats but that growth hormone and glucocorticoids
produced no change in body fat unless the rats were
stressed.

These results

~uggest

that the major effect

of glucocorticoids may be to enhance the effect of epinephrine.

Growth hormone alone again had no effect but

increased lipolysis in response to dexamethasone and
·~·-

theophylline.

These results suggest that glucocorticoids

f
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and theophylline share a common mechanism of action and that
not all of the lipolytic effect of theophylline is due to
its inhibition of phosphodiesterase.

Fain (294) also ob-

served that growth hormone alone was not lipolytic in adipose tissue but that it enhanced the effects of glucocorticoids.

Uroguoti et al (1080) reached the same conclusion

studying ketotic dogs.
The glycogenic effect of glucocorticoids depends upon
their inhibition of pyruvic dehydrogenase, while its ketogenic effect is due to its enhancement of the lipolytic
effect of cyclic adenylate.

Renold et al (818) deter-

mined that cortisone depressed glucose uptake 25 percent
while it depressed lipogenesis from pyruvate 89 percent.
There are many other reports of decreased pyruvate tolerance following glucocorticoid administration (328, 450,
451).

However, it is not clear whether an increase in

the ratio of acetyi coenzyme A to coenzyme A is the mechanism whereby glucocorticoids inhibit pyruvic dehydrogenase.
Welt and Wilhelmi (1133) found that adrenalectomy
increased hepatic lipogenesis.

However, the inhibitory

effect of gluco.corticoids on hepatic lipogenesis may be
masked by the mobilization of lipid to the liver from
1

I

peripheral tissues.

Hill and Drake (460) found an
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increase in hepatic triglycerides but not phospholipids folthe administration of cortisone acetate.

However, although

the enzyme which activates fatty acids to their acyl coenzyme A derivatives was increased 2-fold, triglyceride synthesis was increased only 30 percent.

These results sug-

gest that triglyceride synthesis is primarily inhibited by
glucocorticoids.

Similarly, Hazzard et al (441) noted that

the rise in plasma triglycerides during estrogen therapy
was accompanied by a relative inhibition of triglyceride
synthesis.
The fact that adrenalectomy restores lipogensis in
liver but not in isolated adipose tissue suggests that
glucocorticoids may influence enzymes unique to liver such
as glycerolkinase.

Ashmore et al (25) found that gluco-

corticoids had no effect on the incorporation of glycerol
into glucose.
,,

On the other hand, Glenn et al (368) have

shown that glucoco.rticoids depress glycerol oxidation.
These results suggest that glycerol phosphorylation is not
rate-limiting for gluconeogenesis from glycerol.
In this discussion of the effects of glucocorticoids
on glycolytic regulation glycolytic oscillations have been
neglected.

However, an understanding of such oscillations

appears essential for the complete understanding of gly\·

~.·

~

colytic regulation.

Betz and Chance (75) have summarized
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their findings concerning the causes of glycolytic oscillations:
"If our hypothesis is true, the following
points are responsible for the oscillations:

(a)

the limited activity of pyruvate decarboxylase,
responsible for the accumulation of reduced pyridine nucleotide, pyruvate, fructose-1,6-diphosphate, dihydroxyacetone phosphate, and glyceraldehyde-3-phosphate;

(b) the kinetics of phospho-

fructokinase, which is inhibited by its substrate,
adenosine-5'-triphosphate; and activated by the
products, fructose-1,6-diphosphate, and adenosine5'-diphosphate;

(c) the kinetics of glyceraldehyde-

3-phosphate dehydrogenase, which is inhibited not
only by its products, reduced pyridine nucleotide
and 1,3-phosphoglycerate, but also by its substrate,
blyceraldehyde-3-phosphate;

(d) the intimate connec-

tion between different parts of the glycolytic pathway, by the adenosine-5'-triphosphate and reduced
pyridine nucleotide feedback systems, which brings
an accumulation of glyceraldehyde-3-phosphate just
at the moment when glyceraldehyde-3-phosphate dehydrogenase is inhibited by its products, thus
producing the inversion."
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Effects of Hormon·es on Adipose Tissue

-

The best indications of the sites of hormone action

have come from the study of the metabolism of specifically
radiolabeled glucose in hormone-sensitive tissues such as
adipose tissue.
site of action

As a result of such studies the general

ot

several hormones can be outlined.

Insu-

lin, the hormone of primary interest in diabetes, appears
1

to primarily increase fatty acid synt hesis from pyruvate.
All of its other actions appear to be secondary to its
lipogenic effect.

In accord with this proposed action

those tissues in which lipogenesis is prominent are the
~-

tissues most sensitive to insulin.

On the other hand,

'.

the heart is less affected by diabetes in comparison to
other tissues because of its low rate of lipogenesis.
The main reactions affected by growth hormone, epinephrine, and glucocorticoids are less clear.

Both growth

hormone and epinephrine are lipolytic as well as antilipogenic.

·However, the action of these hormones may

overlap to some extent.

For example, insulin increases

the lipolytic action of epinephrine while growth hormone
and epinephrine may increase the formation of sn-3-glycerolphosphate from glucose.
Perhaps the most striking effect of insulin is the
apparent increase in the efficiency of glucose utilization
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that it produces.

In particular, the low rate of glyceride

glycerol synthesis necessary for the high rate of fatty acid
synthesis indicates how much of the energy of glucose is
wasted in glyceride glycerol synthesis in response to lipolytic hormones.
In fasted-refed rats the most marked effect of growth
hormone is its depression of all phases of glucose metabolism.

These effects are due to the increased utilization

of endogenous triglycerides for oxidation.
hormone inhibits
tions.

~riglyceride

Also, growth

synthesis under these condi-

In rats fed ad libitum growth hormone increases

pyruvate oxidation less than insulin but increases triglyceride synthesis and citrate oxidation more than insulin.
Additionally, growth hormone increases lipogenesis while
epinephrine decreases lipogenesis.

This latter effect of

epinephrine is clearly opposite to that of insulin.
There appears to be a reasonable correlation between
Kreb's cycle activity and glyceride glycerol snythesis.
This indicates that when a molecule of D-glyceraldehyde3-phosphate is used for triglyceride synthesis another
molecule of pyruvate must be oxidized via the Kreb's cycle
to keep the total oxidizable substrate approximately constant.
The low rate of glyceride glycerol synthesis plus the

TABLE IV
EFFECT OF DIET AND HORMONES ON DISTRIBUTION OF GLUCOSE CARBON IN FAT PADS

Treatment

Glucose
Uptake

Pentose
Cycle
co2

Pyruvate
co 2

Kreb's
Cycle
co
2

Total
co2

Fatty
Acid

Glyceride
Glycerol

Lactate

Relative Glucose Carbon Yield
FastedRefed

460

59.8

101.2

13.8

174.8

193.2

32.2

59.8

Fedad libitum

100

8.0

13.0

8.0

29.0

21.0

20.0

30.0

Percent Difference Fran Control Fasted-Refed Rats
Insulin

67.4

54.4

82.6

11.6

67.4

79.3

19.5

54.4

-28.2

-66.8

-54.3

-330.6

-28.2

-67.4

-104.8

-27.1

Growth

Honrone

Percent Difference From Control Fed Ad Libitum Rats
Insulin

140

230.0

269.2

Growth
Honrone

151

25.0

218.4

Epinephrine

150

-6.3

92.3

181.5

311.3

32.0

51.9

351.1

201.8

100.9

441.0

-55.6

431.3

158.7

-16.7

400.0

91.6

-10.0

I-'
......i

From Katz et al (568)

U1

TABLE V
IN VITRO UTILIZATION OF U- 14 c-LABELED GLUCOSE BY
RAT DIAPHRAGM WITH 0.5 UNIT/ML INSULIN

Hypophysectanized

Adrenalectornized/
Hypophysectanized

Nonnal

Diabetic

Adrenalectarnized

Diabetic
Adrenalectomized

Glucose Utilized
rrg/gm/hr

2.87

2.17

3.91

5.20

4.42

6.11

Utilized Glucose
Metabolized to co2
mg/gm/hr

0.22

0.11

0.29

0.18

0.27

0.44

7.7

5.1

7.4

3.5

6.1

7.2

16.3

9.2

25.3

15.9

28.5

33.9

percent
Medium Glucose
Metabolized to co2
percent

Utilized Glucose
Metabolized to Glycogen
rrg/gm/hr
0.62
percent
Utilized Glucose
Unaccounted for
rrg/gm/hr

21.6

0.61
28.1

0.54
13.8

0.71
13.6

1. 71
38.7

2.23
36.5

..... .

-..]

2.03

Fran Villee and Hastings (1103)

1.45

3.03

4.31

2.44

3.44

°'
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iow (25 percent) maximal contribution of the pentose cycle
suggests that the concentration of triose phosphates is
depressed due to their rapid utilization by D-glyceraldehyde-3-phosphate dehydrogenase and that the activity of
the pentose cycle is closely tied to the activity of pyruvate dehydrogenase so that the inhibition of D-glyceraldehyde-3-phosphate dehydrogenase by NADH is not significant
when its other product 1,3-diphosphoglycerate is depleted.
Also, the additional ATP converved when glucose is metabolized via the pentose cycle and bypasses the exergonic
phosphofructokinase reaction of the Embden-Meyerhof pathway is sufficient to convert one of the acetyl coenzyme
A units derived from the hexose into malonyl coenzyme A.
The decrease in the pentose shunt in the refed rat
treated with insulin is due to the diversion of glucose6-phosphate to glycogen synthesis.

The increase in gly-

colysis during glycogenesis provides the energy for that
process through the formation of UTP via the nucleoside
diphosphate kinase reaction.
6-phosphate:

..
'
•.

The high k

of D-glucosem
NADP oxidoreductase (EC 1.1.1.49) for its

substrate reduces its activity when glucose-6-phosphate
is converted to glycogen.
The activation of acetyl CoA carboxylase following
insulin may also be responsible for the decrease in
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cytoplasmic citrate via citrate cleavage to acetyl coenzyme
A and oxalacetate.
In general, the higher the net rate of dihydroxyacetone phosphate utilization, either by its conversion to Dglyceraldehyde-3-phosphate or to sn-3-glycerolphosphate the
lower the extent of equilibration expected in the triose
phosphate.

There is almost complete isotopic equilibra-

tion in the insulin-treated fat pad because most of the
n-glyceraldehyde-3-phosphate is formed via the pentose
cycle as shown in the accompanying diagram.

The non-

isotopic equilibration of triose phosphates in methods
which assume equilibration results in a decrease in the
14
.
14
ratio of glucose-I- C to glucose-6- C incorporated into
acetyl CoA and an increase in the ratio of glucose-1to glucose-6-

14

C

14 C incorporated into glyceride glycerol.

Using their method which corrects for the non-equilibrium of triose phosphates under various hormonal conditions, Katz et al (568) obtained the data in Table IV
relative to the effects of insulin, growth hormone and
epinephrine on metabolism.

In fasted-refed rats, which

are similar to diabetic-refed rats, insulin increases
pyruvate oxidation and fatty acid synthesis much more
than glucose utilization.

Isocitrate oxidation and gly-

ceride glycerol synthesis, on the other hand, are
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selectively decreased.
even greater.

In fed animals, these effects are

The decrease in isocitrate oxidation can be

explained by the elevation of NADH relative to NAD+ produced by the pyruvate dehydrogenase reaction.

However,

the conversion of dihydroxyacetone phosphate to sn-3-glycerolphosphate is not increased, indicating that insulin
increases the synthesis of glyceride fatty acids but not
of glyceride glycerol.
Landau et al '(629) have pointed out that although the
activity of the enzyme D-glyceraldehyde-3-phosphate ketolisomerase (EC 5.3.1.1) is not rate-limiting for glycolysis, the activity of the enzyme is not sufficient to completely equilibrate a label in C-3 of its substrates.
This limitation is important in all studies with specifically-labeled glucose, especially in studies of glycolysis.

For example, the percent of randomization in C-3 of

the triose phosphates was 12 in control fat pads, 22 following insulin, 8 following growth hormone, 4 after thyrotrophin and 10 after epinephrine treatment.
Katz

~t

al (568) investigated the effect of the triose

phosphate isomerase reaction on the estimation of the pentose cycle contribution to glucose metabolism using glucose-1-

14

C, glucose-6-

14

C and glucose-U-

14 .
C and measuring

incorporation into glyceride glycerol and fatty acids.
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FIGURE IV
D-GLYCERALDEHYDE-3-PHOSPHATE FORMATION VIA
THE PENTOSE CYCLE

D-GLYCERALDEHYDE-3-,HOS,HATE FORMATION VIA THE ,ENTOSE CYCLE

181
TheY compared their method using glucose-2-

·14

use only glucose-1-

C and glucose-6-

14

14

C to·those which

C and assume complete

isotopic equilibration in D-glyceraldehyde-3-phosphate-3·and dihydroxyacetone phosphate-1glucose- 2 -

14c

14

C.

14

c

In comparison to the

·
· wh ic
· h isotope
·
·
experiments
in
·equi· 1 i· b ration

need not be assumed, the latter methods give good results
in control and insulin-treated fat pads, but not in growth
hormone and epinephrine-treated fat pads.

The percent of

glucose metabolized by the pentose pathway.was 14 in control fat pads, 25 following insulin, 11 after either growth
hormone or thyrotrophin and 7 after epinephrine-treatment.
The ketogenic effect of glucocorticoids appears to
be due to an enhancement of the effects of cyclic adenylate.

DeBodo and Altszuler (219) demonstrated that hypo-

physectomized-adrenalectomized dogs were insensitive to
epinephrine •. Hypophysectomy also reduced gluconeoge:nesis
by decreasing the supply of 'fatty acids for respiration.
Senft et al (969) found that a glucocorticoid-dependent
protein also decreased the activity of the enzyme phosphodiesterase in adipose tissue thereby decreasing the
hydrolysis· of cyclic adenylate.

The significance of. this

effect is uncertain because glucocorticoids enhance the
effect of cyclic adenylate without ?hanging its concentration (307).

Engel et al (285) noted that the barbiturate
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nembutal markedly enhanced the ketogenic effect of ACTH.
Whether this effect is due to an inhibition of phosphodiesterase activity has not been determined.

However, such

reports stress the necessity to control barbiturate anesthesia in glucocorticoid studies and to use other anesthetics when possible.
Apparently, Kreb's cycle activity reaches a maximum
in the presence of epinephrine but does not keep pace
~n

with lactate production

adipose tissue.

The degree

to which glycolysis is coupled to pyruvate oxidation is
determined by the lactic dehydrogenase isoenzyme composition in the tissue.

Tight coupling occurs with LDH

1

in heart and the level of NADH level i.s more strictly
regulated than it is by LDH

5

in liver so that elevated

levels of pyruvate and NADH prevail during gluconeogenesis.
On the other hand, Denton and Randle (226) have
demonstrated that the concentration of acyl coenzyme A
is decreased in diabetic rat qeart during the increased
triglyceride synthesis which occurs when growth hormone
and glucocorticoids increase lipolysis •. This indicates
that a mechanism other than lipolysis increases triglyceride synthesis during lipolysis. ·
Leboeuf et al (647)

(Table VI) found

tha~

cortisol

183
TABLE VI
THE EFFECTS OF CORTISOL ON GLUCOSE METABOLISM
BY RAT EPIDIDYMAL ADIPOSE TISSUE IN VITRO

Honrones
Added

Total

co2

Glyceride
Glycerol

Fatty
Acids

Glycogen

Percent Difference F:rom Control

,i~

'

Insulin
(O. l unit/ml)

386

Epinephrine
(lo-4 M)

185

175

Cortisol
c10-4 M)

-18.l

-12.2

f',,
,.

•'!·'

534

385

54.7

73.1

-22.4

-28.0

Percent Difference From Honrone Minus Cortisol
Insulin
and Cortisol

,,

37.6

3.68

4.97

Epinephrine
and Cortisol
(Nonnal Rats)

-27.1

-22.0

Epinephrine
and Cortisol
(Adrenalectomi.zed Rats)

-41.3

-50.5

LebOeuf et al (647)

8.10

-33.1

-35.6

-4.48

-55.2
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reduced glycogen synthesis 30% in the presence of insulin
indicating that its effect is not on transport.

Also, the

decrease in glyceride glycerol synthesis by cortisol could
be the basis of its ketogenic effect.

Epinephrine, which

increased glycogen formation, enhanced the inhibitory effeet of cortisol.

These results suggest that cortisol

modifies the effects of cyclic adenylate.
Jungas and Ball (551) found that 0.1 µg/ml epinephrine increased the output of free fatty acids and glycerol by adipose tissue.

Insulin addition increased gly-

cerol release 3-fold but decreased free fatty acid levels
to low values.

The oxygen consumption rose several fold

during treatment.

The effect of insulin in decreasing

free fatty acid release and increasing glycerol release
in the presence of epinephrine is dependent on glucose,
although insulin itself in the absence of epinephrine is
capable of suppressing lipolysis.
~·

When glucose is the sole substrate of adipose tissue,
it can furnish only 63 percent of the reduced nicotinamide
adenine dinucleotide phosphate required for the observed
conversion of glucose to fatty acids.

The rest of the

requirement must come from the oxidation of other substrates and through the transhydrogenation of NADH to
NADPH.

l

This finding is not unusual since Williamson and
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Krebs have observed that glucose alone even in the presence
of insulin can account for only 57 percent of the respiration of rat heart.

In the absence of insulin the propor-

tion falls to 24 percent.

The preferred substrate for

heart is acetoacetate which contributes 73-82 percent of
the respiratory fuel in the absence of insulin and 51-64
percent in the presence of insulin.

In contrast, liver

can form but cannot oxidize acetoacetate, readily.

The

low utilization of acetoacetate by liver and its high
utilization by heart has been attributed to the difference
in Succinyl-CoA:
{

3-oxoacid CoA-transferase (EC 2.8.3.5)

catalyzing the reaction:

0

0

-O-CCH
" 2CH 2C-O
" The enzyme is normally present intramitochondrially in
most tissues except liver.

Heart has 2.5 times the intra-

mitochondrial activity of skeletal muscle.

In addition,

heart muscle is unique in that it contains 20 times the
extramitochondrial activity of skeletal muscle.

The pro-

duction of large amounts of succinate by this reaction is
not without significance.

Krebs has shown that succinate
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is the preferred substrate of mitochondria.

In the presence

of succinate the oxidation of reduced nicotinamide adenine
dinucleotide is decreased and the high energy phosphate
.·associated with reduced NAD:

(ubiquinone) oxidoreductase

(EC 1.6.99.3) is reconverted to reduced NAD.
has been termed reversed electron flow.

This process

With glucose in

the absence of insulin, the heart preferentially utilizes
its own energy stores in preference to the available glucose and this behavior persists even with insulin.

These

results tend to enforce the idea that the body treats glucose as if its only function were to provide the oxalacetate needed to catalyze the respiration of other substrates.
Flatt and Ball (322) have found that the rate limiting
factor in the operation of the pentose cycle is the rate
of regeneration of NADP+ from NADPH.

According to this

view it is the rate of fatty acid synthesis which regulates the operation of the pentose cycle and not vice
versa as is commonly thought to be the case.

Acetate

metabolism provides the minimum amount of reducing equivalents not derived from the tricarboxylic cycle.

There-

fore, when acetate is provided as fuel, more of the cell's
requirements for reducing equivalents is met by transhydrogenation from NADPH to NADH.

This frees more NADP+

!"· .

l

for the pentose cycle and as a result, almost all of the
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glucose metabolized is metabolized via the pentose cycle
and almost all of the glyceraldehyde-3-phosphate formed
via this cycle is converted to fatty acids.

Since glycol-

ysis is more exergonic due to the phosphof ructokinase reaction, some mechanism must operate to inhibit glycolysis.
citrate has been shown to be able to serve this function.
When mitochondria are getting all their energy from acetate, the increase in the pentose cycle provides 95 percent of the reducing equivalents required for the observed
acetate conversion to fatty acids.

Flatt and Ball (322)

found that acetate increases the pentose cycle 83 percent,
the conversion of glucose to fatty acids by 16 percent,
and total fatty acid synthesis by 60 percent.
r·
'

The in-

crease in the pentose phosphate pathway that occurs on

'

the addition of acetate illustrates some of the mechanisms which normally limit the operation of the cycle.
Acetate enters the mitochondrion and is oxidized in preference to pyruvate because of the exergonic nature of the
acetate CoA ligase (AMP) (EC 6.2.1.1) reaction:
0

"

c~3c-o

0

- + CoA + ATP -4

=

CH

3

~-S-CoA

+ AMP- 2 + PP- 3

(1)

Because acetate is oxidized in preference to pyruvate, the
pyruvate is available for reduction in the cytoplasm by
malic enzyme, L-malate:

NADP oxidoreductase (decarboxylating)

188
(EC 1.1. l. 40) :

00

+

1111

CH CCO- + NADPH + H
3

0
II

= co

+ Hco;

HO-~-H + NADP+ + H2o
H-C-H
I

co

-

II

(2)

0

Although the equilibrium constant for the above reaction
lies far to the left, the ratio of NADPH to NADP + and the
·elevated pyruvate drives the reaction.
..

~

diffuses into mitochondria where it undergoes conversion
to oxalacetate by L-malate:

'

'·

The malate then

NAO oxidoreductase (EC 1.1.

1.37):
0
II

CH

0

-

II

co

I

HOCH
NAO+ +

= NADH + 0

HCH

=

c + H+
I

I

HCH

II

co

co 0

-

I

II

(3)

0

The oxalacetate formed is condensed with acetyl CoA to
citrate by citrate oxalacetate lyase (CoA-acetylating)
(EC 4. 1. 3. 7) :
~ .

'·.'

.
-2
oxalacetate
+ acetyl-S-CoA

=

citrate-

3

+

+ CoA-SH + H

(4)
The citrate so produced diffuses _out of the mitochondria and
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is cleaved by ATP:

citrate oxalacetate-lyase (CoA-acetyl-

ating and ATP-dephosphorylating) (EC 4.1.3.B):
citrate- 3 + ATP- 4 + CoA

=

oxalacetate- 2 + acetyl-S-CoA + ADP- 3 + P.- 2

(5)

1

The acetyl CoA produced is used for fatty acid synthesis in
the cytoplasm and the oxalacetate is converted to phosphoenolpyruvate:

phosphoenolpyruvate- 3 + Hco; 1 + IDP- 3 + H+

(6)

The phosphoenolpyruvate so produced is then available for
the regeneration of inosine-5'-triphosphate and pyruvate by
the reaction catalyzed by ATP:

pyruvate phosphotransferase

(EC 2.7.1.40):
H+ + phosphoenolpyruvate- 3 + IDP- 3

= pyruvate-l

+ ITP- 4

(7)
For every two cycles of reactions 1-4, one citrate molecule
diffuses out of the mitochondria leaving behind a reduced
NADH equivalent.

This NADH equivalent was formed at the ex-

pense of NADPH ir the cytoplasm and represents a transhydrogenation and transfer of reducing equivalents into the mitochondria.
The transfer of reduced NADH equivalents into mitochondria
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normally occurs by reversal of reaction 3 in the cytoplasm,
the oxalacetate required being provided by the L-aspartate:
2-oxoglutarate aminotransferase (EC 2.6.1.1) reaction:
0

0

co It
I

H N-C-H
3 I
H-C-H

co II

co
I
--->
c <---

0

II

+

II

C-0

0

c-o
I
II

+

-

I

H-C-H

H N-C-H
3
I
H-C-H

H.-C-H

H-C-H

I

I

I

II

c-o
11

H-C-H

c-o -

0

0

0

I

H-C-H
I

co -

I

I

II

(8)

After the malate and glutamate diffuse into the mitochondria, reaction 3 occurs as well as the reverse of reaction
8.

The a-ketoglutarate and aspartate then diffuse out of

the mitochondria into the cytoplasm to complete the cycle.
Harding et al (427) found that adrenal steroids, testosterone propionate, and growth hormone were without effect
on the above enzyme.

They found, however, that glucocorti-

coids increased the activity of L-alanine:

2-oxoglutarate

aminotransferase and that deoxycorticosterone depressed
this enzyme.

The other hormones were without effect.

Role of Glutamic Dehydro·genase in· Gluconeogenesis
The mitochondrial enzyme L-glutamic:

NAD(P) oxido-

reductase (deaminating) (EC 1. 4 .1. 3) must be considered
as a regulatory enzyme essential for gluconeogenesis.
This enzyme catalyzes the reaction:
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NH + + 2-ketoglutarate- 2 + NAD(P)H + H+
4

(10)

ouring gluconeogenesis from amino acids there is a net proauction of glutamate by transaminase enzymes.

This gluta-

mate must be oxidized if gluconeogenesis is to proceed •.
Frieden (335) has reviewed some of the regulatory aspects
of glutamic dehydrogenase.

The active enzyme is composed

of inactive subunits which associate in the presence of the
amino acids L-methionine, L-leucine and L-isoleucine as well
;t

+

as NAD •

At moderate concentrations of GTP, the enzyme is

very sensitive to activation by ADP even though neither
nucleotide is a reactant.
to product inhibition.

The enzyme is also sensitive

Equimolar 2-ketoglutarate inhibits

the enzyme 43 percent.
Although Yielding and Tomkins

(1188) have described

the non-specific inhibition of this enzyme by a number of
steroids, no steroid was as inhibitory as thyroxine which
was found by Winslow et al (1167) to inhibit the reaction
51 percent at 1.3 x l0- 5Molar.

However, the inhibitory

action of thyroxine on the enzyme appears superficially
to be contrary to the increased contribution of amino acids
to basal metabolism in hyperthyroidism.
Williamson· et ·a1 (1157) have shown that glutamate

192
exerts a catalytic influence on the transport of extramitochondrial NADH reducing equivalents into mitochondria.

There-

fore, when mitochondrial ADP rises glutamic dehydrogenase is
activated leading to glutamate oxidation.

On the other hand,

if GTP is depressed during protein biosynthesis the effect
of ADP on glutamate oxidation is attenuated.

An increase

in glutamate oxidation reduces the transport of extramitochondrial reducing equivalents into the mitochondrion.
a result glycolysis is reduced.

As

Thus, glutamic dehydrog-

enase increases cytoplasmic NADH when it converts the amino
acid glutamate to the oxalacetate precursor 2-ketoglutarate.
Villee (1105) reported that l0- 6Molar corticosterone
increased NAD+ reduction 75 percent indicates that the effeet is not even relatively specific for glucocorticoids.
Krebs (617) has shown that the ratio of NAD+ to NADH
in diabetic liver is decreased extramitochondrially but
increased intramitochondrially.

The ratio fell from 7.25

to 2.08 in the cytoplasm and increased 7.3 to 10.8 in the
mitochondrial matrix.

The cytoplasm is thus in a more

reduced state while the mitochondrial matrix is in a more
oxidized state.

This situation basically reflects a lack

of transfer of reducing equivalent from the cytoplasm into
the mitochondria.
The pyruvate that is not converted to acetyl CoA
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TABLE VII
INFLUENCE OF HORMONES ON THE NICOTINAMIDE
NUCLEOTIDE COENZYMES OF RAT EPIDIDYMAL FAT PAD

Treabrent

NAD+

NADH

NADP+

NADPH

NAD+/NADH

(µg/nq tissue protein)
Control

1.30

0.40

0.14

0.46

3.25

HypOphysectanized

1.14

0.29

0.17

0.25

3.93

Hypophysectomized
+ Growth Horrrone

0.90

0.27

0.09

0.21

3.33

Control

0.75

0.21

0.39

3.57

Alloxan-Diabetic

0.88

0.22

0.13

4.00

~ ..

McLean et al (693)
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because of the inhibition of pyruvate dehydrogenase by the
elevated ratio of acetyl CoA/CoA is converted to oxalacetate by pyruvate:

carbon dioxide ligase (ADP) (EC 6.4.1.1):
oxalacetate

-2 +

ADP- 3 + P.- 2 +HO+
1
3

(11)

A portion of the oxalacetate formed in this reaction condenses with acetyl CoA to form citrate which diffuses out
into the cytoplasm to inhibit phosphofructokinase.
ever, some of the oxalacetate is reduced to malate.

HowThe

increase in mitochondrial malate effectively prevents the
transfer of cytoplasmic reducing equivalents into the mitochondrion by abolishing the malate concentration gradient.
As a result the hepatic ratio of NADH/NAD+ rises leading
to gluconeogenesis.

The malate concentration is increased

so much that oxalacetate formation occurs in spite of the
lower NADH/NAD+ ratio present in mitochondria.

This is

possible only because oxalacetate is also elevated.

A

possible reason for the failure of lipogenesis during gluconeogenesis is that higher concentrations of fructose-1,
6-diphosphate are required for lipogenesis than for gluconeogenesis.

Plate et al (439) found that fructose-1,

6-diphosphate decreases the Michaelis constant of fatty
acid synthetase for NADPH.

Furthermore, low citrate

195

levels slightly increase the level of fructose-1,6-diphosphate and increase the activity of fructose diphosphatase.
Higher levels of citrate further increase the concentration
of the diphosphate which inhibits the diphosphatase and
further channels glyceraldehyde-3-phosphate to glycerol
glyceride formation.

'

f

I
.

.
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CHAPTER VIII
STRUCTURAL ASPECTS OF LIPOPROTEINS

£_omparison of Human and Rat Beta Lipoproteins
Both human and rat S lipoproteins have approximately
the same molecular weight of about 2 million and both are
composed of approximately 10 subunits.

However, while

these subunits are identical in the rat molecule, Shore
and Shore (980) found three types of subunits in human

S lipoprotein.

The fact that delipidated rat S lipopro-

teins form insoluble aggregates less rapidly than human

s

lipoproteins means that protein-protein interactions

which must be overcome during lipid binding are weaker
in rat molecules.

The function of the multiple peptide

chains in the human molecule may be to provide cooperative interactions so that protein-protein interactions
become weaker, and protein-lipid interactions stronger
as more lipid is bound.
Cooperative Interactions in Beta Lipoproteins
In contrast to the findings of Gotto
196

~t

al (402)
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that no cooperative interactions between lipid and protein
existed in S lipoprotein, Camejo et al {157) found that the
binding of phospholipids to apoalphalipoprotein exposed peptide bonds to the solvent with exchange of amide hydrogens.
Phospholipids also appear to be important in insulin inhibition by S lipoprotein.
tack

a

The fact that phospholipases at-

lipoprotein indicate that the phosphoiipids are lo-

cated on the surface of the molecule.
Granada and Scanu {405) have investigated the effects
of lipid extraction on lipoprotein structure.;

Following

the extraction procedure, two components of S lipoprotein
with sedimentation constants of 10.9 S and 15.5 S were
produced.

Lipid extraction following succinylation of

the available amino groups in the molecule resulted in a
single 7.2 S subunit.

This disassociation phenomena is

similar to that reported by Shore and Shore {981) who
found a moelcular weight of 2.8-3.0 x 10 6 for the intact

a

lipoprotein molecule and 6.4 x 10

4

for each of the ten

postulated subunits.
Gotto et al {402) have described a technique for the
preparation of delipidated
detergent mole.cules.

a

lipoprotein subunits free of

This procedure takes advantage of

subtle differences in physical chemistry between dodecyl
sulfate and decyl sulfate.

Decyl sulfate can be reversibly
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bound to the subunit while dodecyl sulfate cannot be completely removed by dialysis after lipid extraction.
Gotto et al (403) further investigated the structure
of the delipidated apolipoprotein by infrared analysis.
They found the molecule to contain S-pleated sheet structure which did not change appreciably on delipidation.
These findings are in basic agreement with those of Scanu
(942) from circular dichroism measurements and indicate
.that there is little or no cooperative interaction between
the apolipoprotein and its lipids.

Camejo et al (157)

have, however, found that the delipidated high density
lipoprotein molecules do have two unique characteristics.
First, it was able to penetrate lipid films at pressures
above the collapse pressure of the protein, and secondly,
the protein itself could form a film even at low salt
concentrations.

This latter characteristic was ascribed

to the absence of disulfide bridges in the molecule.
These findings indicate that modification of the apolipoproteins by introduction of cross-links may provide some
additional information about the.function of the molecule
(431, 462).
Chapman (172) and Colacicco (189) have described
methods applicable to the interaction of apolipoproteins
with lipid monolayers.

These techniques generally involve
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the introduction of the apolipoprotein under a lipid monolayer followed by observations of the changes produced in
surface tension.

This technique has provided more informa-

tion than circular dichroism studies.

A similar technique

might be used to study the action of lipoprotein lipase.
For example, the enzyme along with a apolipoprotein and
acceptor albumin might be introduced into the bulk phase
under the lipid substrate monolayer.
The possibility that polyunsaturated cholesterol esters may be involved in intermolecular bonding of lipoprotein subunl.ts is.indicated by Lindgren et al (667) who
found that dialysis of sf 0-20

s

lipoproteins in the ab-

sence of chelating agents to prevent metal catalysis of
air oxidation results in Sf 0-2 fragments which resembled
HDL • Authentic HDL 1 (immunochemical identification) has
1
density properties similar to the B lipoproteins in rats
and man but has not been further studied.
Abnormal Beta LiJ?oproteins
Alterations in S lipoprotein structure are not unique
to the

s

lipoprotein insulin antagonist but are also found

in other disorders of lipid metabolism.

Swit2er (1044)

noted that an immunochemically distinct S lipoprotein,
lipoprotein X, was formed in, and hence could not be used
to test for the presence of, biliary obstruction.
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Lipoprotein X contains lecithin as its main phospholipid
~omponent,

only traces of triglycerides and cholesterol

esters, but large amounts of

f~ee

cholesterol.

In con-

trast, Gardner et al (357) observed that serum cholesterol
esters were reduced in viral hepatitis.

Eder et al (268)

were among the first to use percent cholesterol esterification as a chemical means of differentiating between viral
hepatitis and obstructive jaundice.
In contrast Hezzard et al (442) noted that the abnormal 8 lipoprotein which migrates electrophoretically as
· a broad bend in Type III hyper-8-lipoproteinemis has an
increased content of esterified cholesterol.

Most of the

individuals with this disorder develop Xanthoma tuberosum,
·characteristic cholesterol deposits in the skin, indica-

However, individuals with Type II hypercholesterolemia
may also be distinguished from Type III individuals by
the presence of Xanthoma tendinosum instead of Xanthe· ma ·tuberosum.

Unfortunately, the appearance of these sub-

cutaneous cholesterol deposits is also indicative of comparable cholesterol deposition in arterial plaques.

CHAPTER IX
STEROID EFFECTS ON SERUM LIPOPROTEINS

Etiology of Atherosclerosis
Both dietary cholesterol and saturated fatty acids
.can contribute to the development of atherosclerosis in
predisposed individuals.

The main predisposition is an

elevation in blood catecholamines due to environmental
stress which increases not only fasting serum triglycerides but also post-prandial hyperlipemia.

Afflicted in-

dividuals can be detected by their elevated catecholamine excretion when exposed to occupational stress (338).
However, excretion patterns may be normal after the subject has been hospitalized.
The rise in norepinephrine secretion in such individuals frequently leads to an elevation in blood pressure so that the latter is associated with a three-fold
increase in the chance of myocardial infarction (558).
In another study Yater et al (1183) observed a 4-fold
increased risk.

It is not clear how hypertension
201
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increases the risk but an effect of pressure on the disposition of lipids from S lipoproteins has not been excluded.
Increased mechanical trauma to the vessel is also a possible explanati'on of the blood pressure effect.

Elevations

in epinephrine, on the other hand, may lead to enhanced
platelet aggregation as well as to the previously described
lipolytic effects.

Past-prandial hyperlipemia may be re-

sponsible for the 20 percent reduction in coronary blood
. flow and the failure of collateral. circulation in some
cardiovascular patients.
.::-

Friedman et al (338) have also

observed the sludging of erythrocytes 3-9 hours following
food ingestion in patients prone to atherosclerosis.
Rane et al (864) have shown that dietary factors
alone could not account for the difference in atherosclerosis in two similar groups of East and West Finnish
farmers indicating that diet alone is not the primary determinant of the disease.

However, that high blood cho-

lesterol levels accelerate the disease process is well
known (558).

In addition, S lipoprotein levels do not

correlate better with the progression of the disease than
do total serum cholesterol levels (380).

It appears, how-

ever, that total cholesterol levels are related to the
tendency for cholesterol to deposit in arterial fissures
during the healing process which is constantly occurring.
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platelet aggregates play an important role in this process
because these lipid-rich cells are phagocytized by macrophages which are then converted to foam cells which are
responsible for the release of cholesterol in the vicinity
of the arterial lesion.
Although men have a higher total cholesterol and
higher ratio of

e

to a lipoprotein compared to women, re-

cent studies have indicated that these differences cannot
account completely for the sex differences in atherosclerosis.

Rosenman and Friedman (910) have indicated that dif-

ferences in behavior and occupational stress may be at
least partly responsible.

Women in the professions, for

example, have a 5-fold increased incidence of atherosclerosis compared to women with less stressful occupations.

However, these results do not rule out the im-

portance of hormonal factors in the control of serum lipids.

For example, atherosclerosis is more frequent

among men with a mesomorphic or muscular physique.

Such

findings may indicate that both physical stature and aggressiveness may reflect patterns of testoserone produc··

tion and target tissue responses and may provide a basis
for the belief that atherosclerosis begins to develop in
man at about the age of puberty.
Saturated fatty acids in the diet increase the

t

l

'

'
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incidence of atherosclerosis by increasing the level of cholesterol.

Apparently, there is a limit on the ratio of sa-

turated to unsaturated fatty acids that may be present in 8
lipoprotein.

Ways et al (1120) have suggested that exces-

sive oxidation of linoleic acid may be an etiologic factor
in acanthcytosis and pointed to their observation that erythrocyte linoleic acid was only 25 percent of normal in
this disorder.

Philips and Dodge (832) also confirmed the

.low levels of essential fatty acids in a-8-lipoproteinemia.
These results are puzzling because a lipoproteins normally
transport essential fatty acids as cholesterol esters.

In

the genetic absence of a lipoproteins which occurs in
Tangiers disease cholesterol esters accumulate in the reticuloendothelial system, but unesterif ied cholesterol is
normal~

Furthermore, low levels of carotene leading to

pigmentary retinitis are observed even though the bulk of
carotene is transported by B lipoprotein.

Jepsco et al

(529) also observed that a deficiency of cholesterol esters occurred in Xanthoma tuberosum characteristic of
Type III hyper-S-lipoproteinemia in which an abnormally
less dense lipoprotein is produced.

The heterogeneous

nature of this molecule is further indicated by the
broad B band which it forms on electrophoresis.

In con-

trast, high unesterified cholesterol levels characterize
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xanthoma tendinosum seen in Type II hyper-B-lipoproteinemia.
These results indicate the importance of polyunsaturated
fatty acids.
Function of Cholesterol
Saturated fatty acids may elevate serum cholesterol
by forming lecithin-cholesterol complexes which increase

the total number of cholesterol binding sites in the B
lipoprotein molecule.

An increase in total cholesterol

and saturated lecithins, for example, is seen during highdosage estrogen therapy.

Recently, Ladbrooke et al (625)

have shown that cholesterol forms a 1:1 molecular complex with dipalmitoyl phosphatidyl choline that abolishes
the mesomorphic phase transition of the phospholipid.
Apparently, cholesterol functions to reduce the random
motion of the hydrocarbon tail of the saturated fatty
acid.

Polyunsaturated fatty acids, on the other hand,

have greater rigidity than their saturated counterparts
because of their double bonds.

The presence of this in-

creased rigidity is not disproven by the generally lower
melting points of the polyunsaturated fatty acids because
the crystal lattice energy, as evidenced by the heat of
fusion, is lower for the polyunsaturated fatty acids.
The important role of polyunsaturated fatty acids
in preventing the elevation of B lipoprotein levels is
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seen in the results of a clinical study by Vergrassen et al
(1094).

They showed that when dietary fat was 50 percent

of total calories, the isocaloric substitution of safflower
oil for olive oil in the diet reduced cholesterol levels by
17 percent.

Such an effect is equivalent to that obtained

with hypocholesterolemic drugs such as 2-(p-chlorophenoxy)2-:-methylproprionic acid and lipod.iactic steroids.

Further-

more, Peifer and Holman (826) have shown that total unsaturation rather than essential unsaturation at carbons 12
and 15 determines the cholesterol-lowering effect of polyunsaturated fatty acids, indicating that physical properties are the main consideration.

However, for other rea-

l

sons related to platelet function, diets rich in the essential fatty acid linolenate are preferable to catalytically dehydrogenated polyunsaturated fatty acids for the
prevention of myocardial infarction.

Besides the mechan-

ism outlined above, Lewis (660) has shown that polyunsaturated fatty acids also increase the conversion of cholesterol to bile acids and lower cholesterol levels by this
means.

On the other hand, patients with Type II hyper-

cholesterolemia have been shown to be resistant to this
latter effect.
Another puzzling aspect of lipid metabolism was re...

,..,

ported by Setsuda and O'Kabe in reference to the low levels
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of linoleic acid in diabetes._

They reported that insulin,

but not sulfonylurea drugs could restore normal levels of
linoleate.

Since the sulfonylureas stimulate insulin re-

lease, it appears that they also antagnoize this effect of
insulin.
The effects of glucocorticoids on serum lipids were
discussed previously.

Generally, these effects include an

increase in phospholipids with lesser increases in cholesterol and triglycerides.

These effects are generally fav-

orable provided that the pancreas can produce sufficient
insulin to overcome the lipolytic effects produced by the
glucocorticoid.

As discussed elsewhere in this disserta-

tion, at least part of this glucocorticoid effect appears
to be due to an action on the liver that is not dependent
on protein biosynthesis.
Sex Differences in the Subunit Structure of HDL
In men S~ 20-100 and 100-400 pre-S-lipoproteins show
an upward trend_ in the third decade and even steeper upward
trends in the fourth decade up to the fifth decade and then
a decline occurs.

In women the S~ 100-400 pre-S-lipopro~

teins are approximately one-third the level in men in the
third decad~.

The S~ 20-100 pre-S-lipoproteins increase

with age in women starting with the fifth decade.
the third and fifth decades, mean HDL

2

Between

a lipoproteins are
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twice as high in women as in men.
HDL

3

and HDL , do not change.
1

The other a lipoproteins,

These findings suggest that

the estriene effect is not on the synthesis of the apo-alipoprotein subunit, but rather that it promotes the conversion of HDL

3

lipoprotein (M. W. 175,000) to HDL

lipo-

2

protein (M. W. 360,000) by promoting a subunit rearrangement in which another high density apolipoprotein subunit
of M. W. 40,000 and a phospholipid-cholesterol complex of
145,000 are added.

Shore and Shore (981) have recently re-

viewed the structural aspects of the serum lipoproteins.
They have noted that the peptide composition of HDL
more

heteroge~eous

than that of HDL •
3

2

is

Whereas both lipo-

protein species contain the two major carboxyl terminal
glutamine and threonine peptides, HDL

2

also contains an-

other peptide which is rich in serine, glutamic acid and
glycine and which is believed to end in carboxy terminal
alanine.

All of these peptides contain methionine but

the alanine containing peptide unique to HDL
of trytophane.

It appears that HDL

3

2

is devoid

contains six poly-

peptide subunits of 15,000 molecular weight while HDL
contains eight.

2

Although the exact role of the two major

peptides is unknown, there presence in all high density
lipoprotein species suggests that they form a dimer which
then binds lipid as in the 40,000

l

M~

W. fragment involved
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in the structure of HDL 2 •
Peefers and Blaton (825) have also identified four peptides in human HDL

2

by isoelectric fodusing which have pI's

of 9.16, 8.97, 6.36 and 5.38.

The peptides which pI's of

s.97 and 6.36 correspond to the carboxy terminal threonine
and glutamine peptides.

The study of these peptides is

complicated by the presence of polymorphic forms which separate on DEAE cellulose but electrophrese identically in
polyacrylamide with 8 M urea.
Reciprocal Effect of Estrogens
Estriene effects on atherosclerosis offer the greatest
hope for preventing the disorder by natural regulatory mechanisms.

The terms androstane and estriene emphasize that

these effects are distinct from those of endogenous hormones.
Changes in S lipoprotein occur in a reciprocal fashion in
response to steroid-induced a lipoprotein changes in 50 percent of human subjects.

However, the net change in choles-

terol levels will depend on the relative changes in lipoprotein species and their cholesterol contents.

In man eleva-

tion in a lipoprotein is generally followed by a larger reduction in S lipoprotein so that total cholesterol levels
are reduced.

In the dog and especially in the rat, a lipo-

proteins predominate over S lipoprotein so that an elevation
in a lipoprotein increases total cholesterol.

The basic
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effects of steroids on the lipoprotein distributions in both
animals, however, is similar.
Studies by Bowers and Schally (105), Fillias (316),
o'Key et al (794), Lyman ·et ·a1 (684) and Kritchersky ·et al
(619) have shown that low-dosage estrogen therapy raises
the level of cholesterol arachidonate in the rat.

The in-

corporation of arachidonate and stearate into hepatic phospholipids is also increased.

On the other hand, Aftergood

· et al (6) reported that the cholesterol esters of arachidonate and linoleate were markedly reduced and replaced by
those of palmitoleate, oleate, and stearate when the human
estrogen dose was administered.

These effects appear to

be secondary to effects on hepatic phospholipid synthesis.
Ramey and Baron (858) observed that the estriene 3,17S-dihydroxy-l,3,5 (10)-estriene-16-one increases the incorporation of acetate and inorganic phosphate into hepatic phospholipids.
The effect of glucocorticoids on serum lipids parallels
its effects on lipid metabolism.

Kobernich and More (602)

showed that the administration of 20 mg of cortisone per day
to rabbits elevated serum cholesterol and unesterified fatty
acids at the time that steroid diabetes ensued.
~

Brady ·et

(112) showed that the elevation in serum fatty acids was

accompanied by reduced fatty acid synthesis from pyruvate
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2-6 hours after glucocorticoid treatment when gluconeogenesis
from pyruvate was increasing.
Adrenalectomized dogs maintained on deoxycorticosterone
acetate show a 75 percent drop in total serum lipids over a
three week period (238).

However, this drop is not accom-

panied by changes in phosphlipid concentration in the liver,
kidney, small intesting, muscle or lung; and the half-life
of plasma phospholipids is not altered.

In contrast to

these results in the dog Migeon (740) found that liver lipids increased in the adrenalectomized rat maintained on
deoxycorticosterone acetate.

Treatment with cortisone re-

stored the liver lipids to normal but did not elevate serum
cholesterol.

The increased mobilization of lipid stores in

the adrenalectomized rat was also reported by Tracht ·et al
(1074).

It is probably the result of the lipolytic activ-

ity of ACTH which increases after adrenalectomy.

The sup-

presion of ACTH release described by Levy and Ramey (657)
will be discussed later in conjunction with the other effects of ergotamine.
Comparison of Cortisone and Prednisone
Furman et al (349) showed that the administration of
500 carbohydrate calories could prevent the elevation of
cholesterol and phopholipids associated with the administration of 30 mg of prednisolone to men.

It is not clear,

TABLE VIII

EFFECTS OF 20 DAYS OF GLUCOCORTICOID TREATMENT
ON THE PLASMA LIPIDS OF THE RABBIT

Percent Difference Fram Control Period
Glucocorticoid
Administered
Cortisol

Neutral
Lipids
+53.5

Cortisone

+482

17a,21-dihydroxy1,4-pregnadiene-3,
11,20-trione

+380

Adlersberg (4)

Total
Phospholipids

Unesterified
Cholesterol

Esterified
Cholesterol

Total
Lipids

+46.6

+100

-28.6

+47.5

+89.3

+186

-29.3

+256

+207

+14.3

+259

+126
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however, whether the suppression of free fatty acid mobilization was due to the glucose or to the insulin which it released.

Lever et al (654) found that glucocorticoids in-

creased a lipoprotein cholesterol and phospholipids to abnormally high values in man.
by Adlersberg et al

Table VIII.

Similar results were obtained

(4) in the rabbit and

a~e

shown in

Especially prominent is the highly significant

decrease in esterified cholesterol.

Este.rified cholesterol

was increased by prednisone but decreased by cortisone.
This difference may be related to the metabolism of the
two steroids.

The decreased esterification seen with endo-

genous glucocorticoids is similar to the effect produced
by estrogens.
The metabolic effect of

predniso~e

is almost the same

as that of cortisone even though the total 17-ketosteroid
excretion is depressed via the effect of the synthetic glucocorticoid on adrenocorticotrophin production.
k

In addi-

tion, Howard et al (483) found that part of the effect of
prednisolone in raising a lipoprotein concentration could
be attributed to a decrease· in adrenal androgen production.
Glucocorticoids seem to exert their effects on phospholipids.

Allersberg et al (5) found that cortisol in-

creased serum phospholipids 24 percent, cholesterol esters
23 percent, and cholesterol 19 percent.

Triglycerides
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were decreased by this hormone.

Oliver and Boyd (797} and

Lever et al (654) confirmed these findings.

The latter

group found increases in a lipoprotein phospholipids and
cholesterol in 7 out of 8 patients.

Unexpectedly, deoxy-

corticosterone acetate, when given at 2.5 percent of the
dose of cortisone acetate, produced a 48 percent rise in
a lipoprotein cholesterol and 10 percent decrease in 8 lipoprotein cholesterol in one-half the time.

Despite the

greater nagnitude of the mineralcorticoid effect, the importance of the glucocorticoid effect is not minimized because the factors which regulate mineralcorticoid release
are largely independent of those which regulate glucocorticoid secretion and vice versa.

However, at least part

of the effect of the adrenal gland on serum cholesterol
is mediated by mineralcorticoids.
Clinical Effects of Free and Sulfate Conjugated Estrienes
Estrogens increase the output of the lipolytic hormone ACTH by the pituitary.

Also, ACTH is sufficient to

produce an increase in cortisol output by the adrenal
cortex.

However, the increased cortisol is not all in the

free form and in fact is partially inactivated by being
bound to transcortin which is also increased following estrogen treatment.
The decreased circulating linoleate seen during estrogen
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therapy is partly attributable to enhanced mitochondrial
chain elongation of this fatty acid to arachidonate (4w6).
Furthermore, increased amounts of eicosatrienoic acid (4w9)
are also formed from oleic acid, indicating that chain
elongation may be increased generally (403).

This process

per se does not seem to be the cause of the insulin resistance seen during estrogen therapy, unless the substrate
specificity of the enzymes which incorporate long-chain
acyl coenzyme A derivatives into triglycerides is such
that chain elongation results in a decreased rate of this
reaction.
A basic difference exists between the effects of estrogens on serum cholesterol and the effects of glucocorticoids on hepatic enzyme induction.

Steinberg (1025)

has shown that growth hormone is required for the estrogen effect.

In contrast, both Csanyi and Greengard {208)

and Liberti et al (661) have shown that growth hormone suppresses glucocorticoid induction of tyrosine aminotransferase and tryptophane oxygenase.

The suppression of cor-

tisol-dependent enzyme induction by growth hormone is opposite to the synergistic anti-insulin action of these
hormones.
Several attempts have been made to synthesize estriene
steroids which would have an estrogen effect on serum lipids
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but not the other effects associated with estrogen therapy.
such steroids have been termed "lipodiactic" steroids, and
many compounds of this type are designed so that the ratio
of lipid lowering effect to estrogenic effect is maximal.
For example, Roussel (patent number 3,032,563) has introduced the steroid 16a-ethinyl-11S,16S-dihydroxy-l,4-androstadien-3-one.

This compound possesses a number of the

structural features usually associated with estrogens,
anabolic steroids, and glucocorticoids.

Particularly note-

worthy is the displacement of the hydroxyl and ethinyl
groups in ring D.

Also, while the function of the 11 -hy-

droxyl group in this compound has not been determined, its
primary effect may be to decrease the conversion of the
compound to the corresponding phenolic derivative (417).
Perhaps the most interesting lipodiactic steroid so
far developed is 16,16-difluoro-17a-ethinyl-3-methoxy-l,
3,5 (10)-estrien-l 7S-ol.

Except for the fluorine subs ti tu-

tions, this compound is identical to the estrogen which
causes the most pronounced elevations in serum triglycerides.

This close similarity in structure suggests that D

ring binding is necessary for the triglyceride effect,
while A ring binding facillitates the binding of D ring.
Humber et al (496) have reported that this compound inhibits cholesterol synthesis 36 percent at l0- 4Molar.
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Arnold et al (20) reported that the lipodiactic/estrogenic ratio for the steroid 17-(3-hydroxy-l-propynyl)-3methoxy-l,3,5(10)-estrien-17S-ol was 1300 times that of
equine estrogen sulfates and 3300 times that of estrone.
The enhancement produced by the 17a side chain is especially
noteworthy.

A similar enhancement of anesthetic steroid ef-

fects was observed by Selye and is also found in progestational steroids.
Several clinical trials have outlined the effects of
estrogen therapy on serum lipids.

In 1957 Furman and

Howard (349) studied the effects of estrone sulfate on a
and B lipoproteins.

In addition to the gynecomastia asso-

ciated with the therapy, they noted that predictable changes
in 8 lipoproteins could be produced in only about 56 percent
of all their subjects.

In 1962 these scientists reported

similar findings in hyperlipemic subjects (350).
In 1962 Marmasten et al (717) reported the results of
lipodiactic therapy following myocardial infarction.

They

found no correlation between serum lipids and survival.
Fu~thermore,

while equine estrogen

s~lfates

significantly

improved survival rates, no such improvement could be demonstrated for the pen-conjugated steroids 17a-ethinyl-l,3,
5(10)-estriene-3,178-diol and 3-methoxy-16a-methyl-l,3,5{10)estriene-16S,17B-diol {895).

The conclusion of such studies
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appears to be that only conjugated lipodiactic steroids are
able to improve post-infarction survival by a mechanism unrelated to serum lipid levels.

Further studies are necessary

to confirm the conjugate effect.
Two additional lipodiactic steroids merit consideration
from a structure-function standpoint.

The first is the pat-

ented adrenal androgen analogue 17a-ethinyl-3-ethoxy-3,5androstadiene-11S,17B-diol which is hydrolyzed in vivo to
17a-ethinyl-11S,17S-dihydroxy-4-androsten-3-one.

This par-

ticular compound is similar to the endogenous cortisol metabolite 11S,17B-dihydroxy-4-androsten-3-one.

In addition,

this steroid is quite similar to the endogenous hypotensive
steroids reported by Sturtevant (1037).
The second lipodiactic steroid that should be considered is that described by Gordon ·et al ( 400) as having good
separation of lipid and estrogenic effects.

The compound

2-methoxy-l,3,5(10)-estriene-3,16a,17S-triol is an endogenous steroid in man and its production is increased by
thyroxine.

Gallagher et al (355) found that the formation

of this particular steroid was reduced in breast tumor
patients.

The relation between its lipodiactic effect and

possible anti-tumor effect should be further investigated.
Estrogen Conjugates
The superiority of estrogen sulfates in lipodiactic
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therapy may be explained by the finding of Fishman· et al
(319) that these conjugates are intermediates in the formation of 2-methoxy estrogens.

Therefore, although previous

studies have been disappointing, these considerations suggest that 16,16-difluoro-17a-ethinyl-2-methoxy-l,3,5(10)estriene-3,118,17S-triol may merit clinical trial as a
lipodiactic drug.
Conjugated equine estrogens (Premarin) have generally
been preferred to the use of non-conjugated estrogens due
to their lower estrogenic side effects.

Approximately 50

percent of myocardial infarction patients experience a maximal decrease in serum cholesterol of 10 percent during the
administration of 4.0 mg/day of conjugated equine estrogens
over a three-month period (1021).

Those patients who do

not respond to this dose may respond to the maximum dose of
10.0 mg/day.

However, not all patients respond to the larg-

er dose and there seems to be an increase in death rate from
2 to 8 percent associated with the maximum dose.
Oliver and Boyd (796) have demonstrated that 17a-ethinyl-l,3,5(10)-estriene-3,17B-diol at a dose of only 0.10 mg/
day produces ch.olesterol lowering effects equivalent to 4. O
mg/day of conjugated estrogens.

Moreover, 0.20 mg/day can

lower cholesterol levels 25 percent in normal subjects and
35 percent in subjects with Type II hypercholesterolemia
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a three-month period.

These studies stress the differ-

ence in individual responses to drugs.

Ideally, each pa-

tient should be titrated with the drug until side effects
occur (895).
In 1963 Stamler et al (1021) further raised doubts
about the efficacy of estrien therapy following myocardial
infarction by showing that the commencement of therapy
within three months following the infarction actually increased patient mortality.

This occurred despite the fact

that five-year mortality was reduced 50 percent.
·

The early

increase in deaths was one of the first indications of the
risks associated with estrien therapy.·

While this finding

has not been explained, it could have been due to enhanced
p1latelet aggregation secondary to the estriene at a time
when factors related to tissue damage were also actively
promoting coagulation.
In order to compare the results of estrogen therapy
with other treatments the data.of Huninghak et al (497)
may be cited as typical of long-term Atromid-S therapy.
They reported that at least 50 percent of their patients
experienced cholesterol reductions of at least 15 percent.
If it is assumed that death rate is approximately proportional to cholesterol and that all other factors were similar, estriene therapy seems to be at least as beneficial
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other hyperlipidemic drugs.
Besides their effects on lipid biosynthesis, estrienes
may also differ with respect to their effects on lipoprotein lipase activity.

Keeping estriene inhibition of the

enzyme to a minimum should be a goal in any series of structural alterations.

This effect has apparently not been con-

sidered in the previous studies and may have contributed to
individual variability if the lipids were not measured in
the fasting state.

CHAPTER X
LIPOPROTEIN LIPASE AND THE LIPOPROTEIN INSULIN AN'l1 AGONIST

!iipoprotein Lipase Activity:

Effect of Insulin, Ethanol,

catecholamines and Cyclic Adenylate
Lipoprotein lipase may be involved in the degradation
of the lipoprotein insulin antagonist.
activity is decreased in diabetes

(578).

Lipoprotein lipase
The sulfated poly-

saccharide heparin is required for enzyme activity and insulin may increase enzyme

act~vity

by increasing heparin

synthesis by mast cells in the arterial wall.

Schiller

and Dorfman (943) have demonstrated decreased incorporation of radioactive sulfate into heparin in diabetes.

The

key role of heparin in the action of the enzyme was shown

by Korn (606) who inactivated it by treatment with heparinase.

Heparin is synthesized in lung, liver, muscle and

intestine but has not been recovered from normal plasma;
its presence there is due to its escape from perfused
tissues.
Insulin may also affect the synthesis of the enzyme
222
1.··..·.·.

l
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protein.

Kessler (578) found that diabetes reduced the hep-

arin-releasable lipoprotein lipase from adipose tissue but
increased the release of the enzyme from myocardial tissue.
Kessler also investigated the activities of the myocardial
and diaphragm enzymes during fasting where the activity increased and decreased respectively following glucose administration.
,

The decrease in activity following glucose is

probably related to the suppression of growth hormone release by glucose.

~

..

Mallov and Cera (703) found that heart lipoprotein
lipase was increased by ethanol intoxication, catecholamines, and ether anesthesia.

The ethanol stimulation of

the enzyme did not occur in adrenalectomized rats or in
puromycin-treated rats indicating that glucocorticoid-dependent protein synthesis may be required.
Wing and Robinson (1164, 1165) observed that serum
lipoprotein lipase from fed animals had a shorter half·life than the enzyme from fasted animals.

They also noted

that actinomycin blockade of DNA synthesis produced an increase in the stable form of the enzyme.

This effect of

actinomycin could be reversed by catecholamines or adrenocorticotrophin, agents which increase cyclic adenylate.

"! .
i

Huttunen and Steinberg (501) have shown that cyclic adenylate activates adipose tissue lipase via a phosphorylation
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of the enzyme mediated by a specific protein kinase.

A sim-

ilar enzyme phosphorylation may be involved in the conversion of lipoprotein lipase to its unstable form.

Catechola-

mine stimulation of this reaction may be.of particular importance in carbohydrate-induced lipemia which is characterized by a primary elevation in sf 20-400 pre-S-lipoproteins (7, 76).
Phospholipase A and Lipoprotein Structure
Although Dbrzaki and Zieve .(253) have shown that lipoprotein lipase is not stereospecific in its hydrolysis of
triglycerides, they did show that the enzyme also possesses
phospholipase A activity.

Vogel and Bierman (1106) have

confirmed the phospholipase activity in vivo.

Dorzaki and

Zieve studied this phospholipase activity in vitro and
found that it was more susceptible to the micellular state
of the substrate as influenced by salts and other agents
than was the lipase activity of the enzyme.

Chylomicrons

contain phosphatidyl ethanolamine which is released as

l

i

t'f ·

chylomicrons are degraded.

If factors which prevent the

degradation of this phospholipid

a~e

present, then its

relative concentration in blood may increase under these

~:.

t

r·
"'·

conditions.

Marinetti (714) studied the effect of phos-

pholipase A action on S-lipoproteins.

Although he found

t\

no change in molecular weight or in other molecular
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parameters, the effect of phospholipid hydrolysis may be different when triglycerides are also being hydrolysed.

Simi-

larly, Banaszak and McDonald (41) reported that treatment
of

s-lipoprote~n

with proteolytic enzymes did not dramati-

cally alter the clarity of lipoprotein solutions.

Although

it.might be argued that some lipoprotein peptide bonds were
buried and not exposed to the attack of the enzyme, these
results do not rule out the importance of lipid-lipid interactions in holding lipoprotein subunits together.

In

contrast, the subunits of de-lipidated S-lipoprotein form
insoluble aggregates.
Effects of Nicotinic Acid, Thyroxine, Atrornid, Polyunsaturated
Acids, Androsterone Estrienes and Cholinesterase Inhibitors
Many drugs affect the activity of lipoprotein lipase.
Nicotinic acid, which inhibits adipose tissue lipase, was
used by Molnar et al (753) in an attempt to reduce lipolysis in diabetes.
··

Although the drug initially reduced free

fatty acid levels, it also had a stimulatory effect on lipoprotein lipase which persisted at a drug level at which
inhibition of adipose tissue lipase did not occur.

The

net effect of the drug was to raise fatty acid levels and
to exacerbate the diabetes.

Nicotinic acid also produces

hypotension.
Porte et al (847) also found that thyroxine increased
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lipoprotein lipase activity.

However, the increase in myo-

. cardial metabolism also produced by the hormone may produce
angina pectoris in patients with narrowed coronary arteries.
Oliver and Boyd (798} have investigated the effect of D-thyroxine in the treatment of hypercholesterolemia.

Although

type III hypercholesterolemia was unaffected by the drug, a
mean decrease of 16 percent in ser.um cholesterol was observed after 6 months of therapy with 7.5 mg of D-thyroxine
per day.

At this dose level 35 percent of the patients ex-

perienced angina.

Furthermore, although no significant in-

creases in basal metabolic rate were observed, most patients
lost weight during therapy.
with the drug,
time.

i.e~

An escape phenomena was noted

the drug became less effective with

One possible explanation of this finding is that

D-thyroxine displaces L--thyroxine from thyroid-binding
globulin so that the hormone inhibits TSH release from the
pituitary.

An escape phenomena has also been observed with

2-(p-chlorophenoxy}-2-methyl-propionic acid (clofibrate}
which may exert this effect by the same mechanism.
·Atromid-S (clofibrate} is often prescribed for the
treatment of type II hypercholesterolernia.

However, Japson

and James (530} reported that the drug produced only a transitory 9 percent reduction in cholesterol in this disorder.
On the other hand, Hood et al (475} observed that the drug
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caused a significant improvement in hypertriglyceridemia due
to its activation of lipoprotein lipase.

This result was

best observed when activity was expressed per milligram of
a-lipoprotein protein.

The enzyme is normally associated

with the lipoprotein and this fact has been used to advantage in its purification by floatation.

Fielding (314)

has purified the enzyme from rat plasma 500-fold.

He ob-

served that the optimum temperature of the enzyme was 37°C,
the optimum pH 8.5, and that the enzyme lost 10-15 percent
of its activity per day even at 0°C.
of the enzyme was found to be 72,600.

The molecular weight
These results indi-

cate that Atromid-S may be an effective drug for the treatment- of hypertriglyceridernia but that D-thyroxine is a
better treatment for type II hypercholesterolemia in those
'.;:·

patients who do not experience angina.
Types I and V hypertriglyceridemia may represent me-

"'.

tabolic defects in the activation of lipoprotein lipase.
The proposed conversion of the stable form of the enzyme
to the less stable form by the action of cyclic adenylate
and the ability of glucocorticoids to enhance the action
of the nucleotide may explain the reports by Bagdade· et ·a1
(35) of a reduction of lipoprotein lipase activity during
glucocorticoid-induced lipemia.

Similar decreases in

enzyme activity may occur in patients with diabetic
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retinopathy.

Ianacone and Kornerup (503) reported elevations

in serum lipids in this condition.

A decrease in the enzymes

sulfating heparin may be partly responsible.

Yde (1186)

found that these enzymes were reduced in diabetes.

In fact,

a negative correlation exists between the fasting levels of
serum sulfation factor and serum glucose.
Rosenman et al (909) found that not all of the hypolipidemic effect of thyroxine could be explained by its
activation of lipoprotein lipase.

They found that thyrox-

ine decreases serum cholesterol by increasing the rate of
bile acid formation, even though it also increases the rate
of cholesterol synthesis.

Estrogens also increase bile

acid formation but have a lesser effect on cholesterol synthesis.

These results indicate that drug effects on the

rate of bile acid formation can dominate effects on cholesterol synthesis and that drugs which can reduce the rate
of the former process without affecting the latter may be
valuable hypocholesterolemic agents.

Polyunsaturated

fatty acids also promote bile acid formation and they,
in conjunction with estrienes may be the most effective
treatment for type II hypercholesterolemia (659, 796, 1021,
1094).

Dayton et al (217) have.shown that when dietary fat

con~titutes

40 percent of calories a diet containing 38 per-

cent of this fat as linoleic acid resulted in 48 deaths

229

over an 8-year study compared to 70 deaths for a diet containing only 10 percent of its fat as linoleic acid.

This

dietary treatment of a lipid disorder is similar to the
dietary restriction of carbohydrate found by Kuo (622) to
aid type IV hyperpre-S-lipoproteinemia.
Non-aromatic steroids may also affect lipoprotein
lipase activity.

Laron and Kowadlo (638) have demonstrated

marked increases in plasma free fatty acids following the
administration of 10 mg/kg of testosterone propionate to
two-day fasted female rats. 'A 78 percent rise occurred in
the treated animals versus a 5 percent rise in the controls.
Although this rise was attributed to fat mobilization from
depot lipid, it could pot be produced in one day-fasted
animals.

Since S-lipoproteins begin to rise after approxi-

mately 48 hours of ·fasting due to lipolysis in adipose tissue, an activation of lipoprotein lipase by the steroid
could also explain the findings.
Androsterone exerts a hypocholesterolemic effect in
normal subjects that has not been explained (446).

Signif-

icant reductions can be obtained by the intramuscular administration of 50 mg/kg of the steroid per day.

In rats

Abdell and Mosbach (1) have reported that 17S-hydroxy-17amethyl-4-androsten-3-one and its metabolite 17a-methyl-5aandrostane-3S,17S-dibl lowered serum cholesterol.

The
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effect of the metabolite appears to be similar to that observed with androsterone in man.

However, the effect of

the testosterone derivative in the rat is opposite to that
observed in man because a-lipoproteins are the predominant
cholesterol-bearing lipoproteins in the rat.
Although androsterone exerts a hypocholesterolemic
·effect in normal men, certain 17a-alkylated C-18 and C-19
steroids appear to exert this effect only in hypertriglyceridemic individuals.
strated that

Sachs and Wolfman (923) demon-

17~-hydroxy-17a-methyl-2-oxa-5a-androstan-3-

one produced a 38 percent reduction in cholesterol, a 40
percent drop in phospholipid, and an 81 percent drop in
triglycerides in subjects with hypertriglyceridemia.

On

the other hand, the same compound produced typical an-'
drogenic effects in normal individuals, namely, changes
of +7 percent, -1 percent, and +65 percent in these same
respective lipids.

Furman and Howard (349) demonstrated

the hypocholesterolemic effect of 17S-hydroxy-17a-methyl4-androsten-3-one in type II hypercholesterolemia and
Gluek et al (375) obtained similar effects with 17a-ethinyl17S-hydroxy-4-estren-3-one in four patients with familial
type V hypertriglyceridemia.

·In fact, a 2-10 fold

reduc~

tion in plasma triglycerides was the major effect of the
therapy.

These reports represent a significant advance

:,

~

~\

l
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in the treatment of this disorder.

Acute abdominal pain is

characteristic of type V hyperlipemia.

Many of the symptoms

resemble those of pancreatitis, including elevations of
serum amylase and serum lipase normally used in the laboratory diagnosis of pancreatitis.

However, the administra-

tion of heparin or the withholding of long-chain triglycerides from the diet lessens the abdominal pain associated
with this disorder

bu~

not that associated with pancreatitis.

Hazzard et al (441) and Fabian et al (292) have shown
that lipoprotein lipase is inhibited by aromatic steroids.
Although

estrienes

inhibit lipoprotein lipase in normal

and hyperlipidemic subjects, the mechanism of the effect
is unknown.

In contrast, Szensikowski et al (1045) have

shown that eserine blocks 50 percent, and tetraisopropyl
phosphoramide 93 percent of the post-absorptive lipolytic
activity in the rat.

The mechanism of this effect appears

to be similar to that involved in the inhibition of the
enzyme by protamine.

The phosphramide may therefore be

valuable in lipoprotein lipase studies.
Effects of Lipids on Platelet Aggregation and Fib!inolysis
Platelet aggregation is one of the initial events in
myocardial infarction and (3-lipoproteins have been shown
to affect this process.

While fatty acids can cause the

reversible aggregation of platelets, the aggregate is real
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and can momentarily block circulation in small capillaries.
If this process leads to anoxic damage in the capillary, tissue thromboplastin is released into the circulation and some
thrombin is formed.

Since platelets are irreversibly aggre-

gated by low levels of thrombin, those factors which control
reversible platelet aggregation also control irreversible
platelet aggregation.
The process of ADP-induced platelet aggregation may
be viewed as a result of depressed cyclic adenylate levels
in the platelet.

As such it represents an effect of cyclic

adenylate on cell surface charge that has not yet been reported for other types of cells.

The mechanism whereby

cyclic adenylate affects surf ace charge appears to be more
closely related to electrolyte metabolism than to glucose
metabolism.
Glucocorticoids also enhance platelet aggregation but
the mechanism is not clear.

Generally, platelet aggre-

gates are formed in narrow pulmonary vessels following the
administration of large doses of glucocorticoids.

Appar-

ently, platelet serotonin, which is releasa:lduring the irreversible phase of platelet aggregation, causes the constriction of bronchioles and may enhance the anoxic effect
of platelet aggregates.
High levels of free fatty acids in plasma promote
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platelet aggregation.

Hoak et al (465) found that both sa-

turated and polyunsaturated fatty acids had this effect.
However, whereas the polyunsaturated fatty acids produced
only microscopic aggregates, saturated fatty acids produced
visible clumps.

According to Goloff et al (386) these ef-

fects are best seen in the vasculature of the wing of an
unanesthesized bat where as little as 0.01 cc of a 0.01 percent suspension of sodium stearate produces vasoconstriction
and thrombogenic effects that cannot be duplicated by larger
doses of oleic or linoleic salts.

This type of aggregation

is not inhibited by heparin and is different from irreversible platelet aggregation induced by thrombin.

However,

Glynn et al (376) found that even reversible platelet aggregation within the microcirculation could produce anoxic
damage in the arterioles and microcirculation.
Many cardiac patients have partially occluded coronary
arteries.

These patients are often treated with heparin

to lessen the chance of intravascular clotting leading to
complete occlusion.

Since lipoprotein lipase is activated

by this treatment, meals high in saturated fat may cause
abnormal increases in saturated free fatty acids which promote reversible platelet aggregation as described above.
This consideration emphasizes the role of diet in the control of atherosclerosis.
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Kerr et al (573) found that platelet aggregation by saturated fatty acids was inhibited by the 18w3 fatty acid
lirolenate but not by the 18w6 fatty acid linoleate.

Thompson

(1059) found increased platelet adhesion in multiple sclerosis and noted that circulating cholesterol linoleate was
depressed in the active stages of the disease.

Since this

ester is synthesized from a linoleate-containing lecithin,
its depression in these stages might be explained by the
presence of phospholipase A activity in the circulation of
these patients.

Bolton and Phillipson {92) presented evi-

dence supporting the presence of an abnormal lysolecithin
in multiple sclerosis that tends to support the above hypothesis.

This lysolecithin increases in the chronic

phases of the disease resulting in increased platelet sensitivity to ADP-induced aggregation.

The abnormal lyso-

lecithin is believed to be formed by the action of phospholipase A on an abnormal lecithin of n.eural origin.

How-

ever, a similar lecithin species has been demonstrated in
patients with vascular disease.

Although the phospholipase

A activity in vascular disease is released from erythrocytes by centrifugation, little is known about this enzyme
nor about the enzyme active in multiple sclerosis.

Platelet

aggregation in response to ADP appears to be more frequent
' .

in venous regions of low turbulance so that these regions
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are more susceptible to thrombosis.
Prostaglandin PGE
gregation.

1

inhibits lipolysis and platelet ag-

Karim and Sharma (563) found that ethanol could

abolish uterine contractions produced by the oral administration of PGE 2 to gravid women at term.

This finding sug-

gests that a decrease in the cytoplasmic ratio of NADH to
NAD+ is one of theI effects of the lipid.

The possibility

that prostaglandins exert some of their effects following
their conversion to coenzyme A derivatives and the incorporation of the latter into phosphatidic acid and triglycerides has not been investigated.
The role of stress in atherosclerosis has already
been discussed.

Delong et al (225) showed that the whole

blood clotting times of stressed rats was decreased relative to non-stressed controls.

These results are consis-

tent with the known affect of epinephrine on platelet aggregation.
ate.

This action is not mediated by cyclic adenyl-

Indeed, Marquis et al (719) have shown.that cyclic

adenylate decreases platelet aggregation in response to
adenosine-5'-diphosphate, ADP.

Therefore, any factor

which decreases the cyclic nucleotide will increase
platelet aggregation in response to ADP.
glandin E

1

While prosta-

decreases the levels of cyclic adenylate in

adipose tissue (146, 297), it increases the levels of the
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cyclic nucleotide in platelets.

In addition, it is inter-

esting to note that although the prostaglandin is the most
potent inhibitor of platelet aggregation yet discovered, it
cannot be used therapeutically because of the hypotension
which it also produces.

This action appears to be opposite

to the action which the prostaglandin has on uterine smooth
muscle.
The arterial intima is continually being injured and
repaired.

The basis of the effect of serum lipids on

thrombus formation is illustrated by the results of Bang
et al (76).

These workers found that chylomicrons and

pre-S-lipoproteins were incorporated into the fibrin clot
and that once incorporated the lipoprotein inhibited fibrinolysis of the thrombus.
The prostaglandins have an important role in modifying the actions of cyclic adenylate in adipose tissue.
First, the mode of transport of prostaglandins does not
seem to have been studied, especially with respect to their
possible transport by lipoproteins.

Bergstrom (70) noted

that these lipids inhibited the lipolytic action of catecholamines but not their effects on heart or on glucose
metabolism.

Fain (297) reported that PGE 1 also inhibited
the lipolytic action of growth hormone and glucocorticoids.

Thus, prostaglandins may directly oppose the interaction of
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glucocorticoids with the postulated growth hormone-dependent
protein.

However, PGE

in some tissues.

1

may increase cyclic adenylate levels

These results suggest that both PGE 1 and

growth hormone along with glucocorticoids affect lipolysis
independently of cyclic adenylate levels.
Effects of Aldosterone Antagonists
Glucocorticoids may act to decrease triglyceride synthesis.

Danowski et al (212) noted that the aldosterone

antagonist 3-(3-keto-7-a-acetylthio-17s-hydroxy-4-androsten-17a-yl)-propionic· acid gamma lactone, like

glycyr~

rhetic acid, could enhance the 'inhibition of triglyceride
synthesis by cortisol.
Sequelle of Initial Myocardial Infarction
The arterial damage resulting from an initial myocar~··

'

dial infarction results in the release of tissue thromboplastinsand higher steady-state levels of plasma thrombin.
Since thrombin preferentially accelerates platelet aggregation, an initial infarction increases the probability of
a subsequent infarction.

Thrombin acts by exposing platelet

factor 3, a platelet membrane lipoprotein which contains
phospholipids active in blood coagulation.
The elevation in S-lipoprotein which occurs following
an infarction and persists for approximately two months
thereafter appears to be due to an inhibition of lipoprotein

k.··.

l
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lipase activity that may be caused by the presence of heparin-neutralizing factors.

However, the significance of the

decrease in sf 12-20 lipoproteins following infarction, first
reported by Dodds and Mills (246) remains obscure.
McDonald and Edgall (688) have verified the hypercoagulability of the blood of patients with angina pectoris or
actual myocardial infarction due to the presence of tissue
thromboplastin as mentioned above.

Agents which increase

platelet aggregation in response to ADP in vitro may also
increase secondary platelet aggregation in response to ADP
released from platelets primarily aggregated by long chain
saturated fatty acids.
The main result of the increased ADP concentration in
platelets is that processes which maintain the repulsive
surface charge on the platelet are reduced so that platelets
show increased adhesiveness to each other and to glass.

This

change in surface charge is reflected by changes in the electrophorectic mobility of the platelet.
French (330) has noted that low levels of thrombin preferentially accelerate platelet aggregation.

After this ini-

tial aggregation which is an irreversible process, the platelets release a lipoprotein, platelet factor 3, which increases the rate of thrombin formation.

It is this second
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surge of thrombin formation which clots fibrinogen.

How-

ever, although platelets are irreversibly aggregated, thrombus formation is still reversible at this stage.

The irre-

versible stage in thrombus formation appears to be the absorption of certain plasma glycoproteins by the developing
thrombus

( 131) •

Role of Phospholipids
The increase in B-lipoprotein which follows myocardial infarction has been investigated by Hampton and Mitchell
(425) and by Bolton et al (89).

They found that the lipopro-

tein in this instance contained an abnormal lecithin which
was converted to a lysolecithin by the action of an enzyme
found to be of red cell origin.

Although the exact nature

of the abnormal lecithin has not been determined, it is believed to be a symmetrical lecithin containing only monoenoic or saturated fatty acids.

A similar type of lecithin

has been shown by Bplton et al (91) to be present in women
taking estrogen-progestin combinations.

The effect was at-

tributed to the estrogen component because the progestin
6-chloro-17a-hydroxy-l,4-pregnadiene-3,20-dione 17 acetate
was without effect when administered alone (843).

The es-

trogen effect under these conditions appears to be due to
,.

an increase in lecithin saturation (423).

An additional

,'~

direct effect of estrogens on B-lipoprotein is not ruled

l
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Indeed, Roberts and Szego (892) have reported the
presence of covalently bound estrogen activity in the S-lipoproteins of human plasma.

The estrogen activity was pres-.

ent in a hydrophilic esterified form equivalent to 18 µg/l
of estriol.
Although the effects of estrogens on blood coagulation
are complex, their enhancement of ADP-induced platelet aggregation appears to be due to an increase in the hepatic
synthesis of monounsaturated lecithins.

For example,

Bolton et al (91) observed that platelet electrophoretic
mobility, a measure of the repulsive negative charges between platelets, was increased by estrogen therapy.

In

addition, the platelets became much more sensitive to the
reduction in their mobility normally caused by 0.05 µg/ml
of ADP.·

For instance, an anurism of the left middle cere-

bral artery was observed in a patient whose platelet mobility was decreased 12 percent by 0.005 µg/ml ADP, the
(

highest sensitivity observed during the study.
Hampton and Mitchell (425) have reported that the
lecithin precursor of the platelet-active lysolecithin,
alt.hough present in normal plasma, is increased 5-fold

.
l
.

following myocardial infarction.

The hydrolysis of this

lecithin to the active lysolecithin was inhibited by cyanide and fluoroacetate anions.

The phospholipase enzyme

241
responsible for the transformation seemed to be specific for
lecithin bound to B-lipoprotein.

Bolton at al (89) noted

that the active lysolecithin was not formed if the lipoprotein had been frozen and thawed and thereby denatured.

The

phospholipase, therefore, shows substrate specificity similar to that shown by lipoprotein lipase.

The function of

the lipoprotein may be to bind the lecithin in an asymmetrical manner for Attwood et al (32) noted that asymmetrical
micelles were more rapidly hydrolyzed by phospholipase A.
The phospholipase as well as its lysolecithin product are
destroyed when incubated in plasma for 1 hour at room ternperature.

The lysolecithin appears to be destroyed by a

separate lysolecithinase of wide distribution.

On the

other hand, the lecithinase is destroyed if the plasma
comes in contact with glass.

This latter inactivation

does not appear to be caused by the proteolytic enzymes
involved in blood coagulation which are surface-activated,
but rather to an instability to glass surfaces similar to
that observed with lipoprotein lipase (314).

The condi-

tions which affect the formation of the lysolecithin are
also similar to those which have been reported for the 8lipoprotein insulin inhibitor by Bornstein (100).
Several questions related to the beneficial effects
of estriene therapy on coronary thrombosis remain unanswered.
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Although Ask-Upmark (29) and Tausk (1053} have reviewed pertinent findings relative to the relationship between estrogens and arterial damage, the fact that estrienes are not
beneficial by virtue of their effects on serum lipoproteins
nor by virtue of their effects on thrombus formation means
that the actual basis of the long-term improvement in postinfarction survival is still unknown.

Furthermore, the

superiority of conjugated estrogens compared to non-con·_jugated estrogens in this type of therapy must be confirmed.
comparison of Estrogen and Cortisol Effects on Platelet
A~gregation

and Glucose Tolerance

Egeberg and Owren (273} observed elevations in two
hemostatic lipoproteins, platelet cofactor I and Factor V
during estrogen therapy.

Platelet cofactor I

(Factor VIII}

was also elevated in diabetic patients, patients with
Cushing's disease, and during pregnancy.

It is noteworthy

that glucose intolerance has also been noted in each of
these conditions.
Little is known about the biochemistry of Factor VIII.
A deficiency of the activity of this factor produces Bemophilia A in males.

It is known, however; that Factor VIII

stimulates blood coagulation in response to tissue thromboplastins as well as in response to surface contact.

Its

action is closely related to that of another lipoprotein,
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platelet factor 3 •. The complex of Factor VIII and platelet
~

factor 3 has been termed "threone" and it accelerates the
generation of thrombin by acting as a catalyst for the rapid
interaction of other clotting factors leading to thrombin
formation.

Therefore, at least part of the estrogen effect

on blood coagulation is due to an increased formation of
Factor VIII, which increases the concentration of threone
in blood.

According to Hemker and Kahn (448), threone pro-

motes the interaction of Factor VII with Factor IX as well
as the interaction of Factors V and X.
Although the membrane lipoprotein platelet factor 3
is not required for the anti-insulin effect of B-lipoproteins, some of its properties will be described since they
may be confused with the lysolecithin species which is believed to be required for insulin antagonism.

The lipid

portion of platelet factor 3 lipoprotein is active in certain coagulation tests such as the thromboplastin generation test and in the Stypven-time deternination.

The exact

nature of this lipid portion of the molecule has not been
determined.

However, it is known that the active componcmt

is a phospholipid which can be formed from sn-1,2-dioleoylphosphatidyl ethanolamine (844).

The active phospholipid

is found in most crude cephalin preparations.

Its in vivo

significance is seen in the results of Marciniak et al (710)
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·who showed that the simultaneous injection of the cephalin
fraction with autoprothrombin C (Factor X) was lethal while
the injection of either factor alone was not lethal.
Platelet aggregation is prevented normally by the action of a membrane bound kinase which introduces negatively
charged phosphate groups into the platelet membrane and
thereby generates repulsive platelet charges.

ATP is the

phosphate donor for this reaction and the process is inhibited by ADP.

This scheme was proposed by Salzman (928).

However, the source of extracellular ATP for the reaction
has not been specified.

It appears that some mechanism

exists by which intracellular ATP equivalents are transported through the membrane and subsequently converted to
extracellular ATP because nucleotides do not penetrate the
platelet membrane.

Furthermore, the high levels of acid

phosphatase contained in platelets may be involved in the
removal of the membrane phosphate groups thereby necessitating their continuous replacement.

Although ATP in-

hibits ADP-induced platelet aggregation, ATP does not
inhibit platelet aggregation produced by thrombin.

Both

ADP and serotonin are known to be stored in platelet granules that are irreversibly disrupted during thrombin aggregation.

This effect of thrombin·on platelet granules

may be related to its effect on platelet phospholipid
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synthesis.

Majewus ·et al (699) have shown that platelet

phospholipid synthesis can be increased 7-f old by thrornbin
within 2 minutes and that this effect is accompanied by the
reduction in the molecular weight of a platelet membrane
protein from 190,000 to 107,000.
The Mechanism of Steroid Effects
Jederkin and White (527), White (1138), and Wade and
Jones (1109) have reported that 6 x l0- 4Molar 3,4-bis (phydroxyphenyl)-trans-3-hexene,4,16-prenadiene-3,20-dione,
progesterone, and 17a-ethyl-17S-hydroxy-4-estren-3-one increased mitochondrial ATP utilization and inhibited the
rate of oxygen consumption.

The first non-steroid was

about 26 times as potent as the first steroid listed.
The chemical progesterone precursor, in turn, was about
3 times as potent as the latter two steroids ·which were
approximately equal in effect, but 3 times as potent as
deoxycorticosterone which was equal to 17S-hydroxy-17amethyl-4-androsten-3-one in potency.

Their data also in-

dicate that the 3-fold difference in activity between the
latter steroid and 17a-ethyl-17S-hydroxy-4-estren-3-one is
due to the difference in the C-17 and not the C-10 substituents (492).

The high activity of 4,16-pregnadien-3,20-

dione also suggests that other flat polycyclic molecules
such as 3-methylcholanthrene and ergolanes may also
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be able to produce these effects.

On a molar basis these

inhibitory effects were greater than those of dicumarol,
dinitrophenol, methylene blue, sodium azide or sodium cyanide.

Essentially similar findings were reported by Jones

and Wade (535) and by Hochster and Quastel (467).
Gordon et al (398, 399) attributed the increased utilization of extramitochondrial ATP to a steroid block in
the reduction of mitochondrial cytochrome C by NADH.

Since

the steroids were effective in the presence of amytal (5ethyl-5-isoamyl-barbituric acid) which inhibits electron
transport at cytochrome C but did block reduction of coenzyme Q (ubiquinone), the steroids were believed to inhibit
electron transfer between coenzyme Q and cytochrome b or
between the latter and cytochrome
reached similar conclusions.

c.

Gordon et al (398)

Jedeikin and White (527}

f

4
also found that 10- Molar deoxycorticosterone inhibited

~· ·

the oxidation of pyruvate and succinate and that NAD +
could overcome this inhibition.
Gallagher (352) also found that cortisol inhibited the
oxidation of NADH.

However, he found that the inhibition

could be reversed-by glutathione and acetyl coenzyme A and
.that the effect could be abolished by preparing mitochondria
in water rather than in 0.25 Molar sucrose.

These results

emphasize the importance of mitochondrial integrity in the
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effect of the steroids.
Blecher (84) further studied the effect of glucocorticoids on lymphatic cells and found that they inhibited glycolysis rather than glycogen formation.

White and Makman

(1139) reported that the effects of glucocorticoids on thymocytes required the presence of an energy source and intact cellular protein and nucleic acid synthetic capacities.
These results suggest that the effects of glucocorticoids
are much more specific than that of the other steroids mentioned above.

That this specific glucocorticoid effect may

be mediated by the S-lipoprotein glycolytic inhibitor is indicated by the findings of Hofert and White {468) demonstrating a major role of the liver in the systemic action
of glucocorticoids in the involution of lymphoid cells.
Jones and Wakil (936) observed that NADH-cytochrome C
reductase in microsomes has an absolute requirement for lysoleci thin and lecithin.

They postulated that these lipids

combined to form micelles of distinctive structure.

This

effect is similar to that reported for the lipid portion of
platelet factor 3.

It was also reported that a similar

type of micelle could be formed by 2-butyryl-3-olelyl-sn-lglycerophosphoryl-choline.

The possibility that certain

steroids disrupt the structure of these micelles should be
investigated.
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Selye (965) first observed the anesthetic effects of
steroids in mice.

He found that female mice were much more

sensitive to anesthesia than .males.

Using 135 gm mice, he

found that as little as 5 mg of deoxycorticosterone or 15
mg of progesterone produced marked anesthesia in females.
The anesthesia was further prolonged by the administration
of 50 mg of androsterone.

The male mice, however, were

hardly affected by 40 mg of deoxycorticosterone.

Winter

(1169) confirmed these findings and showed that the anesthesia could be reversed by glucose.
Gordon (399) reported that 17a.-ethyl-1713-hydr0xy-4androsten-3-one produced anesthesia while estradiol did
not.

However, Wade and Jones

(1109) reported that estra-

diol was about as effective as 513-pregnane-3a.,2013-diol and
testosterone.

The use of non-hormonal steroids as anes-

thetics eliminates side effects such as salt-retention by
deoxycorticosterone.

For example, 21-hydroxy-513-pregnene-3,

20-dione 21-hemisuccinate has been used as a clinical anesthetic.

The administration of 1.5 gm of the compound

(Viadril) to men produces surgical anesthesia sometimes accompanied by profuse salivation which can be eliminated by
atropine (dl-hyoscyamine), an anti-cholinergic belladonna
alkaloid.

In view of the fact that Viadril produces anes-

thesia more readily than analgesia, the substitution of
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scopolamine (hyoscine), a parasympatholytic agent which is
a precursor of atropine, for atropine, should depress the
central nervous system and enable the effective dose and
thrornbophlebities associated with the hemisuccinate ester
to be reduced.

Pedersen (823) reported that the adminis-

tration of 0.5 mg of scopolamine to men produced sedation
in 88.4 percent of them with no excitation or respiratory
depression.

Bradycardia, nausea and vomiting occurred in

20 percent.

These results suggest that the combination of

scopolamine and a more potent anesthetic which is water
soluble may be a clinically useful agent in man.

Scopola-

mine may also be used to treat the pyloric spasm which
occurs in alloxan-diabetic rats, thus improving their
survival.
The llS-hydroxyl group dramatically changes the surface activity of steroids.

Munk (766) found that cortisol

laid on edge at the heptane-water interface while deoxycorticosterone and progesterone took up parallel positions.
Weissman (1130) noted that cortisol counteracted the release of acid hydrolases from liver lysosomes by deoxycorticosterone and progesterone as well as the release of
salts and glucose from synthetic micelles by the latter
steroids.

These findings suggest that glucocorticoids

have specific surface effects.

250

·-

Effects of Other Compounds
Mills and Roberts (745) as well as O'Brien (793) have

shown that a number of clinically used drugs reduce the AOPsensi ti vi ty of platelets.

One of the more interesting is

thorazine [2-chloro-10-(3-dimethyiaminopropyl)-phenothiazine]
'

which is also known as chlorpromazine.

Several seemingly

unrelated effects of this drug are of interest in light of
the hyperglycemic effect of the drug.

Reckless and Hopkin

(869) demonstrated synergism in anesthetic effect of the
phenothiazine and morphine;
been described.

anesthetic steroids have also

Although chlorpromazine alone decreases

respiratory rate, it also counteracts respiratory depression due to morphine (869); glucocorticoids have the same
effect.

Furthermore, the phenothiazine opposes the emetic

effect of serotonin and apomorphine; both of the latter
compounds have hyperglycemic effects (180, 987).

Chlor-

promazine also accelerates the clearing of hyperlipidemic
serum (471) but inhibits ethanol metabolism (118).
While the above observations do not suggest a common
mechanism, reports that an abnormal lecithin molecule
transported by B-lipoprotein following its conversion to
lysolecithin, increases platelet ADP-sensitivity, suggests
that a specific lecithin may mediate glycolytic inhibition
·.

'

by steroids (573, 720, 928).

Furthermore, since Hughes
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·and Tonks have shown that glucocorticoids enhance platelet
aggregation (493), they may exert this effect by increasing
the synthesis of the abnormal lecithin in the liver.

Growth

hormone or estrogens may also affect the synthesis of this
lecithin species.
A platelet membrane lipoprotein, platelet cofactor 3,
is exposed during irreversible platelet aggregation when it
accelerates thrombin formation.

This factor is described

. because it also contains an essential phosphatidyl ethanolamine derivative but is not concerned with reversible platelet aggregation.

On the other hand, Factor XII, Hageman

factor, which is a proteolytic enzyme responsible for the
reduced clotting time of blood exposed to hydrophilic
,.

(glass) surfaces, has been shown by Harmison and Mammen
(429) to increase platelet ADP-sensitivity.

These workers

also found that purified Hageman factor along with purified
r;;:

~,

r

platelet cofactor 3 could activate ·purified prothrombin to
thrombin.
Chlorpromazine, phentolamine (2-[N-(m-hydroxyphenyl)p-toluidinomethyl]-imidazoline), and diphenyldiamine (2diphenylmethoxy-N,N-dimethylethylamine) inhibit ADP-induced
platelet aggregation (213, 1199).
similar structurally.

These drugs are very

In addition to these platelet effects,

Charaton and Bartlett produced hyperglycemia in dogs by the
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administration of 50 mg of chlorpromazine.
:·

Dobkin et al

(241) also produced hyperglycemia in man by the intravenous
administration of 1.5 mg/kg of the drug.

Furthermore, Hiles

(457) noted that patients with a family history of diabetes
were most prone to chlorpromazine hyperglycemia.

The ef-

feet of chlorpromazine on glucose utilization is similar
to that of cortisol.
Chakrelarte et al (167) found that the combination of
the synthetic steroid 17a-ethyl-4-estren-17S-ol and the
oral hypoglycemic agent phenethylbiquanide inhibited ADPinduced platelet aggregation.

A reduction in platelet ad-

hesiveness was produced in most patients by the administration of 50 mg of phenethylbiquanide and 4 mg of the steroid
per day.

Phenethylbiquanide inhibits oxidative phosphoryla-

·,,.

tion, depresses cytoplasmic ATP, and therefore accelerates
glycolysis by its anaerobic effect.

However, if this were

its only action, phenethylbiquanide would promote platelet
aggregation.

The inhibitory effect of this compound could

be due to inhibition of platelet phosphodiesterase with
.resulting elevation in platelet cyclic adenylate which has
been shown to have this effect.
inhibits

platelet

If the steroid also

aggregation by reducing cyclic adenyl-

ate levels, then it appears to have an effect opposite to
that of glucocorticoids which enhance the effects of this

l
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n~cleotide.

However, since platelets are capable of gluco-

neogenesis, the role of protein synthesis in these effects
cannot be determined from present data.
zucher and Peterson (1198) reported that a single dose
of aspirin irreversibly reduced platelet aggregation in response to epinephrine for the platelet life-span of 9-11
days.

Hemostasis was still satisfactory,

however~

The

molecular reaction involved is believed to be the transfer
of the phenolic acetyl group of aspirin to a protein amino
group.

Furthermore, al-Mondhiry et a1· (754) determined

that acetic anhydride could also produce the aspirin effect
whereas sodium acetate could not, even though total acetate incorporation was about the same as with the anhydride.
Apparently, these workers did not distinguish between covalent and non-covalent acetyl groups.

Also, although these

workers were working with whole platelets, only one of many
acetylatable proteins is involved in the ADP-induced aggregation.
In summary, the phenomenon of ADP-induced platelet aggregation provides a model system in which the action of a
unique species of lysolecithin associated with S-lipoprotein may be studied.

The identity of this lipoprotein fac-

tor with the insulin inhibitor cannot yet be made with certainty since the mechanism by which ADP exerts its effect
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is not known.

However, a reduction in platelet ATP is one

of the effects of ADP so that some aspect of platelet metabolism is blocked by B-lipoprotein.

If the insulin antagonist

enhances platelet aggregation, then insulin should counteract
its effect.
Sirek et al (987) and Feldman and Lebowitz (309) further demonstrated that serotonin antagonists could block
the hyperglycemic effect of serotonin.

These latter workers

also showed that the adrenergic blocking agent phentolamine
also had this effect even though it did not block insulin
release by epinephrine.

In additional experiments Sirek

et al (987) showed that 2-bromolysergic acid diethylamide
inhibited the rise in blood pressure following the transfusion of blood from normal dogs treated with growth hor/mone.

These results suggest that growth hormone releases

serotonin into the blood.
adrenal epinephrine.

The serotonin, in turn, releases

In perhaps their most interesting re-

port Sirek (986)showed that dihydroergotamine treatment
abolished the early increase in glucose utilization following the injection of growth hormone into hypophysectomized dogs.

This hypoglycemic effect of serotonin has been

observed by others and may be due to the displacement of
cortisol from some of its binding sites.

In related ex-

periments Levine et al (656) found that serotonin at a

r
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concentration of 4 x 10

-4 M produced glycogenolysis, hypergly-

cemia, and increased phosphorylase activity independently of
the vasomotor effects of the amine on the liver.

These ef-

fects could be. blocked by the serotonin antagonist Nl-methylergonovine.
Adrenalectomized rats are more sensitive to serotonin,
serotonin toxicity and intravenous serotonin hyperglycemia.
Adrenalectomy also decreases blood serotonin, -the induction
of trytophan pyrolase. by serotonin, and the block in serotonin hyperglycemia by dihydroergotamine.

Serotonin de-

#

creases thyroxine release and increases prolactin release.

:'~·

Serotonin induces hypertrophy of the n1anunary gland wi tl1

hyperplasia of the ducts and lobular differentiation in
most ovarectomized rats, but not in hypophysectomized rats.
Serotonin decreases. gluconeogenesis and lowers muscle glycogen but stimulates the growth of Walker carcinocarcinoma.
Growth hormone increases the urinary excretion of 5-hydroxyindoleacetic acid.
Brand et al (113} reported that chlorpromazine could
block the emetic effects of apomorphine, morphine, and dihydrogenated ergot alkaloids.

Ansell and Marshall (14}

reported that chlorpromazine inhibits phospholipid synthesis and Greig and Gibbons (11} have shown that the preservative effect which the phenothiazine has on red cells
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in stored blood is due to the inhibition of a red cell lecithinase by the drug.

These results suggest that chlorpro-

mazine may bind to alkaloid as well as to phospholipid binding sites.
Gey and Pletscher (364) have shown that serotonin
raises blood pyruvate and lactate levels suggesting that
serotonin may interact with the growth hormone dependent
protein which elevates cytoplasmic citrate levels.
Since ergot alkaloids and phenothiazines are not endogenous metabolites, if they are found to compete for
some glucocorticoid-binding sites, this would indicate
that some glucocorticoid effects are due to binding at
non-specific sites and that certain drugs also exert their
effects by binding to these sites.

Furthermore, if ergot

derivatives are found to have the highest binding affinities,
the results may mean that related compounds could be impertant drugs capable of producing the non-specific but not
the specific effects of glucocorticoids.

The anti-inflam-

matory effects and anti-glycolytic effects of the steroid
are believed to be in this latter category.
In conclusion, the ability of S-lipoprotein lysolecithin to enhance (89, 425) platelet aggregation by adenosine-5'-diphosphate may provide a convenient assay system
with which to further study the phenomenon on a molecular
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basis.

With such an assay the factors which regulate the

hepatic synthesis of the lecithin precursor of the lysolecithin may be studied.

In particular, the roles of non-glu-

cocorticoids, phenothiazines, serotonin, and serotonin antagonists in the effect can be determined.

Furthermore,

the hypothesis that such effects are related to a block
in the conversion of diglycerides to triglycerides can be
evaluated.
Role of Growth Hormone in Estrogen Effects
Steinberg (1025) has shown that the effects of estrogens on serum lipids in female hypophysectomized rats requires growth hormone.

In addition, it appears that the

deleterious effect of high-dosage estrogen therapy is also
mediated by a growth hormone-dependent mechanism.

Further-

more, both the effects of glucocorticoids on glucose uptake in adipose tissue (397) as well as the effects of
this hormone on the production of the S-lipoprotein insulin
inhibitor have been shown to be dependent upon growth hormone (98).
Bala et ·a1 (39) have shown that estrogens enhance
growth hormone release while progestational steroids such
as 17a-hydroxy-6a-methyl-4-pregnene-3,20-dione suppress
·growth hormone release in response to insulin or arginine.
These results may indicate that the effects of the estrogen
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and progestin components on growth hormone release may cancel
each other to some extent, depending on their relative potencies and the ratio in which they are present in the medication.

In many cases net effects on growth hormone levels

are observed.

Spellacy et al (1010, 1011) found elevations

in growth hormone following the administration of 0.075 mg
17a-ethinyl-3-methoxy-l,3,5(10)-estrien-17S-ol and 5.0 mg
17a-ethinyl-17S-hydroxy-5(10)-estren-3-one.

Since most com-

binations contain 0.05 mg of estrogen but 5.0 mg of progestin, the nature of the latter may determine the growth hormane effect of the various combinations.

On the other hand,

the sequential use of 0.10 mg of estrogen, double the above
dose, may elevate growth hormone levels more frequently.
Several groups have reported the effects of estrogens
and progestins in clinical studies.

Svandborg and Vikrol

(1041) reported that the percentage of lecithin increased
while that of cholesterol and lysolecithin decreased following estradiol benzoate • . The lipid pattern observed is
somewhat similar to that which occurs in multiple sclerosis.

Wynn et ·a1 (1179) showed that 31 percent of women

taking estrogen-progestin combinations had fasting triglyceride levels higher than the upper limit of normal.

Also,

approximately, 15 percent of these same subjects had abnormal glucose tolerance tests.

~>

~;

.

"'l'
.

.

These changes were not
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due to the progestin component because they could be produced by the estrogen component alone.
The most pronounced change in serum lipids with estrogen-progestin combinations is an approximately 160 percent
rise in the level of pre-B-lipoproteins.

Other increases

found by Wynn ·et al (1179) expressed as the percentage of
pre-medication values include:

triglycerides, 51.5; cho-

lesterol, 7.3; sf 0-12 lipoproteins, 15.9; sf 20-100 lipoproteins 56.2.

Although no change occurred in Sf 12-20

lipoproteins, the atherosclerotic index was elevated 25
~·

percent because of the pre-B-lipoprotein rise.

The over-

all picture closely resembles that seen in type IV carbohydrate-induced hyperpre-B-lipoproteinemia.

The relatively

slight elevation in cholesterol cannot explain the increased incidence of thrombophlebitis nor the changes in
glucose tolerance.

Other studies, however, in which in-

dividual phospholipids were deternined have helped to explain this result.
Brody et ·a1 (20) found that C-18 and C-21 progestins
had different effects in estrogen combinations.

The C-21

progestins partially counteracted the estrogen-induced increase in triglycerides as well as the decrease. in phos-phatidyl ethanolamine.

These results suggest that C-21 pro-

.gestins may inhibit the incorporation of sn-1,2-diglycerides
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into triglycerides.

Di Paola

~t

al (35) have indicated that

the 3-methyl ether of 17a-ethinyl-l,3,5(10) estriene-3,178diol more adversely affects glucose tolerance than the parent
steroid, indicating that the CJ-hydroxyl group is not required when administered for this effect.
Larsson-Cohn

~~

al (640) studied the effects of the

combination of 0.1 mg of the ether

and 3 mg of 17-acetoxy-

6-chloro-4,6-pregnadiene-3,20-dione on serum lipids.

They

found the following percent changes:

triglycerides, + 139;

lecithin, + 46; sphingomyelin, + 12.

Phosphatidyl ethanol-

amine was slightly increased, free fatty acids slightly reduced, and lysolecithin unchanged.

These observations, how-

ever, do not permit a distinction between increased rates
of lipid biosynthesis and decreased rates of lipid degradation.
The above effects on serum lipids are similar to those

f

produced by glucocorticoids as observed by Sherbe (978) in

~'

?,

women prior to adrenalectomy.

Furthermore, the results sug-

gest that the 118 and C-21 hydroxyl groups are not absolutely required for this effect even though they enhance it.
Since the progestin component is usually present at 100 times
the level of the estrogen component on a weight basis, effects that go unnoticed at physiologic progesterone levels
,.

may become significant at these higher levels.
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Jeurand and Oliver (531) found that growth hormone
treatment increased the saturation of serum triglycerides.
Hagopian and Robinson (423) also found that estrogen treatment increased triglyceride saturation.

This effect was

found to occur during the synthesis of phosphatidic acid
which has been shown to occur in mitochondria.

Although

triglyceride and phospholipid synthesis from diglycerides
occurs extramitochondrially, factors regulating the transport of phosphatidic acid from mitochondria have not been
completely elucidated.

Greenbaum and Mc Lean (408) noted

that diglycerides accumulate in the liver of rats following growth hormone treatment.

Steinberg (1025) has also

noted that growth hormone is required for estrogen-,induced
hypocholesterolemia in rats.

These observations suggest

that growth hormone and steroid effects on triglyceride
synthesis occur extramitochondrially.
Phosphatidic Acid Synthesis
The enzymes of phosphaditic acid synthesis have been
studied by several groups.

O'Kuyama et al (795) found

that oleic acid was esterified faster than stearic acid.
Eloison et al (283) observed that 90 percent of palmitic
acid was esterified at the sn-1 position while only 10 percent was esterified at the sn-2 position.

Similar findings

have been observed with oleic and palmitic acids.

It thus
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appears that phospholipid composition is a function of hepatic acyl coenzyme A concentrations.
:,

Since the enzyme involved in the acylation of the sn-2
position is much more active than the enzyme acylating sn-1
position with :i;:almi toyl coenzyme A.

A similar situation also

exists with respect to the enzymes catalyzing acyl transfer
reactions with lysophosphatides.

De Tomas and Renner (231)

observed that unsaturated acyl coenzyme A was incorporated
faster into lysophosphatidyl ethanolamine than into lyso~

phosphatidyl choline.

In addition, Akesson et al· (8)

noted that the enzyme which esterifies palmitoyl coenzyme
A at sn-1 functions best with tetraenoic 2-acyl-sn-glycerol3-phosphorylcholine and ethanolamines, incorporating 90 percent of added palmitate into these species within 5 seconds
after its addition.

Both the specificity in the formation

of phosphatidic acid as well as the specificity in the
acylation of lysophosphatides results in the formation of
unsaturated phosphatidyl ethanolamine and the expense of
saturated phosphatidyl cholines.
The further metabolism of phosphatidic acid does not
appear to take place in mitochondria.

The enzymes required

for the addition of acyl coenzyme A to diglycerides appears
to be in the cytoplasm while the enzymes which catalyze the
formation of phospholipids from diglycerides are found in
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hepatic microsomes.

Recent studies by Reiser et al (876) in-

dicate that triglycerides formed in the cytoplasm may serve
as phospholipid precursors under certain conditions.
Besides being incorporated into phosphatidic acid, longchain acyl coenzyme A derivatives may have several other
fates.

They may be converted to carnitine esters by an en-

zyme which has been found to be increased in the alloxandiabetic rat.
\

However, it should be noted that this reac-

tion is not rate limiting for fatty acid oxidation (1107,
1156).

If the fate of the acyl coenzyme A is to be oxi-

dized, Huixtable and Wakil (463) have determined that the
rate of this oxidation will decrease with increasing unsaturation except for linolenate, which is oxidized faster
than linoleate.

These studies also indicate that effi-

cient incorporation of linoleyl coenzyme A into complex
lipids is necessary to conserve this essential fatty acid
from rapid oxidation.
Another possible fate of long-chain acyl coenzyme A
is chain elongation.

The chain elongation of saturated acyl

coenzyme A such as _palmitoyl coenzyme A occurs to a greater
extent in females than in males (423).

On the other hand,

there is no difference in the chain elongation of linoleyl
coenzyme A to arachidonyl coenzyme A.

While these results

suggest that separate enzymes may be involved in the chain
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elongation of saturated and unsaturated coenzyme A derivatives with only the former under hormonal control, female
rats do have higher serum arachidonate levels than males
50

that the degradation of arachidonate may also be hor-

monally controlled.

This appears to be the case since un-

saturation decreases fatty acid oxidation.
Not only is arachidonate less readily oxidized than
other fatty acids, it is also less readily incorporated into the sn-2 position of phospholipids.

Akesson (8) found

that most of the label in linoleoyl coenzyme A was not incorporated unchanged or after conversion to arachidonyl coenzyme A, but that 60-80 percent of the linoleoyl label was
incorporated as 18w6,9,12 octadecatrienoyl coenzyme A or as
20w6,9,12 eicosatrienoyl coenzyme A.

This indicates that

there is an optimal substrate unsaturation for this reaction ( 8).
In addition to the existence of optimal unsaturation
in the formation of phosphatidic acid, there is also an optimal concentration of each acyl coenzyme A.

Husbands and

Lands (500) have shown that optimal incorporation occurs at
50 µM concentration with substrate inhibition at 60 µM.
This finding suggests that an increase in acyl coenzyme A
produced by lipolysis cannot increase triglyceride synthe,

sis unless the formation of sn-3-glycerophosphate is also
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increased.

However, an elevation in acyl coenzyme A renders

these derivatives more available for oxidation, desaturation
or chain elongation.
The tendency for estrogens to decrease phospholipid unsaturation is enhanced by stimulation of the methylation of
phosphatidyl ethanolamine to phosphatidyl choline (684).
Merkl and _Lands (735) and Lands and Hart (633) have shown
that hepatic enzymes catalyze exchange reactions between
saturated diacylphosphoglycerides and unsaturated acyl coenzyme A.

When the concentration of phosphatidyl ethanol-

amine is depressed by increased methylation, one of these
enzymes can no longer catalyze the unsaturation of phosphatidyl ethanolamine prior to its methylation to phosphatidyl choline.
t.

Estrogens thus enhance the rate of syn-

thesis of saturated lecithins.

Ramey and Baron (858) also

found that the estrogen analogue 17s-hydroxy-3-methoxy-l,
3,5(10)-estriene-16-one increased the incorporation of in-

f:

organic phosphate and acetate into phospholipids.

The ex-

,.'

tent to which estrogen-dependent chain elongation of sa-

I

turated fatty acids depletes hepatic acetyl coenzyme A and

t_·_

·..

r

regenerates coenzyme A remains to be determined.

<

~

t

The net decrease in esterified cholesterol during hyperestrogenic therapy is a direct consequence of the alterations in the composition of phosphatidyl choline which
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donates the acyl group from its sn-2 position and of the
rigid specificity of cholesterol:

lecithin acyl transfer-

ase (373, 849) which has been found to produce cholesterol
esters characteristic of the serum from which it is obtained within the limits of the composition of the lecithin
substrates present.
As previously noted, estrogens promote the conversion
of phosphatidyl ethanolamine to phosphatidyl cholines.

Fur-

thermore, phosphatidyl ethanolamines, in the course of their
synthesis incorporate more highly unsaturated fatty acids
into the sn-2 position and therefore, more highly saturated
fatty acids in the sn-1 position.

Therefore, the lysolec-

ithins derived from these methylated phosphatidyl ethanolamines will also contain more highly unsaturated acids in
the sn-1 position.
Regardless of the mechanism by which estrogens increase the methylation of phosphatidyl ethanolamine to phosphatidyl choline, the fact that ethanol administration which
increases the NADH/NAD+ ratio al~o increases the methyla_tion reaction, suggests that other agents which increase the
reduction potential of the pyridine nucleotides will also
increase the methylation reaction.

Glucocorticoids have just

that effect and may therefore produce changes in hepatic
phospholipids similar to those produced by estrogens.

For
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example, an abnormal species of phosphatidyl choline is produced during high dosage estrogen therapy.

This lecithin is

converted to an abnormal lysolecithin which enhances platelet aggregation in response to adenosine-5'-diphosphate~
This lysolecithin may function by specifically blocking the
incorporation of long-chain saturated acyl coenzyme A into
phosphatidic acid.
Cosgriff (202) has reported that glucocorticoid treatment enhances blood coagulation, but did not elucidate the
·mechanism by which this occurs.

Therefore, an effect on

phospholipid metabolism similar to that caused by estrogens
~·

has not been ruled out.

On the other hand, glucocorticoids

are known to promote the mobilization of phospholipids from
the liver (1197).

Furthermore, the effects of estrogens on

the formation of high-density a-lipoproteins may be mediated by their effects on phospholipids.

The cooperative

nature of the interaction between phospholipids and highdensity lipoproteins lends support to such a conclusion.
As noted earlier, any factor which increases the concentration of acyl coenzyme A will increase the ratio of
NADH to NAD+.

At present, the extent to which inhibition

of the incorporation of these derivatives into triglycerides--a non-specific glucocorticoid effect--can account for
this change is unknown as is the mechanism whereby
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glucocorticoids decrease such incorporation.
In conclusion, the non-glucocorticoid effects of glucocorticoids have been reviewed with respect to their role in
insulin antagonism and glycolytic inhibition.

From consider-

ations of the action of 8-lipoprotein lecithins on platelet
aggregation it appears that the same or similar lecithin
molecule may, after its conversion to lysolecithin, affect
the concentration of acyl coenzyme A in other cells by
blocking the incorporation of these derivatives into phosphatidic acid.
Like estrogens, growth hormone also increases the percent saturation of triglycerides.
is somewhat different.

However, the mechanism

As noted previously, both trigly-

cerides and phospholipids are synthesized from diglycerides.
However, the specificities of the enzymes involved are such
that saturated diglycerides are directed towards triglyceride synthesis while unsaturated diglycerides are directed
towards phospholipid synthesis via cytidine diphosphate choline and cytidine diphosphate ethanolamine.

Growth hormone

appears to exert its effects by decreasing the maximum velocity of triglyceride formation from saturated diglycerides.
Leal and Greenbaum (646) observed that growth hormone
treatment depressed hepatic triglycerides 83 percent.
glycerides, however, were increased 40 percent as was

Di-
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phosphate incorporation into phospholipids.

Acetate incor-

poration into phospholipids was decreased as a result of the
increased diglyceride pool.

Furthermore, because of the in-

creased substrate pool and reduced maximal rate of triglyceride formation, more time is permitted for a better matching of the available substrates to the active site of the
enzyme.
turation.

These factors combine to increase triglyceride saIn addition, the increased pool size of phospho-

lipids and the resulting exchange reactions which they undergo, further increase the saturation of the hepatic acyl
coenzyme A pool from which triglycerides are synthesized.
Ethanol administration, which increases the reduction
potential of the pyridine nucleotide pool, also has an effect on phospholipid synthesis.

Fallon et al (304) re-

ported that the administration of 20 percent ethanol increases the methylation of phosphatidyl ethanolamine, an
effect also produced by estrogens.

Furthermore, Medenhall

et al (732) observed that ethanol administration, like
growth hormone administration, increased triglyceride saturation, but not lecithin or cephalin saturation.

These

~

results confirm the specificity of the phospholipid synthesis.

On the other hand, if the saturation of the di-

glyceride pool is increased, the same specificity may lead
to a reduction in total phospholipid synthesis and to the

E.
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development of fatty infiltration of the liver.
;

'

Although estrogens may impair carbohydrate tolerance by
increasing acyl coenzyme A concentration, this does not appear to be the mechanism by which estrogens affect glucose
tolerance.

Rather, the fact that estrogens produce the same

effects as ethanol indicates that estrogens may increase leeithin unsaturation and decrease glucose tolerance by decreasing the oxidation of mitochondrial NADH.

CHAPTER XI
STEROID EFFECTS IN BREAST TUMOR THERAPY

Steroid hormones have long been employed in the treatment of breast cancer.

Androgens, estrogens, progestins,

and combinations of these hormones have been used without
a complete understanding of how they exert their effects.
The interpretation of the results of these treatments has
been complicated because pharmacological steroid doses
have been employed, because of the complex hormonal dependency of the tissue, and because of steroid metabolism
elsewhere in the body.
Clinical findings in the hormonal treatment of breast

L
t

[.

I,

cancer may be summarized as follows

(76).

~'

First, tumors

are generally more responsive to steroids if the tumor is
hormone-dependent.
treatment.
growth.

This is the prime reason for early

Secondly, low doses of estrogens promote tumor

The quantity of estrogens required for this ef-

feet may be produced in ovarectomized women from androgens
formed in the adrenal gland.

Thirdly, both oophorectomy
273
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and adrenalectorny reduce estrogen production.

Fourthly, and

most importantly, high doses of estrogens have been shown to
inhibit tumor growth more effectively than high doses of androgens.

The fact that this latter estrogen effect is ex-

actly opposite to its hormonal effect on the same tissue
merits further research, especially because this disorder
affects 5 percent of American women and because mortality
from the disease has not decreased in recent decades.

Fur-

therrnore, these steroid effects may be related to glucocorticoid effects.
Mechanism of Steroid Action
Pharmacological doses of estrogens inhibit mammary
tumor growth more than similar doses of androgens.

With

both treatments there is maximal stimulation of the gland
by estrogens.

Treatment of an estrogen-dependent tumor

with natural androgens which are converted to estrogens
(417) is, in effect, a useless treatment because the basis
of the androgen treatment is purported to be to counteract
the stimulation of the hormone-dependent gland by low estrogen levels.

This does not mean that androgens are corn-

~

~

pletely ineffective in treating the disorder.

Androgens

~

may inhibit tumor growth by

an~anti-pituitary

effect.

How-

ever, the beneficial effects of androgens could be improved
"

l

by the use of synthetic analogues which cannot be converted
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to estrogens in vivo.

This same reservation applies to glu-

cocorticoids used to treat the disease.
The mechanisms described above cannot account for all
of the greater effects of estrogens.

There are several doc-

umented cases of both subjective and objective remissions of
breast tumors with synthetic androgens in completely hypophysectomized patients (60).

Since these patients were de-

void of gonadotrophin secretion, the steroid effect was not
mediated by the pituitary but must have been directly on
the tumor tissue.
Experiments with synthetic steroids in the treatment
of breast cancer in animals and women have indicated that
the total effect observed is the summation of endocrine
and non-endocrine effects.

Endocrine effects include

anabolic, anti-estrogenic, and anti-pituitary effects.
Non-endocrine effects include a direct anti-glycolytic ef-

'
~

feet on the tumor.

Thus, the most effective anti-tumor

'

steroid for a given patient may depend on the relative hormonal dependence of the tumor which may change with time.
Obviously, species differences in these influences may be
considerable so that potency in the rat may differ substantially from that found in clinical trials.

Still,

there is reason to believe that the present cure rate of
approximately 25 percent with steroid hormone therapy
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could be doubled to 50 percent or higher by the judicious
use of synthetic anti-tumor steroids which are not estrogen
precursors.
In order to determine the non-endocrine anti-glycolytic
effects of steroid hormones against breast tumors, studies
would have to be carried out in hypophysectomized, oophorectomized, adrenalectomized tumor-bearing animals treated
with growth hormone free of prolactin.

Although such

studies have not been reported, the structure-function relationships for anti-tumor activity may be discerned from
studies already reported.

Clinically, testosterone pro-

pionate has been used with favorable regressions in about
20 percent of patients who are less than 5 years postmenopausal.

In patients who are more than 5 years postmeno-

pausal, the stimulatory effect of physiological amounts of
estrogens no longer counteracts the inhibitory effects of
.,;'j;

these compounds in pharmacological doses.

It is important

to note that these recommendations are based on the limited
comparison of natural estrogens with testosterone propionate, an estrogen precursor.

It is important, also, to

recognize that most of the anti-tumor activity is pharmacological rather than hormonal.

Therefore, although the

net anti-tumor effects of estrogens is less than that of
"~;

testosterone propionate in premenopausal women, synthetic

L
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anti-tumor steroids can be made which are not estrogen precursors and which do not stimulate estrogen-dependent tumor
tissue.

Synthetic

anti~tumor

steroids have effects which

are over 2.5 times that of testosterone propionate.

This

increase in potency does more than offset the 1.4 fold
greater effect that natural estrogens have relative to natural androgens in patients who are more than 5 years postmenopausal.

Thus synthetic anti-tumor steroids should emerge

as the preferred hormonal treatment in all cases of breast
i.

cancer.
Results of Endocrine Ablation
The importance of estrogens in estrogen-dependent tumors
and the production of adrenal androgens which are estrogen
precursors has led to adrenalectomy as a form of therapy for
breast cancer.

Generally, oophorectomy is the first endo-

crine ablative procedure used following mastectomy.

A fav-

orable response to oophorectomy is obtained in 30 percent
of pre-menopausal women.

Approximately 40 percent of soft

tissue, pleural, or skeletal metastases respond compared
to 18 percent of liver, lung or CNS metastases.

If the

response to oophorectomy is favorable, this is an indication that the tumor is estrogen dependent and that the removal of adrenal estrogens may provide additional remission.

'
1·
~·

l

Although adrenalectomy subsequent to oophorectomy does not
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result in remission in all cases, it does not present the
possibility of damage to optic and olefactory nerves associated with hypophysectomy.
use of Steroid Discriminants
The adrenal gland also appears to be the source of
anti-tumor activity which parallels the urinary excretion
of 17-hydroxycorticoids as measured by the Porter-Silber
reaction.

Bulbrook (30, 130) recognized this and devised

a discriminant function based on the excretion of 3a-hydroxyse-androstan-17-one relative to 17-hydroxycorticoids:
80-80 x mg 170HCS/24 hrs +
µg 3 -hydroxy-Ss-androsten-17-one/24 hrs
~-

When this discriminant is used, a number of greater than
zero is associated with remission following adrenalectomy
and vice-versa.

In the initial study a positive discrim-

inant was associated with remission 93 percent of the
time and a negative discriminant with non-remission 85
percent of the time.

Although the causative role of each

discriminant factor need not be known for it to be valid,
such a discriminant will best fit the population data
from which it is derived.
Since the determination of Bulbrook's discriminant
function involved· the determination of 3a-hydroxy-5B-androstan-l 7-one by chromatographic techniques which were
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unsuitable for many laboratories, other workers have devised
discriminants that convey essentially the same information.
Although inherently less specific because it measures groups
of steroids, the simplest discriminant is the ratio of 11deoxy-17-ketosteroids to 17 hydroxycorticoids excreted.

If

this ratio is less than 0.13 the discriminant is considered negative; if the ratio is

greater than 0.16, the dis-

criminant is considered positive.

This determination is

practical in the laboratory because the ll-deoxy-17-ketosteroids can be separated as a group by chromatography on
Sephadex LH-20 and quantitated by the Zimmerman reaction.
It should be noted here that this same information can be
obtained after the conversion of 17 hydroxycorticoids to
C-19 steroids by a method already described in detail.
To understand why these discriminant functions accurately predict the response to adrenalectomy in premenopausal patients it is helpful to assume that anti-tumor
activity is associated with 17 hydroxycorticoids and that
ring A reduced C-19 steroids of adrenal origin excreted
in the urine reflect the formation of the estrogen precursor 4-androstene-3,17-dione by the adrenal gland.

Accord-

ing to these assumptions a high production of estrogen precursors relative to anti-tumor steroids is associated with
a favorable response to adrenalectomy.

l

On the other hand,
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a low production of estrogen precursors relative to anti•

tumor steroids is associated with an unfavorable response
to adrenalectomy.

Empirically, the anti-tumor activity of

the adrenal is associated with the excretion of 17-hydroxycorticoids while the excretion of ll-deoxy-17-ketosteroids
· provides an index of the adrenal as a source of estrogens.
The pituitary gland is necessary for the induction of
mammary cancer by carcinogenic hydrocarbons such as 3-methylcholanthrene.

Presumably the carcinogen can only cause

a mutation when mitosis is stimulated by pituitary hormones.
Alternately, the carcinogen may interact with a receptor
protein produced in response to growth hormone or prolactin.
This finding indicates that the response to carcinogens depends on growth hormone, prolactin, or both.
Peerlman (818) reported that cancerous persons excrete
significantly less 17-ketosteroids than non-cancerous persons.

Moreover, Sokal et al (1000) noted that patients

with malignant conditions generally show marked increases
in 17-ketosteroid excretion during the administration of
300 mg of cortisone acetate per day.

A clear demarcation

with little overlap was observed in cancerous and non-cancerous subjects.

These results suggest that reduced glu-

cocorticoid production with increased conversion of glu<:'·.

;.

'i

cocorticoids to 17-ketosteroids is characteristic of

L
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malignant states.
Function of Estriol
Lemon (552) has recently examined the relationship between breast cancer and estriol excretion.

He found subnor-

mal excretion of estriol relative to estrone and estradiol
in fibrocystic disease, in fibrocystic disease complicating
mammary cancer, and in premenopausal and postmenopausal mammary cancer patients.

Hyperthyroidism was the only non-neo-

plastic syndrome with a similar excretion pattern, but up
to one-fifth of euthyroid premenopausal women without mam1

mary disease had similar excretion patterns.

Marmaston et

al (717) also measured estriol excretion in breast cancer
~

patients and found that both pre- and postmenopausal patients had significantly increased estriol excretion.
These results do not support an anti-tumor effect of estriol.
Saxema and Emerson (941) have found that estrogens produced in the adrenal gland may exacerbate mammary tumors.
Postmenopausal mammary tumor patients who improved following adrenalectomy excreted 0.88 µg estrone per day before
and 3.36 µg estrone per day (340
ment.

~

196%) after ACTH treat-

On the other hand, the negative responders excreted

1.51 µg estrone per day before and 2.25 µg estrone per day
(66 ~ 38%) after ACTH.

Apparently, adrenal estrogen syn-

thesis is more sensitive to ACTH in the patients who respond

L
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to adrenalectomy even though they have lower basal estrogen
excretion.

This may indicate that the responders have lower

endogenous ACTH secretion and also lower glucocorticoid
levels.

These findings further suggest that determination

of the change in the ratio of total urinary estrogens to
total urinary 17-hydroxycorticoids after ACTH treatment
may provide a more precise predicator of the response to
adrenalectomy.

These determinations are available in most

laboratories via the Kober and Porter-Silber reactions respectively.

The optimal age for response to adrenalectomy

following oophorectomy is 50-59 with a remission rate of
56 percent compared to a 29 percent remission rate for the
40-49 age group.
Gallagher et al (355) also reported that male breast
cancer is associated with increased estriol production.
The rise in estriol excretion in this disorder is associated with myxedema and a reduced formation of 2-methoxy
estriol.

This latter steroid has been shown to be the

natural steroid which has the highest lipodiactic/estrogenie ratio.

Decreased production of this steroid in

hypothroidism may explain the elevation of B-lipoproteins
in this disorder.

In female breast cancer, Barclay et al

(45) have confirmed that the pre-B-lipoproteins are decreased secondary to a drop in high-density lipoprotein

. 283

.".

phospholipid.

Despite these changes a marked drop in plasma

triglycerides is the most significant change in plasma lipids.
Effects.of Thyroid and Growth Hormones on Steroid Metabolism

-

Liechty et al (666) and Bulbrook et al (130) have re-

ported that the incidence of breast cancer is greater in
.

hypothyroid than in euthyroid women.

The reason for this

difference may be related to the effects of thyroxine on
glucocorticoid metabolism.
Bradlow et al (111) found that triiodothyronine increased the activities of mitochondrial 4,Sa:-reductases
for a number of steroids thereby increasing the excretion
of andros.terone and decreasing the excretion of 3a:-hydroxySs-androstan-17-one, its 58 diastereoisomer.

In contrast,

thyroid hormone has no effect on the 4,Ss-reductases in the
cytoplasm.

The decreased excretion of 3a:-hydroxy-Ss-andro-

stan-17-one simply reflects the relative competition of the
mitochondrial and cytoplasmic enzymes for available 4-androstene-3,17-dione.

Yates et al (1184) have also found that

thyroxine increases the conversion of cortisone to 17a:,21dihydroxy-5a:-pregnene-3,ll,20-trione by rat liver mitochondria.
Gallagher et al (355) reported that the reduction of llShydroxy-4-androsten-3, l 7-dione to llS-hydroxy-Sa:-androstane-3,
17-dione was increased by thyroid hormone.

The more rapid

formation of the Sa: metabolite resulted in decreased formation
~'

L
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of 3a,11S-dihydroxy-4-androsten-17-one.

In myxedema, the

conversion of cortisol to 3a,11S,17a,21-tetrahydroxy-5Spregnan-20-one is doubled and its conversion to 3a,17a,21trihydroxy-5B-pregnane-ll,20-dione is halved.
changes are seen in hyperthyroidism.

The reverse

The formation of 3a,

11S,17a,21-tetrahydroxy-5a-pregnane-20-one was unaffected
by thyroid hormone.

Although Koerner and Hellman (604)

reported that thyroxine administration reduced the activity
of llS-hydroxy dehydrogenase in rat liver but not in rat
kidney, thyroi9 hormone treatment results in an overall increase in 11-keto glucocorticoid metabolites due to the
peripheral metabolism of the steroid (447).
In myxedemia, the increase in Sa steroid reduction and
decrease in lls-hydroxy dehydrogenase activity results in
increased formation of 3a,11S-dihydroxy-4-androstan-17-one
and its 3s-epimer in approximately equal amounts

(355).

The 3S-epimer is similar to 3S,11S-dihydroxy-5a-androstan17-one.

Kemp et al (575) found that this latter steroid

was somewhat unusual in that it formed an 11 monoacetate
preferentially when esterified with acetic anhydride and
pyridine at room temperature.

This behavior is very dif-

ferent from that of other llS-hydroxylated steroids which
form such a derivative only when heated.

The possible role

of the allylic alcohol in the hyper-S-lipoproteinemia of

L
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myxedema has not been determined.
Triiodothyronine promotes the conversion of cortisol to
cortisone as well as the Sa reduction of cortisone.

The hor-

mone, however, does not promote the Sa reduction of cortisol.

i

(1184) .

,t,

ent ways.

Other steroids may exert the same effect in differFor example, Schriefers et al (9S3) reported that

17S-hydroxy-l-methyl-l-androsten-3-one decreased.both adrenal
weight and corticosterone production rate.

In contrast, 17a-

.ethinyl-178-hydroxy-4-estren-3-one decreased corticosterone
production without affecting adrenal weight.
Not all of the effects of hypophysectomy on the Sa reauction of steroids can be attributed to the lack of thyroid hormone.

Forchielli et al (327) found that the Sa re-

ductase for androstene-3,17-dione could be restored to SO
percent of prehypophysectomy levels by the administration
of 10 I U/day of adrenocorticotrophic hormone or by 10 µg/
day of growth hormone.

These results suggest that this re-

duction may be catalyzed by two distinct enzymes under different hormonal control.
There has been some controversy about the identity of
human growth hormone and human prolactin.

Apparently, these

two hormones are very similar so that they cannot be readily
separated.

However, that the two hormones may be distinct

entities is suggested by the lack of a constant ratio of

"
~L·,
.
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growth hormone to prolactin activities in different preparations.

Furthermore, Brauman et al (114) used tissue cul-

tures from human anterior hypophysis removed from hypothalmic influences to show that prolactin secretion could increase while growth hormone secretion decreased and vice
versa on the addition of hypothalamic extracts, indicating
distinct hormones.
The exact relationship between growth hormone and prolactin is especially important in the treatment of breast
cancer by pituitary stalk section.

This procedure decreases

the output of growth hormone but increases the output of
prolactin.

Since prolactin has a stimulatory effect on

breast tumors, complete hypophysectomy is preferable to
pituitary stalk section.
In the intact rat prolactin may play an important role
in the induction of mammary tumors by estrogens.

Low con-

centrations of estrogens increase prolactin secretion.

Pro-

lactin, in turn, stimulates progesterone production by the
. corpus luteum, and the progesterone, in turn, further stimulates prolactin output so that a state of pseudopregnancy
is produced.

During this state DNA synthesis is greatly

increased in the mammary gland and this event alone may increase the possibility of gene mutation.

Indeed, a number

of enzymes are induced during the development of lactation

L
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these inductions may provide a good biochemical model
..

for the study of the interaction of many hormones in the regulation of metabolism.

For example, Howanitz and Levy (482)

observed large increases in citrate cleavage enzyme and similar increases have been observed in the enzymes of the pentose cycle following parturition.

The interaction of growth

hormone, insulin, ACTH, glucocorticoids, estrogens and prolactin in the metabolism of the gland should provide more
metabolic insight than similar studies of adipose tissue
have provided.
As mentioned previously, the formation of some cortisol
metabolites is influenced by many other hormones so that the
level of the metabolite actually excreted may be an indication of the hormone output that effects the production of
these metabolites.

For example, the excretion of 3a,118-

dihydroxy-Ss-androstan-17-one is increased in myxedema not
only because of the reduced conversion of cortisol to cortisone, but also because the Sa reductases for these glucocorticoids are also decreased.

The close association of

this steroid with rnyxedema and of the latter with cancer
incidence may explain the results of Dobriner et al (242245) who reported that levels of this steroid had prognostic value in breast cancer (242) and in cancer of the prostate (818).

If abnormally elevated levels of this steroid

. 288
are found in the course of urinary steroid excretion studies,
they should be followed up with more modern and definitive
thyroid function studies and with specific prostatic acid
phosphatase determinations.
Another type of steroid metabolite characteristic of

.
I
f
...

myxedema is the allylic alcohol 3a,11S-dihydroxy-4-androsten17-one.

In contrast to the reduction of the double bond, the

reduction of the 3 ketone is not diminished by hypothyroid-

•
ism.

Ringold (887) has shown that the major metabolites of

6a-fluoro-17S-hydroxy-4-androsten-3-one are 6a-fluoro-5Sandrostane-3,17-dione and 6a-fluoro-4-androstene-3a,17S-diol.
The 6a-f luorine decreases Sa enzymatic reduction as well as
the rate of oxidation of the 178 hydroxyl group.
The previous considerations of the effects of estrogens
and progestins on mammary tumor induction may not apply to
established tumors.

f
v
t

[

For example, Crawley and Mac Donald

(205) obtained a 35 percent remission rate in the treatment
of mammary carcinoma in postmenopausal women with estrogens
alone.

However, in estrogen-resistant patients, the simul-

taneous administration of 17a-hydroxyprogesterone caproate
increased their remission rate to 50 percent.

The additional

benefit produced by 17a-hydroxyprogesterone may be due to
inhibition of growth hormone release which has been demonstrated in acromegalics but inconsistently in normal subjects

2.89

(627).

However, as noted previously, therapy with estrogens

or estrogen precursors is inexcusable in view of 'the availability of synthetic steroids which are just as effective
but are not estrogen precursors.
Recently, Lemon (650) has advocated the use of synthetic
glucocorticoids such as prednisone as an alternative to adrenalectomy for the treatment of estrogen-sensitive breast
tumors in oophorectomized patients.

Prior oophorectomy is

required because glucocorticoids stimulate the release of
follicle-stimulating hormone which increases estrogen production.

In addition, prednisone suppresses the release of

ACTH and the production of endogenous cortisol which is a
better estrogen precursor than prednisone.

F'

Since predni-

sone also suppresses thyroid function, triiodothyronine
supplementation was employed.

.Calcium salts were admin-

istered to counteract the catabolic effect of the glucocorticoid on bone.

However, if these were the only mech-

anisms by which the glucocorticoid acted, the treatment
would be no better than oophorectomy alone.

In contrast,

Lemon found that 48 percent of his patients benefited
from prednisone therapy even though one-third of these
had previously failed to respond to cortisone.

This per-

centage is high compared to the 23 percent remission rate
of bone metastases produced by androgens or estrogens and

LL~·.
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compared to the 44 percent remission of soft tissue involvement produced by estrogens.

Symptoms of Cushing's disease

including weight gain, truncal obesity, peptic ulcer and
osteoporesis were prominent side-effects of this medication.
struct.ure-Function Studies on Anti-Tumor Compounds
The prednisone remission rates are high compared to the
,.

figure of 25 percent reported for 17a-hydroxy-6a-methyl-4pregnene-3,20-dione and the figure of 26 percent reported
for 9a-fluoro-11S,17a-dihydroxy-6a-methyl-l,4-pregnadiene3,20-dione.

However, since results for other compounds

such as 6-chloro-9a-fluoro-17a-hydroxy-l,4-pregnadiene-3,
11,20-trione, which should have higher activity on the
basis of previous considerations, were not reported, an
assessment of the role of the C-21 hydroxyl group in these
effects cannot be made.

However, Lemon noted that the glu-

cocorticoids seemed to have an inherent anti-tumor activity.
Glenn et al (368) have determined the relative antitumor and androgenic activities of several synthetic antitumor steroids.

Using their data which is recorded in

Table IX and assuming that the factors by which structural
modifications enhance activity can be multiplied, it is
possible to calculate that the approximate anti-tumor activity of 17S-hydroxy-2a-methyl-5a-estrane-3,ll-dione would
•

~~'

be 2.2 times that of llS-hydroxy-Sa-estrane-3,11-dione which,

L
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TABLE IX
RELATIVE EFFECTIVENESS OF STEROIDS AGAINST BREAST CANCER

steroid Activities Expressed as Percentage of Testosterone Propionate
ga-fluoro-17B-hydroxy-17a-methyl-4-androstene-3,ll-dione •••••••••••• 255
A-nortestosterone proprionate •.••••••••••••••••••••••••••••••••••••• 131
2a-fluoro-17B-hydroxy-4-androsten-3-one 17 proprionate ••••••••••••••• 53
11B,17B-dihydroxy-17 -methyl-4-androsten-3-one ••••••••••••••••••••••• 39
11S,17S-dihydroxy-17 -methyl-1,4-androstadien-3-one •••••••••••••••••• 30
17S-hydroxy-17a-methyl-4,6-androstadien-3-one •••••••••••••••••••••••• 20
17a-ethinyl-17B-hydroxy-4-androsten-3-one ••••••••••••••••••••••••••••• O
17B-hydroxy-6S-methyl-5a-androstan-3-one propionate ••••••••••••••••• 205
9a-fluoro-11B, 17B-dihydroxy-17a-methyl-5B-androstan-3-one •••••••••• 119
17B-hydroxy-17a-methyl-5a-androstane-3,ll-dione •••.•••••••.•••••••••• 89
~;

Sa-androstan-17 S-ol propionate . ................... • ................... 32

17B-hydroxy-17a-methyl-5B-androstan-3-one ••••••••••••••••••••••••••••• O
17a-ethinyl-17S-hydroxy-4-estren-3-one •••.•••.••••••••••••••••••••••• 96
17B-hydroxy-17a-methyl-4-estren-3-one •••••••••••••••••••••••••••••••• 76
17a-ethinyl-17B-hydroxy-5(10)-estren-3-one •••••.••••••••••••••••••••• 65
17B~hydroxy-2a-methyl-4-estrene-3-one •••.•.•••••••••••••••••••••••••• 41

Segaloff (962)

.
L
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in turn, is twice that of testosterone propionate.

Studies

by Gallagher et al {355) suggest that the estradiol metabolite 3-hydroxy-2-methoxy-1,3,5(10)-estren-17-one which is
formed in response to thyroid hormone may be an active antitumor agent.
Segaloff {962) has reported the oral activities of several anti-tumor steroids which are presented in Table IX.
These data indicate that A-nortestosterone propionate is
more active than testosterone propionate and that the 9achloro-118, l 7S-dihydroxy-l 7a-methyl-4-androstene-3-one
has the same anti-tumor activity as its 9a-fluorine analog
but only one-tenth of its androgenic activity.

Also~

6a-

fluorination reduces anti-tumor activity even though Kincl
and Dorfman {581) found that this substitution increased
pituitary gonadotrophin inhibitory activity.
Rooks et al {902) showed that the introduction of an
11-ketone enhanced the potency of 17S-hydroxy-2a,17a-dimethyl-l, {5a)-androstan-3-one in inhibiting the incorporation of glycine into rat tumor protein.

A similar inhibi-

tion of the incorporation of glycine into protein was also
observed by Bornstein (98) in his work on lipoprotein insulin antagonism.
Anti-tumor activity is also distinct from anabolic
activity.

L

The latter activity appears to require both the
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18 methyl group and a pi type molecular orbital at position

2 or 3 in the steroid nucleus.

Wolf

~t

al (1173) demon-

strated that 2a,3a-epoxy-5a-androstan-17S-ol has the same
anabolic effect as testosterone propionate, while 2a,3aepithio-5a-androstan-17S-ol is a potent anti-estrogen as
well.

Kincl and Dorfman (582) reported that 2(5a)-andro-

sten-17s-ol was 60 percent more myotropic and 60 percent
less androgenic than testosterone.
was its most potent ester.

The dichloroacetate

Later, Nutting et ·a1 (791) con-

firmed these findings and, in addition, showed that the lamethyl group further increased its oral anabolic-androgenic
ratio.

Edgren (270) extended these findings and demon-

strated that ethyl groups at the 13S and 17a positions of
4-gonen-3-one greatly increased its anabolic activity but
not its androgenic activity.

The 17S-hydroxyl group

lowered the anabolic-androgenic ratio.

Also, androgenic

activity appeared to be associated with a certain conformation of the non-conjugated 3-ketone that was favored by
the presence of the 19-methyl group.

Fang et al (305) have

isolated a receptor protein for androgens which has a higher
affinity for 5a-androstan-3,17-dione than it has for testosterone.

Although the 6S methyl group markedly enhances

activity, the reduction in activity by 6a-fluorine substitution and the abolishment of activity by the 6a-chlorine
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substitution indicates that steric factors are important at
this position in the steroid nucleus.· In contrast to these
steric effects the presence of a vinylic chlorine in the C-6
position as in 6-chloro-17-hydroxy-4,6-pregnadiene-3,20-dione
acetate may actually enhance anti-tumor activity.
Rooks et al (902) also found that the 6a

m~thyl

as well

as Ga-fluorine substitutions reduced anti-tumor activity in
the steroid 17B-hydroxy-2a,17a-dimethyl-5a-androstan-3-one
while unsaturation at carbon 1 increased activity.

On the

other hand, both 11$-hydroxy-6a-methyl-4-pregnane-3,20-dione
as well as 9a-fluoro-11B-17a-dihydroxy-6a-methyl-l,4-pregnadiene-3,20-dione 17 acetate are active against testosterone
propionate-resistant tumors.

In these compounds the 6a-methyl

group reduces the salt retention caused by the 9a-fluorine
substitution.
Glenn et al (367) found that 17B-hydroxy-2a-methyl-5aandrostene-3,ll-dione was a potent anti-tumor steroid.

They

showed that the shift of the C-19-methyl group to the 2a
position enhanced activity.

Also, the 11$-hydroxy deriva-

tive of this compound was somewhat less active than the 11ketone but was preferred because of its lesser side effects.
Segaloff (962) also found that 11-ketones were more active
than the corresponding 118-hydroxy compounds while the reverse is true for anti-glycolytic effects (293).
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The influence of methyl substitution in ring A on antitumor activity has also been investigated.

De Marco· et al

(224) found that 4,17S-dihydroxy-17a-methyl-4-estren-3-one
was over twice as active as testosterone in inhibiting the
growth of Ehrlick carcinoma in rats.
hydroxy-2a~methyl-Sa-androstan-3-one

Furthermore, both 17sand 17S-hydroxy-4a-

methyl-5a-androstan-.3-one are highly active against mammary
tumors (902).

Although an analogous methyl group is present

in all ergot alkaloids, anti-tumor activity in these compounds
has not been thoroughly studied.
Kim et al (980) have described an anti-tumor triterterpene from Wallenia yunguenis (Myrsinaceae) which was ·active
against Walker 256 I M carcinosarcoma.

This compound, known

as myrsine-saponin (3s,27a-dihydroxyolean-12-ene-28-oic acid),
has a structure similar to glycyrrhetinic acid which has been
shown to have anti-inflammatory but not glucocorticoid effects

(318, 418).

The C-27a hydroxyl group in this compound

is in a position similar to that of the N1 nitrogen in clavine alkaloids.
Other factors which may influence the potency of antitumor steroids are their solubilities in physiological fluids
and their conjugation rates prior to excretion.

Protein

binding, especially as influenced by other drugs or endogenous metabolites, is also an important factor in activity.

l
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Since Glenn et al (371) and Frawley (328) have shown
that glucocorticoids inhibit pyruvate oxidation, it has been
assumed that inhibition of glucose utilization is secondary
to the inhibition of pyruvate oxidation.

The basis of the

block in pyruvate oxidation is the increase in long-chain
fatty acyl coenzyme A which promotes fatty acid oxidation
and an increase in the ratio of acetyl coenzyme A to free
coenzyme A.

The increase in acetyl coenzyme A not only in-

hibits pyruvate dehydrogenase but also increases the formation of cytoplasmic citrate which blocks glycolysis at the
phosphofructokinase step.
Besides glucocorticoids, other non-steroid compounds
have also been shown to inhibit pyruvate oxidation.

Sarker

(936) found that the alkaloid sanguinarine produced by
S-anguinaria

canadensis

inhibited pyruvate oxidation by

pigeon brain mitochondria 35 percent at a concentration of
4.1 x 10 -5 M.

Sublethal doses have been used to produce ex-

perimental glaucoma in animals.

Furthermore, the compound

is also a potent oxytoxic, 0.5 mg/kg produces prompt uterine
contractions.
The inhibition of pyruvate oxidation by sanguinarine
can be abolished by prior addition of mercaptoethanol to
the suspension of pigeon brain mitochondria.

A covalent

sanguinarine derivative was formed but was not identified.

FIGURE VII
STRUCTURE OF

S.Ai.~GU INARINE

SANGUINARINE
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~lthough

sanguinarine contains pentavalent nitrogen, the ex-

tensive conjugation delocalizes the charge in the nucleus of
the molecule.

Furthermore, the base exists in two polymor-

phic crystalline forms and its quaternary salts are reddish
in color.

These properties suggest that labeled sanguinarine

may find use in the affinity labeling of non-specific glucocorticoid sites of the type under discussion here.

The thiol

effect mentioned above is similar to that reported to occur
~

in the glucocorticoid inhibition of yeast hexokinase (507,
508).

In the latter case, treatment of the enzyme with N-

ethylamaleimide prevents the reversal of glucocorticoid inhibi tion by insulin ·in vitro.
Hartwell (433) has reported that sanguinarine and its
analogue chelerythrine have a necrotizing activity against
sarcoma 37 in mice.

The specificity of this effect has not

been investigated but there are reports that Cherokee Indians
used the bloodroot (Sanguinaria canadensis) for the treatment
of warts and polyps as early as 1817 and for the treatment
of breast cancer as early as 1857.
The total synthesis of sanguinarine has not been described and the best source of the compound is probably
argemone oil as described by Sarkar (936).
The enhanced anti-mammary tumor activities of 6a-methyl~

L

ated progesterones appears to be due to the effects which
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these compounds have on the pituitary.

Glenn et al (368)

concluded that both adrenal and gonadal functions were markedly inhibited by 6ct-methylated steroids.

This inhibition

occurred in spite of the fact that the compounds had little
or no effect on bone growth.

These findings are similar to

the results of a comparative study reported by Laron and
Pertzelan (639).

In fact, the suppressive effects of 6a-

methylated hormones on pituitary function were so great
that they persisted for approximately two weeks after the
cessation of steroid administration.

Liddle (663) observed

that the 6a-methyl substitution increased the activity of
cortisol and 11$-hydroxy-4-pregnene-3,20-dione, while it
decreased the activity of 9a-fluoro-11S,17a,21-trihydroxy-l,
4-pregnadiene-3,20-dione.

In aggrement with previous studies

Liddle found that llS-hydroxy-4-pregnene-3,20-dione increased
the excretion of 17-hydroxycorticoids perhaps by competing
with cortisol for feedback inhibition receptors which regulate ACTH release in the pituitary.

Kleeman et al (596)

also observed that the non-glucocorticoid 9a-fluoro-1113,17adihydroxy-6a-methyl-l,4-pregnadiene-3,20-dione had no effect
on nitrogen excretion or eosinophiles but that it suppressed
ACTH secretion and exacerbated diabetes at a dose of 30-80
mg per day.

Lipsett and Bergenstal (669) treated Addisonian

patients with 9a-fluoro-11S,17a-dihydroxy-6a-methyl-l,
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4-pregnadiene-3,20-dione and found that the steroid had lifemaintaining activity equal to that of cortisol.
In contrast to the adverse effects on the induction of
mammary tumors, carcinogenic hydrocarbons have been shown
to enhance the effects of anti-tumor steroids.

Both Huggins

et al (492) as well as Glenn et al (366) reported that 3methyl-cholanthrene acted synergistically with anti-tumor
steroids.

Furthermore, Huggins et al found that only those

steroids which promoted the growth of the normal mammary
gland acted synergistically with 3-methylcholanthrene.
Alone, the latter compound was catabolic.

Its structure

is shown in Figure VIII.
A 17a-alkyl group may enhance anti-tumor activity in
a rather specific manner.

Whereas progestational activity

is enhanced by 17a-(l-butynyl) groups, saturated alkyl
groups larger than ethyl and ethinyl groups reduce antitumor activity.

For example, 17a-ethyl-17B-hydroxy-4-

estren-3-one is a powerful inhibitor of tumor growth while
its 17a-ethinyl analog actually promotes tumor growth.
17a-propyl group abolished activity.

The

These findings may be

related to those of Drill and Riegel (256) who found that
17a-ethinyl-17B-hydroxy-4-estrene-3-one had only 1 percent
of the anabolic activity of the 17a-ethyl analog. The marked
dependency of anti-tumor activity on the nature of the

r

FIGURE VIII

STRUCTURE OF 3-METHYLCHOLANTHRENE

3-METHYLCHOLANTHRENE
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17a-alkyl group suggests that the ethyl group can conform by
free rotation to the requirements of the receptor but that
the more rigid ethinyl and larger propyl groups cannot.
At this point it may be helpful to clarify the effect
of steroid substitutions on androgenic, anabolic, antipituitary and anti-tumor activity.

The steroid 17S-hydroxy-

6S-methyl-4-androsten-3-one has the highest reported androgenic/anabolic ratio.

The C-3 carbonyl oxygen, C-4 double

bond, and C-19 methyl groups increase androgenic activity.
In contrast, the 17a-ethyl group reduces androgenic activity
6-fold, and the C-11 carbonyl oxygen 5-fold.

On the other

hand, the androstane derivative with the highest anti-pituitary/androgenic activity is a 2-formyl-2(5a)-androsten-17Sol (582).

The steroid with the highest anabolic/androgenic

activity ratio is 17a-ethyl-17S-hydroxy-1(5a)-estrene-3,lldione.

The 17a-ethyl group increases anabolic activity and

decreases androgenic activity.

Unsaturated 17a-alkyl groups,

such as the 17a-ethinyl group, decrease both activities.
The evaluation of anti-tumor steroids in vitro may not
reflect therapeutic results because of the absence of the
effect of the steroid on the pituitary.

Inhibition of the

release of pituitary hormones, especially prolactin and
growth hormone, is important in anti-tumor activity.

Pitui-

tary inhibition would result in decreased prolactin output.
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since breast tumors in adrenalectomized-oophorectomized patients may be dependent on pituitary prolactin, reduction of
prolactin secretion, in addition to glycolytic inhibition, appears to be the main action of anti-tumor steroids in
patients.
~nitial

~hese

In contrast, tumors which reactivate following an

remission in response to steroids may be less depen-

dent on prolactin so that steroids with a higher ratio of
anti-glycolytic to anti-prolactin activity may be more effective against these reactivated tumors.
Although hypophysectomy eliminates prolactin output,
growth hormone secretion, which appears to be important in
the anti-glycolytic activity of steroids, is also abolished.
The fact that hypophysectomy removes both tumor-stimulating
as well as tumor-inhibiting factors may explain the lack of
an effect of hypophysectomy in these patients.

The recent

availability of human growth hormone for substitution therapy
may lead to increased use of hypophysectomy to eliminate prolactin output.
Dorfman (251) has shown that the efficacy of anti-tumor
steroids is not related solely to pituitary inhibition.
Dorfman's results are limited by the fact that he evaluated
the parental

activ~ty

be orally active.

of only those derivatives known to

He found that 17S-hydroxy-17~-methyl-4-

androstene-3,ll-dione was the most potent anti-tumor steroid

L
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investigated even though it has no anti-estrogen activity.
from other studies it appears that 4-chloro-17a-hydroxy-2amethyl-19-nor-4-pregnene-3,ll-20-trione 17-acetate may have
higher activity since some anti-tumor activity is sacrificed
in order to obtain oral activity.
The 17a-alkyl group is not the only structural modification that enhances.oral activity by blocking the oxidation of the 17S-hydroxyl group.

For example, 17S-hydroxy-

2a-methyl-l, (Sa)-androsten-3-one (stenbolone) has been patented as a potent, orally active anabolic agent.

The find-

ing that structural modifications in ring A influence enzymatic reactions in ring D and vice-versa indicates that
the overall structure of the molecule and its metabolic
reactions must be considered in the design of steroid drugs.
Such findings raise the possibility of eliminating the hepatic changes associated with 17a-alkylated steroids.
Dorfman (251) has demonstrated that anti-estrogen activity as measured by the action of the compound in inhibiting the effects of estrogens on mouse uterus is not required for anti-tumor activity.

For example, 17S-hydroxy-

17a-methyl-l,4-androstadiene-3,ll-dione was very active
against testosterone-propionate-resistant tumors yet had
no detectable anti-estrogen effect.
urated steroids shared this property.

L

Other C-4 unsatOn the other hand,
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Sa-reduction resulted in compounds which had high anti-estrogen activity in addition to undiminished anti-tumor activity.

Therefore, the structural requirements for anti-

tumor activity are less stringent than those for anti-estrogen activity.

Fluorine substitution in the 9a position

increases anti-estrogen activity (1090) while 2a-f luorine
substitution increases anti-pituitary activity (582).
Antoniades· ·et ·a1 (15} have shown that human plasma fractions II and III which contain the S-lipoprotein and S- and
· y-globulins respectively, preferentially bind the unconjugated steroids corticosterone, llS-hydroxy-4-androstene-3,
17-dione, and cortisol in that order (Table X).

However,

since most of the glucocorticoids in plasma are specifically
bound by transcortin in fraction IV-I, the S-lipoprotein
fraction is the fraction which contains most if not all of
the llS-hydroxy-4-androstene-3,17-dione in plasma.
Sandberg and Slaunwhite (931) further investigated the
metabolism of this steroid and found that it existed in two
pools which were cleared with half-lives of 30 and 80 minutes.

Conjugates of the steroid, although rapidly formed,

were slowly cleared.

Approximately 61 percent of the ex-

creted radioactivity from the steroid was excreted in conjugated form and this fraction had a half-life of 98 minutes.

L

Furthermore, 14 percent of the conjugate fraction

TABLE X
PERCENT DISTRIBUTION OF ADRENAL STEROIDS IN
HUMAN PLASMA FRACTIONS VERSUS
TIME AFTER AN INTRAVENOUS TRACER DOSE

llS-Hydro:xy-4-AndroStene-3,17-Dione
10 Minutes
Time Interval
PlaSI'(la Fraction

11$,21-Dihydro:xy-4Pregnene-3,20-Dione
20 Minutes

11S,17a,21-Trihydro:xy4-Pregnene-3,20-Dione
120 Minutes

Con jugated

Non-Conjugated

Con jugated

Non-Conjugated

Con jugated

Non-Conjugated

I

6.4

5.4

3.9

3.8

3.7

4.9

II + III

16.0

39.1

4.2

23.0

14.4

22.5

IV-1

6.5

13.00

52.0

55.5

27.6

31.1

IV-4

11.2

4.4

8.5

3.5

4.6

4.5

v

60.0

38.1

31.4

15.2

49.7

37.0

(Method 6)

Antoniades et al (15}

w

0
O"I
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could not be accounted for as either sulfate or glucuronide
conjugates.

This 14 percent, however, could be hydrolyzed

with hot acid.

These results suggest that at least one glu-

~·

r

cocorticoid metabolite may be associated with S-lipoprotein

r

and may form unusual conjugates.

['

:;.

Both the identity of the

conjugated steroids and their role in insulin inhibition remain to be determined.
The steroid llS-hydroxy-4-androstene-3,17-dione is
formed from cortisol in a reaction that is promoted by
estrogens (222).

Also, thyroid hormone appears to increase

the conversion of this steroid to 17$-hydroxy-Sa-androstene3,11-dione by promoting its Sa-reduction and 11$-hydroxy
dehydrogenation (111).

All of the intermediates in this

process have been isolated from rat urine by Schubert and
Wehrberger (954).

In euthyroid subjects llS-hydroxy-4-

androstene-3,17-dione is metabolized as follows:

60 per-

cent is converted to 3a,11S-dihydroxy-5a-androstan-17-one;
10 percent is converted to 3a,11S-dihydroxy-5s-androstan17-one; 6 percent to 3a,11S-dihydroxy-5s-androstan-17-one;
and 3 percent to 3a-hydroxy-5a-androstene-ll,17-dione.

In

myxedema, more 3a-hydroxy-5S-androstene-ll,17-dione is
formed from 4-androstene-3,11,17-trione, indicating that
the Sa-reductase for the latter steroid as well as that
for its 11$-hydroxy analog is also depressed.

The extent
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to which any of these alterations are involved in the hypers-lipoproteinemia of myxedema is unknown.
Distinct enzymes appear to be involved in the metabolism
of each steroid.

Tomkin (1070) observed that the enzyme which

catalyzed the 58 reduction of cortisone to be inactive with
cortisol and llB-hydroxy-4-androstene-3,17-dione.

The in-

troduction of a double bond at C-1 completely blocks the
reduction of cortisol but not the reduction of cortisone.
This unsaturation, however, does not block the conversion
~

of prednisolone to prednisone.

This latter reaction is en-

hanced by 4-androstene-3,11,17-tione in which the lla hydrogen of cortisol is transferred to the lla position of the
trione (257, 1194).

The double bond in position 1 is re-

duced in vivo (1078), but it may be reduced after the
double bond in the 4 position in some cases.

Thus, the

presence of the 1 double bond may enhance androgenicity
in the androstene series while it decreases sodium retention in the pregnane series.

Also, Slaunwhite and Sandberg

(990) have found that the presence of the 1 double bond in
glucocorticoids decreases their conversion to 17 ketosteroids.

Similarly, Langecker (634) found that substituents

in ring A influenced the rate of oxidation of the 178-hydroxyl group in the androstene series.

In order of de-

creasing rates of oxidation, the order is testosterone,

L
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17s-hydroxy-5a-androstan-3-one, 176-hydroxy-l, (Sa)-androstan3-one, and 178-hydroxy-l-methyl-l, (Sa)-androstan-3-one.

In

addition, Ringold (888) has pointed out that the opposite
situation

may occur, i.e. substituents in the 16 position

can markedly alter the rate of oxidation of the 3a-hydroxy
group by 3a-hydroxysteroid dehydrogenase.

Clearly, these

examples indicate that caution should be observed in extrapolating the metabolism of one steroid ·to that of another.
Further complicating steroid metabolism are the effects which
one steroid may have on the metabolism of another steroid.
For example, Hagen and Troop (422) found that testosterone
depressed the ring A reduction while accelerating the C-20
reduction of cortisone in both males and females.

Corti-

sone acetate, on the other hand, depressed ring A reduction of cortisone only in males while it depressed C-20 reduction in both males and females.

With cortisol Deckx et

·a1 (222) obtained more C-20 reduction in males and relatively more 4,Sa reduction and 17-ketosteroid formation
with females.

Yates· ·et ·a1 (1184) confirmed these findings,

showing that female rats had from 3 to 10 times the rate
of ring A reduction of cortisol as males had.

The inves-

tigators Schrief ers and Wassmuth (951) have shown that
most of the increase in ring A reduction in females for
cortisone is of the 4,Sa type.

l'

Balieu and Maurais-Jaurvis
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(51), however, reported that the ratio of Sa to 58 reduction
products of 17-ketosteroids depended on the oxidation of the
substituent at position 17.

Thus, the ratio was higher in

women with the 17S-hydroxy derivatives and higher in men with
the 17-keto derivatives.

If one assumes that the same en-

zymes carry out the transformations in either sex, then the
sexes must differ in the ratio of the enzymes which act on
the 178 hydroxyl and 17 keto steroids.

The rate of ring A

reduction is important because this is the rate-limiting
reaction in steroid metabolism (952).

Female rat liver has

also been shown to convert more cortisol to 118-hydroxy-4androstene-3,17-dione (222).
Although it is possible to determine the extent to
which any of these steroids bind to purified s-lipoprotein
using the technique of equilibrium dialysis, it is unlikely
that these studies alone will uncover the mechanism of antiinsulin effect of the lipoproteins.

Bornstein (98) found

that the addition of cortisone to lipoproteins in vitro did
not result in insulin antagonism like that produced when
cortisone was injected into the rat before blood lipoproteins were isolated.
Effects of Clavine and Morphine Alkaloids
Clavine alkaloids are formed by the fungus Claviceps
purpurea which is parasitic on Elymus mollis (rye) or on

..
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£_ennisetium typhohordeum.

The hormone-like potency of d-

lysergic acid diethylamide has prompted research on these
alkaloids in an effort to find other active compounds.

For

example, ergonovine, more correctly termed ergometrine [N(a- (hydroxymethyl)-ethyl)-d-lysergamide], is derived from
the naturally occurring compound ergotamine.

Ergotamine

has the same nucleus as ergonovine (d-lysergic acid) , but
also has a cyclic polypeptide side chain which is derived
from the amino acids alanine, phenylalanine, and praline.
The polypeptide side chain is required for a-adrenergic
blocking activity which is characteristic of ergotamine
and dihydroergotamine.

Thus, ergotamine will block

epi~

nephrine-induced contractions of the isolated rabbit uterus,
but ergonovine will not.

The C-9 double bond enhances the

vasoconstrictive and oxytoxic actions of ergonovine.

This

double bond may be shifted to C-8 as in argoclavine with
retention of both properties.

The structures of ergono-

vine and argoclavine are shown on the following page (948,
1019).

In addition, the structure of elymoclavine is shown

because it is also an important naturally occurring clavine
alkaloid.
Yanai and Nagasawa (1182) have shown that 2-brominated
ergot alkaloids suppress mammary lobulo-alveolar formation
and decrease the frequency of mammary pre-cancerous

FIGURE IX
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TABLE XI
PHYSICAL PROPERTIES OF CLAVINE ALKALOIDS RELATED TO STEROIDS

CO!mon

N~

Configuration

Melting Point

8pecific Rotation

20S-206

-182

182

+44

Agroclavine

(Sex) , 8--Methyl-8-Ene

Costaclavine

(S8), 8a.-Methyl

Elyrroclavine

(Sa.) , 8--Hydroxyrnethyl-8-Ene

248-2S2

-S9

Festuclavine

(Sa.) , 8a.-Methyl

203-204

-90

Isolysergine

(Sa.) , 8(3-Methyl-9-Ene

134-137

+203

Lysergine

(Sa.) , 8a.-Methyl-9-Ene

288-289

+64

Lysergene

(Sa.) , 8--Methylene-9-Ene

244-24S

+407

Pyroclavine

(Sa.) , 88-Methyl

243-244

-109

Ultraviolet Absorption Maxima (run)
Unconjugated ••••••••••• 22S,

284, 293,

Conjugated ••••••••••••• 22S, 240,

284, 293, 31S,

Lysergene •••••••••••••• 22S,

243, 263,

33S

'

'

'

'

~
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hyperplastic aleovolar nodules by decreasing prolactin output from the pituitary.

Knew-Hseung et al (599) have also

suggested that ergocornine directly blocks estrogen-stimulated prolactin release.

These effects resemble the in-

hibition of prolactin release by high levels of estrogens.
The enhancement of anti-tumor activity by 4-methylation and 2a-formylation in the steroid series has been previously noted (251, 902).

The analogous modifications in

the clavine alkaloids are ~ -methylation (present in all

6

ergolanes) and 8a-formylation.

Another important modifi-

cation is the introduction of bromine in the C-2 position.
Savine (939) found that the 2-brominated derivative of dlysergic acid diethylamide was a more potent antagnoist
of serotonin and catecholamines even though it was devoid
of vasoconstrictive and psychomimetic effects.

Berde (66)

has reviewed the comparative effects of these compounds.
These effects are of interest because Gay and Pletscher
(364) have reported that serotonin elevates blood pyruvate
and lactate when administered systemically.
1
Elymoclavine, 8-hydroxymethyl-8-ergolene, or its N methyl or 2-bromo derivative may show some anti-tumor activity.

This should be increased by the oxidation of the

primary hydroxyl group to the aldehyde with dicycloheximide
and dimethylsulfoxide yielding 8-formyl-6-methyl-8-ergolene:
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Elymoclavine is 8-hydroxymethyl-6-methyl-8-ergolane.

The

corresponding saturated derivative might be prepared by the
hydroboration of agroclavine.

Brown et al (124, 125) have

described the conversion of a-pinene to S-pinene in 54 percent yield via hydroboration.

This result suggests that

the endocyclic C-8 double bond of agroclavine may be hydroborated with diisocampheylborane, and the product either
oxidized to 8a-hydroxymethyl-6-ergolane or hydrolyzed with
acetic acid to festuclavine.

The same compound might also

be made from dihydroergotamine following hydrolysis and reduction of the carboxyl group.
The preparation of ergonovine from ergotamine via the
hydrazide is accompanied by racemization to isolysergic
acid hydrazide due to the acidic hydrogen at C-8.

The pos-

sibility of preventing this racemization by protecting the
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c-9 double bond does not seem to have been investigated.
This double bond might be protected by the formation of its
cis glycol with hydrogen peroxide using osmium tetroxide as
catalyst.

Following the formation and reaction of hydra-

zide intermediates the double bond can be regenerated by the
procedure of Corey and Winter (197).

This procedure in-

volves the reaction of the glycol with N,N'-thiocarbonylimidazole to form the cyclic thiocarbonate.

The carbonate

is then treated with trimethyl phosphate to regenerate the
double bond with the formation of trimethylthiophosphate
and carbon dioxide.
Kornfield et al (608) have described the total synthesis of 2,3-dihydro-6-methyl-9-ergolen-8-one [9-keto-7-methyl4,5,5a,6,6a,7,8,9-octahydroindolo-(4,3-f,g)-guinoline].

The

keto group in the above compound may be replaced by a methylene group by the use of the Wittig reagent methylene
diphenylphosphorane.

The ethyl reagent has been used to

introduce the side chain into 17 ketosteroids.'

The result-

ing lysergene derivative can be converted to the Ba-methyl
or 8a-hydroxymethyl compound by the method of Brown et al
(124).

This, in turn, can be directly converted to the C-12

hydroxy indole with potassium nitrodisulfonate as described
by Stadler et al (1020).

The corresponding C-12 hydroxy

ergot alkaloids are not found in nature because the enzyme
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involved in the initial biosynthetic step cannot utilize 5-

t:

hydroxytryptophan in place of tryptophan.

1·

f

On the other hand, Jacobs and Gould (520) have reported
the total synthesis of racemic 6,8-dimethylergolane by a method that can be modified to permit the synthesis of the 12hydroxy derivative.

However, they did not compare the par-

ticular diastereomer which they isolated with authentic festuclavine and the optical rotation which they reported indi.cates that their product was contaminated by other diastereoisomers.

Esterification of the C-12 hydroxyl group with an

optically active acid such as that derived from 8-pinene
by hydroboration offers the possibility of asymmetric inauction in the subsequent reductive steps.
Ergot alkaloids have been shown to block hepatic glycogenolysis in response to cyclic adenylate (432).

Ergo-

novine may act as a glucocorticoid analog in adrenalectomized rats because it is able to block ACTH release.·
Rezabeck et al (882) have shown that 8a-cyanomethyl-6methyl-ergolane has hormone-like activity.

When adminis-

tered at a dose of 1 mg/kg daily, the compound prevented
conception.

When administered at 10 mg/kg daily, the com-

pound caused abortion up to the 7th day after copulation.
The structure of the alkaloid is similar to 2a-cyano-17Shydroxy-4,4,17a-trimethyl-5-androsten-3-one, an inhibitor

r
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of pituitary function and steroidogenesis in the rat (582).
Related ergolanes may also be active against mammary tumors.
Structure-function studies have indicated that other
modifications besides 2-bromination may decrease the action
of clavine alkaloids on smooth muscle.

In particular, methyl

ation of the adjacent N-1 nitrogen significantly reduces the
oxytoxic and vasoconstrictive actions of these compounds.
The best known compound of this type is Sansert [N-(hydroxymethyl)propyl]-1-methyl-d(+)-lysergamide.

This compound has

found application in the treatment of migraine headache (983).
Migraine headache is believed to be caused by a genetic
deficiency of monamine oxidase in the brain which results in
the accumulation of tyramine and 5-hydroxyindoleacetic acid
formed from serotonin.

The vasodilation produced by the

latter compound induces the headache.

Sansert is believed

to act by inhibiting the formation of 5-hydroxyindoleacetic
acid and it does not share the vasoconstrictive properties
of other clavine alkaloids (66).
Although the treatment of migraine with Sansert is
effective, the treatment can produce a condition known as
retroperitoneal fibrosis in about 1 out of 10,000 patients
taking the drug.

Retroperitoneal fibrosis is a disease in

which pulmonary and aortic complications resemble those
seen in rheumatoid disorders.

This is not surprising
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since serotonin is believed to be involved in the inf lammation reaction.

Graham (404) has also reported endocardial

lesions resembling those found in the carcinoid syndrome.
Although these changes are partially reversed when the drug
is withdrawn, some changes persist.
Changes of particular interest during retroperitoneal
fibrosis include thrombophlebites and fibrotic obstruction
in the great vessels and lymphatics as well as in the ureters
and bowel.

These early lesions involve the infiltration of

fat by lymphocytes followed by plasma cells and then f ibrosis.

These changes can lead to pleural thickening in the

lung causing friction rub.

The great vessel changes appear

grossly similar to the changes that take place during
atherosclerosis.
A similar type of cystic degeneration and its relation to mammary cancer has been described by Davis et al
(216).

They showed that women with cystic disease have

26 times more cancer of the breast than do women in general.

Moreover, biopsy tissue removed during surgery

revealed an 18 percent incidence of malignant degeneration.
The chance of developing lesions in the breast remaining
after partial mastectomy is about 20 percent.

For this

reason, a complete mastectomy is often done initially.
The important point is that the superficially normal
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breast removed during the complete operation affords an opportunity to study those biochemical and histological changes
associated with the precancerous state.

The fact that ergot

'

rt'

alkaloids can produce similar and somewhat reversible changes
similar to those found in cystic disease suggests that the
alkaloid may be mimicking the effect of an endogenous metabolite.
Other similarities appear to exist between ergot alkaloids and steroids.

Zellwige

~t

al {1196) have described

the teratogenic effect of lysergic acid diethylamide in a
single case of unilateral fibular aplastic syndrome in a
child born to parents who had taken the drug.

Chromatid

breaks were observed in the white cells of mother, father
and child.

The relationship between these breaks and the

production of retroperitoneal fibrosis during migraine
therapy with Sansert [N-{hydroxymethyl)-propyl-1-methyld{+)-lysergamide] is not clear.
Takano et al {1047) observed more fetal malformations
in pregnant rabbits given 1 mg/kg chlormadinone acetate
than in those given 1 percent mestranol in norethisterone.
Also, Carr (160) has described a higher incidence of spontaneous abortions with progestins due to the formation of
triploid chromosomes.

However, only 2.5 percent of XO

abnormalities came to term as female infants with Turner's
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syndrome.
While these and other findings may possibly explain the
recent withdrawal of chlormadinone acetate from the market,
genetic effects do not appear to be involved in the antiinsulin effects of these compounds.
Bergen

~t

al (67) also found that glucocorticoids may

compete with lysergic acid diethylamide for some binding
sites.

Cortisol, cortisone, corticosterone, deoxycorti-

costerone and progesterone at l0- 7Molar inhibited the metabolism of the alkaloid by 88,88,73,62 and 20 percent respectively.
Morphine may also share some receptor sites with serotonin, glucocorticoids and estrogens.

Gaddum and Picarelli

(351) described two types of serotonin receptors in intestine.

The M receptors could be blocked by morphine and

were .mainly found in nerves.

The D receptors, on the other

hand, were blocked by dihydroergotamine and were found
mainly in muscle.

The anesthetic, muscle-relaxant, and res-

piratory depression produced by morphine may be due to inhibition of serotonin.
Pee Ping and Walsh (824) found that morphine increased
glucose uptake in diaphragms from normal rats but decreased
glucose uptake in diaphragms from morphinized rats.
sol antagonized the effect of morphine.

Corti-

On the other hand,
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morphine antagonized cortisol-stimulated respiration but enhanced the effect of cortisol on glycogenesis.
In further studies Ng and Walsh (783) found that either
epinephrine or cortisol reduced glucose uptake by rat diaphragm.

When epinephrine was added first, the secondary ad-

dition of cortisol increased glucose uptake.

However, if

the diaphragms were from chronically morphinized rats, the
addition of epinephrine had no effect and cortisol increased
glucose uptake.

This effect of cortisol alone was abolished

if epinephrine was also added.

In addition, these workers

(784) found that the block in glucose uptake by epinephrine
in normal diaphragm was restored to morphinized diaphragm
in the presence of morphine.

These results indicate that

cortisol and morphine have similar effects on normal and
morphinized diaphragms respectively.

Further analysis of

the results suggests that morphine antagonizes the inhibitory effect of cortisol upon glucose transport.

Also, most

glucocorticoid sites in morphinized tissue, including that
of the growth hormone-dependent protein which acts as a
glucocorticoid receptor and leads to citrate elevation,
is occupied by morphine in morphinized tissues.

Further-

more, the morphine-protein complex appears to be more
effective than the glucocorticoid-protein complex in increasing cytoplasmic citrate.

L

Therefore, when cortisol
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displaces morphine, citrate is lowered and glucose uptake is
increased.

These results suggest that citrate elevation in

response to morphine is dependent on growth hormone and may
be abolished by

hypophysectomy.

Levy and Ramey (657) have shown that ergotamine, like
morphine, inhibits ACTH release and fat mobilization in
adrenalectomized rats.

On the other hand, Harvey et al

(432) showed that ergonovine inhibits epinephrine-induced
hyperglycemia and that dihydroergotamine treatment actually
increased hepatic glucose
adenylate.

upta~e

in response to cyclic

These results suggest that clavine alkaloids

block the effects of cyclic adenylate on phosphorylase b
kinase and on trasferase I kinase.

These latter effects

are directly opposite to the enhancement of cyclic adenylate effects by cortisol.

Therefore, it appears that clavine

alkaloids block the effects of cortisol at specific receptor
sites but not at relatively non-specific sites.
Anti-tumor activity appears to be closely related to but
distinct from progestational activity.

Rooks et ·a1 (902)

have observed that 9a-fluoro-6a-methyl-11S,17a-dihydroxy4-pregnene-3,20-dione 17-acetate caused little or no inhibition of glycine uptake in fibroadenoma in rats.

Glenn

et ·a1 (368) made similar observations with the corresponding C-1 unsaturated analog but also observed that it

'

L
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produced a 73 percent inhibition of a testosterone propionateresistant fibroadenoma.

Dorfman (251) observed an 87 percent

inhibition of ,an adenocarcinoma with the C-1 unsaturated analog.

He further noted that 11S-hydroxy-6a-methyl-4-pregnene-

3,20-dione caused a 48 percent inhibition of fibroadenoma
while Glenn et al (368) reported that 17a-hydroxy-6a-methyl4-pregnene-3,20-dione 17 acetate inhibited fibroadenoma potently but actually stimulated a testosterone propionateresistant fibroadenoma.

In summary, these findings indicate

that an oxygen at carbon 11 is _required for the inhibition
of testosterone propionate-resistant tumors.

Apparently,

the oxygen at C-11 blocks the conversion of testosterone
to estradiol by these resistant tumors.

The 9a-fluorine

substitution abolishes inhibition of fibroadenomas.

The

fact that the 2a-methyl substitution abolishes progestational activity suggests that 17-acetoxy-2a-methyl-19-nor4-pregnene-3,11,20-trione may show anti-tumor activity.
The metabolism of 2a-methyl steroids, especially C-11 oxygenated glucocorticoids, has been discussed by Bush and
Mahesh (142).
As shown in Table XII, the steroid 9a-bromo-4-pregnene-3,11,20-trione is a C-11 oxygenated steroid with a
high ratio of progestational to glucocorticoid activity.
It is noteworthy that Huggins et al (490) found that this
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TABLE XII
GLUCOCORTICOID AND PROGESTATIONAL
AC~IVITIES

OF SUBSTITUTED PROGESTERONES

Substituted Progesterone

Progestational*

9a-Br, 11 -OH

0.12-0.18

0.08

1.5-2.3

9a-Cl, 11 -OH

0.06

0.35

0.16

9a-Fl, 11 -OH

0.18-0.30

0.85

0.22-0.36

9a-Br, 11-=0

0.18-0.30

0.03

6.0-10.0

9a-Cl, 11-=0

0.06

0.15

0.60

9a-Fl, 11-=0

0.12-0.18

1.10

0.10-0.16

1. 75-3.50

5.0****

9a-Br-11B-OH-17a-CXXX::H ***
3
6a-CH , 17a-CXXX::H
3
3
l 7a-cx:ncH
3

*Oral Clauberg Assay.

GluooCortiooid**

10

20

0.07-0.15

Ratio

****

0.2****

17a-ethinyl-17B-hydroxy-4-estren-3-one

Miyake and Rooks (751)
**Liver Glycogen Deposition.

Cortisol

= 1.0

Fried and Borman (333)
***Bergstrom and Nicholson (68)
****Subcutaneous Clauberg Assay.

Progesterone

= 1.0

= 1.0
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steroid markedly enhanced the anti-tumor effects of estrogens as well as the carcinogenic and catabolic effects of
3-methylcholanthrene.

These results are in agreement with

clinical studies in which 17a-hydroxyprogesterone caproate
was found to enhance the anti-tumor activity of pharmacol

~

logical doses of estrogens

(490).

It appears that estrogens

~

~·
~·

should always be administered in combination with progestins
for maximal anti-tumor activity.
In summary, it appears that the anti-tumor effect of
9a-bromo-4-pregnene-3,ll,20-trione is greater in combination
with estrogens.

While it is unknown whether C-19 progestins

are also synergistic with estrogens, it appears that the
function of the C-11 oxygen is not to prevent the progestin
from acting as an estrogen precursor.

Finally, further work

will be needed to elucidate the mechanism of the direct
anti-tumor effects of steroids which are independent of
other hormones.

L

CHAPTER XII
MATERIALS AND METHODS

Tables XIII and XIV list the major chemicals used according to their sources.

Other chemicals used but not

specifically listed were of reagent grade.

Solutions were

prepared in deionized, glass-distilled water.

The melting

points listed were determined between cover glasses using
a Fisher melting point apparatus and are uncorrected.
Since one of the main purposes of this work was to
compare the effects of fluprednisolone and 20B-hydroxyfluprednisolone, it was necessary for the author to synthesize the latter compound from the former.

Norymberski

and Woods (790) have described a technique for the selective reduction of steroid C-20 carbonyl groups which employs a 1.5 molar excess of sodium borohydride at 0°C for
1 hour.

Their technique was employed to synthesize the

6a-fluoro-11S,17a,20S,21-tetrahydroxy-l,4-pregnadien-3one used in this study.

The reduced steroid was separated

from fluprednisolone by preparative thin-layer chromatography
330
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TABLE XIII
CHEMICALS

Abbott LabOratories
PentbraneR (methoxy flurane) - 2,2-dichloro-1,1-difluoroethyl methyl ether,
List No. 6864
Amersharn/Searle
o-Glucose-6-14c, 52.4 rrCi/mrole, Number CFA 351, Lot 10
14
Hexadecane-1- c, 2220 df!I1/rrg
Cal-Atomic
14
D-Glucose-6- C, 10 rrCi/rmole, Lot 78101
International Chemical Company
4-androstene-3,11,17-trione, Lot 439211
3a-hydroxy-5a.-androstene-ll,17-dione, Lot 19(3-0330
3(3-hydroxy-5(3-androstene-11,17-dione, Lot 198-1580
3B-hydroxy-5a.-androsten-17-one, Lot 578-0480
3(3-hydroxy-ll-oxoolean-12-ene-30-oic acid (glycyrrhetic acid),
mp 155-161°C
21-hydroxy-4-pregnene-3,20-dione acetate, Lot 4097, mp 137°C
llf3,17a,20a.,21-tetrahydroxy-4-pregnen-3-one 21 acetate, Lot 023199
Mann Research Laboratories

17a,21-dihydroxy-5f3-pregnene-3,ll,20-trione, Lot T207
118,17a,21-trihydroxy-4-pregnene-3,20-dione, Lot T3305
llf3,17a.,21-trihydroxy-58-pregnene-3,20-dione, Lot Tl828

L
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TABLE XIV
CHEMICALS

Nutritional Biochemical Company
Diabetic Rat Diet, Lot TD-68580, Composition:
3% Sodium-free salt mixture
5% Safflower oil
1% Vitamin fortification mixture, corrplete
55% Casein, high protein
5% Non-nutritive fiber
21% D-fructose
10% Sodium succinate .6 H20
Sigma Chemical Company
17a,21-dihydroxy-5s-pregnene-3,ll,20-trione 21 acetate, Lot 95S-2390-l
3a-hydroxy-5a-androstan-17-one, Lot 28S-2430
3a-hydroxy-5S-anqrostan-17-one, 98%, Lot 127S-2500
3S-hydroxy-5S-androsten-17-one, Lot 97S-0330
313-hydroxy-5-androsten-17-one, Lot 18S-3030
t!pjohn Pharmaceuticals
6a-fluoro-11S,17a,21-trihydroxy-l,4-pregnadiene-3,20-dione
(fluprednisolone), Lot WA 701, mp 206-208°C, acetate,
m p 235-238°C

r

t
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on 20 cm x 20 cm glass plates coated with silica gel G-254
and fluorescent indicator (Brinkman Instruments).

Several

solvent systems were satisfactory for this purpose.

Among

these were the upper phase of tertiary amyl alcohol, anisole, water (190/600/10, Rf 0.12 and Rf 0.42 respectively);
the system 1,8-epoxy-p-menthane, n-propanol, water (100/20/5,
Rf 0.23 and Rf 0.59 respectively) and the system methylcyclohexane, n-propanol-water (75/25/5) where the separation was
equivalent.

It should be noted that this latter solvent

system is similar to the ternary minimum boiling azeotrope
'

of methylcyclohexane, ethanol, water (66/24/10, b p 66°C).
The reduced 206-hydroxyl derivative was detected by its
quenching of the fluorescence of the phosphor in the silica
gel.

Therefore, if reduction of the conjugated C-3 ketone

occurred, the resulting compound would not have been detected.

As expected, the more polar 20B-hydroxyl deriva-

tive migrated slower than the parent steroid.

Zones which

contained the steroids were located under ultraviolet light
and scraped from the plate into a beaker containing methanol.
After thorough mixing, the methanol was passed through a
fine sintered glass filter and flash evaported to dryness
under reduced pressure.

Recrystalized 20S-hydroxyflu-

prednisolone had a melting point of 188-192°C compared to
206-208°C for fluprednisolone.

The diacetate of the
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reduced derivative was also prepared with acetic anhydride
and pyridine and it had a melting point of 210°C.

As

far as

the author could determine, the melting points for these rei

duced derivatives have not been reported.
While on the subject of steroid chromatography, it
should be noted that cortisol and f luprednisolone migrate

I·

together in such solvent systems at t-amyl alcohol, chloro-

ff

benzene, water (150/590/10, Rf 0.18), 95 percent ethanol-

~.·

[

'·~·

t

water saturated with cyclohexane (Rf 0.227); in 95 percent
ethanol-water, benzotrifluoride water (115,360,25, Rf 0.226),
and in cyclopentanol, dibromomethane water (10/10/1, Rf 0.81).
Thus, these steroids and possibly their metabolites would be
most difficult to separate in studies of the metabolism of
the labeled hormones.

Other considerations suggest that

these steroids may be separated as C-21 esters in the ternary
azeotrope of cyclooctane, n-propanol-water.
Inf rared spectra were recorded using a double-beam
Perkin-Elmer 337 grating spectrophotometer.

The resolution

obtained with this instrument is better than that in spectra
found in the literature so that direct comparisons are not
possible.

The steroid spectra were recorded using redis-

tilled carbon disulfide (odorless) as solvent in 2.0 mm
sodium chloride cavity cells manufactured by Barnes Engineering, Inc.

....

Solvent evaporation was excessive when the
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flexible plastic stoppers supplied with these cells were
used.

They were replaced with solid teflon stoppers ground

from a teflon rod with the aid of a pencil sharpener.

How-

ever, since excessive sealing pressure on-the stoppers resulted in the splitting of the cavity cells, solvent evaporation during the recording of spectra had to be routinely
monitored and sealing pressure increased slightly if necessary.
Infrared spectra were recorded on transmittance paper
so that the transmittance of the solvent could be subtracted
from that of the solvent plus solute in the longer path
length cell.

That is, the blank cell did not completely

compensate for the infrared absorption of the solvent.
Still, there were negative absorbance regions due to the
displacement of solvent by solute in regions of high solvent
absorption.

The same set of cells was used for all spectra

in the 1300-400 cm-l region.

The cells cleaned with methyl-

ene chloride and carbon disulfide and air-dried before use.
The scanning time was 72 minutes and the slit program was
one-tenth normal slit width.

Melting points were determined

between cover glasses on a Fisher melting point apparatus
and are uncorrected.

The solution spectroscopy of steroid

esters was chosen because it eliminates hydrogen bonding
and polymorphism associated with the spectra of solid
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hydroxylic steroids.

Although steroid acetates are suitable

for this purpose, steroid benzoates have better chromate-

[

graphic properties (121).

Furthermore, the ultraviolet ab-

f~

sorption of the benzoyl group facilitates the collection of

"

chromatographically separated steroid peaks.
Krahl et ·a1 (365) have demonstrated the effect of the
rat S-lipoprotein insulin antagonist in vitro on rat diaphragm but no one has yet evaluated its action in vivo.
A very sensitive in vivo assay of insulin in fasting alloxan-diabetic adrenalectomized rats has been described
by Bornstein and Trewhella (95).

However, it is a two-

point assay based on the drop in blood glucose produced
by insulin in exactly one hour at 37°C.

Insulin antago-

nism counteracts the drop in blood glucose.

In order to

overcome the limitations of the two-point assay, multipoint assays have been devised in which the specific activity of expired

co 2

is measured at intervals during the

infusion of labeled glucose (220, 311, 1029).
specific activity of expired

co 2

Since the

approaches that of the

infused glucose in approximately 4 hours, all measurements
must be made in this interval.

Demonstration of glucocor-

ticoid-dependent insulin inhibition by lipoproteins in vivo
is essential to the concept of inherited insulin antagonism
in diabetes mellitus.
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In these experiments S-lipoproteins isolated from the
sera of steroid-treated donor rats are administered to

re-

cipient rats and the effect of the lipoprotein on the oxidation of glucose-6-

14

c

to carbon dioxide is measured.

Steroid

contamination was minimized by withholding steroid treatment
for 6 hours before lipoprotein isolation as well as by the
washing step applied to the precipitated lipoprotein during
its isolation.
Male Sprague-Dawley rats weighing approximately 175
grams were obtained locally.

The following procedure was

used to produce alloxan-diabetes.

First, the rats were

fasted about 24 hours to deplete hepatic glycogen.

Sec-

ondly, a solution of 65 mg/ml of alloxan monohydrate in
saline was injected intravenously at a dose of 1.0 ml/kg.
The animals were then given food ad libitum.

Approximately

two-thirds of the rats developed a 24-hour fasting glucose
in excess of 2.0 gm/l within 2 days after alloxan administration.

However, one-half of the diabetic animals died

and one-third of the original number of rats did not become diabetic according to the above criterion.

Insulin

and electrolyte therapy were not used because such treatment would have increased the variation between rats.

All

rats having fasting glucose levels less than 2.0 gm/l were
recycled and subsequently received 1.5 ml/kg of alloxan.
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The wide variation in the response of individual rats to the
standard dose of alloxan remains unexplained.

However, the

dose of 65 mg/kg appeared optimal with respect to the yield
of viable alloxan-diabetic rats.
Acidosis was associated with obesity in the alloxan-diabetic rats.

Also, growth was self-limiting in the diabetic

rats in that it tended to exacerbate the insulin deficiency.
However, those alloxan-diabetic rats that remained alive for
at least one week were adrenalectomized under pentobarbital
anesthesia.

An abdominal approach was used in which both

kidneys and adrenals were clearly visible.
insured complete adrenalectomy.

This approach

All rats were injected with

10 mg/kg of 6a-fluoro-11B,17a,21-trihydroxy-l,4-pregnadiene3,20-dione to prevent hypoglycemia during the immediate postoperative period.

Also, the rats were transferred to a low

glucose diet high in fructose and protein with glycyrrhetinic acid in saline as drinking fluid.

This diet is des-

cribed in detail on page 332.
Adrenalectomy produces an approximate reduction of 50
percent in serum glucose.

That is, the severity of diabe-

tes is reduced by this amount.

Afterwards it is possible

to further reduce insulin secretory capacity by administering additional alloxan to raise the glucose levels to
pre-adrenalectomy levels.

Those adrenalectomized rats

r
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ft

who had fasting glucose levels less than 400% mg prior to

,t~

adrenalectomy were again given the standard dose of 65 mg/kg

'c

of alloxan intravenously.

Then the fasting serum glucose

was again determined to select those rats having 6-hour fasting glucose levels of at least 200% mg when maintained on the
low-glucose diet.

These rats could not be fasted for more

than 6 hours without risk of death from spontaneous hypoglycemia.

This procedure is listed stepwise on the following

pages.

It results in the preparation of severely diabetic

rats without insulin treatment.
Experimental Procedure
1.

Obtain 180-gram male Sprague-Dawley rats locally and
maintain them on a standard laboratory diet for 2 days.

2.

Fast all rats for 24 hours, then inject 65 mg/kg of
alloxan monohydrate in saline into the tail vein.

3.

Feed all rats ad libitum for 2 days.

4.

Fast all rats again for 24 hours.

5.

Anesthetize the rats with 20 mg/kg sodium pentobarbital
and obtain 400 µl samples of tail blood.

6.

Measure serum glucose with a glucose oxidase method.

7.

Reject as non-diabetic all rats with serum glucose less
than 2. 0 gm/l.

8.

Feed the remaining diabetic rats ad libitum for at
least 1 week.
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9.
10.

Adrenalectomize all surviving diabetic rats.
Inject adrenalectomized rats with 10 mg/kg fluprednisolone post-operatively and then transfer them to the low
glucose diet and the saline-glycyrrhetinate drinking
fluid.

11.

Allow at least 1 week for recovery from adrenalectomy.

12.

Fast rats having pre-adrenalectomy glucose values between 2.0 and 4.0 gm/l for 6 hours and then inject 65
mg/kg of alloxan monohydrate as previously described.

13.

Feed all rats ad libitum for 2 days.

14.

Fast all rats for 6 hours and measure serum glucose as
previously described.

15.

Reject as non-diabetic all rats having serum glucose
levels less than 2.0 gm/l.

16.

Group the diabetic rats in pairs on the basis of weight
and fasting serum glucose.

Designate the heavier of

the pair the donor rat and the lighter the recipient
rat.
17.

Inject the donor rat with 10 mg/kg of either 6a-fluoro11S,17a,21-trihydroxy-l,4-pregnadiene-3,20-dione or 6afluoro-11S,17a,20S,21-tetrahydroxy-l,4-pregnadiene-3one in propylene glycol subcutaneously at 48, 24 and
6 hours before exsanguination via the abdominal aorta.

18.

Fast the donor rat for 6 hours prior to exsanguination.
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Exsanguinate the donor rats under methoxyf lurane anesthesia.

At the same time begin to fast the recipient

rat for 6 hours.
2 o.

Transfer the blood from a 10 cc syringe to a 25 ml plastic International centrifuge (PR-2) tube and centrifuge
for 10 minutes at 8,000 x g at 0°C using the high speed
attachment and head number 298.

21.

Remove the serum from the clot with a clean calibrated
syringe and needle.

22.

Precipitate the serum S-lipoproteins with dextran sulfate and calcium chloride as described in the text.

23.

Wash the S-lipoprotein precipitate with calcium acetate.

24.

Dissolve the precipitate in 1.0 ml of tris(hydroxymethyl)-aminomethane-EDTA buffer, pH 9.1 that has been
saturated with blue dextran.

25.

Equilibrate Bio-Gel DM-100 {a polyacrylamide sieving
gel containing diethylaminoethyl anion exchange groups)
with isotonic tris(hydroxymethyl)aminomethane-HCl buffer, pH 7.40 at 37°C and pack it into a column 2.0 x
30 cm.

26.

Apply the blue lipoprotein solution in a narrow zone
at the top of the above column and elute it with the
isotonic buffer which has a pH of 7.8 at 0-4°C.

27.

Collect 0.5 ml fractions and pool the 4 fractions
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having the highest concentration of blue dextran and
hence of the S-lipoprotein which is excluded from the
gel with it.
28.

Inject 2.0 ml of the S-lipoprotein solution intraperitoneally into the recipient rat anesthetized with penthrane.

29.

Inject the recipient rat with a priming dose of 50
µCi/kg of glucose-6-

14

c.

Then follow with a constant

infusion of insulin and glucose-6-

14

c

{0.05 µCi/mmole)

as described in the text.
30.

Collect 5 samples of

14

co 2 of 45-minutes duration each

directly in scintillation vials as described in the
text.
31.

Terminate the experiment after 225 minutes in one of
two ways:

1) Place the rat in a cage under a labora-

tory hood for 1 week so that the rat may return to
background radioactivity levels prior to receiving
lipoproteins from rats treated with other steroids;
2) Following the second experiment with the recipient
rat place him in liquid nitrogen in preparation for
liver and muscle glycogen analysis.

32.

Measure the specific activity of the expired

14

co 2

with a liquid scintillation counter using an open
window.
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33.

Plot the specific activity of the

14

co 2 versus time and

fit the best straight line to these points which also
passes through the origin.

The slope of this regression

line is then taken as a measure of the rate of glucose
oxidation.

The details of the statistical treatment

have been described by Sokal and Rohlf (1001) •
Serum glucose was determined with a commercial glucose
oxidase reagent (Glucostat Regular, Worthington Biochemical

I

corporation).

The lyophilized reagent was reconstituted in

30 ml of 0.10 M tris(hydroxymethyl)aminomethane-maleate buffer, pH 6.9, instead of 83 ml of water in order to provide a
greater excess of enzyme for glucose determinations in the
diabetic range.

This added buffer strength necessitated the

use of twice the volume of 5.0 N HCl to stop the reaction.
Also, the reaction time was reduced from the recommended 15
minutes to 5-10 minutes to increase the linearity of the
reaction.

The glucose oxidase-peroxidase reagent was stored

frozen and it was filtered through Whatman 50 filter paper
immediately before use to remove pigment.

Glucose standards

were preserved with benzoic acid and the actual determinations were carried out at ambient temperature using an ultramicro technique.

The reagent described above loses ac-

tivity during prolonged use at ambient temperature.
When the method described in step 31 is used for
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reducing the radioactivity of expired

t~.

els.

co 2

to background lev-

Arrangements should be made to insure that the hood

ventilating system is not shut down during the procedure.
Ideally, the radioactive rat should be maintained in a large
metabolic cage.

The room air could first be bubbled through

sodium hydroxide and then through a constant humidity solution in order to maintain a comfortable environment for the
rat during the week.

This would result in the production of

about 225 grams of barium carbonate for disposal.

The dis-

advantage of this procedure is that it requires a separate
metabolic cage for each rat to avoid cross contamination.
In the absence of the necessary equipment the author thought
that it would be safer to vent the

14 co

2

directly into the

atmosphere rather than into the sewage system where it may
have come into contact with acid without the benefit of a
hood.
Rats were anesthetized with the inhalation anesthetic
2,2-dichloro-1,1-difluoroethyl methyl ether (Penthrane,
methoxyflurane) or with 2-chloro-1,1,2-trifluoroethyl ethyl
ether.

Poznak and Artersio (850) compared several deriv-

atives of 1,1-difluoroethyl methyl ether as anesthetic
agents and found that the 2,2-dichloro compound was both
a potent anesthetic as well as non-flammable in the concentrations required for anesthesia.

The vapor pressure
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of the anesthetic in inspired air was regulated by bubbling
room air first through sodium hydroxide to absorb carbon dioxide and then through a gas trap containing the anesthetic
at a temperature approaching -21.1°C which was maintained by
surrounding the trap with frozen sodium chloride eutectic
(23.3 percent NaCl).

Although the use of a single tempera-

['

"
i

ture limits precise control of the depth of anesthesia, this
can be accomplished by controlling the flow rate of carbonqioxide-free air through the vaporization trap.

Faster flow

rates reduce the concentration of the anesthetic agent in
inspired air (Figure XIII).
In early experiments the S-lipoprotein fraction of rat
serum was isolated by a modification of the ethanol precipitation technique described by Krahl et al (306).

The modi-

fication was that manipulations other than centrifugation
at -5°C were conducted at 0°C.

The precipitation reagent

was composed of the following ingredients:
38 ml absolute ethanol
0.6 ml of 0.8 M HOAc-NaOAc buffer, pH 4.0
4.0 ml of 0.06 M NaCl
0.42 ml of 1.0 M HOAc

H2o to 200 ml
The precipitation reagent was cooled to 0°C.

Approximately

2.0 ml of donor rat serum was slowly added with continuous
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by 1.0 ml of 0.4847 M tris(hydroxymethyl)aminomethane(58.783
gm/1)-0.0810 M ethylenediaminetetraacetic acid (3.946 gm/l)
buffer, pH 9.2.

The suspended precipitate and crystals were

shaken in the cold room for approximately 30 minutes and then
centrifuged.as previously described.

The resulting solution,

saturated with blue dextran marker, was applied to an ion exchange-gel exclusion column consisting of diethylaminoethyl
groups on a polyacrylamide matrix (Bio-gel DM-100).

This

gel excludes protein having molecular weights in excess of
100,000.

The column, 20 mm x 300 mm, was equilibrated with

the isotonic tris-HCl buffer, pH 7.8 at 0°C (pH 7.40 at
37°C) described above.

Both the blue dextran and the S-li-

poprotein were excluded from the gel and emerged from the
column with the void volume of approximately 16.6 ml.

The

dextran sulfate and EDTA anions were exchanged for chloride ions while chelated calcium and protein contaminants
entered the gel.

The four bluest

o.s

ml eluant fractions

were pooled and administered to recipient rats.

Since the

concentration of blue dextran and tris buffer administered
to each recipient rat was the same, these agents should
not affect the results.

The dextran sulfate precipitation

procedure is superior to the ethanol precipitation procedure because it avoids solvent denaturation and removes
low molecular weight phospholipases which may be present.
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However, it employs high pH, 9.2, and may result in the loss
of dializable lipoprotein constituents during passage through
the gel exclusion column.

These potential limitations have

not been evaluated but should be kept in mind when the technique is used.
Following the administration of the B-lipoprotein fraction from the steroid-treated donor rats to the anesthetized
recipient rat, a continuous infusion of glucose and insulin
was initiated.
in Table XV.

The composition of this solution is shown
The specific activity of the glucose infusion

solution was measured by counting a weighed sample of glucose 2,5-dichloro-phenylhydrazone, mp 152-152.5 (lit 160°C)
which was prepared as described by Mandl and Newberg (708).
The derivative was formed in anhydrous n-propanol and recrystallized from 1,1,2-trichloroethane.

For example, a

solution diluted to contain 0.05 µCi/mmole according to
manufacturer's specifications was found to contain 0.0676
µCi/mmole by the above technique.

The discrepancy between

calculated and experimentally determined glucose infusion
rates is attributed to the viscosity of the 27 percent
glucose solution.
An ethanolic solution of glucose-6-

14

C was diluted

to contain 5.0 µCi/ml and used as such to prime the body
glucose pool of the rat.

l

This solution was administered
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TABLE XV
GLUCOSE INFUSION SOLUTION
,,

l

Concentration

Canponent
Glucose

272.11 mg/l

Infusion·Rate
83.3 mg/hr

Sodium heparin

O.Olmg/l

0.003 mg/hr

Phenobarbital

0.54 mg/l

0.17 mg/hr

Insulin

0.02 mg/l

0.14 units/hr

Infusion Rate

= 0.3

ml/hr

to the rat at a dose of 1.0 ml/kg in order to raise the specific activity of the body glucose pool to that of the glucose infusion solution, i.e. 0.05 µCi/mmole.

At this level

of radioactivity approximately 10.1 µCi of radioactivity
was required per 200 gm rat.
In preliminary experiments the respiratory carbon dioxide

was isolated as barium carbonate and counted at infinite thickness (20 mg/cm 2 ) in an end window planchet

counter.

These experiments indicated that the specific

activity of the carbon dioxide reached a plateau after
about 4 hours of infusion.

In another series of experi-

ments an attempt was made to increase counting efficiency
and to by-pass the plating procedure associated with planchet counting by converting barium carbonate to quaternary
ammonium carbonate in toluene prior to homogeneous liquid
scintillation counting.

Finely divided barium carbonate

was mechanically shaken for 24 hours at ambient temperature with quaternary ammonium tosylate in toluene for reaction according to the equation:

The fact that carbonate is isolated as its barium salt is
somewhat disadvantageous because the barium salts of organic sulfonates are among the most soluble sulfonate salts.
Since the equilibrium in the above reaction depends on the

r

l
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relative solubilities of barium carbonate and barium sulfonate, the forward reaction may be enhanced by using sulfonates which form barium salts that are relatively insoluble in toluene, i.e. barium methanesulfonate.

In order to

be competitive to the direct trapping of carbon dioxide in
quaternary ammonium hydroxide, a method described below,
the above reaction would have to proceed almost to completion.

The solubility of cesium carbonate in 2-propanol

(.025 M) was determined in order to test the feasibility
of related reactions employing different metal carbonates.
All steroid comparisons are based on the direct trapping of respiratory carbon dioxide in a 0.5 molar solution
of quaternary

ammonium hydroxide in toluene.

A special·

gas trapping device was constructed which permitted the use
of standard liquid scintillation vials.
is shown in Figure XIV.

Its construction

Since the device was constructed

of several pieces, it was necessary to use vacuum grease
on crevices and threads to prevent gas leaks.

With the

exception of the tef lon coupling a similar single-piece
device may be constructed entirely of glass thus greatly
reducing the possibility of leakage.
Collection vials were changed at 45-minute intervals
up to 225 minutes.

Then the anesthetized rat was removed

from the metabolic cage and either placed in a cage under
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a fume hood to allow expired radioactivity to return to background levels or placed in liquid nitrogen for subsequent
muscle and hepatic glycogen analysis following the second lipoprotein treatment administered to the rat.

This protocol

allowed both steroid treatments to be compared in the same
rat.

Following freezing in liquid nitrogen the rat carcas-

ses were stored at 120°C in a deep freeze.

For glycogen

analysis the carcasses were removed and warmed in a cold
room at 0°C, the limbs were removed and the digits and skin
were disgarded in the appropriate manner with the rest of
the radioactive carcass with the exception of the liver.
The resulting mass of tissue was weighed and digested in
hot KOH.

When cooled, the digestion mixture was decanted

from the bones and filtered through alkali-resistant fiber
glass.

The bones were then dried and their weight was

subtracted from the total weight of the tissue.

The glyco-

gen was then precipitated with ethanol according to the
technique of Good et al (367).

However, despite the ad-

ministration of glucose and insulin, only traces of glycogen were found in some experiments.

CHAPTER XIII
RESULTS

Part I:

Infrared Studies

For convenience in confirming the identity of commercial steroids, the melting points and specific rotations
of some endogenous 3-hydroxy-17-ketosteroids and their
acetates can be found in Table XVI.
rameters are not very definitive.

Note that these paExceptions include the

low melting point and high specific rotation of 3a-hydroxy5$-androstan-17-one, the high melting point of its llShydroxyl derivative, and the high specific rotation of the
latter's dehydration product.

In contrast, 3$-hydroxy-5-

androsten-17-one has a low specific rotation.

In general,

5a-epimerization and ester formation lower specific rotation with the exception of uncertain entries which are
underlined.
The infrared spectra of these 3-hydroxy-17-ketosteroids are more definitive.

Note that, from the data of

Jones et al (538-547) in Table XVII, C-11, C-17, and
355

TABLE XVI
MELTING POINTS AND POSITIVE SPECIFIC ROTATIONS OF
MAJOR 17-KETOSTEROIDS AND THEIR ACETATES

17-Ketosteroid

Alcohol

3a-hydroxy-5a-androstan-17-one

184-185,

3a-hydroxy-5S-androstan-17-one

Acetate
160-161,

77°

143-144, 111°

151-155,

98.4°

3a-hydroxy-9(11), (5a)-androstan-17-one

187-188, 136°

190-192, 135°

3a-hydroxy-9(11), (5S)-androstan-17-one

169-170, 151°

3a,11S-dihydroxy-5a-androstan-17-one

199-200,

98.4°

3a,11S-dihydroxy-5S-androstan-17-one

237-238,

96°

3a-hydroxy-5a-androstane-ll,17-dione

153-155, 127°

184-185, 113°

3a-hydroxy-5S-androstane-ll,17-dione

188-189,

95.8°

163-164, 145°

3S-hydroxy-5a-androstan-17-one

178-179,

87.5°

3S-hydroxy-5--androstan-17-one

152-153,

11°

171-172,

3S-hydroxy-5S-androstan-17-one

154-155,

ago

157-158,

94.6°

86-88
240-242

96-97,

68°
3.9°
82°

w

Ul

O'i
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TABLE XVII
INFRARED ABSORPTION MAXIMA OF STEROID KETONES

Ketone
C-3

(an-1 ) (CE1 )
4

(an-1 ) (CHC1 )
3

1717-1713.

1711-1706

1
6 -C-3
64-C-3

1680-1684

1670

1674-1678

1666

61,4-C-3

1666-1663

64,6-C-3

1669-1666

C-11

1712-1706

1705-1698

C-17

1745-1743

1736-1733

C-20

1709-1706

1707-1694

616-c-20

1666-1670

1652-1662

17a-OH-C-20

1706-1710

1698-1702

1708, 1693

1723-1728

17a-OH-C-20-21-oAc
C-20-21-oAc
C-3,11

1720-1727
1713

1
6 -C-3,17

1719, 1745

C-3,20

1719, 1710

C-11,17

1719-1714, 1754

C-11,20

1713

17a-OH-C-3,ll,20

Jones et al (538 - 547)

1711
1705, 1685
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c-11,17 ketones can be readily distinguished.

However, C-3

acetate esters in chloroform absorbing at 1739-1735 cm-l
-1

mask C-17 ketones absorbing at 1736-1733 cm

Likewise,

c-3 benzoates in chloroform absorbing at 1724-1717 cm-l mask
1
c-11 ketones in 17-ketosteroids absorbing at 1719-1714 cm- •
Unfortunately, the absorption shift of C-3

o~chlorobenzoates

to lower frequencies is not quite large enough to eliminate
this masking.
To test the feasibility of the infrared analysis of
mixtures of these 17-ketosteroids, a unique absorption peak
was found which characterized each compound in the mixture.
Then the absorption coefficient of each compound at each
wave length was.determined.

It was assumed that the absor-

bence at all other frequencies is proportional to its absorbence at its unique frequency.

However, it should be noted

that all compounds absorb at the unique frequency of any
particular compound.

It is possible to consider the ob-

served spectrum of a mixture of these pure compounds as a
linear summation of the spectra of the individual compounds.
That is, the absorbence at each unique frequency of the
spectrum of the mixture is given by:
Af

=

bB f + cC f + dD f + dE f + ••••••••••

where the lower case letter represent the proportion of
each compound in the mixture.

When the total number of
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FIGURE XXI
3a-HYDROXY-5S-ANDROSTANE-ll,17-DIONE
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TABLE XVIII
INFRARED ABSORPTION CHARACTERISTICS OF 17-KETOSTEROIDS
IN CARBON DISULFIDE SOLUTION

Extinction Coefficients (0 • 2% I 0.2 cm)

17-Ketosteroid
-1
Frequency cm

·105g

1034

994

988

955

932

802

3a-hydroxy-5a-androstan-17-one

0.049

0.027

0.301

0.061

0.003

0.028

0.007

3a-hydroxy-5S-androstan-17-one

0.220

0.270

0.115

0.088

0.022

0.015

0.000

3S-hydroxy-5a-androstan-17-one

0.079

0.387

0.042

0.042

0.022

0.044

0.009

3S-hydroxy-5S-androstan-17-one

0.099

0.027

0.028

0.032

0.085

0.009

0.007

3S-hydroxy-5-androstan-17-one

0.069.

0.076

0.062

0.042

0.036

0.022

0.066

3a-hydroxy-5a-androstane-11,17-dione

0.024

0.062

0.081

0.237

0.015

0.015

0.012

3a-hydroxy-5S-androstane-ll,17-dione

0.046

0.155

0.054

0.016

0.024

0.073

0.012

w

°'
°'
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compounds in a mixture is unknown, the criteria for including
another compound in the summation is that its inclusion decreases the deviation of the summated from the observed
spectrum.
While only obviously unique frequencies have been
treated here, each compound has a definite absorption at
each frequency.

Using computerized methods, the summation
-1

process may be repeated at 1 cm

intervals or less, depend-

_ing on the slit width program of the instrument.

Such a

procedure would necessitate the direct recording of infrared spectra on magnetic tape or disc.
The infrared results in Table XVIII indicate that there
is little difficulty in distinguishing pairs of C-5 epimeric steroid alcohols.

Note that the absorbences which

are underlined are not necessarily at the best frequencies
for this particular purpose.

The resolution of the spec-

trometer is a key factor in the analysis of complex mixtures of these steroids at the selected frequencies.

For

example, the absorption of 3a-hydroxy-5s-androstan-17-one
-1

at 1034 cm

occurs as a trough between two peaks and may

decrease with better resolution thus making this frequency
more specific for 38-hydroxy-Sa-androstan-17-one.
Although it was necessary to scan the entire finger
print region in carbon disulfide in order to determine

368
characteristic frequencies, the fact that these frequencies
are between 1058 and 802 cm

-1

means that less volatile sol-

vents which produce greater concentration accuracy can be
used if they have an infrared window in the region.

Bromo-

form, which has an absorbence relative to air of less than
0.36 between 1050 and 900 cm-l in a 2.0 mm cell is almost
adequate for this purpose.
be investigated in this use.
cm

-1

Deuterated bromoform should also
It is possible that the 802

frequency may be replaced by another frequency which

is masked in the 835-900 cm-l region of carbon disulfide
absorption.

The melting points that were determined for

3a-hydroxy-5s-androstan-17-one and 3S-hydroxy-5a-androstan17-one are somewhat lower than previously reported values
suggesting contamination by 3S-hydroxy-5-androstan-17-one.
However, the infrared analysis does not support that explanation.
The inf rared spectra of the corresponding o-chlorobenzoates are much less distinctive.

This is expected

since all these derivatives share the absorptions of the
o-chlorobenzoate group including peaks at 1280, 1240 and
-1

745 cm

However, characteristic frequencies do exist

for the 11-deoxy derivatives which are markedly different
from the characteristic frequencies in the corresponding
steroid alcohols.

The

frequency (700 cm

-1

) appears to
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be associated with the C-3 hydrogen.

This vibration is in-

f luenced by the conformation of the ester group as well as
by the nature of the A-B ring juncture and the presence of
the C-11 ketone.

This is hard to explain and may be further

investigated by comparison with the.spectra of the metaand para-chloro-substituted benzoyl esters.
The C-11 oxygenated steroid esters seem to be devoid
of characteristic frequencies.

However, these frequencies

may be present in a region of solvent absorption as discussed previously.

This disadvantage is partially offset

by the fact that C-11 ketonic and non-ketonic steroids are
much more easily separated as C-3 esters rather than alcohols.

The wide melting point range of 3a-hydroxy-5S-andro-

stan-17-one 3-o-chlorobenzoate confirms the presence of impurities noted in the alcohol which are difficult to separate chromatographically.

Also noteworthy is the fact

that the ester of 3S-hydroxy-5a-androstan-17-one had a
melting point close to that of the parent steroid.

The un-

corrected exteinction coefficients of the 17-ketosteroid
3-o-chlorobenzoates are shown in Table XIX.

The same data

has been recalculated to correct for differences in concentration caused by the evaporation of carbon disulfide.
This was done by assuming that the absorbence at 1050 cm-l
was 0.300 in the spectrum of all esters.

The main effect

TABLE XIX
INFRARED ABSORPTION CHARACTERISTICS OF 17-KETOSTEROID
3-o-CHLOROBENZOATES IN SOLUTION

Extinction Coefficients (0.2%, 0.2 cm)

3-o-chlorobenzoate
Frequency cm-l

1025

1015

1005

970

795

700

3a-hydroxy-5a-androstan-17-one

0.059

0.079

0.090

0.176

0.030

0.032

3a-hydroxy-5S-androstan-17-one

0.056

0.052

0.057

0.038

0.086

0.125

3S-hydroxy-5a-androstan-17-one

0.046

0.046

0.159

0.032

0.004

0.022

3S-hydroxy-5S-androstan-17-one

0.079

0.203

0.139

0.076

0.071

0.114

3S-hydroxy-5-androstan-17-one

0.176

0.079

0.127

0.013

0.000

0.602

3a-hydroxy-5a-androstane-ll,17-dione

0.052

0.052

0.052

0.028

0.031

0.194

3a-hydroxy-5S-androstane-ll,17-dione

0.038

0.036

0.067

0.024

0.036

0.796

w

-...J
0\

TABLE XX
INFRARED ABSORPTION CHARACTERISTICS OF 17-KETOSTEROID
3-o-CHLOROBENZOATES IN SOLUTION NORMALIZED TO AN
EXTINCTION COEFFICIENT OF 0.300 AT 1050 cm-l
Extinction Coefficients (0. 2%, 0 ~ 2 cm)

3-o-Chlorobenzoate
-1

Frequency cm

1025

1015

1005

970

795

700

3a-hydroxy-Sa-androstan-17-one

0.055

0.076

0.085

0.168

0.029

0.031

3a-hydroxy-5s-androstan-17-one

0.052

0.048

0.053

0.035

0.079

0.115

3S-hydroxy-5a-androstan-17-one

0.046

0.046

0.159

0.032

0.004

0.022

3s-hydroxy-ss-androstan-17-one

0.051

0.130

0.089

0.048

0.045

0.073

3e-hydroxy-5-androstan-17-one

0.186

0.084

0.134

0.014

0.000

0.636

3a-hydroxy-5a-androstane-11,17-dione

0.057

0.057

0.057

0.031

0~034

0.213

3~-hydroxy-5s-androstane-11,17-dione

0.062

0.058

0.109

0.039

0.059

1.129
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of this approximation is to reduce the extinction coef f icients of 3a-hydroxy-5$-androstan-17-one.

Otherwise, the

qualitative interpretation of the data is the same.

The

corrected data is shown in Table XX.
Part II:

Rat Maintenance

The second important experimental result is also qualitative.

It was found possible to maintain alloxan-dia-

betic adrenalectomized rats on the specially compounded
diet shown on page 332 of Chapter XII.

This diet was admin-

istered in conjunction with a saturated solution of sodium
glycyrrhetate in saline at pH 8.0.

The solubility of so-

dium glycyrrhetate in 0.9 percent saline was found to be
0.213 gm/l at this pH.

Rats maintained on the solid low-

carbohydrate diet remained hyperglycemic.

No deficiencies

were noted in the diet during prolonged feeding.

The diet

was palatable to the rats and it served its purpose of
maintaining healthy diabetic-adrenalectomized animals in
the absence of insulin injections.
A minor result of these investigations is the verification of the effect of the halogenated anesthetic 2chloro-1,1,2-trifluoroethyl ethyl ether on fasting serum
glucose.

Although it is important to be aware of this

effect, it does not appear to be an important factor in
these experiments because they were carried out during

379

TABLE XXI

The Effect of 2-Chloro-1,1-2-trifluoroethyl Ethyl
Ether on Blood Glucose of Fasting (4 Hours) Rats.

Non-anesthetized

Anesthetized

1.10 grn/l

1.31 grn/l

0.99 grn/l

1.13 grn/l

0.93 grn/l

1.20 grn/l

1.01 grn/l

Means

1.21 grn/l
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an infusion of glucose at a level of approximately 500 mg
per 100 ml.

Furthermore, the effect of the anesthetic was

constant in all experimental treatments so that it should
not be a factor in differences between treatments.
Although the focus of the experimental approach has
been on the transport of steroid-dependent anti-insulin
factors by 8-lipoproteins, some experiments were also performed to test direct steroid effects.

Of course, gluco-

corticoids cannot be tested directly because of their gluconeogenic effects on the liver.

However, other steroids

may be tested for their effect on glucose oxidation.

Per-

haps the best way to do this is to administer the steroid
treatment to a diabetic-adrenalectomized rat prior to the
administration of labeled glucose and the measurement of
glucose oxidation in a metabolic cage.
A somewhat simpler approach consists of the measurement of the effects of such steroids on the survival time
of adrenalectomized rats following the administration of
glucose and excess insulin.

The results from this type

of study are shown in Table XXII.

Although the results

indicate that so-called anesthetic steroids have antiinsulin effects, the variable length of time between the
onset of hyperglycemic convulsions and hypoglycemic death
made the latter event unsatisfactory as an experimental
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TABLE XXII

The Effect of Pretreatment with 2.1 mg of the Anesthetic
Steroid 17a,21-Dihydroxy-5B-Pregnane-3,ll,20-Trione 21Acetate on the Onset of Hypoglycemic Death Following the
Injection of 1 ml of 44 Percent Glucose and 1 unit of Insulin Into 6-Hour Fasted Alloxan-Diabetic Adrenalectanized
Rats.

Survival Times (Minutes)
Control

Steroid-Treated

195

309

284

410

193

387

223

Means

369

382
endpoint.
Part II:

Research on the Me·asurement of C02 Specific

Activity by Liquid Scintillation Techniques
A method was designed for the homogeneous liquid scintillation counting of barium carbonate as quaternary ammonium carbonate following its reaction with quaternary ammonium tosylate.

This method was found to be less sensitive

than the measurement of relative specific activity by planchet counting at infinite thickness.

The cause of the re-

duced sensitivity was not the efficiency of liquid scintillation counting which was high, but the low percentage
conversion of the reaction forming quaternary ammonium
carbonate.

Solubility considerations suggest that the

percentage conversion may be increased by reaction with
quaternary ammonium mesylate.

The plot of efficiency versus

external standard ratio employing quaternary ammonium tosylate is shown in Figure XXVIII.
The method of determination of specific activity of

co 2

actually used in these experiments is based on the di-

rect trapping of the gas by a quaternary ammonium hydroxide
dissolved in toluene.

The specially designed and con-

structed apparatus used by the author for this purpose is
shown in Figure XIV, page 353.

The efficiency plot for this

method of counting is shown in Figure XXIX.

Since the
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TABLE XXIII
EFFICIENCY VERSUS EXTERNAL STANDARD RATIO FOR 0.5 MOLAR QUATERNARY AMMONIUM
BICARBONATE IN TOLUENE CONTAINING 6.0 GRAMS/LITER 2,5-DIPHENYLOXAZOLE

External

Standard
Ratio
0.323

Vial Weight
+Hexadecane-1-14c 3026.1
.
14
61.1
-Hexadecane-1- C
Net .•.•••...•••••• 2965.0

0.360

+Hexadecane-1-14c
14
-Hexadecane-1- c

6575.3
453.3

Net ••••••••••••••• 6122.0

14
Hexadecane-1- C
Specific
Activity

14278.8 mg
14277.3 mg
1.5 mg x 2220 dpn/mg
16765.8 mg
16762.9 mg

Efficiency

2965 cpm

- - - = 89.0%
3330 dpn

= 3330

dpn

6122 cpm

- - - = 95.1%
6438 dpn

2. 9 mg x 2220 dpn/mg = 6438 dp:n
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FIGURE XXIX
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combining capacity of the organic base must be saturated in
order to calculate specific activities by this method, the
low efficiency of

co 2

and the low rate of

collection (approximately 50 percent)

co 2

production by the rat combine to

limit the frequency of specific activity measurements.
Another liquid scintillation method for the determination of specific activity was devised with the hope of increasing the efficiency of

co 2

collection.

However, the

method was not tested because i t requires temperature-control led counting.

In the method an aqueous cesium hydrox-

ide solution is saturated with

co 2 •

Cesium bicarbonate

and primary fluor are then precipitated by the addition
of 2-phenoxyethanol saturated with primary fluor, thereby
forming a four-phase invariant system at constant temperature and pressure.

After equilibration below ambient

temperature, the organic phenoxyethanol phase containing
cesium bicarbonate, water and primary fluor should remain
homogeneous for counting at ambient temperature.

Studies

were carried out to determined the comparative counting
efficiencies of a number of organic solvents.

As seen

in Table XXIV, the efficiency of phenoxyethanol is 76.7
percent, or approximately 85 percent of the efficiency
of toluene.

The same solvent phenoxyethanol was also

used to determine the specific activity of the glucose
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TABLE XXIV
EFFICIENCIES OF SCINTILLATION SOLVENTS CONTAINING
6.0 GMS/LITER DIPHENYLOXAZOLE AS PRIMARY FLUOR AS
DETERMINED WITH HEXADECANE-l-c 14 (2220 DPM/MG)

Activity

Hexadecane .

(gm)

Efficiency

Toluene
Spike ••• 35126.6
Bkg •••••••• 98.0
Net ••••• 35028.6

16674.4 mg
16656.7 m::;
17.7 mg x 2220 dµn/mg

351028 •6 cp:n = 89.1%

= 39,284.0 dp:n

Benzyl Alcahol
Spike •••• 8747 .1
Bkg •••••••• 69.l
Net •••••• 8878.0

Spike •••• 9784.5
Bkg •••••••• 75.2
Net •••••• 9709.3

16485.6 mg
16478.2 mg
7.4 mg x 2220 dµn/mg
Phenoxyethanol
16472.8 mg
16467.1 mg
5.7 mg x 2220 dpn/ItB

81878 •0 cp:n

= 16,428.0

dp:n

91709 • 0 cpn

= 12,654.0

= 54.0%

= 76.7%

dp:n

Anisole
Spike ••• 13096.5
Bkg ••••••• 129.4
Net ••••• 12967.1

17081.8 mg
17075.3 m::;
6.5 mg x 2220 dµn/mg

121967 •0 cp:n

= 89.9%

= 14,430.0 dp:n

Dioxane
Spike •••• 3863.l
Bkg .... ~ ••• 73.5
Net •••••• 3789.6

16666.4 mg
16659.3 mg
7.1 mg x 2220 dµn/mg

31789 • 0 cpn

= 15,762.0 dp:n

= 24.0%
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infusion solution.

Glucose was isolated from the solution

and counted as its 2,5-dichlorophenylhydrazone.

It is appro-

priate to note that labeled 2,5-dichlorophenylhydrazine may
be synthesized from chlorine-36 labeled p-dichlorobenzene
of known specific activity so that glucose specific activity
may be determined solely from radioactivity measurements.
An additional advantage of 2,5-dichlorophenylhydrazones over
nitrophenylhydrazones as derivatives is that they are not
colored and therefore they are less quenching to the liquid
scintillation process.

The specific activity of glycogen

glucose can also be determined by this method following
hydrolysis with sulfuric acid and neutralization with barium carbonate.
Despite the fact that excess insulin and glucose were
infused in these experiments and despite the fact that all
limb muscles were taken for the isolation of muscle glycogen, sufficient muscle glycogen could not be recovered
from enough rats to make valid comparisons between steroid
treatments.

It is doubtful that significant muscle glyco-

genolysis occurred during freezing in liquid nitrogen because one would expect the limbs to freeze rapidly.
Part III:

Effects of Steroid Treatments

Results from the best executed series of comparisons
of f luprednisolone and 20S-hydroxyfluprednisolone treatments
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is shown in Table XXV and plotted in Figure XXX.

In these

experiments the effects of S-lipoproteins from rats receiving each of the steroid treatments were determined in different recipient rats because only a limited number of experiments were completed by the proposed method in which a
single recipient rat received S-lipoproteins from both types
of steroid-treated rats.

It appears that the second use of

a recipient is more critical than the first in that the rat
is more susceptible to respiratory depression and respiratory arrest.
The slope of the regression line for each set of observations was determined by the regression analysis in
Table XXVI.

The assumption that the regression line passes

through the origin is theoretically correct and provides
more meaningful regression slopes than those obtained by
treating the origin as just another data point.

The sta-

tistical treatment was simplified by treating the independent variable time in units of 45 minutes.

However, the

slope, b, so obtained must be divided by 45; hence the b/45
term in Table XXVI.

Random variations in the rates of glu-

cose oxidation were greater than those due to steroid treatments.

The greatest variation was uncontrolled respiratory

depression and anoxia produced by the anesthetic and the
deficits of carbon dioxide and oxygen in the inspired air.

TABLE XXV
GLUCOSE OXIDATION AFTER LIPOPROTEINS FROM FLUPREDNISOLONE
AND 208-HYDROXYFLUPREDNISOLONE TREATMENTS

Regression
Line
Symbol

Experimental
Weight
GMS

Fasting
Glucose

Counts Per Minute
Per Microrrole C02

GMS/L

45 Min

90 Min

135 Min

6a-fluoro-11S,17a,20S,21-tetrahydroxy-l,4-pregnadiene-3-one
A

330

1.96

39.1

268.4

417.9

B

329

1.96

76.7

151.9

389.0

E

358

4.88

14.8

46.9

179.3

F

429

2.02

16.2

73.9

165.4

6a-fluoro-11S,17a,21-trihydroxy-l,4-pregnadiene-3,20-dione

\

.

c

323

3.16

25.0

145.1

202.6

D

401

2.99

12.8

83.5

184.8

G

386

4.67

14.3

55.7

98.9

H

314

3.69

15.0

42.8

84.6
w

\,0

0
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FIGURE XXX
GLUCOSE OXIDATION AFTER LIPOPROTEINS FROM FLUPREDNISOLONE
AND 208-HYDROXYFLUPREDNISOLONE TREATMENTS

FIGURE

XI

GLUCOSE OXIDATION AFTER LIP,PROTEINS FROM

fLUPREDNISOLONE AND 208-HYDROXYFLUPREDNISOLONE TREATMENTS
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TABLE XXVI
REGRESSION STATISTICS

s
I

= T/45,

Regression

A
B
E

F

~s

= Specific Activity,

S = bI,

T = Time,

I = Interval Time

::E:I2 = 14,
(::E! I 2 )/4 = 9,
[::E:I 2 -(~ I) 2/4] = 5
::E!IS
[::E:S 2-(::E:IS) 2/::E:I 2]
[::E!IS-::E!I::E!S/4]
b/45

::E! I= 6,

::E:S2

6a-fluoro-11B,17a,20B,21-tetrahlaroxy-l,4-pregnadiene-3-one
725.4 526,205.16
1,829.6
287,094.74
741.50
617.6 180,277.50 1,547.7
9,178.26
459.60
255.5
33,080.81 I 646.5
30,095.37
263.25
241.0
34,567.14
546.5
13,324.12
185.00
339,602.49
1649.35

2.904
2.456
1.026
0.867
1.813 + 1.019

6a-fluoro-11B,17a,21-trihydro~-l,4-Eregnadiene-3,20-dione

c
D

G
H

Totals:

372.7
281.1
168.9
142.4

2804.6

62,725.77
41,287.13
13,088.19
9,214.00

900,445.70

923.0
734.2
422.4
354.4

7,004.3

2,588.00

5,958.03

363.95
312.55
169.05
140.80
986.35

345,560.52

2635.70

2,783.58
343.78
242.67

1.465
1.165
0.672
0.563
0.966 + 0.424

Critical Sum of Squares= F. 90 [7.7] x ::E!d~i/3 = 2.78 x 345,560.52/3 = 320,219.42
.
2
Sum of Squares Arrong All Slopes= 345,560.52 - (2635.70) /8 x 5 = 171,877.66

w
\,0

N

Since 171,877.66<<320,219.42, the slopes are not significantly different at the
90 percent confidence level. In contrast, a Student's t value of 1.535 for the
difference between the mean slopes of steroid treatments is greater than t. 90fGl
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This variation and that in infusion rates could be eliminated
by the use of a mechanical respirator and positive displace-

ment infusion pump.
In order to demonstrate significant differences between
steroid treatments the specific activity of the glucose administered to the rat will have to be increased 5-10 fold
and more frequent specific activity measurements will have
to be made.

Provided that 20B-hydroxyfluprednisolone does

not stimulate glucose oxidation, then the demonstration that
the rate of glucose oxidation is lower with the fluprednisolone treatment than with the 20B-hydroxyfluprednisolone
treatment proves that the effect of f luprednisolone is significant in vivo.

The possibility that 20B-hydroxyflupred-

nisolone does stimulate glucose oxidation may be eliminated
by comparing both steroid treatments with the basal glucose
oxidation rate.

To do this one must be able to predict.the

latter portions of the specific activity versus time curve
from measurements of its initial portion.

Each recipient

rat could be subjected to a control peiiod and then to an
experimental period after lipoprotein administration.

Dif-

ferences between the experimentally determined and calculated specific activity curves could then be observed.

~

.

CHAPTER XIV
DISCUSSION

The purpose of this dissertation is to evaluate insulin inhibition by glucocorticoids in vivo.

It includes

an evaluation of the specificity of the effect.

For the

purposes of this discussion the author defines a specific
glucocorticoid effect as one which requires all of the
functional groups present in cortisol.

If insulin inhib-

ition by glucocorticoids is non-specific, then 20S-hydroxy
glucocorticoids should produce insulin antagonism in vivo.
On the other hand, if insulin inhibition by glucocorticoids
is specific, it should not be produced by the 20S-hydroxy
glucocorticoids in vivo because these metabolites are
formed irreversibly from glucocorticoids in the rat (486)
and thus are not precursors of glucocorticoids.
If the anti-insulin effect of fluprednisolone is significantly greater than that of 20S-hydroxy fluprednisolone, what are possible explanations of this specificity?
One explanation is that the C-20 ketone interacts with a
394
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receptor protein through anil formation.

It is unlikely that

differences in hydrogen bonding between the C-20 ketone and
c-20 hydroxyl group could account for the differences in the

observed effects.

On the other hand, the C-21 deoxy deriva-

tive which may be formed from the C-21 mesylate, could be
used to evaluate the effect of hydrogen bonding on the glucocorticoid effect.

For example, Munk (766) has shown that

the llS-hydroxyl group markedly alters the surface activity
.of steroids.
The following tentative sequence of events is thought
to occur during glycolytic inhibition by glucocorticoids.
First, the glucocorticoid combines with a growth hormone
dependent protein and the resulting steroid-protein complex
causes a decrease in triglyceride synthesis which leads to
an increase in the synthesis of saturated lecithins which
are transported to peripheral tissues by s-lipoproteins.
Enzymes of red cell origin hydrolyze the lecithin to an active lysolecithin species which inhibits oxidative phosphorylation in mitochondria perhaps by displacing the essential phospholipids of cytochrome C.

Thus, the specificity

of the phospholipid effect is due mainly to the protein and
not to any special properties of the lysolecithin itself.
However, since the mitochondria contain an enzyme which
normally converts the lysolecithin species back to lecithin,
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the lysolecithin which affects the activity of the mitochondria is probably resistant to this conversion and derived
from non-mitochondrial species of lecithin {633).
The hypothesis that these steroid effects are caused
by species of S-lipoprotein lysolecithin can be investigated
by correlating S-lipoprotein lysolecithin composition with
the magnitude of inhibition of glucose oxidation.

Lysolec-

ithin species may be characterized following hydrolysis
with lysolecithinase and gas chromatography of the methyl
esters of the resulting fatty acids.
Since S-lipoproteins are synthesized in the liver, and
since the liver has been implicated in the anti-insulin effect of glucocorticoids, the possibility that the time
course of the synthesis of the inhibitor parallels the induction of gluconeogenic enzymes such as tryptophane pyrolase and

ty~osine

mined.

Experiments with actinomycin D may not decide whe-

transaminase {208, 661) should be deter-

ther protein synthesis is required for the anti-insulin effect because this inhibitor of DNA synthesis may also block
the synthesis of the S-lipoprotein necessary to transport
the inhibitor.

On the other hand, considerations

~n

pre-

ceeding chapters suggest that growth hormone is required
for the anti-insulin effect of glucocorticoids because it
is necessary for the production of a particular receptor
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protein for the glucocorticoid.

This particular receptor

protein might be detected by comparing the hepatic cortisol
binding proteins of hypophysectomized rats before and after
growth hormone treatment.
The specificity of the insulin antagonism by glucocorticoids is its most interesting and critical aspect.

As

previously noted, many polycyclic compounds such as estrogens and chlorpromazine produce hyperglycemic effects which
appear to be mechanistically similar to that of glucocorticoids.

Therefore, the possibility that must be eliminated

is that pharmacological doses of these synthetic compounds
exert their hyperglycemic effect by interacting with the
growth hormone dependent receptor protein.
Serotonin is a hyperglycemic compound released in response to growth hormone treatment.

Since the hyperglyce-

mic effect- of serotonin is caused by its release of adrenal
epinephrine, the effect of serotonin should not be important in adrenalectomized rats.

However, the effect of sero-

tonin and serotonin antagonists may be significant modi-.
fiers of insulin inhibition by endogenous glucocorticoids
in intact animals.
can suppress ACTH

For example, some serotonin antagonists
~elease

in addition to displacing sero-

tonin from its binding sites.
The mechanism of the enhanced platelet aggregation
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which is found in diabetes mellitus and which contributes to
diabetic retinopathy by blocking blood flow in the stagnant
regions of the venous circulation of the retina may be similar to the mechanism of glycolytic inhibition by glucocorticoids.

For example, it is known that platelet glycolysis

is necessary to maintain the repulsive electrical charges
between platelets.

Furthermore, platelets are capable of

triglyceride and phospholipid synthesis so that they are
susceptible to factors which affect these processes.

The

importance of platelet function in the pathology of diabetes mellitus is evident from the fact that 60 percent
of patients with diabetes for more than 10 years have
retinal hemmorhages and from the fact that 69.4 percent
with diabetes for over 15 years die of atherosclerosis.
Fructose overcomes glycolytic inhibition by glucocorticoids in. liver and adipose tissue.

Although fructolysis

bypasses the inhibition of phosphofructokinase by citrate
in insulin deficient tissues, it is not clear how fructose
reverses the inhibition of lipogenesis which is the cause
of the elevated citrate levels.

It appears that fructose

or fructose-1-phosphate has a direct effect on triglyceride synthesis in mitochondria which counteracts the inhibition of this process postulated to be produced by a complex of glucocorticoids with a growth hormone-dependent

r

399

~

~
~

r.

protein.

Thus, the effect of fructose is similar to that of

insulin under these circumstances.

However, the presence of

fructose or its esters in mitochondria has not been reported.
In multiple sclerosis the phospholipase A which forms
the B-lipoprotein lysolecithin species that enhances platelet aggregation is released from damaged nervous tissue
(92).

The phospholipase A activity of lipoprotein lipase

appears to be more specific in that it is not responsible
for the formation of the insulin-inhibitory lysolecithin
species.

Indeed, since insulin resistance is associated

with diabetic lipemia, the insulin inhibitory lysolecithin
species may block the activity of lipoprotein lipase.

Ap-

parently, this reduction in lipoprotein lipase activity obscures the inhibition of triglyceride synthesis in diabetes.
Hill et al (460} have shown that triglyceride synthesis is
impaired by glucocorticoids even though the activities of
triglyceride-synthesizing enzymes in tissue extracts is
increased (439).

Hazzard et al (441} also noted a relative

inhibition of triglyceride synthesis in estrogen-induced
hypertriglyceridemia which suggests that estrogens may interact with the growth hormone-dependent receptor protein
for glucocorticoids.

The presence of lysolecithinase ac-

tivity in plasma (848) may explain the instability of the
B-lipoprotein insulin inhibitor which was reported by

400
Bornstein (98).
The anoxia suggested by the low recoveries of glycogen
is probably due to respiratory depression produced by the
anesthetic methoxyflurane.

This respiratory depression is

accentuated by the absence of carbon dioxide, a respiratory
stimulant, in the inspired air.

Methoxyflurane, unlike

nitrous oxide, does not contribute to anoxia by displacing
oxygen because its partial pressure is only 10 mm Hg at
6.27°C and approximately 5 mm Hg at the temperature of
-21.1°C used in these experiments.

Respiratory depression

leading to anoxia might be counteracted by a slight reduction in the_pH of the glucose infusion solution.

Alter-

nately, diethyl ether, _which is a respiratory stimulant,
may be used as a substitute anesthetic with exactly the
·same apparatu·s.
Restatement of the Problem
The general problem treated was the role of cortisol
in Diabetes Mellitus.

The particular aspect studied was

the evaluation in vivo of insulin antagonists transported
'

by rat 8-lipoproteins in response to the glucocorticoid
6a-fluoro-11$,17a,21-trihydroxy-l,4-pregnadiene-3,20-dione.
The specificity of the steroid effect was also evaluated
by comparison with its derivative 6a-fluoro-11$,17a,208,21tetrahydroxy-1,4-pregnadiene-3-one•
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Restatement of the Approach
8-lipoproteins were isolated from the sera of steroidtreated donors and administered to recipient rats and the effect of the lipoprotein on the oxidation of glucose-6carbon dioxide was measured.

14

c

to

The assumptions made were:

1) that the rate of glycolysis was the main determinant in
the rate of
14 co

2

14

co 2

.
14
formation from glucose-6- C; 2) that the

was mainly formed in extra hepatic tissues; 3) that

the proportion of glucose metabolized directly to

14

co 2

is

the same in all experiments, and 4) that gluconeogenesis
is not a factor in these experiments.
Results
Provided .that the reduced steroid 6a-fluoro-11B,17a,
20a,21-tetrahydroxy-l,4-pregnadiene-3-one does not stimulate
glucose oxidation, the rate of glucose oxidation was lower
with lipoproteins from rats treated with
21-trihydroxy-l,4-pregnadiene-3,20-dione.

6a-fluoro~llB,17a,

However, this

difference was not statistically significant.
Discussion
An approach to the evaluation of insulin antagonism
in vivo has been developed and its limitations have been
determined.

The frequency with which specific activity

measurements could be made was the limiting factor in these
experiments.

The absolute specificity of the steroid effect
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cannot be determined until the absolute effect of the steroid on glucose oxidation is determined with respect to a
non-treatment control.

The insulin inhibitor appears to be

a species of lysolecithin which inhibits but does not uncouple oxidative phosphorylation leading to lower levels of
ATP as a function of NADH concentration, or, conversely, to
higher levels of NADH as a function of ATP concentration.
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